5th Schizophrenia International Research Society Conference

Deconstructing Schizophrenia
Towards Targeted Treatment

FLORENCE, ITALY
2 – 6 APRIL 2016
Dear Attendees,

It is our great pleasure to welcome you to the 5th Biennial Schizophrenia International Research Society (SIRS) Conference. SIRS is a non-profit organization dedicated to promoting research and communication about schizophrenia among research scientists, clinicians, drug developers, and policy makers internationally. We sincerely appreciate your interest in the Society and in our conference. The fourth congress in 2014 was a major success for the field attracting more than 1700 attendees from 53 countries. We anticipate an even higher attendance at this congress with most of the best investigators in the world in attendance.

SIRS was founded in 2005 with the goal of bringing together scientists from around the world to exchange the latest advances in biological and psychosocial research in schizophrenia. The Society is dedicated to facilitating international collaboration to discover the causes of, and better treatments for, schizophrenia and related disorders. Part of the mission of the Society is to promote educational programs in order to effectively disseminate new research findings and to expedite the publication of new research on schizophrenia.

The focus of the 5th Biennial Conference is ‘Deconstructing Schizophrenia Towards Targeted Treatment.’ Under the outstanding leadership of Program Committee Chairs Akira Sawa and Neeltje van Haren, we have an exciting scientific program planned for this year. The Program Committee selected thirty-five outstanding symposia sessions out of 108 submissions. The number of submissions for symposia increased by 18% over 2014 while poster submissions saw an increase of 21%. They also put together a Pharmaceutical Pipeline session for Monday and selected ninety-six superior oral presentations to be presented on Tuesday from more than 650 abstracts submitted. Plan to visit the poster sessions during lunch on Sunday, Monday and Tuesday to see the over 1,000 posters.

Please remember to complete an evaluation at the end of the conference so the Society can continue to improve its educational offerings. If you are not already a member, please stop by the registration desk and inquire about member benefits and how to join. We hope you enjoy this conference and in addition to learning about the latest, cutting edge research in the field, you will enjoy the beautiful city of Florence and its rich history.

Sincerely,

The Organizers
René Kahn, M.D. Ph.D., President
Patrick McGorry, FRCP, M.D., Ph.D., President-Elect
John Kane, M.D., Past-President
Cynthia Shannon Weickert, Ph.D., Secretary
Til Wykes, Ph.D., Treasurer
Akira Sawa, M.D., Ph.D., Program Committee Chair
Neeltje van Haren, Ph.D., Program Committee Co-Chair
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>General Information</td>
<td>2</td>
</tr>
<tr>
<td>Saturday, 2 April</td>
<td>22</td>
</tr>
<tr>
<td>Sunday, 3 April</td>
<td>24</td>
</tr>
<tr>
<td>Monday, 4 April</td>
<td>34</td>
</tr>
<tr>
<td>Tuesday, 5 April</td>
<td>44</td>
</tr>
<tr>
<td>Wednesday, 6 April</td>
<td>62</td>
</tr>
<tr>
<td>Sunday Posters</td>
<td>68</td>
</tr>
<tr>
<td>Monday Posters</td>
<td>97</td>
</tr>
<tr>
<td>Tuesday Posters</td>
<td>127</td>
</tr>
<tr>
<td>Index of Presenters and Authors</td>
<td>157</td>
</tr>
<tr>
<td>Notes</td>
<td>167</td>
</tr>
</tbody>
</table>
Disclosures

Disclosures for 2016 speakers, plenary, symposia, oral presentations and poster presenters may be found online at www.SchizophreniaConference.org. A copy of the disclosures will be available at the registration desk.

Acknowledgements

The Schizophrenia International Research Society appreciates the generous support of the Society from our 2015-2016 Supporting Corporations.

Gold

![Gold Sponsors Logos]

Silver

![Silver Sponsors Logos]

Other Sponsorships

![Other Sponsorship Logos]

Educational Grants:
The Society expresses appreciation to the following companies for their support of this educational activity by providing unrestricted educational grants:

- Otsuka America Pharmaceuticals, Inc.
- Eli Lilly and Company

The Junior Travel Award Fellowship Program is partially sponsored by a grant from the U.S. National Institute Drug Abuse to Harvard Medical School (Lynn DeLisi, PI).
General Information

OFFICERS:

René Kahn
M.D., Ph.D.
President

Patrick McGorry
FRCP, M.D., Ph.D.
President-Elect

Cynthia Shannon Weickert
Ph.D.
Secretary

Til Wykes
Ph.D.
Treasurer

BOARD OF DIRECTORS (2014-2016):

Anissa Abi-Dargham
USA

Celso Arango
Spain

Geraldo Busatto
Brazil

Tyrone Cannon
USA

Eric Chen
China

Paolo Dazzan
United Kingdom

Michael Green
USA

Stephan Heckers
USA

Patrick McGorry
Australia

Herbert Meltzer
USA

Sophia Vinogradov
USA

Cynthia Shannon-Weickert
Australia

INCOMING OFFICERS:

Patrick McGorry
Australia, President

Lynn DeLisi
USA, President-Elect

Til Wykes
United Kingdom, Secretary

Shitij Kapur
United Kingdom, Treasurer

René Kahn
The Netherlands, Past-President
INTERNATIONAL ADVISORY COUNCIL

Jean Addington  
Deanna Barch  
Alessandro Bertolino  
Robert Buchanan  
Mary Cannon  
David Castle  
Eric Chen  
Siow Ann Chong  
Christoph Correll  
Christina Dalman  
Anthony David  
F.W. Deakin  
Lynn DeLisi  
Wolfgang Fleishhacker  
Kyung Sue Hong  
Matti Huttunen  
James Kennedy  
Shon Lewis  
Mario Maj  
John McGrath  
Paulo Menezes  
Preben Mortensen  
Patricio O'Donnell  
Emmanuelle Peters  
Anita Riecher-Rössler  
Sibylle Schwab  
Iris Sommer  
Dawn Velligan  
Mark Weiser

2016 Meetings Committees

TRAVEL AWARD SELECTION COMMITTEE

Robin Emsley  
Paola Dazzan  
Wagner Gattaz  
Lorna Lopez  
Douglas Noordsy  
Joseph McEvoy  
Si Tianmei

South Africa, Chair  
United Kingdom  
Brazil  
Ireland  
USA  
USA  
China
2016 PROGRAM COMMITTEE

Akira Sawa
USA
Chair

Neeltje van Haren
Netherlands
Co-Chair

Larry Alphs
USA
Robert Buchanan
USA
Raymond Chan
China
Barbara Cornblatt
USA
Paola Dazzan
United Kingdom
J.F.W. Deakin
United Kingdom
Sophia Dollfus
France
Robin Emsley
South Africa
Peter Falkai
Germany
Wolfgang Fleischhacker
Austria
Phil Harvey
USA
Oliver Howes
United Kingdom
Hilleke Hulshoff Pol
Netherlands
Shitij Kapur
United Kingdom
James Kennedy
Canada
Steve Marder
USA
Patrick McGorry
Australia
John McGrath
Australia
Phillip McGuire
United Kingdom
Igor Nenadic
Germany
Christos Pantelis
Australia
Maxine Patel
United Kingdom
Charles Schulz
USA
Michael Spedding
France
Rajiv Tandon
United States
Jari Tiihonen
Finland
Aristotle Voineskos
Canada
Thomas Weickert
Australia
Continuing Medical Education

ACCME:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Vanderbilt University School of Medicine and the Schizophrenia International Research Society. Vanderbilt University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Vanderbilt University School of Medicine designates this live activity for a maximum of 24 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

To obtain credit, registered participants must complete an online evaluation. The evaluation may be completed at www.SchizophreniaConference.org. There will be a $50.00 USD charge for scientific registrants to obtain CME credits.

COURSE OBJECTIVES:

After participating in the CME Activity, Clinicians should be able to describe and discuss:
• Strategies for determining an approach to manage patients with schizophrenia
• The status of genetic findings and how they can be incorporated into strategies for managing patients with schizophrenia
• The use of brain imaging data about pathophysiology and disease progression to revise or continue a strategy for managing patients with schizophrenia
• The implications of basic neuroscience findings for managing patients with schizophrenia

After participating in the CME Activity, Researchers should be able to describe and discuss:
• Approaches to develop novel treatments for schizophrenia
• Strategies for translating basic neuroscience into knowledge that can be used in clinical practice
• Differences in schizophrenia research across diverse cultures and geographic areas
• Novel intervention studies that will promote the development of advanced knowledge about schizophrenia
• Methods to advance the clinical application of genetic research in schizophrenia

DISCLOSURES:
It is the policy of Vanderbilt University School of Medicine and Schizophrenia International Research Society to require disclosure of financial relationships from individuals in a position to control the content of a CME activity; to identify and resolve conflicts of interest related to those relationships; and to make disclosure information available to the audience prior to the CME activity. Presenters are required to disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentations. Disclosures for 2016 speakers, plenary, symposia, oral presentations and poster presenters may be found online at www.SchizophreniaConference.org. A copy of the disclosures will be available at the registration desk.
EACCME:
The 5th Biennial Schizophrenia International Research Society Conference has been granted 24 European CME credits (ECMEC) by the European Accreditation Council for Continuing Council for Continuing Medical Education (EACCME). Physicians should claim on the credits commensurate with the extent of their participation in the activity. To obtain credit, registered participants must complete an online evaluation. The evaluation may be completed at www.SchizophreniaConference.org. There will be a $50.00 USD charge to obtain credits.

CONFERENCE EVALUATION:
All conference attendees are urged to complete an evaluation of the meeting. Attendees who are requesting CME (ACCME, EACCME) credit for the meeting are required to complete the evaluation. This form is available online only. You may complete the evaluation in the Computer Center or on-line at www.SchizophreniaConference.org. All evaluations must be completed by Friday, 6 May 2016.

VIDEOTAPING SESSIONS:
Attendees may not videotape, audiotape, or photograph (camera or camera phone) presentations at the conference without prior permission from the session chair.

General Information

REGISTRATION
Registration for the 5th Biennial Schizophrenia International Research Society Conference is located at the Main Entrance of Firenze Fiera Congress Center, Piazza Adua.

<table>
<thead>
<tr>
<th>DATE</th>
<th>TIME</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, 2 April</td>
<td>1:00 PM – 8:00 PM</td>
</tr>
<tr>
<td>Sunday, 3 April</td>
<td>8:00 AM – 6:30 PM</td>
</tr>
<tr>
<td>Monday, 4 April</td>
<td>8:00 AM – 7:00 PM</td>
</tr>
<tr>
<td>Tuesday, 5 April</td>
<td>8:00 AM – 8:00 PM</td>
</tr>
<tr>
<td>Wednesday, 6 April</td>
<td>8:00 AM – 12:00 PM</td>
</tr>
</tbody>
</table>

REGISTRATION TYPES:
Delegate: Scientific Attendee
Student: Full-time graduate students, medical students, or students in the first two years of a post-doctoral fellowship program at a university in a field relevant to schizophrenia research. A letter from the student’s immediate supervisor verifying his/her student status and relevant field will be required for registration.
REGISTRATION FEES:

<table>
<thead>
<tr>
<th>Category</th>
<th>Up to 1 March 2016</th>
<th>2 March or later</th>
</tr>
</thead>
<tbody>
<tr>
<td>SIRS 2015 and 2016 Member</td>
<td>450.00€</td>
<td>500.00€</td>
</tr>
<tr>
<td>SIRS 2016 New Member</td>
<td>490.00€</td>
<td>540.00€</td>
</tr>
<tr>
<td>SIRS 2015 and 2016 Student Member</td>
<td>170.00€</td>
<td>220.00€</td>
</tr>
<tr>
<td>SIRS 2016 New Student Member</td>
<td>210.00€</td>
<td>260.00€</td>
</tr>
<tr>
<td>Non-Member Delegate</td>
<td>700.00€</td>
<td>750.00€</td>
</tr>
<tr>
<td>Non-Member Student</td>
<td>250.00€</td>
<td>300.00€</td>
</tr>
<tr>
<td>Welcome Reception Ticket</td>
<td>60.00€</td>
<td>60.00€</td>
</tr>
</tbody>
</table>

WELCOME RECEPTION TICKET:
The welcome reception ticket is included in the registration fee. If a guest would like to attend, the cost is €60 per ticket.

REGISTRATION TIME FRAMES:
Regular: Register August 2015 – 1 March 2016
Late: Register 2 March 2016 – onsite

COMPUTER ACCESS
Complimentary wireless internet is available in the conference center. To access the wireless internet, choose the SIRS2016 network. “SIRS2016” is the password. Conference attendees may also use the Computer Center located in Limonaia.

The Computer Center is provided this year for the convenience of meeting attendees. The Computer Center will be open the following hours:

- Saturday, 2 April: 1:00 PM – 7:00 PM
- Sunday, 3 April: 8:00 AM – 6:30 PM
- Monday, 4 April: 8:00 AM – 6:30 PM
- Tuesday, 5 April: 8:00 AM – 6:30 PM
- Wednesday, 6 April: 8:00 AM – 1:00 PM
**SPEAKER READY ROOM:**
The speaker ready room is available in Sala 103 in the Palazzo Congressi. All presenters are required to come to the speaker ready room to upload their presentation, preferably 24-hours prior to the presentation. Presentations from individual computers are not permitted. Below are the hours for the Speaker Ready Room:

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, 2 April</td>
<td>1:00 PM – 7:00 PM</td>
</tr>
<tr>
<td>Sunday, 3 April</td>
<td>8:00 AM – 7:00 PM</td>
</tr>
<tr>
<td>Monday, 4 April</td>
<td>8:00 AM – 7:00 PM</td>
</tr>
<tr>
<td>Tuesday, 5 April</td>
<td>8:00 AM – 7:00 PM</td>
</tr>
<tr>
<td>Wednesday, 6 April</td>
<td>8:00 AM – 12:00 PM</td>
</tr>
</tbody>
</table>

**ABSTRACTS:**
Abstracts for all presentations will be published electronically by *npj Schizophrenia* and will be available as an electronic flipbook and as a PDF document at [www.SchizophreniaConference.org](http://www.SchizophreniaConference.org).

**Awards**
The Awards Committee and Board of Directors of the Schizophrenia International Research Society are pleased to announce the Society’s Honorary Award Winners.

**SIRS LIFETIME ACHIEVEMENT AWARD**

**Herbert Meltzer, M.D.**
Herbert Y. Meltzer, M.D., is Professor of Psychiatry and Behavioral Sciences and Professor of Pharmacology and Physiology at the Feinberg School of Medicine Chicago, Ill. Prior to that, he was Professor of Psychiatry at the University of Chicago, held endowed Professorships at Case Western Reserve and Vanderbilt University Schools of Medicine. He has been President of ACNP and CINP, and is a founder of the Brain Behavior Research Foundation (formerly NARSAD). He has over 900 peer reviewed publications and 150 book chapters. Among numerous awards he has received are the Efron and Paul Hoch awards of the ACNP, the Noyes Prize of the Commonwealth of Pennsylvania, the Lieber Prize for Schizophrenia Research from NARSAD, the Stanley Dean Award for Research in Schizophrenia of the American College of Psychiatry, the Gold Medal Award of the Society of Biological Psychiatry, the Earl Sutherland Prize for Lifetime Research Achievement of Vanderbilt University, the Research Prize of the American Psychiatric Association, the Lifetime Achievement Award of the Winter Conference on Psychosis Research. He chaired the International Psychopharmacology Algorithm Project, a WHO-recognized web-based algorithm to guide the treatment of schizophrenia ([www.IPAP.org](http://www.IPAP.org)). His Hirsch index is 111. The total number of citations of his research (Web of Science:2/23/2016) is 54,167.

*continued on next page*
Herbert Meltzer, M.D. (continued)

The highlights of his research achievements include: 1) establishing the superior efficacy of clozapine and other atypical antipsychotic drugs for positive symptoms for treatment resistant schizophrenia; 2) discovery of the 5-HT<sub>2A</sub>/D<sub>2</sub> ratio as the general pharmacologic principle of atypical antipsychotic drugs and the contribution of 5-HT<sub>1A</sub> partial agonism to antipsychotic drug action, leading to the development of most such clinically used drugs; 3) discovery of the antisuicidal properties of clozapine and leading the InterSePT Trial to obtain FDA approval for this indication; 4) discovery of the ability of clozapine and other atypical APDs to improve some domains of cognition in schizophrenia, and preclinical studies to demonstrate the basis for this mechanism of action using the NMDAR rodent model; 5) discovery of the ability of pimavanserin (ACP-103), a selective 5-HT<sub>2A</sub> inverse agonist, now the first approved non-dopamine based antipsychotic drug, with applications to schizophrenia and other psychotic disorders forthcoming; and 6) pharmacogenomic studies identifying biomarkers for treatment resistant schizophrenia and prediction of the efficacy and side effects of atypical antipsychotic drugs based upon candidate genes and GWAS.

OUTSTANDING BASIC RESEARCH

Anthony Grace, Ph.D.

Dr. Anthony A. Grace is a Distinguished Professor of Neuroscience and a Professor of Psychiatry and Psychology at the University of Pittsburgh in Pittsburgh, PA. He received his Ph.D. from Yale University School of Medicine with Dr. Benjamin S. Bunney and had postdoctoral training with Dr. Rodolfo Llinas in the Department of Physiology and Biophysics at New York University School of Medicine. Dr. Grace has been involved in translational research related to the dopamine system for over 30 years. His early work pioneered the mode of action of antipsychotic drugs, and the identification and characterization of dopamine-containing neurons, and was the first to provide a means to quantify their activity state and pattern in a way that is the standard in the literature. His current work involves novel treatments for schizophrenia and its prevention, the role of dopamine in anhedonia and affective disorders, and the mode of action of ketamine and novel antidepressant drugs. Dr. Grace has received several awards for his research, including the William K. Warren Award for Excellence in Schizophrenia Research, the Paul Janssen Schizophrenia Research Award and the Lilly Basic Scientist Award from the International College of Neuropsychopharmacology, the Efron Award and the Axelrod Award from the American College of Neuropsychopharmacology, the Gold Medal award from the Society of Biological Psychiatry, as well as a NIMH MERIT award, a Distinguished Investigator award from the National Alliance for Research in Schizophrenia and Depression, the Judith Silver Memorial Investigator Award from the National Alliance for the Mentally III, a Fellow of the American Association for the Advancement of Science, and appointment as a Distinguished Professor of Neuroscience at the University of Pittsburgh. He is also a past member of the governing council of the American College of Neuropsychopharmacology and the Schizophrenia International Research Society and is on the editorial board for numerous leading journals in the field. Dr. Grace has made a substantial impact on the field, publishing more than 280 articles...
(H index 88) spanning basic and clinical research, and has been cited more than 29,000 times. Tony is one of a handful of individuals that not only performs important basic research, but can to integrate this work into testable models relevant to the human condition.

**OUSTANDING CLINICAL/COMMUNITY RESEARCH**

**Larry Siedman, Ph.D.**

Dr. Siedman is Professor of Psychology in the Harvard Medical School Department of Psychiatry at Beth Israel Deaconess Medical Center (BIDMC) and Massachusetts General Hospital. He has been Director of the Massachusetts Department of Mental Health funded Center of Excellence in Clinical Neuroscience and Psychopharmacological Research since 2002 and Vice Chair (Research), Massachusetts Mental Health Center Public Psychiatry Division, BIDMC since 2005. Dr. Siedman obtained his B.A. in Psychology at the City College of New York in 1971 and his doctorate in Clinical-Community Psychology at Boston University in 1980. He has been an associate editor for *Neuropsychology*, and for the *Journal of the International Neuropsychological Society (JINS)*, and on the editorial boards of the *American Psychologist*, *Schizophrenia Bulletin*, *Journal of Abnormal Psychology*, *Asian Journal of Psychiatry*, and several others. He has authored over 400 journal articles. In 2014 and 2016, he was recognized by Thompson Reuters Science Watch as one of the “The World’s Most Influential Scientific Minds” based on his highly cited papers. He has received 31 grants, mainly from NIMH, and has collaborated with many investigators around the world. He has been involved extensively in mentoring young investigators with more than 50 mentees in academic positions, at least 23 of whom have received independent funding. This has been recognized by a number of mentorship and teaching awards at Harvard Medical School. His laboratory has focused on prefrontal cortex, hippocampus, executive and memory functions, largely in schizophrenia and other psychotic disorders, but also in ADHD. His studies have utilized neurocognitive and brain imaging measures, and have been applied to relatives, children and adolescents at risk for psychosis as well as patients. He has long-standing interests in treatment and prevention of schizophrenia and has helped facilitate prodromal and first episode intervention programs at BIDMC and in the Commonwealth of Massachusetts.
Alan Anticevic, Ph.D

Dr. Anticevic trained in Clinical Psychology and Cognitive Neuroscience at Washington University in St. Louis where he worked with Drs. Deanna Barch and David Van Essen. Following his graduate training, Dr. Anticevic completed his internship in Clinical Neuropsychology at Yale University. After internship, he joined the Yale University Department of Psychiatry as research faculty while concurrently serving as the Administrative Director for the Center for the Translational Neuroscience of Alcoholism. Subsequently, he was appointed as an Assistant Professor of Psychiatry and Psychology at the Yale University School of Medicine, where he directs a clinical neuroimaging laboratory focused on severe psychiatric illness such as schizophrenia. Dr. Anticevic is a recipient of the NARSAD Young Investigator Award, the International Congress of Schizophrenia Research Young Investigator Award, the NIH Director’s Early Independence Award, the NARSAD Independent Investigator Award and the Klerman Prize for Exceptional Clinical Research. He currently serves as the Co-Director of the Division of Neurocognition, Neurocomputation, and Neurogenetics (N3) at Yale School of Medicine.

Broadly, his research interests are centered on cognitive neuroscience of psychiatric illness, functional connectivity, as well as functional neuroimaging analysis methodology. Specifically, Dr. Anticevic is interested in characterizing brain circuits involved in cognitive operations such as working memory as well as their interaction with neural systems involved in affective processes, with the focus of understanding how these interactions may go awry in the context of severe neuropsychiatric illness (e.g. schizophrenia, bipolar disorder and substance abuse). Methodologically, his research harnesses the combination of task-based, resting-state, pharmacological functional neuroimaging, as well as computational modeling approaches to mechanistically understand neural circuit dysfunction in disorders such as schizophrenia.
**RISING STAR**

**Aristotle Voineskos, M.D., Ph.D.**

Dr. Voineskos is Director of the Slaight Family Centre for Youth in Transition, and Head of the Kimel Family Translational Imaging-Genetics Laboratory at the Centre for Addiction and Mental Health in Toronto, Canada. He is also Canada Research Chair in Neuroimaging of Schizophrenia and Associate Professor of Psychiatry at the University of Toronto.

Dr. Voineskos’s work combines multi-modal neuroimaging and genetics approaches to map gene effects on brain circuitry with a view to discovering vulnerability pathways for severe mental illness using a lifespan approach. A related area of Dr. Voineskos’s work includes using structural and functional neuroimaging in medication-based, brain stimulation, and behavioural treatment studies in schizophrenia and related disorders. He is currently leading several multi-site neuroimaging studies spanning a number of sites in North America. He also holds a special interest in early identification and intervention for young people with emerging mental illness. Dr. Voineskos presently holds operating funding as Principal Investigator from the National Institute of Mental Health, Canadian Institutes of Health Research, Canada Foundation for Innovation, Ontario Ministry of Research and Innovation, and as a NARSAD Independent Investigator.

**AWARD COMMITTEE MEMBERS**

- Shitij Kapur, United Kingdom, Chair
- Anthony David, United Kingdom
- Paola Dazzan, United Kingdom
- John McGrath, Australia
- Akira Sawa, USA

**POSTER AWARDS**

*Cognitive Neuropsychiatry, npj Schizophrenia, and Schizophrenia Bulletin* will award poster prizes during the Closing Session on Wednesday, 6 April at 9:30 AM. The Schizophrenia International Research Society Awards Committee will collaborate with journal editors to select the awards recipients. All three journals require that researchers be less than 40 years of age at the time of the conference for consideration.

The winners of the *Schizophrenia Research Founding Editors Award* are as follows:

- Rajiv Tandon: Best Paper by a Senior Investigator
- Hans-Gert Bernstein: Best Paper by a Junior Investigator
CONGRATULATIONS TO THE 2016 TRAVEL FELLOWS:

Myrto Samara  
Johanna Seitz  
Emily Kline  
Marta Rapado-Castro  
Godefridus Koevoets  
Donna Cosgrove  
Simone Ciufolini  
Paulo Lizano  
Jennifer Donegan  
Martine Van Nierop  
Patricia Di Prinzio  
Rashmi Patel  
Shinichiro Nakajima  
Sze Chun Lee  
Jose Cortes-Briones  
Michael Benros  
Babatunde Fadipe  
Giovanni Mansueto  
Anne-Kathrin Fett  
Marc Bohlken  
Emma Neilson  
Leslie Horton  
Agnieszka Potasiewicz  
Marcos Leite Santoro  
Linda Scoriels  
Marie Labouesse  
Gabriëlla Blokland  
Laila Asmal  
Sonja de Zwart  
Aoife O’Gorman  
Jessica Hartmann  
Meenakshi Dauwan  
Hannah Jongsm  
Daniel Shapiro  
Andrea Jones  
Kyle Minor  
André Schmidt  
Sarah McEwen  
Ran Barzilay  
Hugh Ramsay  
Joanne Newbury  
Hideaki Tani  
Nicolas Crossley  
Oleg Papsuev  
Onur Kucukcaban  
Sanja Andric  
TianHong Zhang  
Sri Mahavir Agarwal  
Ahmed Mhalla

General Information

CONGRATULATIONS TO THE 2016 TRAVEL FELLOWS:

Myrto Samara  
Johanna Seitz  
Emily Kline  
Marta Rapado-Castro  
Godefridus Koevoets  
Donna Cosgrove  
Simone Ciufolini  
Paulo Lizano  
Jennifer Donegan  
Martine Van Nierop  
Patricia Di Prinzio  
Rashmi Patel  
Shinichiro Nakajima  
Sze Chun Lee  
Jose Cortes-Briones  
Michael Benros  
Babatunde Fadipe  
Giovanni Mansueto  
Anne-Kathrin Fett  
Marc Bohlken  
Emma Neilson  
Leslie Horton  
Agnieszka Potasiewicz  
Marcos Leite Santoro  
Linda Scoriels  
Marie Labouesse  
Gabriëlla Blokland  
Laila Asmal  
Sonja de Zwart  
Aoife O’Gorman  
Jessica Hartmann  
Meenakshi Dauwan  
Hannah Jongsm  
Daniel Shapiro  
Andrea Jones  
Kyle Minor  
André Schmidt  
Sarah McEwen  
Ran Barzilay  
Hugh Ramsay  
Joanne Newbury  
Hideaki Tani  
Nicolas Crossley  
Oleg Papsuev  
Onur Kucukcaban  
Sanja Andric  
TianHong Zhang  
Sri Mahavir Agarwal  
Ahmed Mhalla

KEYNOTE LECTURE

Susannah Cahalan began her investigative reporting career at the New York Post when she took an internship in her senior year of high school. She has now been there for ten years. Her work has also been featured in the New York Times and the Czech Business Weekly, where she worked when she studied abroad during her junior year of college. She was the recipient of the Silurian Award of Excellence in Journalism for Feature Writing for the article “My Mysterious Lost Month of Madness,” on which this book is based. She lives in Jersey City, New Jersey.
PLENARY SESSIONS

Sunday, 3 April
Auditorium
8:30 AM – 9:30 AM
Positive Allosteric Modulators Acetylcholine Receptors as a Novel Approach for Treatment for Schizophrenia
Jeff Conn

10:00 AM – 11:00 AM
The Recovery Project: The Who, What, Where, and When of Psychological Treatments
Til Wykes

Monday, 4 April
Auditorium
8:30 AM – 9:30 AM
Toward Predictive Psychiatry – Prognostic and Diagnostic Applications of Pattern Recognition Methods
Nikolaos Koutsouleris

10:00 AM – 11:00 AM
Precision Medicine for Psychosis: Challenges and Promise
Raquel Gur

Tuesday, 5 April
Auditorium
8:30 AM – 9:30 AM
Convergent Evidence Linking Neonatal Vitamin D Status and Risk of Schizophrenia
John McGrath

10:00 AM – 11:00 AM
Balancing Plasticity/Stability Across Brain Development
Takao Hensch

Wednesday, 6 April
Auditorium
8:30 AM – 9:30 AM
Feeding From Bedside Into Bench, and Back to Bedside: Towards Better Understanding of Schizophrenia
Koko Ishizuka
SYMPOSIA SESSIONS
The title and location of each symposium is indicated in the program. The presentations in each session are scheduled at approximately 20 – 25 minute intervals. A general discussion period is scheduled after the last presenter in each session. Symposia are scheduled:

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday, 3 April</td>
<td>1:00 PM – 3:00 PM</td>
</tr>
<tr>
<td></td>
<td>3:30 PM – 5:30 PM</td>
</tr>
<tr>
<td>Monday, 4 April</td>
<td>1:00 PM – 3:00 PM</td>
</tr>
<tr>
<td></td>
<td>3:30 PM – 5:30 PM</td>
</tr>
<tr>
<td>Tuesday, 5 April</td>
<td>1:00 PM – 3:00 PM</td>
</tr>
<tr>
<td>Wednesday, 6 April</td>
<td>10:30 AM – 12:30 PM</td>
</tr>
</tbody>
</table>

ORAL PRESENTATIONS
Two oral presentation sessions are scheduled on Tuesday, 5 April from 3:15 PM – 5:15 PM and again from 5:30 PM – 7:30 PM. Within the concurrent sessions, there are 8 individual presentations. Oral presentation sessions scheduled:

- **Cognition: Multifaceted Approach**
  Chair: Philip Harvey

- **Epidemiology: Roles for Environmental Factors**
  Chair: James MacCabe

- **Neurodevelopment: Childhood, Adolescence and Adulthood**
  Chair: Aristotle Vowoneskos

- **Brain Imaging-I: Molecules, Structures and Functions**
  Chair: Igor Nenadic

- **Genetics: Multifaceted Approach**
  Chair: James Kennedy

- **Phenomenology and Dimensional Discussion**
  Chair: Celso Arango

- **Neurobiology**
  Chair: John F. Deakin

- **Clinical Trials**
  Chair: Hilleke Hulshoff Pol
Psychosocial Functioning  
Chair: Merete Nordentoft

Treatment and Clinical Service  
Chair: Patrick McGorry

Brain Imaging-II: Molecules, Structures and Functions  
Chair: Paola Dazzan

Biomarkers  
Chair: Christos Pantelis

POSTERS  
Three poster sessions are scheduled. Presenters should put their poster up by 9:30 AM and remove the poster by 5:00 PM on the day it is scheduled. Poster presentations are grouped by general topic when possible. All three poster sessions are located in the Cavaniglia. Lunch will be served each day with the poster session. Poster viewing will be open until 5:00 PM; E-Posters are available for viewing online at www.SchizophreniaConference.org.

Sunday, 3 April  
Poster Session I  
11:00 AM – 1:00 PM

Monday, 4 April  
Poster Session II  
11:00 AM – 1:00 PM

Tuesday, 5 April  
Poster Session III  
11:00 AM – 1:00 PM

REFRESHMENT BREAKS:  
All registered individuals are invited. Coffee and light pastries are available Sunday through Wednesday beginning at 8:00 AM. The morning break will be located in the Passi Perduti, located outside the Auditorium.

Afternoon coffee/tea will be available beginning at 12:45 PM Sunday – Wednesday outside the Palazzo Affari meeting rooms, the Auditorium and the Sala Verde.

LUNCHEONS:  
Buffet lunch will be served Sunday through Tuesday from 11:00 AM – 1:00 PM in the Cavaniglia during the poster sessions. Boxed lunches will be served on Wednesday from 12:30 PM – 1:00 PM in the Passi Perduti, located outside the Auditorium.
Poster Sessions and lunches will be held at the Fortezza da Basso in the Cavaniglia. This is a short 3 to 5 minute walk from the Palazzo de Congressi.
Concurrent Symposia and Oral Presentations will be held on the Lower Level, Ground Level, First Level, Second Level of the Palazzo degli Affari.

The Computer Center will be located in the Limonaia building just between the Palazzo Degli Affari and the Villa Vittoria.
Keynote, Plenary Sessions and some Symposia and Oral Presentations will be held in the Auditorium.
The Speaker Ready Room (Sala 103) and other small meeting rooms and committee meetings will be in the Villa Vittoria Building on the 1st Floor and 2nd Floor. The Villa Vittoria building is connected to the Auditorium.

The Sala Verde room is on the 2nd floor of the Villa Vittoria building.
<table>
<thead>
<tr>
<th>Time</th>
<th>Auditorium</th>
<th>Passi Perduti</th>
<th>Palazzo Affari Entrance</th>
<th>Sala 103</th>
<th>Limonaia</th>
</tr>
</thead>
<tbody>
<tr>
<td>7 AM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8 AM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9 AM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10 AM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11 AM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Legend:**
- Keynote
- Special Session
- Speaker Ready
- Registration
- Computer Center
- Symposia
- Poster Session
- Plenary
- Oral Presentation
- Coffee Break
FINAL PROGRAM
FLORENCE, ITALY
2 – 6 APRIL 2016

Saturday, 2 April 2016

SIRS EXECUTIVE BOARD MEETING (INVITATION ONLY)
Location: Congressi 101
11:00 AM - 1:00 PM

REGISTRATION
Location: Palazzo Entrance
1:00 PM - 8:00 PM

COFFEE BREAK
Location: Congressi, Passi Perduti
5:30 PM - 6:00 PM

CONFERENCE OPENING AND KEYNOTE SESSION
KEYNOTE LECTURE: An Evening with Susannah Cahalan, author of Brain on Fire
Location: Congressi Auditorium
6:00 PM - 7:15 PM

OPENING NIGHT RECEPTION
Location: Congressi, Passi Perduti
7:15 PM - 9:00 PM

Schizophrenia Bulletin
remains at the forefront of the quickly evolving field of psychosis.

VISIT our booth in the Salone Club of the Palazzo Dei Congressi

READ our Related Disorders collection now at oxford.ly/relateddisorders

OXFORD UNIVERSITY PRESS
<table>
<thead>
<tr>
<th>Time</th>
<th>Auditorium</th>
<th>Sala Verde</th>
<th>Palazzo Affari Ground Level</th>
<th>Palazzo Affari Lower Level</th>
<th>Palazzo Affari 1st Level</th>
<th>Palazzo Affari 2nd Level</th>
<th>Cavanigilia</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 AM - 10:00 AM</td>
<td>Positive Allosteric Modulators... Coffee Break</td>
<td>Coffee Break</td>
<td>11:00 AM - 1:00 PM</td>
<td>11:00 AM - 1:00 PM</td>
<td>11:00 AM - 1:00 PM</td>
<td>Coffee Break</td>
<td>11:00 AM - 1:00 PM</td>
</tr>
<tr>
<td>10:00 AM - 12:00 PM</td>
<td>The Recovery Project</td>
<td>How Can Sex Hormones Influence Psychosis and Cognitive Abilities in Men and Women With Schizophrenia? Coffee Break</td>
<td>Childhood Trauma and Psychosis; Mechanisms, Symptom Profiles, Outcome, and Treatment Coffee Break</td>
<td>1:00 PM - 3:00 PM</td>
<td>1:00 PM - 3:00 PM</td>
<td></td>
<td>11:00 AM - 1:00 PM</td>
</tr>
<tr>
<td>12:00 PM - 2:00 PM</td>
<td></td>
<td>How Can Sex Hormones Influence Psychosis and Cognitive Abilities in Men and Women With Schizophrenia? Coffee Break</td>
<td>1:00 PM - 3:00 PM</td>
<td>1:00 PM - 3:00 PM</td>
<td>1:00 PM - 3:00 PM</td>
<td>1:00 PM - 3:00 PM</td>
<td></td>
</tr>
<tr>
<td>2:00 PM - 4:00 PM</td>
<td></td>
<td>Alterations in Hippocampal Activity, Glutamate and GABA Before the Onset of Psychosis Coffee Break</td>
<td>3:00 PM - 5:00 PM</td>
<td>3:00 PM - 5:00 PM</td>
<td>3:00 PM - 5:00 PM</td>
<td>3:00 PM - 5:00 PM</td>
<td></td>
</tr>
<tr>
<td>4:00 PM - 6:00 PM</td>
<td></td>
<td>Alterations in Hippocampal Activity, Glutamate and GABA Before the Onset of Psychosis Coffee Break</td>
<td>3:30 PM - 5:00 PM</td>
<td>3:30 PM - 5:00 PM</td>
<td>3:30 PM - 5:00 PM</td>
<td>3:30 PM - 5:00 PM</td>
<td></td>
</tr>
<tr>
<td>6:00 PM - 8:00 PM</td>
<td></td>
<td>Alterations in Hippocampal Activity, Glutamate and GABA Before the Onset of Psychosis Coffee Break</td>
<td>3:30 PM - 5:00 PM</td>
<td>3:30 PM - 5:00 PM</td>
<td>3:30 PM - 5:00 PM</td>
<td>3:30 PM - 5:00 PM</td>
<td></td>
</tr>
<tr>
<td>8:00 PM - 10:00 PM</td>
<td></td>
<td>Alterations in Hippocampal Activity, Glutamate and GABA Before the Onset of Psychosis Coffee Break</td>
<td>3:30 PM - 5:00 PM</td>
<td>3:30 PM - 5:00 PM</td>
<td>3:30 PM - 5:00 PM</td>
<td>3:30 PM - 5:00 PM</td>
<td></td>
</tr>
<tr>
<td>10:00 PM - 12:00 AM</td>
<td></td>
<td>Alterations in Hippocampal Activity, Glutamate and GABA Before the Onset of Psychosis Coffee Break</td>
<td>3:30 PM - 5:00 PM</td>
<td>3:30 PM - 5:00 PM</td>
<td>3:30 PM - 5:00 PM</td>
<td>3:30 PM - 5:00 PM</td>
<td></td>
</tr>
</tbody>
</table>

**Legend:**
- **Keynote**
- **Special Session**
- **Speaker Ready**
- **Registration**
- **Computer Center**
- **Symposia**
- **Poster Session**
- **Plenary**
- **Oral Presentation**
- **Coffee Break**
Sunday, 3 April 2016

REGISTRATION
Location: Palazzo Entrance

MORNING COFFEE
Location: Congressi, Passi Perduti

PLENARY SESSION: POSITIVE ALLOSTERIC MODULATORS OF MUSCARINIC ACETYLCHELINE RECEPTORS AS A NOVEL APPROACH FOR TREATMENT OF SCHIZOPHRENIA
Location: Congressi Auditorium

P. Jeffrey Conn
Vanderbilt University Medical Center, United States

Abstract: Previous clinical studies as well as a large number of cellular and animal behavioral studies suggest that selective activators of M1 and/or M4 subtypes of muscarinic acetylcholine receptors (mAChRs) could provide a novel approach to treatment of schizophrenia. Especially exciting is the possibility that such agents could have efficacy in treatment of positive, negative, and cognitive symptoms in schizophrenia patients. Unfortunately, previous efforts to develop selective agonists of individual mAChR subtypes have not been successful and previous compounds have failed in development because of adverse effects due to activation of multiple mAChR subtypes. Furthermore, the relative roles of M1 and M4 in mediating the overall therapeutic effects of less selective mACh agonists are not understood. We have been highly successful in developing highly selective positive allosteric modulators (PAMs) of both M1 and M4 that have excellent properties for in vivo studies and potential development as drug candidates. Interestingly, selective M1 PAMs have robust efficacy in improving specific domains of cognitive function in animal models but do not have antipsychotic-like effects. In contrast, selective M4 PAMs have robust antipsychotic-like effects in animal models. Electrophysiolgy and genetic studies are providing important new insights into the mechanisms by which M1 and M4 PAMs act in specific cortical and midbrain circuits. These studies provide an exciting new approach to that has potential for treatment of multiple symptom clusters in schizophrenia patients.

COFFEE BREAK
Location: Congressi, Passi Perduti
PLENARY SESSION: THE RECOVERY PROJECT: THE WHO, WHAT, WHERE AND WHEN OF PSYCHOLOGICAL TREATMENTS
Location: Congressi Auditorium

Til Wykes
Institute of Psychiatry, Psychology & Neuroscience, United Kingdom

Abstract: Psychological treatments aimed at symptoms or behaviours that impede recovery now have a relatively strong database but it is not clear which treatments are more effective and when. Tailoring treatment, considering adherence and personal goals will tax the current evidence base but clinicians still need to make decisions. Data to help them will be discussed in this plenary lecture.

POSTER SESSION I AND LUNCH
Location: Cavanigia
Buffet Lunch will be served daily in the poster session
Please see page 68 for a complete listing of posters

CONCURRENT SYMPOSIA

ALTERATIONS IN HIPPOCAMPAL ACTIVITY, GLUTAMATE AND GABA BEFORE THE ONSET OF PSYCHOSIS
Location: Congressi Auditorium
Chair: Philip McGuire

1:00 PM  Elevated Hippocampal Glutamate Levels Predict the Later Onset of Psychosis
Matthijs Bossong

1:25 PM  Resting Hyperperfusion of the Hippocampus, Midbrain and Basal Ganglia in People at High Risk for Psychosis
Paul Allen

1:50 PM  GABAergic Dysregulation in Individuals at Ultra-High Risk for Psychosis Investigated With Proton Magnetic Resonance Spectroscopy
Gemma Modinos

2:15 PM  Altered Relationship Between Hippocampal Activation and Subcortical Dopamine Function in People at Ultra High Risk of Psychosis
Toby Winton-Brown

Discussant: Anthony Grace
HOW CAN SEX HORMONES INFLUENCE PSYCHOSIS AND COGNITIVE ABILITIES IN MEN AND WOMEN WITH SCHIZOPHRENIA?
Location: Congressi, Sala Verde
Chair: Thomas Weickert

1:00 PM  Sex Differences and Effects of Sex Steroid Hormones in Animal Models of Schizophrenia
Maarten van den Buuse

1:25 PM  Sex Hormones to Improve Symptoms and Cognition in Schizophrenia
Iris Sommer

1:50 PM  Molecular Explanation for Estrogens Role in Schizophrenia Lays the Foundation of Novel Treatment for Men and Women
Cynthia Shannon Weickert

2:15 PM  Hormonal Influences on Cognition and Brain Activity in Schizophrenia
Thomas Weickert

Discussant: Raquel Gur

CHILDHOOD TRAUMA AND PSYCHOSIS: MECHANISMS, SYMPTOM PROFILES, OUTCOME, AND TREATMENT
Location: Affari, Ground Level
Chair: Ruud Van Winkel

1:00 PM  Trauma, Attachment and Dissociation: Moving Towards Process-Focused Psychological Interventions for Psychosis
Filippo Varese

1:25 PM  Using a Stratified Approach in Psychiatry – Implications for Treatment and the Search for Underlying Mechanisms of Mental Illness
Martine Van Nierop

1:50 PM  The Role of Childhood Abuse in the Course and Outcome of Psychotic Disorders Over 10 Years
Helen Fisher

2:15 PM  Treating PTSD in Psychosis With Prolonged Exposure of Eye Movement Desensitization and Reprocessing: A Randomised Controlled Trial
Mark Van der Gaag

Discussant: Robin Murray
I DID IT! THE EXPERIENCE OF SELF-AGENCY IN SCHIZOPHRENIA

Location: Affari, Lower Level
Chair: Neeltje Van Haren

1:00 PM  Self Disturbance: A Construct to Integrate Phenomenology and Neurocognition in Early Psychosis?
          Barnaby Nelson

1:25 PM  Premotor Signals Affecting the Subjective Experience of Agency - An fMRI Study in Schizophrenia Patients and Healthy Volunteers
          Martin Voss

1:50 PM  Schizotypy and the Awareness of Intention: Variability in the Timing of Intention Awareness Predicts Schizotypy Scores
          James Moore

2:15 PM  Neural and Clinical Consequences of Self-Agency Processing in Schizophrenia
          Neeltje Van Haren

Discussant: Tilo Kircher

IMPROVING IDENTIFICATION AND TREATMENT OF EARLY PHASE PSYCHOSIS

Location: Affari, First Level
Chair: John Kane

1:00 PM  Pathways to Care in Early Psychosis: The Role of the Internet and Social Media
          John Kane

1:25 PM  The Step-Ed Project: A Population Based Approach to Early Intervention for Psychosis
          Vinod Srihari

1:50 PM  Effectiveness of Early Intervention Services for Patients With Early Psychosis: Systematic Review and Meta-Analysis of Specialized Care Versus Usual or Modular Care
          Christoph Correll

2:15 PM  Mobile Behavioral Sensing in Outpatients and Inpatients With Schizophrenia
          Dror Ben-Zeev

Discussant: Robert Zipursky
CANNABIS AND PSYCHOSIS: WHAT NOW FOR DOPAMINE?

Location: Affari, Second Level
Chair: Michael Bloomfield

1:00 PM  Psychosis and the Psychopharmacology of Cannabinoids
Amir Englund

1:25 PM  The Effects of Delta-9-Tetrahydrocannabinol (THC) on Dopamine Synthesis and Release: Evidence From Pre-Clinical and Clinical Studies
Michael Bloomfield

1:50 PM  Clinical Neuroimaging Studies of the Effects of Cannabis in Psychosis
Romina Mizrahi

2:15 PM  Non-Dopaminergic Pathways From THC to Psychosis: GABA Deficits Enhance the Psychotomimetic Effects of Δ9-THC
Deepak D’Souza

Discussant: Marta Di Forti

COFFEE BREAK 3:00 PM - 3:30 PM
Location: Passi Perdutti, Affari Foyers, and the Sala Verde Foyer

CONCURRENT SYMPOSIA 3:30 PM - 5:30 PM

EXCITING NEW FINDINGS ABOUT DOPAMINE

Location: Congressi Auditorium
Chair: Bita Moghaddam

3:30 PM  Dopamine Neurotransmission in Schizophrenia: New Findings From Combined PET and fMRI Studies
Anissa Abi-Dargham

3:55 PM  Adolescent Dopamine Development, Netrin-1, and Vulnerability to Schizophrenia
Cecillia Flores

4:20 PM  A Novel Role for Dopamine Regulation of Striatal and Cortical Information Processing
Bita Moghaddam

4:45 PM  A Molecular Signature of Dopamine Dysregulation Exists in the Substantia Nigra in Schizophrenia
Tertia Purves-Tyson

Discussant: Marco Bortolato
THE PIVOTAL ROLE OF GLIA IN SCHIZOPHRENIA: PROVIDING MOLECULAR INSIGHTS FOR DEVELOPING NEW THERAPIES
Location: Congressi, Sala Verde
Chair: Johann Steiner

3:30 PM  Histology and Biochemistry of White Matter in Psychiatric Disease
          Andrew Dwork

3:55 PM  Connecting the Energy Dysfunction Observed in Schizophrenia Brains to Glia Cells in Vitro
          Daniel Martins-De-Souza

4:20 PM  Clozapine Promotes Glycolysis and Myelin Lipid Synthesis in Cultured Oligodendrocytes
          Johann Steiner

4:45 PM  DISC1 Induced Expansion of the Hindbrain Oligodendrocytes Progenitors in Forebrain During Development – Relevance to Schizophrenia
          Pavel Katsel

Discussant: Kolja Schiltz

COGNITIVE REMEDIATION: EFFECTS ON SOCIAL COGNITION AND NEW INSIGHTS ON MEDIATORS AND MODERATORS OF TREATMENT OUTCOMES
Location: Affari, Ground Level
Chair: Marieke (Gerdina) Pijnenborg

3:30 PM  Improvement of Social Cognition Deficits in Chronic Schizophrenia After CRT
          Natalia Ojeda

3:55 PM  Exploring the Role of Metacognition in Cognitive and Functional Change Following a New Generation Metacognitive Cognitive Remediation Programme for People With Schizophrenia
          Clare Reeder

4:20 PM  Reading the Mind of the Avatar: Demonstration of a New Virtual Reality Social Cognition Training for People With Psychotic Disorders
          Saskia Nijman

4:45 PM  Training of Social Cognition in Psychotic Disorders: A Meta-Analysis
          Marieke (Gerdina) Pijnenborg

Discussant: Torill Ueland
THE WHO INTERNATIONAL CLASSIFICATION OF FUNCTIONING CORE SETS: A CONSENSUS PROCESS FOR
KEY COMPONENTS OF FUNCTIONING FOR SCHIZOPHRENIA

Location: Affari, Lower Level
Chair: Oscar Pino

3:30 PM   Social Disconnectedness in Schizophrenia and in the General Community: Do They Look the Same?
           Junghee Lee

3:55 PM    A Closer Look at Functioning – What Are International Classification of Functioning, Disability and Health Core Sets and How They Can Be Used
           Michaela Coenen

4:20 PM    Preliminary Studies for the Development of the International Classification of Functioning, Disability and Health Core Sets (ICF-CS) for Schizophrenia
           Georgina Guilera

4:45 PM    The Comprehensive and Brief International Classification of Functioning, Disability and Health Core Sets (ICF-CS) for Schizophrenia
           Oscar Pino

Discussant: William Carpenter

SCHIZOPHRENIA AND MORTALITY - DIFFERENT ASPECTS, DIFFERENT SOLUTIONS

Location: Affari, First Level
Chair: Carsten Hjorthøj

3:30 PM   Substance Use and Mortality in Schizophrenia, Bipolar Disorder, and Unipolar Depression
           Carsten Hjorthøj

3:55 PM    Mortality in Schizophrenia and Bipolar Disorder: Clinical and Serological Predictors
           Faith Dickerson

4:45 PM    Epidemiological and Biological Correlates of Premature Mortality in People With Psychosis
           Cherrie Galletly

5:10 PM    Homelessness as a Risk Factor for Mortality: A Danish Nationwide Register-Based Cohort Study
           Sandra Feodor Nilsson

Discussant: John McGrath
PSYCHOTIC EXPERIENCES IN THE E-GENERATION: MEASURING SYMPTOMS, FUNCTIONING AND LONG TERM COURSE IN YOUNG PEOPLE

Location: Affari, Second Level
Chair: Annegien Bartels-Velthuis

3:30 PM  *Psychotic Experiences in a Community Sample of Youths: Relationship With Mental Distress and Global Functioning*
Ian Kelleher

3:55 PM  *Introducing the White Noise Task in Childhood: Associations Between Speech Illusions and Psychosis Vulnerability*
Martin Rimvall

4:20 PM  *Course of Auditory Vocal Hallucinations in Childhood: 11-Year Follow-Up Study*
Annegien Bartels-Velthuis

4:45 PM  *The MHASC Application Assessing Early-Onset Hallucinations in the Touch-Screen Generation*
Renaud Jardri

Discussant: Pia Jeppesen

**SIRS BUSINESS MEETING (SIRS MEMBERS ONLY)**

Location: Congressi Auditorium
### Conference Schedule

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Event Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 AM</td>
<td>Sala Verde</td>
<td>Registration</td>
</tr>
<tr>
<td>8:30 AM</td>
<td>Auditorium</td>
<td>Tumor Predictive Psychiatry</td>
</tr>
<tr>
<td>9:30 AM</td>
<td>Sala Verde</td>
<td>Pharmaceutical Pipeline</td>
</tr>
<tr>
<td>10:00 AM</td>
<td>Palazzo Affari</td>
<td>Alzheimer’s Biomarkers for Psychiatric Disorders in Adolescence and Young Adults</td>
</tr>
<tr>
<td>10:30 AM</td>
<td>Palazzo Affari</td>
<td>Duration of Early Intervention and the Critical Period</td>
</tr>
<tr>
<td>11:00 AM</td>
<td>Palazzo Affari</td>
<td>Psychosis in Children and Adolescents: From the Prodrome to Schizophrenia</td>
</tr>
<tr>
<td>12:00 PM</td>
<td>Palazzo Affari</td>
<td>Elephant in the Room: Glia Contribution to Mental Disorders</td>
</tr>
<tr>
<td>1:00 PM</td>
<td>Palazzo Affari</td>
<td>Neuroimaging Approaches to Treatment Outcome in Schizophrenia</td>
</tr>
<tr>
<td>2:00 PM</td>
<td>Palazzo Affari</td>
<td>Characterizing a Putative &quot;Traumatic&quot; Subtype of Psychosis</td>
</tr>
<tr>
<td>3:00 PM</td>
<td>Palazzo Affari</td>
<td>Movement Disorders: A Non-Mental Core Symptom of Psychotic Disorders</td>
</tr>
<tr>
<td>4:00 PM</td>
<td>Palazzo Affari</td>
<td>Neuroimaging Approaches to Treatment Outcome in Schizophrenia</td>
</tr>
<tr>
<td>5:00 PM</td>
<td>Palazzo Affari</td>
<td>Characterizing a Putative &quot;Traumatic&quot; Subtype of Psychosis</td>
</tr>
<tr>
<td>6:00 PM</td>
<td>Palazzo Affari</td>
<td>Movement Disorders: A Non-Mental Core Symptom of Psychotic Disorders</td>
</tr>
<tr>
<td>7:00 PM</td>
<td>Palazzo Affari</td>
<td>Neuroimaging Approaches to Treatment Outcome in Schizophrenia</td>
</tr>
<tr>
<td>8:00 PM</td>
<td>Palazzo Affari</td>
<td>Characterizing a Putative &quot;Traumatic&quot; Subtype of Psychosis</td>
</tr>
</tbody>
</table>

### Venue Information
- **Auditorium**: 8:00 AM - 9:30 AM, 9:30 AM - 10:00 AM, 10:00 AM - 11:00 AM
- **Sala Verde**: 1:00 PM - 3:00 PM, 3:30 PM - 5:00 PM
- **Palazzo Affari Ground Level**: 11:00 AM - 1:00 PM
- **Palazzo Affari Lower Level**: 11:00 AM - 1:00 PM
- **Palazzo Affari 1st Level**: 11:00 AM - 1:00 PM
- **Palazzo Affari 2nd Level**: 11:00 AM - 1:00 PM
- **Cavanigia**: Poster Session II and Lunch
- **Palazzo Affari Entrance**: 8:00 AM - 7:00 PM
- **Sala 103**: Speaker Ready Room
- **Limonaia**: 8:00 AM - 6:30 PM
- **Passi Perduti**: Coffee Available

### Legend
- **Keynote**
- **Special Session**
- **Speaker Ready**
- **Registration**
- **Computer Center**
- **Symposia**
- **Poster Session**
- **Plenary**
- **Oral Presentation**
- **Coffee Break**
Monday, 4 April 2016

REGISTRATION
Location: Palazzo Entrance
8:00 AM - 7:00 PM

MORNING COFFEE
Location: Congressi, Passi Perduti
8:00 AM - 8:30 AM

PLENARY SESSION: TOWARD PREDICTIVE PSYCHIATRY – PROGNOSTIC AND DIAGNOSTIC APPLICATIONS OF PATTERN RECOGNITION METHODS
Location: Congressi Auditorium
8:30 AM - 9:30 AM

Nikolaos Koutsouleris
Ludwig-Maximilian-University, Germany

Abstract: Recently, both high-dimensional ‘omics’ data and powerful multivariate pattern analysis tools have become available for psychiatric research. These developments have stirred the hope that predictive signatures could be extracted from these multi-modal databases with far-reaching potential for individualized prognosis and (differential) diagnosis of schizophrenic, affective and neurodegenerative disorders. Yet, given the crisis of the current neuropsychiatric taxonomy and the inefficiencies of univariate statistics, it remains unclear (1) if robust mappings between neurobiological patterns and the traditional clinical diagnostic entities actually exist, and (2) whether these patterns generalize enough to be encapsulated into clinically useful ‘biomarkers’.

The lecture will first review concepts and the state-of-the-art of multivariate pattern analysis (MVPA) in psychiatric research, putting the focus on candidate markers for individualized risk stratification and differential diagnosis of schizophrenia-spectrum and mood disorders. Strengths and pitfalls of MVPA will be discussed in terms of sensitivity to overfitting, to center and data acquisition effects as well as to population biases. Preliminary data from the PRONIA study (www.pronia.eu) will be presented in order to exemplify the current status and the challenges to be addressed by predictive psychiatry.

Candidate neuroimaging, neurocognitive and clinical prediction models developed by means MVPA technology will be described by (1) reporting sensitivity, specificity and accuracy of prognostic and (differential) diagnostic predictions in patients with schizophrenia-spectrum and affective psychoses, (2) visualizing underlying patterns, and (3) discussing the moderating influence of diagnostic boundaries psychopathological features, disease courses, brain maturation and environmental variables on prediction performance.

MVPA may provide a powerful and adaptive set of statistical tools to decompose the complexity of psychiatric phenotypes into their most predictive components. The designs of the next-generation translational studies have to take into account the strengths and pitfalls of these methods in order to assess which of these components have the highest bench-to-bedside potential.
Abstract: Consistent with the goals of precision medicine to re-define illness mechanistically through elucidating the pathophysiology from gene action to symptoms, large scale genomic studies have been linking genomic variation to continuous quantitative phenotypes. Such an approach can lead to early detection and pathological processes enabling early intervention. This paradigm shift is now applied in psychiatry with an increased focus in schizophrenia research on early identification of psychosis as the process emerges. Convergent approaches integrate phenotypic features with neurocognitive and neuroimaging measures in large-scale studies. Most studies have examined help seeking youths.

This presentation highlights complementary strategies to probe the underlying neurobiology of psychosis risk. The first, most widely applied is the study of help-seeking individuals who present with subthreshold psychotic symptoms and are at high risk for psychotic illness. The second, community-based samples of youths with no known neurogenetic syndrome. The Philadelphia Neurodevelopment Cohort illustrates such an approach. The third, the study of youths with a known genetic syndrome, the 22q11.2 Deletion Syndrome (22q11DS) that confers significant increased risk for psychosis (~25%), emerging in adolescence and early adulthood.

Methodological considerations and emerging finding across strategies will be discussed and the implication for early identification and intervention emphasized.
CONCURRENT SYMPOSIA

PHARMACEUTICAL PIPELINE

Location: Congressi Auditorium
Chair: Akira Sawa

1:00 PM  
**Drug Development Strategies for Schizophrenia Using a Novel PDE10A Inhibitor: TAK-063**  
Tom Macek

1:20 PM  
**Can Pharmacogenetics Improve Drug Discovery? : Insights From a Naturalistic Study and a Randomized Controlled Trial for Schizophrenia Treatment Outcomes**  
Eric Huang

1:40 PM  
**Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Encenicline as Pro-Cognitive Treatment in Patients With Schizophrenia on Chronic Stable Atypical Antipsychotic Therapy**  
Stephen Brannan

2:00 PM  
**A Phase 2 Study of PF-02545920 (PDE10A Inhibitor) in Adjunctive Treatment of Outpatients With Sub-Optimally Controlled Symptoms of Schizophrenia**  
Nicholas Demartinis

2:20 PM  
**The Open Translational Science in Schizophrenia Project: Janssen Clinical Trial and NIH Data Together in an Open-Science Collaboration**  
Marsha Wilcox

2:40 PM  
**Evenamide (NW-3509), a Putative Antipsychotic, Targets Abnormal Electrical Activity and Glutamatergic Abnormalities in Improving Psychotic Symptoms in Patients With Schizophrenia in a Phase II, Placebo-Controlled Trial**  
Ravi Anand

NEUROIMAGING BIOMARKERS FOR PSYCHIATRIC DISORDERS IN ADOLESCENCE AND YOUNG ADULTHOOD: PREDICTION OF RISK, TRANSITION AND ILLNESS COURSE

Location: Congressi, Sala Verde
Chair: Hugo Schnack

1:00 PM  
**Machine Learning in Psychiatric Neuroimaging: Introduction and Applications in Adolescent Offspring of Patients With Schizophrenia or Bipolar Disorder**  
Hugo Schnack

1:25 PM  
**Neuroanatomical Features as Transdiagnostic Biomarkers of Psychosis and Autism Spectrum Disorders**  
Joost Janssen

1:50 PM  
**MRI-Based Risk Stratification in Clinical High-Risk Individuals: State-of-the-Art and Challenges Ahead**  
Nikolaos Koutsouleris
2:15 PM  *Stratifying Psychosis Outcome at Illness Onset Using MRI-Based Univariate Approaches and Pattern Classification Methods*  
Paola Dazzan  

**Discussant:** Stephen Lawrie

**PSYCHOSIS IN CHILDREN AND ADOLESCENTS: FROM THE PRODROME TO SCHIZOPHRENIA**  
**Location:** Affari, Ground Level  
**Chair:** Anne Katrine Pagsberg

**1:00 PM**  *Age-Related Characteristics of Attenuated Positive Symptoms Syndrome*  
Miriam Gerstenberg

**1:25 PM**  *Differentiation Between the Prodrome to Schizophrenia-Spectrum and Bipolar-Spectrum Disorders: Can We Separate Clinical High-Risk States?*  
Christoph Correll

**1:50 PM**  *Illness Course and Outcome in Early Onset Schizophrenia: A Nationwide Danish Register Case-Control Study*  
Ditte Lammers Vernal

**2:15 PM**  *Antipsychotic Treatment for Children and Adolescents With Schizophrenia Spectrum Disorders: A Systematic Review and Network Meta-Analysis*  
Anne Katrine Pagsberg  

**Discussant:** Celso Arango

**NEUROIMAGING APPROACHES TO TREATMENT OUTCOME IN SCHIZOPHRENIA**  
**Location:** Affari, Lower Level  
**Chair:** Robert Buchanan

**1:00 PM**  *Advantages and Challenges of Multi-Site Neuroimaging Data in Schizophrenia*  
Jessica Turner

**1:25 PM**  *Neuroimaging and Machine Learning Algorithms to Identify Biological Subtypes of Schizophrenia*  
Aristotle Voineskos

**1:50 PM**  *The Role of PET in Optimizing Treatment Outcome*  
Anissa Abi-Dargham

**2:15 PM**  *From the Genome to the Connectome: Detecting Biomarkers of Antipsychotic Drug Response*  
Anil Malhotra  

**Discussant:** Shitij Kapur
CHARACTERIZING A PUTATIVE “TRAUMAGENIC” SUBTYPE OF PSYCHOSIS

Location: Affari, First Level
Chair: Mary Cannon

1:00 PM  Trauma and Transition to Psychosis in the Ultra High Risk Population: Results From a Long Term Follow Up Study
Andrew Thompson

1:25 PM  Childhood Events and Psychosis in Bipolar Affective Disorder
Rachel Upthegrove

1:50 PM  Trauma, Stress Reactivity and Prediction of Outcome in the Ultra High Risk Population: Data From the Neurapro-E Study
Barnaby Nelson

2:15 PM  Interplay Between Childhood Victimisation and Familial Liability in the Persistence of Psychotic Symptoms During Adolescence
Helen Fisher

Discussant: Ian Kelleher

NMDAR ANTIBODIES AND THEIR RELEVANCE FOR SCHIZOPHRENIA

Location: Affari, Second Level
Chair: Belinda Lennox

1:00 PM  Antibodies to Neuronal Cell Surface Antigens in Psychiatric Disease
Angela Vincent

1:25 PM  Impact of Anti-NMDA Receptor Autoantibody From Schizophrenic Patients on Membrane Receptors Using Single Molecule Imaging
Laurent Groc

1:50 PM  Neurocognitive Phenotype and Imaging Abnormalities of Patients With NMDAR Antibodies
Carsten Finke

2:15 PM  Clinical Phenotype of Patients With NMDAR Antibodies
Belinda Lennox

Discussant: Joseph Masdeu

COFFEE BREAK 3:00 PM - 3:30 PM
Location: Passi Perdutti, Affari Foyers, and the Sala Verde Foyer
CONCURRENT SYMPOSIA

THE ROLE OF DEVELOPMENT AND STAGE OF PSYCHOTIC ILLNESS ON CHARACTERISTICS OF LONGITUDINAL NEUROCOGNITIVE FUNCTIONING

Location: Congressi Auditorium
Chair: Larry Seidman

3:30 PM  
Cognitive and Functional Outcome in Early-Onset Schizophrenia: 13- and 20-Year Follow-Up
Merete Øie

3:55 PM  
Cognitive Profile and Cognitive Recovery After a First Episode of Adult-Onset Schizophrenia: One-Year Longitudinal Study
Keith Nuechterlein

4:20 PM  
Neurocognition and Duration of Psychosis Before and After Start of Treatment: What Predicts the Course of Schizophrenia?
Bjorn Rund

4:45 PM  
Neurocognitive Functioning in the Second Phase of the North American Prodrome Longitudinal Study
Larry Seidman

Discussant: Abraham Reichenberg

DURATION OF EARLY INTERVENTION AND THE CRITICAL PERIOD

Location: Congressi, Sala Verde
Chair: Merete Nordentoft

3:30 PM  
Duration of Early Intervention and the Critical Period: Insights From Cohort and Controlled Studies From Hong Kong
Eric Chen

3:55 PM  
A Randomized Controlled Study of Five vs. Two Years of Specialized Early Intervention Service
Ashok Malla

4:20 PM  
How Long Should Early Intervention Last? Results From a Randomized Clinical Trial of the Effect of Five-Years Versus Two-Years Specialized Assertive Intervention for First Episode Psychosis – The OPUS-II Trial
Nikolai Albert

4:45 PM  
Neurobiological Changes During the Early Phase of Psychosis and Clinical Response
Oliver Howes

Discussant: Max Birchwood
ELEPHANT IN THE ROOM: GLIA CONTRIBUTION TO MENTAL DISORDERS
Location: Affari, Ground Level
Chair: Mikhail Pletnikov

3:30 PM  Cell-Specific Vulnerability to Adolescent Cannabis Exposure: The Expanding Role of Astrocytes
Mikhail Pletnikov

3:55 PM  Interactions Between Glia and Extracellular Matrix in Schizophrenia
Sabina Berretta

4:20 PM  Glial Dopamine Controls Neuronal Network Activity and Functions in the Prefrontal Cortex
Jean-Pierre Mothet

4:45 PM  Glioproteomics to Define the Role of Glia in Neuroinflammatory Diseases
Kyoungho Suk

Discussant: Akira Sawa

NEGATIVE SYMPTOMS - INTEGRATING CLINICAL AND NEUROIMAGING PERSPECTIVES
Location: Affari, Lower Level
Chair: Silvana Galderisi

3:30 PM  Progressive Brain Changes Associated With Persistent Negative Symptoms Following a First Episode of Psychosis
Martin Lepage

3:55 PM  The Impact of Negative Symptom Domains on Real-Life Functioning of People With Schizophrenia and First-Degree Relatives
Armida Mucci

4:20 PM  The Neural Basis of Distinct Negative Symptom Dimensions in Schizophrenia
Stefan Kaiser

George Foussias

Discussant: Celso Arango
NON-TRADITIONAL METHODS OF CLASSIFICATION IN PSYCHOSIS: APPLYING A PRECISION MEDICINE MODEL
Location: Affari, First Level
Chair: Katherine Burdick

3:30 PM  Empirical Classification of Psychotic Patients Using Neurocognitive Profiles
Katherine Burdick

3:55 PM  Polygenenic Risk Scores Among Cognitive Subtypes of Psychosis
Melissa Green

4:20 PM  Prospects for Genetic Subtyping in Polygenic Disease
Shaun Purcell

4:45 PM  Parsing Neurobiological Variance in Psychosis via Brain Based Biomarkers
Brett Clementz

Discussant: John McGrath

MOVEMENT DISORDERS: A NON-MENTAL CORE SYMPTOM OF PSYCHOTIC DISORDERS AND THE IMPORTANCE OF INSTRUMENTAL SCREENING
Location: Affari, Second Level
Chair: Peter Van Harten

3:30 PM  Instrumental Measurement of Bradykinesia and Dyskinesia in Psychosis and Individuals at Risk
Peter Van Harten

3:55 PM  Decreased Right-Handedness and Somatosensory Asymmetry in Youth at Ultrahigh Risk for Psychosis
Vijay Mittal

4:20 PM  Resting State Functional Connectivity in the Motor Loop Correlates With Hypokinesia in Schizophrenia
Sebastian Walther

4:45 PM  Instrument-Based Assessment of Dyskinesia Across Dimensions of Genetic Liability for Psychosis and Severity of Psychopathology
Jerillyn Kent

Discussant: Jim Van Os

TRAVEL AWARD RECEPTION (Invitation Only)  5:45 PM - 6:45 PM
Location: Affari, 4th Floor
<table>
<thead>
<tr>
<th>Time</th>
<th>Auditorium</th>
<th>Sala Verde</th>
<th>Palazzo Affari Ground Level</th>
<th>Palazzo Affari Lower Level</th>
<th>Palazzo Affari 1st Level</th>
<th>Palazzo Affari 2nd Level</th>
<th>Cavaniglia</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30 AM - 9:30 AM</td>
<td>Convergent Evidence Linking Neonatal Vitamin D Status and Risk of Schizophrenia</td>
<td>Coffee Break</td>
<td>1:00 PM - 3:00 PM</td>
<td>Negative Symptoms: Why Are They So Important and Yet So Difficult to Treat?</td>
<td>1:00 PM - 3:00 PM</td>
<td>1:00 PM - 3:00 PM</td>
<td>11:00 AM - 1:00 PM (Poster Session III and Lunch)</td>
</tr>
<tr>
<td>9:30 AM - 10:00 AM</td>
<td>Coffee Break</td>
<td>Coffee Break</td>
<td>3:00 PM - 5:00 PM</td>
<td>Symptom Dimensions in Schizophrenia - Brain Correlates and Personalised Treatment Options</td>
<td>3:00 PM - 5:00 PM</td>
<td>3:00 PM - 5:00 PM</td>
<td></td>
</tr>
<tr>
<td>11:00 AM - 12 PM</td>
<td>1:00 PM - 3:00 PM</td>
<td>5:00 PM - 7:00 PM</td>
<td>5:00 PM - 7:00 PM</td>
<td>Neurodevelopment: Childhood, Adolescence, and Adulthood</td>
<td>5:00 PM - 7:00 PM</td>
<td>5:00 PM - 7:00 PM</td>
<td></td>
</tr>
<tr>
<td>12 PM - 1 PM</td>
<td>1:00 PM - 3:00 PM</td>
<td>5:15 PM - 7:30 PM</td>
<td>5:15 PM - 7:30 PM</td>
<td>Epidemiology: Roles for Environmental Risk Factors</td>
<td>5:15 PM - 7:30 PM</td>
<td>5:15 PM - 7:30 PM</td>
<td></td>
</tr>
<tr>
<td>1 PM - 2 PM</td>
<td>1:00 PM - 3:00 PM</td>
<td>5:30 PM - 7:30 PM</td>
<td>5:30 PM - 7:30 PM</td>
<td>Treatment and Clinical Service</td>
<td>5:30 PM - 7:30 PM</td>
<td>5:30 PM - 7:30 PM</td>
<td></td>
</tr>
<tr>
<td>2 PM - 3 PM</td>
<td>1:00 PM - 3:00 PM</td>
<td>5:30 PM - 7:30 PM</td>
<td>5:30 PM - 7:30 PM</td>
<td></td>
<td>5:30 PM - 7:30 PM</td>
<td>5:30 PM - 7:30 PM</td>
<td></td>
</tr>
<tr>
<td>3 PM - 4 PM</td>
<td>1:00 PM - 3:00 PM</td>
<td></td>
<td></td>
<td></td>
<td>5:30 PM - 7:30 PM</td>
<td>5:30 PM - 7:30 PM</td>
<td></td>
</tr>
<tr>
<td>4 PM - 5 PM</td>
<td>1:00 PM - 3:00 PM</td>
<td></td>
<td></td>
<td></td>
<td>5:30 PM - 7:30 PM</td>
<td>5:30 PM - 7:30 PM</td>
<td></td>
</tr>
<tr>
<td>5 PM - 6 PM</td>
<td>1:00 PM - 3:00 PM</td>
<td></td>
<td></td>
<td></td>
<td>5:30 PM - 7:30 PM</td>
<td>5:30 PM - 7:30 PM</td>
<td></td>
</tr>
<tr>
<td>6 PM - 7 PM</td>
<td>1:00 PM - 3:00 PM</td>
<td></td>
<td></td>
<td></td>
<td>5:30 PM - 7:30 PM</td>
<td>5:30 PM - 7:30 PM</td>
<td></td>
</tr>
<tr>
<td>7 PM - 8 PM</td>
<td>1:00 PM - 3:00 PM</td>
<td></td>
<td></td>
<td></td>
<td>5:30 PM - 7:30 PM</td>
<td>5:30 PM - 7:30 PM</td>
<td></td>
</tr>
<tr>
<td>8 PM - 9 PM</td>
<td>1:00 PM - 3:00 PM</td>
<td></td>
<td></td>
<td></td>
<td>5:30 PM - 7:30 PM</td>
<td>5:30 PM - 7:30 PM</td>
<td></td>
</tr>
</tbody>
</table>

**Legend:** Keynote, Special Session, Speaker Ready, Registration, Computer Center, Symposia, Poster Session, Plenary, Oral Presentation, Coffee Break
Tuesday, 5 April 2016

REGISTRATION
Location: Palazzo Entrance

MORNING COFFEE
Location: Congressi, Passi Perduti

PLENARY SESSION: CONVERGENT EVIDENCE LINKING NEONATAL VITAMIN D STATUS AND RISK OF SCHIZOPHRENIA
Location: Congressi Auditorium

John McGrath
University of Queensland, Queensland Brain Institute

Abstract: Unravelling the aetiology and pathogenesis of brain disorders is a task that requires multidisciplinary skills, integration of data from different domains and tenacity. This lecture will present convergent evidence from epidemiology, genetics, and neuroscience aimed at finding modifiable risk factors for schizophrenia. In this lecture, Dr. McGrath will outline the results of a large replication study that confirms the association between low neonatal vitamin D concentration and an increased risk of schizophrenia. In addition, based on slice electrophysiology and wide-field calcium imaging, Dr. McGrath will present new evidence that links vitamin D with neurobiological mechanisms identified in recent GWAS studies for schizophrenia. Most importantly, if future studies confirm the association between developmental vitamin D deficiency and risk of schizophrenia, then it raises the tantalizing prospect of the primary prevention of mental disorders, in a manner comparable to folate supplementation and the prevention of spina bifida.

COFFEE BREAK
Location: Congressi, Passi Perduti
PLENARY SESSION: BALANCING PLASTICITY / STABILITY ACROSS
BRAIN DEVELOPMENT
Location: Congressi Auditorium

Takao Hensch
Harvard University

Abstract: Maturing neural circuits are dramatically shaped by their environment, creating sequential windows of opportunity and vulnerability to early experience across brain regions. This lecture examines the biological bases of such ‘critical periods’ in development. Targeting specific GABA circuits by genetic or pharmacological manipulation can robustly accelerate or delay onset. Conversely, lifting a variety of brake-like factors which normally emerge to stabilize adult networks can reactivate plasticity. Notably, the mechanisms which open (excitatory-inhibitory circuit balance) or close (molecular brakes) these windows of circuit rewiring are increasingly implicated in cognitive disorders, such as autism and schizophrenia. This suggests mis-timed maturational processes may contribute, which in turn could be strategically leveraged to rescue circuit function. In particular, the interplay of most of these cell-autonomous and extrinsic factors converge upon fast-spiking, parvalbumin-positive cells, whose high metabolic demands render them sensitive to oxidative stress. Focusing on the cellular/molecular biology of these pivotal cells underlying trajectories of cortical processing and plasticity offers new insights into disease etiology and potential therapeutic approaches.

POSTER SESSION III AND LUNCH
Location: Cavaniglia
Buffet Lunch will be served daily in the poster session

Please see page 127 for a complete listing of posters
CONCURRENT SYMPOSIA

EXCITATION/INHIBITION BALANCE DISTURBANCES IN SCHIZOPHRENIA: FROM CIRCUITS TO LARGE-SCALE NETWORKS
Location: Congressi Auditorium
Chair: Peter Uhlhaas

1:00 PM  
Neural Oscillations and E/I-Balance Parameters Across the Schizophrenia Spectrum: Insights from Magnetoencephalography (MEG)  
Peter Uhlhaas

1:25 PM  
Schizophrenia and NMDA Receptor Deficiency: Rebalancing Excitation/Inhibition Disturbances  
Lawrence Kegeles

1:50 PM  
Genetic Evidence for the Disruption of Excitatory and Inhibitory Signalling in Schizophrenia  
Andrew Pocklington

2:15 PM  
Inhibitory and Disinhibitory GABAergic Interactions in the Hippocampus of Schizophrenics  
Francine Benes

Discussant: Patricio O’Donnell

TRAJECTORIES OF CHILDREN-ADOLESCENTS AT RISK OF MAJOR AFFECTIVE AND NON-AFFECTIVE DISORDERS: EXPLORING THE PERIOD PRECEDING THE “CHR RISK PHASE” FOR PRECLINICAL STAGING OF RISK AND IMPLICATIONS IN CLINICAL PRACTICE
Location: Congressi, Sala Verde
Chair: Michel Maziade

1:00 PM  
Aggregation of Risk Indicators in Offspring of Patients Affected by Affective or Non-Affective Psychoses: Teachings From Québec Longitudinal High-Risk Families for the Staging of the Childhood-Adolescence Risk Trajectory  
Michel Maziade

1:25 PM  
Transdiagnostic Antecedent-Based Strategy for Early Detection of Individuals at Risk of Severe Mental Illness: A FORBOW Study Report  
Rudolf Uher

1:50 PM  
The Determinants of the Onset and Course of Early Mood Disorders: A Controlled 10-Year Follow-Up Study of Offspring of Parents With Bipolar and Unipolar Mood Disorders  
Martin Preisig

2:15 PM  
Early Signs of Bipolar Disorder. A Study on Symptomatology Among Prospectively Followed Bipolar Offspring  
Manon Hillegers

Discussant: Patrick McGorry
NEGATIVE SYMPTOMS: WHY THEY ARE SO IMPORTANT AND YET SO DIFFICULT TO TREAT?
Location: Affari, Ground Level
Chair: Matteo Cella

1:00 PM  Reduction of Negative Symptoms With the Rehacop in Chronic Patients With Schizophrenia
Natalia Ojeda

1:25 PM  Changes in Dimensions of Negative Symptoms Differentially Predict Self-Rated and
Observer-Rated Functional Outcomes Following Cognitive Remediation
Christopher Bowie

1:50 PM  Cognitive Remediation Can Improve Social Functioning and Symptoms in First Episode
Schizophrenia
Joseph Ventura

2:15 PM  Cognitive Remediation for Negative Symptoms of Schizophrenia: A Network Meta-Analysis
Matteo Cella

Discussant: Til Wykes

SYMPTOM DIMENSIONS IN SCHIZOPHRENIA – BRAIN CORRELATES AND PERSONALISED TREATMENT OPTIONS
Location: Affari, Lower Level
Chair: Werner Strik

1:00 PM  The Neurobiology of Formal Thought Disorder: Specific for Schizophrenia?
Tilo Kircher

1:25 PM  Formal Thought Disorder in Non-Clinical Individuals With Auditory Verbal Hallucinations
Iris Sommer

1:50 PM  Causes of the Variable Efficacy of rTMS in the Treatment of Auditory Hallucinations in
Schizophrenia: From Placebo Effect to Brain Morphology Modifications
Sonia Dollfus

2:15 PM  A Three Dimensional Symptom Structure of Schizophrenia is Linked to Specific Structural
and Functional Brain Changes
Werner Strik

Discussant: Stephan Heckers
LIFESPAN DEVELOPMENT OF SCHIZOPHRENIA AND HOW THE TREATMENTS IMPROVE THE OUTCOMES

Location: Affari, First Level
Chair: Matti Isohanni

1:00 PM  MRI-Based Risk Stratification in Clinical High-Risk Individuals: State-of-the-Art and Challenges Ahead  
Nikolaos Koutsouleri

1:25 PM  Somatic Comorbidity and Its Outcomes in Schizophrenia During Lifespan  
Jussi Seppälä

1:50 PM  Long-Term Outcome of Psychosis: Modulation by Environmental Factors Like Exercise  
Peter Falkai

2:15 PM  Antipsychotic Medication and Outcomes in Schizophrenia From a Lifespan Perspective  
Hannu Koponen

Discussant: Silvana Galderisi

SOCIAL (COGNITIVE) FUNCTIONING IN SCHIZOPHRENIA: MECHANISMS, COURSE AND TREATMENT

Location: Affari, Second Level
Chair: Avi Reichenberg

1:00 PM  The 20-Year Longitudinal Trajectories of Social Functioning in Psychotic Disorders  
Eva Velthorst

1:25 PM  Origins of Social Deficits in the Psychosis Phenotype  
Avi Reichenberg

1:50 PM  Oxytocin for Schizophrenia: A Randomized Controlled Trial  
Mark Weiser

2:15 PM  Trust vs. Paranoia: The Dynamics of Social Interaction in Early and Chronic Psychosis  
Anne-Kathrin Fett

Discussant: Junghee Lee

COFFEE BREAK 3:00 PM - 3:30 PM
Location: Passi Perdutti, Affari Foyers, and the Sala Verde Foyer
ORAL PRESENTATIONS

BRAIN IMAGING-I: MOLECULES, STRUCTURES, AND FUNCTIONS

Location: Congressi Auditorium
Chair: Igor Nenadic

3:15 PM  
Accelerated Gray and White Matter Aging in Schizophrenia  
Vanessa Cropley

3:30 PM  
Structural Connectivity Correlates of Planning and Executing Goal-Directed Behaviour in Schizophrenia  
Ishraq Siddiqui

3:45 PM  
Differences in Global Brain Abnormalities Between Offspring, Siblings, Cotwins and Parents of Patients With Schizophrenia  
Sonja de Zwarte

4:15 PM  
Cortical Thickness Changes With Age in a Subset of First Episode Psychosis Patients Presenting With Persistent Negative Symptoms: A Longitudinal MRI Study  
Carolina Makowski

4:30 PM  
A Sensitized Prefrontal Dopamine Response to Psychosocial Stress in the Early Stage of Psychosis  
Huai-Hsuan Tseng

4:45 PM  
Cellular and Extracellular Abnormalities in Healthy Subjects With Auditory Verbal Hallucinations  
Ofer Pasternak

5:00 PM  
Glutamate in Psychosis: A Meta-Analysis of Proton Magnetic Resonance Spectroscopy (1H-MRS) Studies  
Kate Merritt

★ – Travel Awardee
COGNITION: MULTIFACETED APPROACH
Location: Congressi, Sala Verde
Chair: Philip Harvey

3:15 PM  
*Polygenic MiR-137 Pathway Scores Explain Variability in Cognitive Performance in Patients With Schizophrenia and Controls*
- Donna Cosgrove

3:30 PM  
*Neuropsychological Functioning Over Time in the North American Prodrome Longitudinal Study (NAPLS)-2 Clinical High Risk Cohort*
- Kristen Woodberry

3:45 PM  
*Educational Achievement in Psychiatric Patients and Their Siblings; A Register-Based Study in 30,000 Individuals in the Netherlands*
- Fabian Termorshuizen

4:00 PM  
*Source Memory Distortions May Be Related to Attenuated Psychotic Experiences in Young Offspring of Parents Affected by Major Psychoses*
- Elsa Gilbert

4:15 PM  
*Relational and Item Specific Memory Markers of Psychosis Risk*
- J. Daniel Ragland

4:30 PM  
*Schizophrenia Patients With Delusions Show a Specific Deficit in Updating Beliefs From Positive But Not Negative New Evidence*
- James Gilleen

4:45 PM  
*Self Assessment of Social Cognition in Schizophrenia: Impairments in Evaluating Task Difficulty and Adjusting Effort Accordingly*
- Philip Harvey

5:00 PM  
*Long-Term Cariprazine Treatment for the Prevention of Relapse in Patients With Schizophrenia: Additional Analyses From a Randomized, Double-Blind, Placebo-Controlled Trial*
- Wolfgang Fleischhacker

★ – Travel Awardee
GENETICS: MULTIFACETED APPROACH

Location: Affari, Ground Level
Chair: James Kennedy

3:15 PM  Association of Schizophrenia GWAS Risk Variants With Cognitive Deficits in the Genus Consortium Schizophrenia Sample Collection
★ Gabriëlla Blokland

3:30 PM  Gene Expression Analysis in Peripheral Bloodmononuclear Cells of First Episode Psychosispatients From the Genetic and Psychotic Disorders (GAP) Study
Daniel Leirer

3:45 PM  Phenotypic Manifestation of Genetic Risk for Schizophrenia During Adolescence in the General Population
Stanley Zammit

4:00 PM  Genetic Variation in Schizophrenia Liability Explained Through Intellectual Ability and Brain Structure
★ Marc Bohlken

4:15 PM  Genetic Overlap Between Schizophrenia and the Big Five Personality Traits
Olav Smeland

4:30 PM  Unique Dual Cortico-Striatal Action of Dopamine D2 Receptor Functionally Selective Ligands Modulate Schizophrenia-Like Phenotypes
Marc Caron

4:45 PM  Association of the Polygenic Risk Score for Schizophrenia With Mortality and Suicidal Behavior - A Danish Population-Based Study
Thomas Laursen

5:00 PM  Exploiting Epidemiological Links Between Rheumatoid Arthritis and Schizophrenia Refines GWAS in the HLA Region
Tulsi Malavia

★ – Travel Awardee
NEURODEVELOPMENT: CHILDHOOD, ADOLESCENCE AND ADULTHOOD 3:15 PM - 5:15 PM

Location: Affari, Lower Level
Chair: Aristotle Voineskos

3:15 PM  
Adult Neurogenesis in the Striatum: Effect of Psychiatric Treatment  
Dragos Inta

3:30 PM  
Maternal Symptoms and Neonatal Behaviour in Postpartum Psychosis  
Katie Hazelgrove

3:45 PM  
Accumulation of Risk Endophenotypes in Children and Adolescents at Genetic Risk of Major Psychoses: Longitudinal Findings From the Eastern Quebec Densely Affected Families  
Thomas Paccalet

4:00 PM  
Offspring With Familial Risk for Severe Mental Illness and Incidences for Having a Child and Adolescent Psychiatric Diagnosis at Age 0-17 Years – a Danish Register Study  
Anne Thorup

4:15 PM  
Mood Disorders and Schizophrenia in the Offspring of Antenatally Depressed Mothers in the Northern Finland 1966 Birth Cohort: Relationship to Parental History of Severe Mental Disorder  
Pirjo Mäki

4:30 PM  
Cognitive Developmental Trajectories in the Extended Psychosis Phenotype  
Josephine Mollon

4:45 PM  
The Impact of Cannabis Use on Emerging Psychotic Experiences Explained by the Presence of Affective Symptoms  
Josiane Bourque

5:00 PM  
Childhood and Adolescence Physical Activity Patterns – Effects on Psychosis Risk  
Elina Sormunen
EPIDEMIOLOGY: ROLES FOR ENVIRONMENTAL RISK FACTORS 3:15 PM - 5:15 PM

Location: Affari, First Level
Chair: James MacCabe

3:15 PM  Artistic Creativity, IQ and Risk for Schizophrenia and Bipolar Disorder: A Swedish Population-Based Case-Control Study and Sib Pair Analysis in 4.5 Million Individuals
James MacCabe

3:30 PM  Children of Parents With Severe Psychiatric Disorders: With Whom Do They Grow up? - A Prospective, Population-Based Study
Anne Ranning

3:45 PM  Age-At-Migration and Risk of First Episode Psychosis in England: Epidemiological Evidence From the Sepea Study
James Kirkbride

4:00 PM  Toxic Social Environments and Psychosis: The Role of Violence and Multiple Adversities in Childhood
Craig Morgan

4:15 PM  Exposure to Anti-Infective Agents and the Risk of Severe Mental Disorders – A Nationwide Study
Ole Köhler

4:30 PM  Incidence of Psychotic Disorders in England, France, Italy, the Netherlands, Spain and Brazil: Data From the EU-GEI Study
Hannah Jongsma

4:45 PM  Is There a Cumulative Effect of Social Disadvantage on Risk of Psychosis?
Simona Stilo

5:00 PM  Mortality and Deliberate Self-Harm During Clozapine Use in Treatment-Resistant Schizophrenia: Results From the Crestar Collaboration
Maria Theresa Wimberley

★ – Travel Awardee
PHENOMENOLOGY AND DIMENSIONAL DISCUSSION 3:15 PM - 5:15 PM
Location: Affari, Second Level
Chair: Celso Arango

3:15 PM  Exploring the Applicability of a Network Approach to Psychosis
Johanna Wigman

3:30 PM  Childhood Trauma and Social Stress Reactivity in Psychosis: A Virtual Reality Study
Wim Veling

3:45 PM  Premorbid and Social Determinants of Formal Thought Disorder in Early Psychosis
Eric Roche

4:00 PM  A Dimensional Approach to Elucidating the Neural Basis of Psychotic Spectrum Traits
Samantha Abram

4:15 PM  Conversion from Psychosis Like Experiences in the Community to Not Only Psychotic Disorders; But Also to Depression and Anxiety Disorders: Six Years Follow-Up Study in a Community Based Population
Umut Kirli

4:30 PM  Auditory Hallucinations in Adults With Hearing Impairment
Mascha Linszen

4:45 PM  Cognitive Heterogeneity on the Schizophrenia – Bipolar Spectrum
Tamsyn Van Rheenen

5:00 PM  Outcomes of Non-Transitioned Cases in a Sample at Ultra-High Risk for Psychosis
Ashleigh Lin

COFFEE BREAK 5:00 PM - 5:30 PM
Location: Passi Perdutti, Affari Foyers, and the Sala Verde Foyer
ORAL PRESENTATIONS 5:30 PM – 7:30 PM

BRAIN IMAGING-II: MOLECULES, STRUCTURES, AND FUNCTIONS 5:30 PM – 7:30 PM

Location: Congressi Auditorium
Chair: Paola Dazzan

5:30 PM Aberrant Salience and Dysfunctional Neural Processing of Self-Reference in Unmedicated Schizophrenia Patients
Teresa Katthagen

5:45 PM Single Dose of Cannabidiol Attenuates Neurofunctional Abnormalities Present in Individuals at High Risk of Psychosis
Sagnik Bhattacharyya

6:00 PM Hippocampal Perfusion and Novelty-Dependent Learning in Individuals at Ultra High Risk for Psychosis
Mathilde Antoniades

6:15 PM Does Dopaminergic Function Underlie Clinical Response in First Episode Psychosis: An 18F-DOPA PET Study
Sameer Jauhar

6:30 PM Altered Glutamine, Glutamate and GABA Levels in Schizophrenia Patients and Their Healthy First-Degree Relatives: A 1H-MRS Study at 7T
Lara Rösler

6:45 PM Environmental Influences on White Matter Integrity in Psychotic Disorder: A Longitudinal Family-Based DTI Study
Patrick Domen

7:00 PM Heterogeneity- A Novel Way to Study Microstructural Gray Matter Organization in Schizophrenia?
Johanna Seitz

7:15 PM Frontal White Matter Tract Profiles Underpin Continuous Individual Differences in Positive Schizotypy: Evidence From a Large Nonclinical Sample
Rachael Grazioplene

★ – Travel Awardee
FINAL PROGRAM
FLORENCE, ITALY
2 – 6 APRIL 2016

BIOMARKERS
5:30 PM – 7:30 PM

Location: Congressi, Sala Verde
Chair: Christos Pantelis

5:30 PM  Anti-Inflammatory and Antioxidant Effects of Risperidone on Drug Naïve First Episode Psychosis
Cristiano Noto

5:45 PM  Dose-Related Target Occupancy and Engagement of the Glycine Transporter-1 Inhibitor PF-03463275, in Healthy Humans Subjects and Schizophrenia Subjects
Deepak D’Souza

6:00 PM  Maternal Markers of Inflammation During Pregnancy and Schizophrenia in the Offspring
Håkan Karlsson

6:15 PM  Event-Related Potentials Changes Associated With Violence in Violent Patients With Schizophrenia
Menahem Krakowski

6:30 PM  Clinical Staging and Profiling in Psychiatry
Dorien Nieman

6:45 PM  Glutamatergic Dysfunction is Associated With Feedback Learning Dysfunction and Myelination Deficiency in Schizophrenia: Multi-Modal Imaging Evidence From 1H-MRS, mcDESPOT and Functional MRI
Elias Mouchlianitis

7:00 PM  Cannabis-Induced Attenuated Psychotic Symptoms: Implications for Prognosis in Young People at Ultra-High Risk for Psychosis
Barnaby Nelson
5th Schizophrenia International Research Society Conference
Deconstructing Schizophrenia Towards Targeted Treatment

NEUROBIOLOGY

Location: Affari, Ground Level
Chair: John F. Deakin

5:30 PM Pathogenic Neuronal Autoantibodies in Patients With a Psychotic Disorder: Results of Screening Three Large Cohorts
Hans van Mierlo

5:45 PM Exposure to Childhood Physical and Sexual Abuse is Associated With Divergent Cortical Abnormalities in First Episode Psychosis Patients and Controls and With Diurnal Cortisol Concentration Only in Controls
★ Simone Ciufolini

6:00 PM Protein Pathology in Chronic Mental Illnesses - Towards a Biological Definition
Carsten Korth

6:15 PM TAK-063, a Phosphodiesterase 10A Inhibitor With Balanced Activation of Direct and Indirect Pathways, Provides Potent and Dose-Dependent Antipsychotic-Like Effects in Multiple Paradigms
Haruhide Kimura

6:30 PM Hyperprolactinaemia in First Episode Psychosis- A Longitudinal Assessment
John Lally

6:45 PM Early Treatment Non-Response as a Predictor of Lack of Clinically Significant Antipsychotic Effect in Youth With a First Episode of Psychosis: 12-Week Results From a Randomized Controlled Trial
Pia Jeppesen

7:00 PM Thalamic Reticular Nucleus Dysfunction as a Driver of Thalamo-Prefrontal Dysconnectivity in NMDA Receptor Antagonist and Disc1 Schizophrenia Models
Judith Pratt

7:15 PM The DSM-5-Defined Attenuated Psychosis Syndrome and Conversion to Full Scale Schizophrenia Spectrum Disorders, an Institution-Wide Retrospective Review
Zachary Zuschlag

★ – Travel Awardee
CLINICAL TRIALS

Location: Affari, Lower Level
Chair: Hilleke Hulshoff Pol

5:30 PM  Cariprazine as Monotherapy for the Treatment of Predominant Negative Symptoms of Patients With Schizophrenia: A Double-Blind, Active Comparator-Controlled Phase-3 Trial
Wolfgang Fleischhacker

5:45 PM  The Neurapro-E Study: A Multicentre RCT of Omega-3 Fatty Acids and Cognitive- Behavioural Case Management for Patients at Ultra-High Risk of Psychosis
Patrick McGorry

6:00 PM  The Randomized, Double-Blind Switch Study: Do Non-Imenders Benefit From a Change of the Antipsychotic After 2 Weeks of Treatment?
Stephen Heres

6:15 PM  Positive Phase 3 Clinical Trial of ITI-007 for the Treatment of Schizophrenia: Efficacy Results From a Randomized, Double-Blind, Placebo-Controlled Trial
Kimberly Vanover

6:30 PM  Effects of Estrogen and SERM Augmentation on Symptom Severity and Cognition in Schizophrenia: A Meta-Analysis
Sophie Heringa

6:45 PM  rTMS for the Treatment of Schizophrenia Negative Symptoms - Clinical, Neurocognitive and Imaging Results From a Large-Scale Multi-Centric Trial
Alkomiet Hasan

7:00 PM  Antipsychotic Medication Continuity Following Housing First: Results of a Randomized Trial
Julian Somers

7:15 PM  A Double-Blind, Randomised, Placebo-Controlled, Parallel Group Trial of Cannabidiol as Adjunctive Therapy in the First Line Treatment of Schizophrenia or Related Psychotic Disorder
Philip McGuire
TREATMENT AND CLINICAL SERVICE

Location: Affari, First Level
Chair: Patrick McGorry

5:30 PM  Can Non-Invasive Brain Stimulation Improve Working Memory in Schizophrenia?
          Kate Hoy

5:45 PM  Smartphone-Enhanced Symptom Management and Relapse Prevention: A Randomised Controlled Trial
          Shon Lewis

6:00 PM  Adding Aerobic Exercise to Cognitive Training Enhances the Impact on Cognition and Work Functioning: A UCLA Pilot RCT in First Episode Schizophrenia
          Keith Nuechterlein

6:15 PM  Antipsychotic Treatment Algorithm for First Episode Schizophrenia – A Guide for Clinicians
          Ofer Agid

6:30 PM  Ultra High Risk for Psychosis is Not Associated With Greater Rates of Transition to Psychosis Compared to Those Not at Such Risk
          Vaughan Carr

6:45 PM  How Many Psychiatric Beds per Capita Do We Need?
          Richard O’Reilly

7:00 PM  An Investigation of the Potential Specificity of Childhood Maltreatment Trauma in Patients With Non-Affective Psychosis as Compared to Other Mental Health Disorders
          Nina Morkved

7:15 PM  12-Year Follow-Up Study of Mortality Due to Suicide Among First Episode Psychosis
          COHORT: Is the Early Intervention Program More Effective in Reducing Excess Mortality Due to Suicide in Psychosis
          Kit Wa Sherry Chan
PSYCHOSOCIAL FUNCTIONING
Location: Affari, Second Level
Chair: Merete Nordentoft

5:30 PM  Persistent or Recurrent Course of Co-Morbid Disorders is Associated With Functional Impairment at 6-YEAR Follow-Up in Patients at Clinical High Risk for Psychosis
Grazia Rutigliano

5:45 PM  Personalised Predictions of Global Functioning in Chronic Patients Across 17 European Sites
Dominic Dwyer

6:00 PM  Mechanisms of Formal Thought Disorder in First Episode Psychosis and Psychometric Schizotypy: The Role of Affective and Cognitive Systems
★ Kyle Minor

6:15 PM  Using Ehealth Technology to Detect Barriers to Social Functioning in People With Schizophrenia
Matteo Cella

6:30 PM  Persistent Negative Symptoms in First Episode Psychosis: Prevalence, Predictors and Long Term Prognosis
Stephen Austin

6:45 PM  The Core Role of Metacognition in Mediating Between Cognition, Functional Capacity and Real-Life Function in First-Episode Psychosis
Geoff Davies

7:00 PM  The Daily Activity Report to Assess Productive Activity
Dawn Velligan

7:15 PM  Prediction of Longer-Term Functional Outcome in the Vienna Omega-3 Study
G. Paul Amminger

★ – Travel Awardee
### Schedule of Events

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Program Area</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 AM - 12:00 PM</td>
<td>Auditorium</td>
<td>Registration</td>
<td>8:00 AM - 12:00 PM</td>
</tr>
<tr>
<td>8:00 AM - 10:30 AM</td>
<td>Sala Verde</td>
<td>Zooming in on the Synapse in Schizophrenia</td>
<td>10:30 AM - 12:30 PM</td>
</tr>
<tr>
<td>8:00 AM - 10:30 AM</td>
<td>Palazzo Affari Ground Level</td>
<td>Global Perspectives on Stigma in the Clinical High Risk State for Psychosis: New Empirical Advances</td>
<td>10:30 AM - 12:30 PM</td>
</tr>
<tr>
<td>8:00 AM - 10:30 AM</td>
<td>Palazzo Affari Lower Level</td>
<td>Second Chance: What Would Senior Schizophrenia Researchers Do If They Could Start Over Again?</td>
<td>10:30 AM - 12:30 PM</td>
</tr>
<tr>
<td>8:00 AM - 10:30 AM</td>
<td>Palazzo Affari 1st Level</td>
<td>Clinical and Neurobiological Impact of Physical Exercise Interventions in Schizophrenia</td>
<td>10:30 AM - 12:30 PM</td>
</tr>
<tr>
<td>8:00 AM - 10:30 AM</td>
<td>Palazzo Affari 2nd Level</td>
<td>Back to the Hippocampus: Investigating Hippocampal Abnormalities in Early Psychosis</td>
<td>10:30 AM - 12:30 PM</td>
</tr>
<tr>
<td>8:00 AM - 12:00 PM</td>
<td>Cavanigilia</td>
<td>Coffee Available</td>
<td></td>
</tr>
<tr>
<td>8:00 AM - 12:00 PM</td>
<td>Palazzo Affari Entrance</td>
<td>Registration</td>
<td></td>
</tr>
<tr>
<td>8:00 AM - 12:00 PM</td>
<td>Sala 103</td>
<td>Speaker Ready Room</td>
<td></td>
</tr>
<tr>
<td>8:00 AM - 10:30 AM</td>
<td>Limonaia</td>
<td>Computer Center</td>
<td></td>
</tr>
<tr>
<td>8:00 AM - 10:30 AM</td>
<td>Passi Perduti</td>
<td>Coffee Available</td>
<td></td>
</tr>
</tbody>
</table>

### Legend
- **Keynote**
- **Special Session**
- **Speaker Ready**
- **Registration**
- **Computer Center**
- **Symposia**
- **Poster Session**
- **Plenary**
- **Oral Presentation**
- **Coffee Break**
Wednesday, 6 April 2016

REGISTRATION 8:00 AM - 12:00 PM
Location: Palazzo Entrance

MORNING COFFEE 8:00 AM - 8:30 AM
Location: Congressi, Passi Perduti

PLENARY SESSION: FEEDING FROM BEDSIDE INTO BENCH, AND BACK TO BEDSIDE: TOWARDS BETTER UNDERSTANDING OF SCHIZOPHRENIA 8:30 AM - 9:30 AM
Location: Congressi Auditorium

Koko Ishizuka
Johns Hopkins School of Medicine

Abstract: The diagnostic boundaries defined by current diagnostic systems are being challenged by recent advances in the genetic architecture of psychiatric disorders. The field of psychiatry is now moving towards a “dimensional” approach to understanding mental disorders, based on specific phenotypes with defined biological etiology and pathophysiology.

We have built an infrastructure to conduct preclinical and clinical studies seamlessly to seek the goal of early diagnosis and intervention for psychotic and mood disorders.

Study participants are characterized at the levels of clinical psychiatry and psychology. Then, we study the patients, according to molecular and/or cellular phenotypes obtained from their cells via biopsies, in combination with brain imaging and other physiological studies that provide the information at the circuitry level. In the clinical study domain, we explore correlations among molecular, cellular, circuitry, and behavioral characteristics. Mechanistic link among these characteristics at the different levels is addressed by using animal models in which we use cutting-edge methodologies of molecular and circuitry interventions in pathological trajectories. In summary, we aim to clarify common pathophysiological pathways for the mental conditions downstream of a wide variety of etiopathogenesis.

This talk will include the following topics:
1) Utility of nasal biopsy: genome-wide epigenetic study and a novel, non-invasive brush swab approach.
2) Combination of stem cells, brain imaging, neuropsychology, and animal models: elucidating the role for specific phosphorylation of DISC1 protein in neurodevelopment and cognitive function.
3) Perspectives: how are preclinical and clinical studies integrated to address clinical and scientific questions?

AWARDS CEREMONY 9:30 AM - 10:00 AM
Location: Congressi Auditorium
5th Schizophrenia International Research Society Conference
Deconstructing Schizophrenia Towards Targeted Treatment

**COFFEE BREAK**
Location: Congressi, Passi Perduti
10:00 AM - 10:30 AM

**CONCURRENT SYMPOSIA**
10:30 AM - 12:30 PM

**MICROGLIA IN SCHIZOPHRENIA**
Location: Congressi Auditorium
Chair: René Kahn

10:30 AM  Microglial Activity in Schizophrenia: PET Data in the Prodrome and the Effects of Antipsychotic Treatment
Oliver Howes

10:55 AM  Maternal Immune Activation Increases Inflammatory Cytokine Expression in the Offspring’s Brain Without Overt Signs of Microglia Anomalies
Urs Meyer

11:20 AM  Increased Inflammatory Markers Associated With Astrogliosis in the Midbrain in Schizophrenia
Cynthia Shannon Weickert

11:45 AM  Neuroinflammation at Different Stages of Schizophrenia: A PET Study of Microglial Activation
Christos Pantelis

Discussant: Darryl Eyles

**ZOOMING IN ON THE SYNAPSE IN SCHIZOPHRENIA**
Location: Congressi, Sala Verde
Chair: David Cotter

10:30 AM  Role of Lifespan Expression Trajectories in Psychiatric Disease Onset
Nathan Skene

10:55 AM  Proteomic Analysis of the Postsynaptic Density in the Major Psychoses Schizophrenia and Bipolar Disorder
Melanie Foecking

11:20 AM  Dysregulated Intracellular Targeting and Synaptic Abnormalities of Receptor Proteins in Schizophrenia
James Meador-Woodruff

11:45 AM  Focusing on Synaptosomal and Mitochondrial Proteomes From Schizophrenia Postmortem Brains
Daniel Martins-De-Souza

Discussant: Chang-Gyu Hahn
GLOBAL PERSPECTIVES ON STIGMA IN THE CLINICAL HIGH RISK STATE FOR PSYCHOSIS: NEW EMPIRICAL ADVANCES

Location: Affari, Ground Level
Chair: Lawrence Yang

10:30 AM  Risk of Psychosis, Mental Illness Stigma and Suicidality
Nicolas Rüsch

10:55 AM  Self-Perceptions of Having a Mental Illness and Relationship With Help - Seeking From Brazilian and UK Community Samples of Young People At-Risk of Psychosis
Sara Evans-Lacko

11:20 AM  Stigma of People at Clinical High Risk State for Psychosis in a Chinese Population
Lin Jingxia

11:45 AM  Stigma Related to Initial Self-Identification of Being ‘at High Risk for Psychosis’ vs. a ‘Non-psychotic Disorder’ in Individuals at Clinical High-Risk for Psychosis
Lawrence Yang

Discussant: Antonio Lasalvia

SECOND CHANCE: WHAT WOULD SENIOR SCHIZOPHRENIA RESEARCHERS DO IF THEY COULD START OVER AGAIN?

Location: Affari, Lower Level
Chair: E. Fuller Torrey

10:30 AM  A Schizophrenia Research Plan as Psychiatry Merges With Neurology
E. Fuller Torrey

10:55 AM  On Recovering From a Delusion
Robin Murray

11:20 AM  Possibilities and Pitfalls - Reflections on 42 Years in Academic Psychiatry and Lessons for a Suggested Repeat Performance
Eve Johnstone

11:45 AM  A Personal Retreat and Advance
William Carpenter

Discussant: Mark Weiser
CLINICAL AND NEUROBIOLOGICAL IMPACT OF PHYSICAL EXERCISE INTERVENTIONS IN SCHIZOPHRENIA

Location: Affari, First Level
Chair: Hilleke Hulshoff Pol

10:30 AM  Changes in Brain Connectivity After Endurance Training in Schizophrenia  
Hilleke Hulshoff Pol

10:55 AM  The Impact of Endurance Training on Brain Structure and Function in Schizophrenia Patients  
Berend Malchow

11:20 AM  An Exercise Intervention for Patients With Antipsychotic-Resistant Schizophrenia  
William Honer

11:45 AM  Translational Evidence of the Impact of Exercise on Brain Structure and Function in Animal Models and Healthy Humans  
Andreas Meyer-Lindenberg

Discussant: Peter Falkai

BACK TO THE HIPPOCAMPUS: INVESTIGATING HIPPOCAMPAL ABNORMALITIES IN EARLY PSYCHOSIS

Location: Affari, Second Level
Chair: Mary Cannon

10:30 AM  Evidence of Hippocampal Change in Adolescents Reporting Psychotic Experiences: A Population-Based MRI Study  
Erik O’Hanlon

10:55 AM  Age-Dependent Patterns of Aberrant Brain Structure in Youth With Psychosis Spectrum Symptoms  
Daniel Wolf

11:20 AM  Hippocampal Shape Analysis Yields New Clues About Symptom Progression in Youth at Ultrahigh Risk for Psychosis  
Vijay Mittal

11:45 AM  Longitudinal Changes in Hippocampal Volume in Adolescents With Psychotic Symptoms – Relationship to Functioning, Co-Morbid Disorder and Stressful Life Events  
Ana Calvo

Discussant: Anthony David

LUNCH  12:30 PM - 1:00 PM
Take away box lunches available in the Passi Perduti.
Wednesday 6 April
S1. REACTIVITY TO SOCIAL STRESS IN SECOND-GENERATION MOROCCAN-DUTCH MEN, A PROXY FOR SOCIAL DEFEAT  
Martin Gevonden*, Inez Myin-Germeyns, Marieke Wichers, Jan Booij, Wim van den Brink, Ruud van Winkel, Jean-Paul Selten  

S2. ASSESSMENT OF CARDIAC AUTONOMIC MODULATION IN ANTIPSYCHOTIC-INDUCED AKATHISIA  
Jae Seung Chang, Sang Hoon Yi, Yeni Kim, Hee-Yeon Jung, Yong Sik Kim*  

S3. INTERMEDIATE RESULTS OF A STUDY ABOUT SEXUAL DYSFUNCTION IN PATIENTS WITH SCHIZOPHRENIC DISORDERS TREATED WITH ATYPICAL ANTIPSYCHOTICS  
Joaquín Carlos Martín*, María José Acuña, Matilde Blanco, Víctor García de la Borbolla, Vanesa Hervás, Reyes Navarro, Olalla Santamaría, Beatriz Torres  

S4. NEUROCOGNITIVE PROFILE OF CHILDHOOD TRAUMA-RELATED MIXED PSYCHOPATHOLOGY PHENOTYPE IN PSYCHOSIS  
Giovanni Mansueto*, Martine van Nierop, Koen Schruers, Fiammetta Cosci, GROUP investigators, Ruud van Winkel  

S5. IMPACT OF DIFFERENT CHILDHOOD ADVERSITIES ON 1-YEAR OUTCOMES OF PSYCHOTIC DISORDER IN THE GENETICS AND PSYCHOSIS STUDY  
Antonella Trotta*, Robin Murray, Anthony David, Anna Kolliakou, Jennifer O’Connor, Marta Di Forti, Paola Dazzan, Valeria Mondelli, Craig Morgan, Helen Fisher  

S6. EXTRAPYRAMIDAL SYMPTOMS DURING TREATMENT WITH QUETIAPINE VERSUS ARIPIPRAZOLE IN CHILDREN AND ADOLESCENTS WITH PSYCHOSIS, THE TEA TRIAL.  
Ditte Rudå*, Karsten Gjessing Jensen, Dea Gowers KLauber, Marie Stenteberg-Olesen, Jens Richardt Jepsen, Pia Jeppesen, Birgitte Fagerlund, Christoph U Correll, Anne Katrine Pagsberg, Anders Fink-Jensen  

S7. VIOLENCE RISK PREDICTION IN SCHIZOPHRENIA - A FRAMINGHAM APPROACH?  
Seena Fazel*, Achim Wolf, Susan Mallett, Paul Lichtenstein, Henrik Larsson, Thomas Fanshawe  

S8. VARIANTS IN DOPAMINE-RELATED GENES ARE ASSOCIATED TO ABDOMINAL OBESITY AND METABOLIC ABNORMALITIES CAUSED BY ANTIPSYCHOTIC TREATMENT.  
Mercedes Zumárraga*, Nieves Basterreche, Ainara Arnaiz, Mª Isabel Zamalloa, Olga Olivas, Estibaliz Gordo, Ihintza Angoitia, Leire Erkoreka, Aurora Arrúe  

S9. ARE ANTIPSYCHOTIC DRUGS ASSOCIATED WITH INCREASED OR REDUCED MORTALITY AND SERIOUS ADVERSE EVENTS? A META-ANALYSIS  
Johannes Schneider, Maximilian Huhn*, Philipp Rothe, Myrto Samara, Yikang Zhu, Susanne Bächer, Matteo Rabaioli-Fischer, Stefan Leucht
S10. COMPARISON OF 3-MONTHLY VERSUS 1-MONTHLY PALIPERIDONE PALMITATE FOR TIME TO ONSET AND TIME TO RESOLUTION OF EXTRAPYRAMIDAL SYMPTOMS IN PATIENTS WITH EXACERBATED SCHIZOPHRENIA
Maju Mathews*, Isaac Nuamah, David Hough, Dean Najarian, Edward Kim, Srihari Gopal

S11. PREVIOUS ATTEMPTS OF SUICIDE IN FIRST EPISODE OF PSYCHOSIS AND PREMORBID ADJUSTMENT
Manuel Canal-Rivero*, Alba Yañez Castro, Gloria Benitez, Jorge Garcia Egea, Jordi E. Obiols Llandrich, Miguel Ruiz Veguilla

S12. BENZODIAZEPINES LONG-TERM CONSUMPTION IS ASSOCIATED WITH HIGHER AGGRESSIVENESS IN SCHIZOPHRENIA. RESULTS FROM THE FACE-SZ DATASET.
Guillaume Fond*, Maurine Favez, Franck Schurhoff, Laurent Boyer, Pierre-Michel Llorca

S13. TREATMENT WITH ANTI-TOXOPLASMIC ACTIVITY (TATA) FOR TOXOPLASMA POSITIVE PATIENTS WITH BIPOLAR DISORDERS OR SCHIZOPHRENIA: A CROSS-SECTIONAL STUDY.
Guillaume Fond*, Nora Hamdani, Laurent Boyer, Marion Leboyer

S14. LIPIDOMIC STUDY OF THE ANTI-PYSCHOTIC-INDUCED METABOLIC SYNDROME IN SCHIZOPHRENIA PATIENTS. TOWARDS A LIPIDIC BIOMARKER OF METABOLIC SYNDROME?
Cedric Tessier, Julien Thomas, Antonin Lamaziere, Philippe Seksik, Philippe Nuss*

S15. MOLECULAR PREDICTION OF METABOLIC SYNDROME IN PSYCHOSIS
Conrad Iyegbe*, Olesya Ajnakina, Lauren Allen, John Lally, Daniel Leirer, Hamel Patel, Poonam Sood, Stephen Newhouse, Marta Di Forti, richard dobson, Robin Murray, Fiona Gaughran

S16. EXPRESSION PROFILES AND SOCIAL FUNCTION AS A PREDICTIVE BIOMARKER OF SCHIZOPHRENIA: A PILOT STUDY
Yuko Okahisa*, Shinji Sakamoto, Manabu Takaki, Norihito Yamada

S17. CHILDHOOD INFLAMMATORY CYTOKINES AS PREDICTORS OF ADULT PSYCHOSIS
Lorna Lopez*, Melanie Foecking, Mary Clarke, Patrick Dicker, Mary Cannon, Stanley Zammit, David Cotter

S18. A COMPREHENSIVE ANALYSIS OF CORTISOL SECRETION IN EARLY PSYCHOSIS
Boris Chaumette*, Oussama Kebir, Yannick Morvan, Célia Mam-Lam-Fook, Julie Bourgin, Bill P. Godsil, Marion Plaze, Raphaël Gaillard, Thérèse M. Jay, Marie-Odile Krebs

S19. NEONATAL LEVELS OF GROWTH FACTORS IN NON-AFFECTIVE PSYCHOSIS
Renee Gardner*, Christina Dalman, Carmen Fourier, Håkan Karlsson

S20. NEUROANATOMICAL CORRELATES OF STRESS AND INFLAMMATORY BIOMARKERS AMONG CHILDREN AT ELEVATED RISK FOR SCHIZOPHRENIA
Alexis Cullen*, Sajani Sagar, Maria Calem, Ruth Roberts, Carmine Pariante, Helen Fisher, Patricia Zunszain, Kristin Laurens
S21. INCREASED NEURAL NOISE IS ASSOCIATED WITH THE PSYCHOSIS-LIKE EFFECTS OF THC
Jose Cortes-Briones*, John Cahill, Patrick Skosnik, Mohini Ranganathan, Deepak D’Souza

S22. DEFICIENT MYELINATION IN TREATMENT RESISTANT SCHIZOPHRENIA: EVIDENCE USING MCDSPOT IMAGING
Lucy Vanes*, Elias Mouchilianitis, Sukhi Shergill

S23. COMBINATORIAL NEUROANATOMICAL AND COGNITIVE SIGNATURES OF REMISSION AND RELAPSE IN SCHIZOPHRENIA
Newfei Ho*, Lawrence JK Wee, Mingyuan Wang, Min Yi Sum, Kang Sim

S24. USING METABOLOMICS TO IDENTIFY BIOMARKERS OF PSYCHOTIC EXPERIENCES AT AGE 17 IN THE AVON LONGITUDINAL STUDY OF PARENTS AND CHILDREN (ALSPAC) COHORT
Aoife O’Gorman*, Lorraine Brennan, Matej Oresic, Tom Suvitaival, Tuulia Hyotylainen, Stanley Zammit, Mary Cannon, David Cotter

S25. STUDYING THE INFLUENCE OF CLINICAL AND DEMOGRAPHIC MODERATORS IN MULTIVARIATE MODELING OF BRAIN FUNCTION IN SCHIZOPHRENIA
Carlos Cabral*, Lana Kambeitz-Ilankovic, Joseph Kambeitz, Sebastian Von Saldern, Dominic Dwyer, Vince Calhoun, Maria Urquijo, Peter Falkai, Nikolaos Koutsouleris

S26. A COMPARISON OF B CELL REPERTOIRE IN CEREBROSPINAL FLUID OF HEALTHY INDIVIDUALS AND PATIENTS WITH SCHIZOPHRENIA
Sehba Husain-Krautter*, Anil Malhotra, Thomas Rothstein

S27. IMPROVING TREATMENT OF PATIENTS WITH SCHIZOPHRENIA – GLUTAMATE AS A MARKER FOR CHOICE OF TREATMENT
Kirsten Borup Bojesen*, Brian V. Broberg, Kasper Jessen, Anne Sigvard, Egill Rostrup, Birte Glenthøj

S28. QUANTIFICATION OF THE SERUM LEVELS OF NR1 AND NR2 NMDA RECEPTOR IN PATIENTS IN THE FIRST EPISODE PSYCHOSIS
Camila Loureiro*, Rosana Shuhama, Paulo Menezes, Cristina Del-Ben, Paulo Louzada-Junior

S29. HUMAN PROTEIN ATLAS ENABLED NEUROPROTEOMIC PROFILING OF BODY FLUIDS
David Just, Peter Nilsson*

S30. EFFECTS OF OMEGA-3 PUFA ON THE VITAMIN E AND GLUTATHIONE ANTIOXIDANT DEFENSE SYSTEM IN INDIVIDUALS AT ULTRA-HIGH RISK OF PSYCHOSIS
Stefan Smesny*, Berko Milleit, Miriam Schafer, Uta-Christina Hipler, Jana Hesse, Heinrich Sauer, G Paul Amminger

S31. LOW LEVELS OF VITAMIN D POORLY RESPONSIVE TO DAYLIGHT EXPOSURE IN PATIENTS WITH THERAPY-RESISTANT SCHIZOPHRENIA
Jan Rogers*, Tijmen Bostoen, Broekman Theo

S32. EEG COHERENCE AS A TRAIT MARKER OF SCHIZOPHRENIA
Yu Sang Lee*, Eunsoog An
S33. COGNITIVE AND PSYCHOSOCIAL CORRELATES OF SUSPICIOUS YOUNG MINDS: A UK-HONG KONG FOLLOW-UP STUDY OF 9- TO 16-YEAR-OLDS
Keri Wong*

S34. TWELVE-MONTH PSYCHOSIS-PREDICTIVE VALUE OF THE ULTRA-HIGH RISK CRITERIA IN CHILDREN AND ADOLESCENTS
Marco Armando*, Maria Pontillo, Franco De Crescenzo, Luigi Mazzone, Elena Monducci, Nella Lo Cascio, Stefano Vicari, Benno G. Schimmelmann, Frauke Schultze-Lutter

S35. HIGH-RISK SYMPTOMS FOR PSYCHOSIS THROUGH ADOLESCENCE: ARE THERE AGE-RELATED PECULIARITIES IN THE PROFILE OF NEGATIVE SYMPTOMS?
Olga Puig-Navarro*, Inmaculada Baeza, Elena De la Serna, Ana Sintes, Clara Espelt, Jordina Tor, Gisela Sugranyes, Vanessa Sanchez-Gistau, Mireia Rosa, Marta Pardo, Montserrat Dolz

S36. RELATIONSHIP BETWEEN EMOTIONAL AND REASONING SCHEMATA ABOUT SELF AND OTHERS AND TYPE OF DELUSIONAL SYMPTOMS IN A SAMPLE OF CHILD AND ADOLESCENTS AT CLINICAL RISK FOR PSYCHOSIS
Ana Sintes, Jordina Tor, Marta Pardo, Olga Puig-Navarro, Clara Espelt, Daniel Muñoz, Elena De la Serna, Inmaculada Baeza, Montserrat Dolz*

S37. ABNORMAL INVOLUNTARY MOVEMENTS ARE LINKED TO PSYCHOSIS-RISK IN CHILDREN AND ADOLESCENTS: RESULTS OF A POPULATION-BASED STUDY
Jochen Kindler*, Frauke Schultze-Lutter, Chantal Michel, Alexandra Martz-Irngartinger, Caroline Linder, Stefanie Schmidt, Benno G. Schimmelmann, Sebastian Walther

S38. INTERACTION BETWEEN DISC1 MUTATION AND CANNABIS EXPOSURE IN ADOLESCENCE RESULTS IN ABERRANT BEHAVIORAL AND NEUROBIOLOGICAL PHENOTYPES IN A TRANSLATIONAL MOUSE MODEL OF SCHIZOPHRENIA
Hadar Segal-Gavish, Neta Gazit, Yael Barhum, Tali Ben-Zur, Michal Taler, Nissim Peretz, Irit Gil-Ad, Abreham Weizman, Inna Slutzki, Raphael Mechoulam, Atsushi Kamiya, Akira Sawa, Daniel Offen, Ran Barzilay*

S39. THE DANISH HIGH RISK AND RESILIENCE STUDY – VIA 7 -A COHORT STUDY OF 520 7 YEAR OLD CHILDREN BORN OF PARENTS DIAGNOSED WITH EITHER SCHIZOPHRENIA, BIPOLAR DISORDER OR NEITHER OF THESE TWO MENTAL DISORDERS
Anne Thorup*, Jens R. Jepsen, Ditte V. Ellersgaard, Birgitte K. Burton, Camilla J. Christiani, Nicoline Hemager, Katrine S. Spang, Ditte L. Gaarup, Aja Greve, Ole Mors, Kerstin J. Plessen, Merete Nordentoft

S40. ABERRANT LINGUISTIC SALIENCE ATTRIBUTION AS A RISK FACTOR FOR PSYCHOSIS-PRONENESS: INSIGHTS FROM THE TWINSSCANCHINA STUDY
Winifred Mark*, Francesca Cotier, Pearl Chen, Jim van Os, Timothea Touloupoulou

S41. THE ROLE OF AUTOIMMUNITY ON NEURODEVELOPMENT: STUDY ON OFFSPRING OF SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS
Maria Gariup*, Azucena Gonzalez, Ricard Cervera, Roger Borrás, Carles Serra-Pagés, Astrid Morer
S42. IS IT STILL CORRECT TO DIFFERENTIATE BETWEEN EARLY AND VERY EARLY ONSET PSYCHOSIS?
Ashleigh Lin*, Klaas Wardenaar, Maria Pontillo, Franco De Crescenzo, Luigi Mazzone, Stefano Vicari, Stephen Wood, Amanda Beavan, Marco Armando

S43. CLINICAL PROFILE AND PREDICTORS OF OUTCOMES IN OUTPATIENTS WITH PRODROMAL PSYCHOSIS IN SHANGHAI, CHINA
Huijun Li, TianHong Zhang, LiHua Xu, Kristen Woodberry, Daniel Shapiro, Larry Seidman*, Jijun Wang

S44. MECHANISMS OF TRANSMISSION OF HEALTH AND RISK IN PARENTS WITH SCHIZOPHRENIA OR BIPOLAR DISORDER AND THEIR OFFSPRING (THE WARM STUDY)
Angus MacBeth*, Kirstine Davidsen, Jenna-Marie Lundy, Katrine Røhder, Christopher Trier-Lind, Maja Nyström-Hansen, Emilie Nayberg, Andrew Gumley, Susanne Harder

S45. GENOME-WIDE METHYLATION CHANGES FOLLOWING EARLY AND LATE PRENATAL IMMUNE ACTIVATION: FOCUS ON THE PREFRONTAL CORTEX
Juliet Richetto*, Renaud Massart, Moshe Szyf, Marco A. Riva, Urs Meyer

S46. NEUROCHEMICAL CHANGES UNDERLYING ANTIPSYCHOTIC PHENOTYPE IN MGLU4 KNOCKOUT MICE.
Paulina Cieslik*, Marcin Marciniak, Piotr Branski, Andrzej Pilc, Joanna M. Wieronska

S47. DIFFERENTIAL REGULATION OF VENTRAL TEGMENTAL AREA DOPAMINE NEURONS BY INFRALIMBIC PREFRONTAL CORTEX AND LATERAL HABENULA: IMPLICATIONS FOR SCHIZOPHRENIA
Jared Moreines*, Zoe Owrutsky, Anthony Grace

S48. A RANDOMISED CONTROLLED TRIAL OF COGNITIVE BEHAVIOURAL THERAPY VERSUS NON-DIRECTIVE REFLECTIVE LISTENING FOR YOUNG PEOPLE AT RISK OF DEVELOPING PSYCHOSIS: THE DETECTION AND EVALUATION OF PSYCHOLOGICAL THERAPY (DEPTH) TRIAL.
Helen Stain*, Sandra Bucci, Amanda Baker, Vaughan Carr, Richard Emsley, Sean Halpin, Terry Lewin, Ulrich Schall, Vanessa Clark, Kylie Crittenden, Mike Startup

S49. SELECTIVE ESTROGEN RECEPTOR MODULATION INCREASES DORSOLATERAL PREFRONTAL CORTEX ACTIVITY DURING EMOTIONAL INHIBITION IN SCHIZOPHRENIA
Thomas Weickert*, Jochen Kindler, Rhoshel Lenroot, Peter Schofield, Cynthia Shannon Weickert

S50. AGGRESIVITY MANAGEMENT IN SCHIZOPHRENIA DIAGNOSED PATIENTS USING CALCIUM CHANNEL ALPHA-2 DELTA LIGANDS
Daniel Vasile*, Octavian Vasiliu, Diana Gabriella Vasiliu, Florin Vasile

S51. WEIGHT REDUCTION WITH REBOXETINE TREATMENT: A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REBOXETINE AND CITALOPRAM AS ADJUNCTS TO ATYPICAL ANTIPSYCHOTICS
Cristina V. Oliveira, Raquel López-Carrilero, Miquel Bernardo*, Roberto Rodriguez-Jimenez, Iluminada Corripio, Jose Carlos Gonzalez-Piqueras, Ana Espliego, Blanca Fernandez, Angela Ibáñez, Judith Usall
S52. EFFECTS OF COMMUNITY MENTAL HEALTH SERVICE IN SUBJECTS WITH EARLY PSYCHOSIS
Young Chul Chung*, Yin Cui, Eunjin Na

S53. RESULTS OF AN EXPLORATORY PHASE II STUDY WITH MIN-101, A 5-HT2A/SIGMA2 ANTAGONIST, FOR THE TREATMENT OF SCHIZOPHRENIA.
Corrine Staner, Michael Davidson*, Nadine Noel, Jay Saoud, Michael Detke, Remy Luthringer

S54. SEX AND GENDER DIFFERENCES IN EMERGING PSYCHOSIS – RESULTS FROM THE BASEL FEPSY PROJECT
Anita Riecher-Rössler*

S55. INCREASING SIGNAL DETECTION IN CLINICAL TRIALS: IMPROVING FIDELITY OF INSTRUMENTS
Jonathan Rabinowitz*, Nina Schooler

S56. COMBINING AEROBIC EXERCISE AND COGNITIVE TRAINING DECREASES NEGATIVE SYMPTOMS AND IMPROVES SOCIAL FUNCTIONING IN FIRST EPISODE SCHIZOPHRENIA: A UCLA PILOT RCT
Joseph Ventura*, Sarah McEwan, Kenneth Subotnik, Luana Turner, Yurika Sturdevent, Gerhard Hellemann, Keith Nuechterlein

S57. WHY DO CLINICAL TRIALS FAIL SO OFTEN IN SCHIZOPHRENIA? A QUANTITATIVE SYSTEMS PHARMACOLOGY APPROACH TO ACCOUNT FOR THE EFFECT OF COMEDICATIONS AND GENOTYPES
Hugo Geerts*, Athan Spiros

S59. INITIAL DEVELOPMENT OF A PATIENT REPORTED OUTCOME MEASURE OF EXPERIENCES WITH COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA
Raymond Rosen, Lisa C. Welch, Jeremiah Trudeau, Steven Silverstein, Michael Sand*

S60. EFFICACY AND SAFETY OF PALIPERIDONE PALMITATE 3-MONTH VERSUS 1-MONTH FORMULATION IN SCHIZOPHRENIA: GLOBAL AND ASIAN SUBGROUP ANALYSIS OF A RANDOMIZED, DOUBLE-BLIND, NON-INFERIORITY STUDY
Adam Savitz*, Srihari Gopal, Yu Feng, Haiyan Xu, Jianmin Zhuo, Lu Yu, Isaac Nuamah, Paulien Ravenstijn, Cathy Wu, David Hough

S61. TOWARD A NEGATIVE SYMPTOM SYSTEM OF SCHIZOPHRENIA: A NETWORK APPROACH
Stephen Levine*, Stefan Leucht

S62. OUTCOMES OF MAINTENANCE ANTIPSYCHOTIC TREATMENT VERSUS DISCONTINUATION STRATEGIES FOLLOWING REMISSION FROM FIRST EPISODE PSYCHOSIS: A SYSTEMATIC REVIEW AND META-ANALYSIS
Andrew Thompson*, Catherine Winsper, Steven Marwaha, Mario Alvarez-Jimenez, Alba Realpe, Laura Vail, Jon Haynes, Sarah Hetrick, Sarah Sullivan
S63. PREDICTION OF TRANSITION TO PSYCHOSIS IN PATIENTS WITH A CLINICAL HIGH RISK FOR PSYCHOSIS: A SYSTEMATIC REVIEW OF METHODOLOGY AND REPORTING
Erich Studerus*, Avinash Ramyead, Anita Riecher-Røssler

S64. THE PRACTICAL IMPLICATIONS OF METACOGNITIVE PSYCHOTHERAPY IN PSYCHOSIS: FINDINGS FROM A PILOT STUDY
Steven De Jong*, Rozanne van Donkersgoed, Andre Aleman, Mark van der Gaag, Lex Wunderink, Johan Arends, Paul Lysaker, Marieke Pijnenborg

S65. LONG-TERM EFFECTIVENESS OF ARIPIPRAZOLE ONCE-MONTHLY IS MAINTAINED IN THE QUALIFY EXTENSION STUDY
Dieter Naber*, Ross A. Baker, Anna Eramo, Carlos Forray, Karina Hansen, Christophe Sapin, Timothy Peters-Strickland, Anna-Greta Nylander, Peter Hertel, Simon Nitschky Schmidt, Jean-Yves Loze, Steven G. Potkin

S66. ITI-007 EXHIBITS UNIQUE PHARMACOLOGY: COMBINED RESULTS FROM POSITRON EMISSION TOMOGRAPHY (PET) STUDIES IN HEALTHY VOLUNTEERS AND PATIENTS WITH SCHIZOPHRENA
Robert Davis, Kimberly Vanover*, Cedric O’Gorman, Jelena Saillard, Michal Weingart, Sharon Mates

S67. PSYCHIATRIC STABILITY MAINTAINED IN TARDIVE DYSKINESIA SUBJECTS TREATED WITH VALBENAZINE
Jean-Pierre Lindenmayer*, Richard Josiassen, Joshua Burke, Scott Siegert, Bill Aurora

S68. SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF TAK-063, A PDE10A INHIBITOR, AFTER A SINGLE DOSE IN HEALTHY JAPANESE AND NON-JAPANESE SUBJECTS
Max Tsai, Tom Macek*, Lambros Chrones, Jinhui Xie, Hakop Gevorkyan

S69. FIVE-YEAR FOLLOW-UP OF A RANDOMIZED-CONTROLLED TRIAL ON 2-YEAR VS. 3-YEAR SPECIALIZED EARLY INTERVENTION FOR YOUNG PATIENTS PRESENTING WITH FIRST-EPISODE PSYCHOSIS
WY Kwong, Wing Chung Chang*, LM Hui, SK Lau, KW Chan, HM Lee, EYH Chen

S70. PROBABILISTIC REINFORCEMENT LEARNING IN PATIENTS WITH FIRST-EPISODE SCHIZOPHRENA-SPECTRUM DISORDER: PRELIMINARY RESULTS OF A 1-YEAR FOLLOW-UP STUDY
SI Chan, Wing Chung Chang*, TCW Chan, J Waltz, J Gold, EYH Chen

S71. TESTING DIFFERENTS DOMAINS OF SOCIAL COGNITION IN THE PREDICTION OF SOCIAL FUNCTIONING IN PATIENTS WITH SCHIZOPHRENA
Rafael Penades*, Alexandre González-Rodríguez, Clemente García-Rizo, Rosa Catalán, Miquel Bernardo
S72. VALIDATION OF THE TABLET-BASED BRIEF ASSESSMENT OF COGNITION (BAC APP) FOR ASSESSMENT OF COGNITION IN SCHIZOPHRENIA
Richard Keefe*, Alexandra Atkins, Vicki Davis, Tina Tseng, Adam Vaughn, Philip Harvey, Thomas Patterson, Meera Narasimhan

S73. TO ACT AS ONE WHILE REMAINING TWO -- SELF-OTHER DISTINCTION IN CHILDREN AT RISK FOR PSYCHOSIS
Neeltje Van Haren*, Merel Prikken, Manon Hillegers, Anouk Van Der Weiden

S74. ANALYSIS OF AKT1 AND CANNABIS MODERATION EFFECTS ON PSYCHOTIC EXPERIENCES AND COGNITIVE PERFORMANCE IN HEALTHY SUBJECTS
Barbara Arias*, Manuel Ignacio Ibañez, Jorge Moya, Generós Ortet, Lourdes Fañanás, Mar Fatjó-Vilas

S75. ARE COGNITIVE FUNCTIONS DETERIORATING DURING THE FIRST 5 YEARS AFTER AN EARLY-ONSET PSYCHOSIS?
Elena De la Serna*, Inmaculada Baeza, Gisela Sugranyes, Covadonga Martinez-Caneja, Jéssica Merchán-Naranjo, Celso Arango, Josepina Castro-Fornieles

S76. A COMPARISON OF NEUROCOGNITIVE BATTERIES AFTER SINGLE DOSE MODAFINIL IN EARLY SCHIZOPHRENIA AND HEALTH
Richard Drake*, Jane Lees, Panagiota Michalopoulou, Gahan Pandina, Shon Lewis

S77. THEORY OF MIND FUNCTIONING IS NO LONGER A NATURAL PROCESS IN PRODROMAL PSYCHOSIS: A MODEL OF SOCIAL COGNITION COMPENSATED BY NEUROCOGNITION
TianHong Zhang*, HuiJun Li, William S. Stone, HuiRu Cui, Daniel I. Shapiro, YingYing Tang, LiHua Xu, Larry J. Seidman, JiJun Wang

S78. IMPROVEMENT IN DEPRESSIVE SYMPTOMS AND FUNCTIONING IN SCHIZOPHRENIA: A TREATMENT STUDY
Philip Harvey*, Masaaki Ogasa, Cynthia Siu, Antony Loebel

S79. SOCIAL COGNITION OVER TIME IN INDIVIDUALS AT CLINICAL HIGH RISK FOR PSYCHOSIS: FINDINGS FROM THE NAPLS-2 COHORT
Danijela Piskulic*, Lu Liu, Kristin Cadenhead, Tyrone Cannon, Barbara Cornblatt, Mcglashan Thomas, Diana Perkins, Larry Seidman, Ming Tsuang, Elaine Walker, Scott Woods, Carrie Bearden, Daniel Mathalon, Jean Addington

S80. DYSEXECUTIVE IMPAIRMENT IN FIRST-EPIISODE OF SCHIZOPHRENIA
Gricel Orellana Vidal*, Andrea Slacheksky

S81. META-ANALYSIS OF COGNITIVE PERFORMANCE IN DRUG-NAïVE PATIENTS WITH SCHIZOPHRENIA
Helena Fatouros-Bergman, Simon Cervenka, Lena Flyckt*, Gunnar Edman, Lars Farde

S82. COMPREHENSIVE ASSESSMENT OF AUDITORY PERCEPTION AND ITS RELATION TO IMPAIRED EMOTION RECOGNITION IN SCHIZOPHRENIA
Michael Kraus*, Trina Walker, L. Fredrik Jarskog, Robert Millet, Richard Keefe
S83. COGNITIVE REMEDIATION AND OCCUPATIONAL OUTCOME IN SCHIZOPHRENIA SPECTRUM DISORDERS: A 2 YEAR FOLLOW-UP STUDY
June Øystad*, Erik Falkum, Helen Bull, Stig Evensen, Torill Ueland

S84. IMPROVEMENT OF EXECUTIVE FUNCTIONS USING THE OCCUPATIONAL GOAL INTERVENTION METHOD IN PATIENTS WITH TREATMENT-RESISTANT SCHIZOPHRENIA: RESULTS OF THE FOLLOW-UP PHASE
Adriana Vizzotto, Diego Celestino, Patricia Buchain, Alexandra Oliveira, Graça Oliveira, Elaine Di Sarno, Isabel Napolitano, Helio Elkis*

S85. COGNITIVE IMPAIRMENT AS A VULNERABILITY MARKER FOR PSYCHOSIS: THE ROLE OF CHILDHOOD TRAUMA
Marieke Begemann*, Kirstin Daalman, Sophie Heringa, Maya Schutte, Iris Sommer

S86. EMOTIONAL INTELLIGENCE AND NON-SOCIAL COGNITION IN SCHIZOPHRENIA AND BIPOLAR-I-DISORDER
Beatrice Frajo-Apor*, Georg Kemmler, Silvia Pardeller, Tamara Plass, Moritz Muehlbacher, Anna-Sophia Welte, Wolfgang Fleischhacker, Alex Hofer

S87. THE COGNITIVE UNDERPINNINGS OF MULTITASKING OF DAILY LIFE ACTIVITIES IN PERSONS DIAGNOSED WITH SCHIZOPHRENIA: VALIDATION OF A NEW MODEL.
Julien Laloyaux*, Martial Van der Linden, Keith H. Nuechterlein, Frank Larøi

S88. COGNITIVE ARCHITECTURE OF INDIVIDUALS AT RISK TO PSYCHOSIS: FINDINGS FROM LYRIKS
Max Lam*, Jimmy Lee, Attilio Rapisarda, Michael Kraus, Richard Keefe

S89. FAMILIARITY OF COGNITIVE PERFORMANCE AND ITS RELATIONSHIP WITH THE NEUROCOGNITIVE EVOLUTION PROFILE IN PSYCHOTIC PATIENTS
Claudia Prats Balado*, Panagiotis Ferentinos, Jordi Soler Garcia, Salvador Miret, Silvia Campanera, Maria Giralt, Maria José Muñoz, Lourdes Fañanás, Mar Fatjó-Vilas

S90. EEG MU-RHYTHM SUPPRESSION IN PATIENTS WITH SCHIZOPHRENIA AND SCHIZOAFFECTIVE DISORDER AND ITS RELATION TO PSYCHOPATHOLOGY
Yulia Zaytseva*, Zhanna Garaikh

S91. THE RELATIONSHIP BETWEEN CORTISOL AND COGNITIVE FUNCTIONS IN THE PSYCHOSIS PRODROME AND THOSE AT CLINICAL HIGH-RISK IN NAPLS2
Daniel Shapiro*, Elaine Walker, NAPLS PIs, Larry Seidman

S92. NEUROANATOMICAL CORRELATES OF SOCIOECONOMIC STATUS IN SCHIZOPHRENIA AND ITS IMPLICATIONS FOR COGNITION
Leire Zubiaurre-Elorza, Ainara Gómez-Gastiasoro, Naroa Ibarretxe-Bilbao, Javier Peña, Natalia Ojeda*, David Schretlen
S93. CLINICAL USEFULNESS OF THE SCREEN FOR COGNITIVE IMPAIRMENT IN PSYCHIATRY (SCIP) IN PATIENTS WITH SCHIZOPHRENIA BEFORE AND AFTER COGNITIVE REMEDIATION
Gabriele Sachs*, Eva Maihofer, Manuela Neuwirth, Hemma Swoboda, Andreas Erfurth

S94. AN INVESTIGATION OF SEMANTIC MEMORY IN FIRST-EPISTODE PSYCHOSIS
Susan Rossell*

S95. LEARNING TO TRUST: TRUST AND ATTACHMENT IN EARLY PSYCHOSIS
Anne-Kathrin Fett*, Sukhi Shergill, Nikie Korver-Nieberg, Paula Gromann, Lydia Krabbendam

S96. IMPLICIT MENTALIZING IN SCHIZOPHRENIA: A MULTIVARIATE FMRI STUDY AND ASSOCIATION WITH GENETIC RISK VARIANTS
Andrew Martin*, Ivana Dzafic, Gail Robinson, David Reutens, Bryan Mowry

S97. COGNITIVE INSIGHT IN SCHIZOPHRENIA: STUDY ABOUT 30 TUNISIAN PATIENTS.
Ahmed Mhalla*, Bochra Ben Mohamed, Ahmed Hadj Mohamed, Soumaya Chatti, Ferid Zaafra, Lotfi Gaha

S98. EXECUTIVE DYSFUNCTION IN PSYCHOSIS FOLLOWING TRAUMATIC BRAIN INJURY
Rachel Batty*, Andrew Francis, Neil Thomas, Malcolm Hopwood, Jennie Ponsford, Susan Rossell

S99. NEUROLOGICAL SOFT SIGNS IN CHRONIC SCHIZOPHRENIA
Christina J. Herold, Marc Montgomery Lässer*, Ulrich Seidl, Philipp Arthur Thomann, Johannes Schröder

S100. DOES COGNITIVE PERFORMANCE MAP TO CATEGORICAL DIAGNOSES OF SCHIZOPHRENIA, SCHIZOAFFECTIVE DISORDER AND BIPOLAR DISORDER? A DISCRIMINANT FUNCTIONS ANALYSIS.
Tamsyn Van Rheenen*, Shayden Bryce, Eric Tan, Erica Neill, Caroline Gurvich, Stephanie Louise, Susan Rossell

S101. CHANGE IN VERBAL MEMORY PERFORMANCE IN SCHIZOPHRENIA PATIENTS AND THEIR SIBLINGS
Rosa Ayesa-Arriola*, Neelje Van Haren, Jessica De Nijs, Wiepke Cahn, René S. Kahn

S102. UNDERSTANDING THE PROGRESSION OF SEMANTIC DYSFUNCTION IN SCHIZOPHRENIA: INSIGHTS USING THE SCHIZOTYPY ANALOGUE
Eric Tan*, Giorgia Wagner, Susan Rossell

S103. BUILDING A NEUROCOGNITIVE PROFILE OF AUDITORY VERBAL HALLUCINATIONS IN SCHIZOPHRENIA

S104. MUSIC & EMOTIONS IN SCHIZOPHRENIA PATIENTS
Christian Mikutta*, Andreas Altorfer, Werner Strik, Daniel Mathalon
S105. CIGARETTE SMOKING AND COGNITIVE FUNCTIONING IN SCHIZOPHRENIA
Faith Dickerson*

S106. HIGH PREVALENCE OF OBSTRUCTIVE SLEEP APNOEA IN PATIENTS TAKING CLOZAPINE COMPARED TO AGE MATCHED CONTROLS
Cherrie Galletly*, Hannah Myles, Robert Adams, Nick Antic, Madhu Chandratilleke, Dennis Liu, Jeremy Mercer, Andrew Vakulin, Andrew Vincent, Nicholas Myles, Gary Wittert

S107. HIGH METABOLIC RISK FACTORS DO NOT SUBSIDE BY ROUTINE OUTCOME MONITORING; DATA FROM THE PHAMOUS PROJECT.

S108. THE EFFECTIVENESS OF SHORT-TERM GROUP SCHEMA COGNITIVE BEHAVIORAL THERAPY (SCBT-G) FOR PEOPLE WITH PSYCHOTIC DISORDERS AND CO-MORBID PERSONALITY PROBLEMS
Ellen Horsselenberg*, Hugo Wolters, Johans Brink, Esther Sportel

S109. THE BIAS EFFECT OF CNVS CONFERRING RISK FOR BOTH AUTISM AND SCHIZOPHRENIA
Ahmad Abu-Akel*, Stephen Wood, Peter Hansen, Ian Apperly

S110. DEPRESSION AND CLINICAL HIGH-RISK STATES: CLINICAL PRESENTATION OF DEPRESSED VS. NON-DEPRESSED PARTICIPANTS IN THE NAPLS-2 COHORT
Emily Kline*, Jean Addington, Kristen Woodberry, Carrie Bearden, Kristin Cadenhead, Tyrone Cannon, Barbara Cornblatt, Thomas McGlashan, Diana Perkins, Ming Tsuang, Elaine Walker, Scott Woods, Larry Seidman

S111. HALLUCINATIONS AND TRAUMA: A COMPLEX RELATION
Jack J.A. Jenner, B.J. Kollen, H. Burger, Bert L.B. Luteijn*

S112. UNIQUE AND OVERLAPPING SYMPTOMS IN SCHIZOPHRENIA SPECTRUM AND DISSOCIATIVE DISORDERS IN RELATION TO MODELS OF PSYCHOPATHOLOGY: A SYSTEMATIC REVIEW
Selwyn Renard*, Rafaele Huntjens, Paul Lysaker, Andrew Moskowitz, Andre Aleman, Marieke (Gerdina) Pijnenborg

S113. DOES AGE OF FIRST CANNABIS USE AND FREQUENCY OF USE INFLUENCE AGE OF FIRST-EPIsode PSYCHOSIS (FEP)? A COMPARISON BETWEEN NORTH AND SOUTH OF EUROPE
Caterina La Cascia, Fabio Seminerio*, Lucia Sideli, Laura Ferraro, Alice Mulè, Crocettarachele Sartorio, Giada Tripoli, Marta Di Forti, Daniele La Barbera, Robin Murray

S114. LONG-TERM EFFECTS OF ADOLESCENT THC ON THE ADULT BRAIN: AN VIVO MRI / 1H-MRS STUDY WITH EX VIVO AND POST-MORTEM CONFIRMATION
Anthony Vernon*, Sotiris Kakanos, William Crum, David Lythgoe, Marie-Caroline Cotel, Po-Wah So, Sagnik Bhattacharyya, Kapur Shitij
S115. NICOTINE DEPENDENCE IN PATIENTS WITH SCHIZOPHRENIA: RELATIONSHIPS TO PSYCHOPATHOLOGY, INSIGHT AND SEVERITY OF ILLNESS
Zeynep Baran Tatar*, Erhan Kurt

S116. THE IMPACT OF CANNABIS USE IN PSYCHOSIS: REFLECTIONS AND ANALYSIS OF MOTIVATIONAL INTERVIEWING/COGNITIVE BEHAVIOUR THERAPY TRIALS IN ESTABLISHED PSYCHOSIS
Sandra Bucci*, Christine Barrowclough, Amanda Baker, Lynsey Gregg, Richard Emsley

S117. YOUTH OFFENDING, THE NARROW LINE BETWEEN SUBSTANCE ABUSE AND PSYCHOSIS.
Yolanda Rendal*, Teresa Jimeno, Carolina Roset, Patricia Herbera, Joana M. Andrés, Jaume Morey

S118. STRONG ASSOCIATION BETWEEN SEVERE NICOTINE DEPENDENCE AND DEPRESSION IN SMOKERS WITH SCHIZOPHRENIA. RESULTS FROM THE FACE-SZ DATASET.
Romain Rey*, Thierry D’Amato, Pierre-Michel Llorca, Guillaume Fond

S119. THE NATURE OF THE RELATIONSHIP OF PSYCHOMOTOR SLOWING WITH NEGATIVE SYMPTOMATOLOGY IN SCHIZOPHRENIA
Chris Bervoets*, Lise Docx, Bernard Sabbe, Manuel Morrens

S120. TACKLING MENTAL HEALTH STIGMA AND DISCRIMINATION BY CHANGING THE NAME: THE CASE AGAINST SCHIZOPHRENIA
Antonio Lasalvia*

S121. CONVERSION INTO OVERT PSYCHOSIS IN INDIVIDUALS AT ULTRA-HIGH RISK FOR PSYCHOSIS: POSSIBLE ROLES OF SCHIZOTYPY AND BASIC SYMPTOMS
Minji Bang*, Eun Lee, Suk Kyoung An

S122. IS DISORGANIZED SCHIZOPHRENIA A RISK FACTOR FOR TREATMENT RESISTANCE IN SCHIZOPHRENIA? NEW EVIDENCE FOR A TRADITIONAL SUBTYPE.
Bruno Ortiz*, Cintia Higuchi, Cristiano Noto, Daiane Medeiros, Deyvis Rocha, Rodrigo Bressan, Ary Gadelha

S123. CLINICAL NETWORK ANALYSIS: INSIGHT IN VARIATION IN SYMPTOM SEVERITY AND CLUSTERING TO IMPROVE SCHIZOPHRENIA CARE; A CASE REPORT
Maarten Bak*, Marjan Drukker, Jim Van Os

S124. AFFECTIVE FEATURES AND GENDER IN PSYCHOSIS: DURATION OF ILLNESS MAKES A DIFFERENCE
Santiago Latorre, Jesús Cobo, Lourdes Nieto, Susana Ochoa, Esther Pousa, Judith Usall, Iris Baños, Isabel Ruiz, Carles García-Ribera, Ada Ruiz*

S125. SELF-EVALUATION OF NEGATIVE SYMPTOMS (SNS): A NOVEL TOOL TO ASSESS NEGATIVE SYMPTOMS
Sonia Dollfus*, Cyril Mach, Rémy Morello
S126. CULTURAL INFLUENCES ON SCHIZOTYPY AMONG BRITISH AND TRINIDADIAN ADULTS: A LATENT MEAN COMPARISON AND EVENT-RELATED POTENTIAL STUDY
David Barron*, Kevin Morgan, Viren Swami, Gerard Hutchinson, Tony Towell

S127. PSYCHOTIC SYMPTOMS IN PATIENTS WITH ANXIETY AND DEPRESSION – CLINICAL CORRELATES AND IMPLICATIONS FOR PSYCHIATRIC SERVICE UTILIZATION
Nomi Werbeloff*

S128. SCHIZOTYPAL PERSONALITY QUESTIONNAIRE-BRIEF: FACTOR STRUCTURE ANALYSIS IN GENERAL POPULATION IN FRANCE
Louise Todorov*, Aziz Farchiou, Grégoire Baudin, Mohamed Lajnef, Baptiste Pignon, André Szöke, Marion Leboyer, Franck Schürhoff

S129. THE RELATION BETWEEN CHILDHOOD TRAUMA HISTORY AND PSYCHOTIC SYMPTOMS IN PATIENTS WITH FIRST EPISODE PSYCHOSIS
Ahmet Ayer*, Esra Aydinli, Koksal Alptekin

S130. TRAJECTORIES OF DEPRESSION IN A PRAGMATIC, RANDOMIZED TRIAL
Eirik Kjelby*, Rolf Gjestad, Igne Sinkeviciute, Rune A Kroken, Else-Marie Løberg, Hugo A Jørgensen, Erik Johnsen

S131. INTRODUCTION AND VALIDATION OF THE QUESTIONNAIRE FOR PSYCHOTIC EXPERIENCES: A CLINICAL TOOL TO ASSESS PSYCHOTIC SYMPTOMS ACROSS DIAGNOSES
Maya Schutte*, Dominic ffychte, Mascha Linszen, Sanne Koops, Edwin van Dellen, Sophie Heringa, Arjen Slooter, Rob Teunisse, Odile van den Heuvel, Evelien Lemstra, Elizabeth Foncke, Ralph Hoffman, Clara Strauss, Neil Thomas, Susan Rossell, Iris Sommer

S132. SEARCHING ACROSS THE DIAGNOSTIC DIVIDE: TOWARDS A MECHANISTIC UNDERSTANDING OF DISEASE PROGRESSION THROUGH SYMPTOM AND COGNITIVE TRAJECTORIES
Rico Sze Chun Lee*, Daniel Hermens, Jan Scott, Nick Glozier, Bridianne O’Dea, Ian Hickie

S133. BAYESIAN CONFIRMATORY FACTOR ANALYSIS FAILS TO CONFIRM FIVE-FACTOR MODEL OF THE POSITIVE AND NEGATIVE SYNDROME SCALE FOR SCHIZOPHRENIA (PANSS) IN A REPRESENTATIVE BRAZILIAN SAMPLE.
Cinthia Higuchi*, Hugo Cogo-Moreira, Bruno Ortiz, Rosana de Freitas, Cristiano Noto, Quirino Cordeiro, Sintia Belangero, Bernardo dos Santos, Rodrigo Bressan, Helio Elkis, Ary Gadelha

S134. RISK FACTORS FOR AGGRESSION IN FIRST EPISODE PSYCHOSIS – A NATURALISTIC DATABASE STUDY IN SINGAPORE
Sutapa Basu*, Edimansyah Abdin, Swapna Verma

S135. SOCIAL MEDIA IN FIRST EPISODE PSYCHOSIS: A LINGUISTIC ANALYSIS
Asra Rizvi*, Michael Birnbaum, Leonardo Lopez, Ryan Boyd, John Kane
S136. THE FACTOR STRUCTURE OF PSYCHOTIC SYMPTOMS IN EARLY PSYCHOSIS
Eric Roche*, Ricardo Segurado, Brian O’Donoghue, Laoise Renwick, Caragh Behan, Kevin Madigan, John Lyne, Mary Clarke

S137. THE ASSOCIATIONS BETWEEN PATERNAL AGE, AGE AT ONSET OF PSYCHOSIS IN PATIENTS AND SCHIZOTYPAL TRAITS IN GENERAL POPULATION
Sanja Andric*, Marina Mihaljevic, Tijana Mirjanic, Nadja Maric

S138. DELUSIONS IN FIRST-EPILOGUE PSYCHOSIS: FACTOR ANALYSIS OF TWELVE TYPES OF DELUSIONS AND THEIR DEMOGRAPHIC AND CLINICAL CORRELATES
Enrico Paolini*, Patrizia Moretti, Michael Compton

S139. IS A NARROW DEFINITION OF SCHIZOPHRENIA MORE HERITABLE THAN WHEN WE EMBRACE THE FULL SPECTRUM OF THE ILLNESS? HERITABILITY OF SCHIZOPHRENIA AND SCHIZOPHRENIA SPECTRUM IN THE NATIONWIDE DANISH TWIN AND HEALTH REGISTERS
Rikke Hilker*, Dorte Helenius, Birgitte Fagerlund, Axel Skytthe, Kaare Christensen, Thomas Werge, Merete Nordentoft, Birte Glenthøj

S140. EMPIRICALLY BASED QUALITATIVE AND QUANTITATIVE VARIATIONS ON THE PSYCHOSIS CONTINUUM IN THE ‘HOWNUTSARETHE DUTCH’ POPULATION SAMPLE
Johanna Wigman*, Klaas Wardenaar, Rob Wanders, Sanne Booij, Bertus Jeronimus, Lian van der Krieke, Marieke Wichers, Peter de Jonge

S141. MORTALITY IN FIRST EPISODE PSYCHOSIS: A 20-YEAR FOLLOW-UP OF THE DUBLIN FIRST EPISODE PSYCHOSIS COHORT
Roisin Doyle*, Donal O’Keeffe, Anthony Kinsella, Ailish Hannigan, Kevin Madigan, Elizabeth Lawlor, Aine Kelly, Ann Sheridan, Mary Clarke

S142. HAS DEINSTITUTIONALIZATION AFFECTED INPATIENT SUICIDE? PSYCHIATRIC INPATIENT SUICIDE RATES BETWEEN 1990 AND 2013 IN ISRAEL
Linda Levi*, Nomi Werbeloff, Inna Pugachova, Rinat Yoffe, Matthew Large, Michael Davidson, Mark Weiser

S143. PREVALENCE AND PERSISTENCE OF PSYCHOTIC-LIKE EXPERIENCES IN HONG KONG
Kit Wai Lee*, Kit Wa Chan, Wing Chung Chang, Edwin Ho Ming Lee, Christy Lai Ming Hui, Jingxia Lin, Eric Yu Hai Chen

S144. PHYSICAL ACTIVITY IN PEOPLE LIVING WITH PSYCHOTIC ILLNESS: FINDINGS FROM THE SURVEY OF HIGH IMPACT PSYCHOSIS
Shuichi Suetani*, Anna Waterreus, Vera Morgan, Debra Foley, Cherrie Galletly, Johanna Badcock, Gerald Watts, Andrew McKinnon, David Castle, Sukanta Saha, James Scott, John McGrath

S145. SYSTEMATIC REVIEW AND META-ANALYSIS OF THE PREVALENCE OF PSYCHOTIC EXPERIENCES IN COUNTRIES OUTSIDE OF NORTH AMERICA, EUROPE, AND AUSTRALASIA.
Suttha Supanya*, Craig Morgan, Ulrich Reininghaus
S146. PATHWAYS TO CARE AND PATTERNS OF CARE IN FIRST EPISODE PSYCHOSIS PATIENTS TREATED IN COMMUNITY-BASED MENTAL HEALTH SERVICES OVER 5 YEARS. FINDINGS FROM THE PICOS-VENETO PROJECT
Elisabetta Miglietta*, Antonio Lasalvia, Dorian Cristofalo, Sarah Tosato, Chiara Bonetto, Gioia Zanatta, Silvia Zoppei, Sara Petterlini, Carla Comacchio, Giorgia Dimitri, Carla Cremonese, Luana Ramon, Mirella Ruggeri

S147. INVESTIGATING THE ASSOCIATION OF MATERNAL SEVERE MENTAL ILLNESS AND EXPOSURE TO OBSTETRIC COMPLICATIONS WITH RATES OF INTELLECTUAL DISABILITY.
Patricia Di Prinzio*, Vera Morgan, Jonas Jonas Björk, Maxine Croft, Assen Jablensky, Thomas McNeil

S148. WHY ARE CHILDREN LIVING IN URBAN NEIGHBOURHOODS AT INCREASED RISK FOR CHILDHOOD PSYCHOTIC SYMPTOMS? FINDINGS FROM A UK LONGITUDINAL COHORT STUDY
Joanne Newbury*, Louise Arseneault, Avshalom Caspi, Terrie Moffitt, Candice Odgers, Helen Fisher

S149. LOWER GLOBAL ASSESSMENT OF FUNCTIONING (GAF-F) SCORES PREDICT THE RISK OF HOSPITALIZATION IN MALE PATIENTS WITH A FIRST-TIME SCHIZOPHRENIA DIAGNOSIS
Ole Köhler*, Henriette Thisted Horsdal, Lone Baandrup, Ole Mors, Christiane Gasse

S150. PREVALENCE AND INCIDENCE OF SCHIZOPHRENIA IN TAIWAN: 10-YEAR POPULATION-BASED APPROACH
Szu-Nian Yang*, Yu-Hsiang Kao

S151. PSYCHOSIS SYMPTOM PROFILES AND VARIABILITY OVER TIME IN A COHORT OF MARGINALLY HOUSED ADULTS IN VANCOUVER, CANADA

S152. A NEW APPROACH TO INVESTIGATING THE ASSOCIATION BETWEEN DURATION OF UNTREATED PSYCHOSIS AND OUTCOMES IN PSYCHOSIS USING INSTRUMENTAL VARIABLES.
Sarah Sullivan*, Robert Carroll, Tim Peters, Tim Amos, Peter Jones, Helen Fisher, Sonia Johnson, Max Marshall, Max Birchwood, David Fowler, Kate Tilling

S153. UNHELPFUL METACOGNITIVE BELIEFS IN EARLY PSYCHOSIS ARE ASSOCIATED WITH AFFECTIVE SYMPTOMS AND CHILDHOOD SOCIAL ADJUSTMENT
Tiril Østefjells*, Ingrid Melle, Roger Hagen, Kristin L. Romm, Nasrettin Sönmez, Ole A. Andreassen, Jan Ivar Røssberg

S154. DEMOGRAPHIC AND SOCIO-ENVIRONMENTAL PREDICTORS OF PREMORBID CANNABIS USE AMONG PATIENTS WITH FIRST-EPISTEME PSYCHOSIS
Luca Pauselli*, Michael Birnbaum, Beatriz Paulina Vázquez Jaime, Enrico Paolini, Mary E. Kelly, Beth Broussard, Michael Compton
S155. IDENTIFYING PATIENTS WITH AN INDICATION FOR CLOZAPINE IN DUTCH OUTPATIENT SETTINGS.
Yvonne van der Zalm*, Raphael Schulte, Iris Sommer, Jean-Paul Selten

S156. PREVALENCE OF CHILDHOOD TRAUMA IN RECENT ONSET PSYCHOSIS AND ARMS SUBJECTS: A CONTROLLED STUDY
Alba Valiente*, Rosa Marine, Eduard Izquierdo, Montse Sole, Angel Cabezas, Sara Arranz, Alfonso Gutierrez-Zotes, Javier Labad, Vanessa Sanchez-Gistau

S157. THE EPIDEMIOLOGY OF FIRST EPISODE PSYCHOSIS IN EARLY INTERVENTION IN PSYCHOSIS SERVICES: FINDINGS FROM THE SOCIAL EPIDEMIOLOGY OF PSYCHOSES IN EAST ANGLIA [SEPEA] NATURALISTIC COHORT STUDY
James Kirkbride*, Yasir Hameed, Gayatri Ankireddipalli, Nikolett Kabacs, Carolyn Crane, Antonio Metastasio, Ashkan Espandian, Stella Styliani, Suneetha Siddabattuni, Konstantinos Ioannidis, Ben Walden, Rebecca Webster, Jesus Perez, Peter Jones

S158. SCHIZOTYPY AND MIGRATION IN A GENERAL POPULATION SAMPLE IN FRANCE
Andrea Tortelli*, Andrei Szoke, Gregoire Baudin

S159. CLOSING THE GAP: SENSITIVITY AND SPECIFICITY OF NEUROLOGICAL SIGNS ACROSS THE LIFESPAN PROFILING IN SCHIZOPHRENIA SPECTRUM DISORDERS

S160. NEUROBIOLOGICAL SUBTYPING OF SCHIZOPHRENIC AND AFFECTIVE PSYCHOSES IN CROSS-DISORDER COHORTS
Oliver Gruber*

S161. EARLY PARENTAL LOSS AND NRG1 HAPICE GENOTYPES ARE DIFFERENTIALLY ASSOCIATED WITH COGNITIVE FUNCTION IN SCHIZOPHRENIA
Vaidy Swaminathan*, Ruth Wells, Avril Pereira, Leonid Churilov, Chad Bousman, Vanessa Cropley, Christos Pantelis, Andrew Zalesky, Rhoshel Lenroot, Jason Bruggemann, Cyndi Shannon Weickert, Thomas Weickert, Suresh Sundram

S162. CORRELATION OF BDNF MRNA EXPRESSION WITH VAL66MET POLYMORPHISM IN BRAIN Sern Yih Cheah, Leesa Wockner, Robert McLeay, Bruce Lawford, Ross Young, Charles Morris, Joanne Voisey*

S163. AUDITORY PROCESSING IN AUTISM SPECTRUM DISORDER: MISMATCH NEGATIVITY DEFICITS
Niels Bilenberg*, Chantal Vlaskamp, Gitte Falcher Madsen, Jens Richardt Jepsen, Sarah Durston, Cathriona Cantio, Birte Glenthoj, Bob Oranje

S164. PRIMARY AND SECONDARY ALTERATIONS OF WHITE MATTER CONNECTIVITY IN SCHIZOPHRENIA: A WHOLE-BRAIN TRACTOGRAPHY-BASED ANALYSIS
S165. THE BENEFIT OF MACRO-ANATOMICAL ALIGNMENT FOR FMRI-BASED IMAGING GENETICS OF COMMON SCHIZOPHRENIA RISK VARIANTS
Robert Bittner*, Peter Hahn, Christina Novak, Tom Lancaster, Astrid Rehner, Anna Seitz, Danko Nikolic, Andreas Reif, David Linden

S166. PREFRONTAL-STRIATAL FUNCTIONING OF EFFORT-BASED REINFORCEMENT IN SCHIZOPHRENIA
Il Ho Park*, Byong-Chul Lee, Joong Il Kim, Min-Seung Koo

S167. BRAIN ACTIVATION DURING FACIAL AFFECT PERCEPTION DIFFERENTIATES HIGH VS. LOW FUNCTIONING INDIVIDUALS WITH SCHIZOPHRENIA
Tatiana Karpolouzian, Matthew Schroeder, Eva Alden, Samantha Abram, James Reilly, Matthew Smith*

S168. TASK-RELATED NETWORK ANALYSIS IN SCHIZOPHRENIA PATIENTS WITH AUDITORY VERBAL HALLUCINATIONS
Leonie Bais*, Ans Vercaemen, Edith Liemburg, Henderikus Knegtering, André Aleman

S169. FUNCTIONAL CONNECTIVITY OF THE DEFAULT MODE NETWORK IN FIRST EPISODE PSYCHOSIS: PRELIMINARY FINDINGS
Eleni Ganella, Vanessa Copley, James Olver, Bernhard Baune, Patrick D McGorry, Ian Everall, G Paul Amminger, Christos Pantelis, Andrew Zalesky, Cali Bartholomeusz*

S170. NEURAL MECHANISMS OF HOW MOOD MODULATES REALITY-MONITORING IN SCHIZOPHRENIA
Karuna Subramaniam*, Ryan LoPilato, Jenny Marino, Daniel Mathalon, Srikanth Nagarajan, Sophia Vinogradov

S171. FRONTAL HYPER-ACTIVATION DURING CAUSAL WORD GENERATION IN SOCIAL CONTEXTS IN SCHIZOPHRENIA
Kim Wende*, Carolin Wagener, Andreas Jansen, Benjamin Straube, Mirjam Stratmann, Tilo Kircher, Arne Nagels

S172. FUNCTIONAL CONNECTIVITY AND DELUSIONAL COGNITIVE BIAS: A RESTING STATE FUNCTIONAL MAGNETIC RESONANCE IMAGING STUDY ON SCHIZOPHRENIA
Jun Miyata*, Akihiko Sasamoto, Nobukatsu Sawamoto, Yasuo Mori, Masanori Isobe, Shinichi Urayama, Toshihiko Aso, Hidenaoka Fukuyama, Toshiya Murai, Hidehiko Takahashi

S173. FUNCTIONAL NEUROIMAGING OF WORKING MEMORY ENCODING IN A ORIENTATION CHANGE DETECTION TASK IN SCHIZOPHRENIA AND FIRST-DEGREE RELATIVES
Michael Stäblein*, Dominik Kraft, Helena Storchak, Denis Ghinea, Christian Knöchel, Robert Bittner, Andreas Reif, Viola Oertel-Knöchel

S174. NEURAL, COGNITIVE, AND CLINICAL CORRELATES OF CEREBELLAR-DEPENDENT ASSOCIATIVE LEARNING IN INDIVIDUALS WITH SCHIZOPHRENIA
S175. FUNCTIONAL CONNECTIVITY BETWEEN MIDLINE STRUCTURES OF THE DEFAULT MODE NETWORK IS INCREASED IN FIRST-EPISODE PSYCHOSIS DURING A MOVIE STIMULUS (ALICE IN WONDERLAND)
Eva Rikandi*, Teemu Mäntylä, Jaana Suvisaari, Tuukka Raij

S176. WIDESPREAD REDUCTIONS IN RESTING-STATE FUNCTIONAL CONNECTIVITY IN A TREATMENT-RESISTANT SCHIZOPHRENIA GROUP
Eleni Ganella*, Cali Bartholomeusz, Christos Pantelis, Ian Everall, Christina Phassouliotis, Andrew Zalesky

S177. HYPOFUNCTION OF BASAL GANGLIA INDIRECT PATHWAY IN SCHIZOPHRENIA
Jong Yoon*

S178. THE PREDICTIVE VALUE OF DIFFERENT NEUROCHEMICAL PROFILES FOR TREATMENT OUTCOME IN ANTIPSYCHOTIC-NAIVE SCHIZOPHRENIA PATIENTS
Anne Sigvard*, Kirsten Borup Bojesen, Kasper Jessen, Egill Rostrup, Lars Thorbjørn Jensen, Albert Gjedde, Birte Genthøj

S179. THALAMIC AND HIPPOCAMPUS DRIVEN ALTERATIONS IN LARGE-SCALE NEURAL OSCILLATIONS DIFFER ACROSS THE DIFFERENT ILLNESS STAGES OF SCHIZOPHRENIA: AN MEG RESTING-STATE STUDY.
Tineke Grent-'t-Jong*, Tobias Navarro Schroeder, Limin Sun, Christine Grützner, F. Markus Leweke, Davide Rivolta, Andreas Sauer, Michael Wibral, Wolf Singer, Peter Uhlhaas

S180. PROLACTIN LEVELS IN PATIENTS WITH A FIRST PSYCHOTIC EPISODE WITH NO PREVIOUS ANTIPSYCHOTIC TREATMENT. RELATIONSHIP WITH SEXUAL SIDE EFFECTS. PRELIMINARY RESULTS.
Marta Coromina*, Núria Del Cacho, Anna Butjosa, Regina Vila-Badia, Christian Núñez, Elena Rubio-Abadal, Marta Pardo, Sheila López-Romero, GRUP PEP-PROLACTINA, Judith Usall

S181. ORAL HEALTH IN FIRST EPISODE PSYCHOSIS: QUANTITATIVE AND QUALITATIVE STUDY ON PREVALENCE OF ORAL HEALTH PROBLEMS, RISK FACTORS AND NEED FOR INTERVENTION
Aaltsje Malda*, Annemieke Zwart, Sonja Kuipers, Nynke Boonstra

S182. CONNECTOMIC CORRELATES OF RESPONSE TO TREATMENT IN FIRST-EPISODE PSYCHOSIS
Nicolas Crossley*, Tiago Reis Marques, Heather Taylor, Christopher Chaddick, Flavio Dell’Acqua, AAT Simone Reinders, Valeria Mondelli, Marta Di Forti, Andrew Simmons, Anthony David, Shitij Kapur, Carmine Pariente, Robin Murray, Paola Dazzan

S183. STRUCTURAL BRAIN ABNORMALITIES IN MEDICATION NAIVE OFFSPRING OF SCHIZOPHRENIA AND BIPOLAR PATIENTS
Godefridus Koevoets*, Neeltje Van Haren, Matthijs Vink, Rene Kahn, Manon Hillegers
S184. ALTERATIONS OF STRUCTURAL CONNECTIVITY IN PATIENTS WITH SCHIZOPHRENIA: A SYSTEMATIC REVIEW
Hyerim Oh*, Tae Young Lee, Jun Soo Kwon

S185. HERITABILITY OF VOLUMETRIC BRAIN CHANGES IN ADOLESCENCE
Rachel Brouwer*, Marinka Koenis, Suzanne Swagerman, Dorret Boomsma, Hilleke Hulshoff Pol

S186. BRAIN METABOLITES IN ULTRA HIGH RISK PATIENTS FOR PSYCHOSIS
Therese van Amelsvoort, Mariken de Koning, Tobias Gleich, Matthan Caan, Oswald Bloemen*

S187. ARCUATE FASCICULUS SIZE IS ASSOCIATED WITH AUDITORY HALLUCINATIONS
Liv E. Falkenberg*, René Westerhausen, Kenneth Hugdahl

S188. INFLUENCE OF ENVIRONMENTAL RISK FACTORS ON WHITE MATTER MICROSTRUCTURE: A DIFFUSION TENSOR IMAGING STUDY
Elena Fischer*, Bruno Dietsche, Felicitas Meier, Jennifer Engelen, Henrike Bröhl, Udo Dannlowski, Axel Krug, Tilo Kircher

S189. RELATIONSHIPS BETWEEN CORPUS CALLOSUM VOLUME AND FUNCTIONAL ASYMMETRY IN THE LANGUAGE NETWORK IN SCHIZOPHRENIA AND BIPOLAR DISORDER
Maxime Tréhout*, Leroux Elise, Delcroix Nicolas, Sonia Dollfus

S190. RESTING STATE DEFICITS IN THETA BAND CONNECTIVITY IN SCHIZOPHRENIA USING MAGNETENCEPHALOGRAPHY
Sarah Lancaster*, Susan Rossell, William Woods, Matthew Hughes

S191. STRUCTURAL BRAIN NETWORK DISTURBANCES IN THE PSYCHOSIS SPECTRUM
Edwin van Dellen*, Marc Bohlken, Laurijn Draaisma, Prejaas Tewarie, Remko Van Lutterveld, Rene Mandl, Cornelis Stam, Iris Sommer

S192. INSIGHT AND WHITE MATTER CHANGES IN FIRST-EPISODE SCHIZOPHRENIA
Laila Asmal*, Stefan du Plessis, Matthijs Vink, Bonginkosi Chiliza, Robin Emsley

S193. BRAIN MORPHOMETRY CORRELATES OF SOCIAL COGNITION IN SCHIZOPHRENIA: A SYSTEMATIC REVIEW
Abhinav Nahar*, Ramajayam Govindaraj, Urvakhsh Meherwan Mehta

S194. FUNCTIONAL DYSCONNECTIVITY IN MEDICATION-NAïVE SCHIZOPHRENIA PATIENTS WITH AUDITORY VERBAL HALLUCINATIONS
Xiao Chang*, Guusje Collin, Yibin Xi, Longbiao Cui, Huaning Wang, Hong Yin, René S. Kahn, Martijn Van Den Heuvel

S195. MUSICAL DEFICITS AND CORTICAL THICKNESS IN PATIENTS WITH SCHIZOPHRENIA
Ryoshuke Fujito, Ken Sawada*, Masayoshi Minese, Sanae Hatada, Shigeru Morinobu, William Honer

S196. PHENOTYPIC CHARACTERIZATION OF SCHIZOPHRENIA PATIENTS WITH LINKAGE TO CHROMOSOME 13Q, 1P AND 13Q + 1P
Johannes Roos*, Pierre Malherbe, René Ehlers, Maria Karayiorgou
S197. RESULTS FROM A GENOME-WIDE ASSOCIATION STUDY WITH CLINICAL RESPONSE TO DULOXETINE AND PLACEBO
Daniel Müller*, Malgorzata Maciukiewicz, Victoria Marshe, Arun Tiwari, Trehani Fonseka, Natalie Freeman, James Kennedy, Susan Rotzinger, Jane Foster, Sidney Kennedy

S198. INVESTIGATION OF THE GENETIC BASIS OF SPECIFIC PSYCHOTIC EXPERIENCES IN ADOLESCENCE
Oliver Pain*, Frank Dudbridge, Alastair Cardno, Daniel Freeman, Paul Lichtenstein, Stanley Zammit, Robert Plomin, Angelica Ronald

S199. ASSOCIATION OF POLYGENIC RISK SCORE OF DOPAMINERGIC PATHWAY WITH SCHIZOPHRENIA AND ITS GREY MATTER VOLUME ALTERATION OF PUTAMEN
Jian Zhang*, Hongyan Ren, Qiang Wang, Tao Li

S200. FURTHER EVIDENCE FOR VULNERABILITY-STRESS MODEL OF SCHIZOPHRENIA: POSSIBLE ROLE OF FKBP5 GENE HAPLOTYPES IN A SERBIAN POPULATION
Marina Mihaljevic*, Katarina Zeljic, Sanja Andric, Tijana Mirjanic, Ivana Novakovic, Nadja Maric

S201. THE ROLE OF A CATHECHOL-O-METHYLTRANSFERASE (COMT) VAL158/MET GENETIC POLYMORPHISM IN SCHIZOPHRENIA: A SYSTEMATIC REVIEW AND UPDATED META-ANALYSIS OF 32 816 SUBJECTS
Tania Gómez Peralta*

S202. METHYLOMIC CHANGES IN INDIVIDUALS EXPOSED IN UTERO TO DIETHYLSILBESTROL
Fabrice Rivollier*, Oussama Kebir, Boris Chaumette, Marie-Odile Krebs

S203. GENETIC OVERLAP BETWEEN AMYOTROPHIC LATERAL SCLEROSIS AND SCHIZOPHRENIA
Dick Schijven*, Russell McLaughlin, Jurjen Luykx, Wouter van Rheenen, Ammar Al-Chalabi, René Kahn, Leonard van den Berg, Orla Hardiman, Jan Veldink

S204. MATERNAL IMMUNE ACTIVATION REDUCES TRANSLOCATOR PROTEIN (TSPO) EXPRESSION IN THE OFFSPRING PREFRONTAL CORTEX
Tina Notter*, Urs Meyer

S205. THE ACUTE AND CHRONIC EFFECTS OF ANTIPSYCHOTIC TREATMENT ON SYNAPTIC DOPAMINE LEVELS: PRELIMINARY RESULTS FROM A META-ANALYSIS OF MICRODIALYSIS STUDIES
Joseph Kambeitz*

S206. ASSESSING FACTORS OF TREATMENT RESISTANCE TO ANTIPSYCHOTICS: NICOTINE AND CAFFEINE AFFECT HALOPERIDOL-INDUCED EFFECTS ON BEHAVIORS AND ON MOLECULES OF THE POST-SYNAPTIC DENSITY.
Elisabetta F. Buonaguro*, Carmine Tomasetti, Federica Marmo, Gianmarco Latte, Rodolfo Rossi, Camilla Avagliano, Felice Iasevoli, Andrea de Bartolomeis
S207. INFLUENCE OF VAL158MET POLYMORPHISM IN COMT GENE ON EXECUTIVE FUNCTION AND GREY MATTER IN EARLY ONSET-FIRST EPISODE PATIENTS
Elisa Rodríguez-Toscano, David Fraguas, Miquel Bíoque, Ana Gonzalez-Pinto, Antonio Lobo, Miguel Bernardo Arroyo, Mara Parellada, Marta Rapado-Castro*

S208. PHENOTYPE AND FUNCTION OF MYELOID CELLS IN SCHIZOPHRENIA PATIENTS

S209. ABNORMALITIES IN THE UNFOLDED PROTEIN RESPONSE IN SCHIZOPHRENIA
Pitna Kim*, Vahram Haroutunian, James Meador-Woodruff

S210. THE ROLE OF ATP SIGNALING IN CANNABIS-INDUCED PSYCHOTIC EXPERIENCES
Yujie He*

S211. PROTEASOME ABUNDANCE AND ACTIVITY IN THE SUPERIOR TEMPORAL GYRUS OF PATIENTS WITH SCHIZOPHRENIA
Madeline Scott*, Maria Rubio, Vahram Haroutunian, James Meador-Woodruff

S212. MATERNAL IMMUNE ACTIVATION INDUCES EARLY CHANGES IN NEURODEVELOPMENT OF MALE AND FEMALE RATS
Michelle Edye*, Katie Murray, Joanna Dennison, Herve Boutin, Michael Harte, Irene Knuesel, Eric Prinssen, Joanna Neill

S213. RETICULAR THALAMIC CONTRIBUTION IN THE CONTROL OF THALAMOCORTICAL PATHWAYS: INVOLVEMENT IN SCHIZOPHRENIA RELATED BEHAVIORS
Hasna Elboukhari*, Zakaria Ouhaz, Saadia Ba M’Hamed, Mohamed Bennis

S214. PUPILLARY CHANGES AS SIGNS OF AUTONOMIC DYSBALANCE IN A RAT MODEL OF NEUROPSYCHIATRIC DISORDERS
Alexandra Büki*, Gabriella Kekesi, Gyongyi Horvath

S215. FAMILIAL AGGREGATION OF SCHIZOTYPAL TRAITS AND ITS CORRELATION WITH THE PRESENCE OF DERMATOGLYPHIC ANOMALIES: A STUDY BASED ON HEALTHY RELATIVES OF PATIENTS WITH SCHIZOPHRENIA-SPECTRUM DISORDERS
Jordi Soler Garcia*, Panagiotis Ferentinos, Claudia Prats Balado, Salvador Miret, Maria Giralt, Lourdes Fananas, Mar Fatjó-Vilas

S216. A ROLE FOR BDNF IN MEDIATING ADOLESCENT GABAERGIC INTERNEURON EXPRESSION
Xin Du*, Kelsey Serena, Candace Wu, Wu Jeong Hwang, Schroeder Anna, Adrienne Grech, Rachel Hill

S217. SALIENCE PROCESSING AND PSYCHOPATHOLOGY FOLLOWING VERY PRETERM BIRTH
Jasmin Kroll*, Philip Brittain, Sean Froudist-Walsh, Slava Karolis, Jane Tseng, Chiara Nosarti

S218. M-RESIST, AN INTEGRATIVE M-HEALTH SOLUTION FOR TREATMENT-RESISTANT SCHIZOPHRENIA ACCORDING TO USER’ NEEDS: FOCUS GROUPS FINDINGS
S219. CHANGE - A RANDOMIZED CLINICAL TRIAL TO INVESTIGATE THE EFFECT OF AN INDIVIDUALIZED LIFESTYLE INTERVENTION COMPARED TO CARE COORDINATION COMPARED TO TREATMENT AS USUAL
Ane Jakobsen*

S220. EFFECT OF BRIEF INDIVIDUAL COGNITIVE BEHAVIORAL THERAPY FOR AUDITORY HALLUCINATIONS ON NEGATIVE SYMPTOMS IN A SAMPLE OF EGYPTIAN PATIENTS WITH SCHIZOPHRENIA
Dalia Nagui Rizk*, Hoda Salama, Tarek Molokhiya, Layla Kassem

S221. THE IBEEP STUDY: EXPLORING THE FEASIBILITY AND EFFECTS OF EXERCISE IN EARLY PSYCHOSIS
Joseph Firth*, Rebekah Carney, Rebecca Elliott, Paul French, Alison Yung

S222. THE EFFICACY OF NON-PHARMACOLOGICAL INTERVENTIONS (NPIS) ON BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) IN PATIENTS WITH SCHIZOPHRENIA: A SYSTEMATIC REVIEW.
Kenji Sanada*, Iñaki Zorrilla, Mónica Martinez-Cengotitabengoa, Ana Gonzalez-Pinto

S223. THE ROLE OF COMPREHENSIVE PSYCHOSOCIAL OUTPATIENT PROGRAMMING IN THE TREATMENT OF FIRST EPISODE PSYCHOSIS PATIENTS.
Laura Pientka*, S. Charles Schulz, Kelvin Lim, Suzanne Geier Jasberg

S224. MODEN: A THERAPEUTIC INTEGRATIVE EDUCATIONAL PROGRAM FOR PEOPLE WITH SCHIZOPHRENIA FOCUSING ON NEGATIVE AND COGNITIVE SYMPTOMS: PRELIMINARY RESULTS IN 22 PATIENTS
Marie-Cécile Bralet*, Sarah-Lise Farhat, Christophe Hochard, Sandrine Orens, Thierry Lambert, Corine Gautier, Corine Bismuth, Adrian Melac, Audrey Tanguy

S225. A NEW RECOVERY FOCUSED INTERVENTION COMBINING PEER SUPPORT AND SKILL TRAINING FOR PEOPLE WITH SCHIZOPHRENIA: RESULTS OF A PILOT STUDY
Jelle Sjoerd Vogel*, Mark Van der Gaag, Stynke Castelein, Marte Swart, Edith Liemburg, Petrie Roobol

S226. INTERVENTIONS FOR CARERS OF PEOPLE WITH PSYCHOSIS: IS IT TIME TO CONSIDER A ROLE FOR MASSIVE OPEN ONLINE COURSES (MOOCs)?
Juliana Onwumere*, Shitij Kapur, Elizabeth Kuipers

S227. THE PRACTICE AND EFFECTIVENESS OF ELECTROCONVULSIVE THERAPY
Sung Woo Joo*, Chang Yoon Kim, Jung Sun Lee, Yeon Ho Joo

S228. PREDICTIVE VALUE OF THE PREMORBID ADJUSTMENT SCALE AND THE STRAUSS AND CARPENTER PROGNOSTIC SCALE FOR GLOBAL FUNCTIONING AT 2 YEARS AFTER THE FIRST PRESENTATION OF PSYCHOTIC SYMPTOMS IN ADOLESCENTS WITH EARLY ONSET PSYCHOSIS
Raquel Vicente, Pilar Baos, Celso Arango, Beatriz Paya, Angel del Rey-Meijas, Josefina Castro-Fornieles, Ana Gonzalez-Pinto, Montse Graell, Dolores Moreno, Marta Rapado-Castro*
S229. COULD EVENTS OF WONDERLAND HAPPEN IN REAL LIFE—GENERALIZATION OF REALITY DISTORTION IN FIRST EPISODE PSYCHOSIS.
Tuukka Raji*, Teemu Mäntylä, Eva Rikandi, Tuula Kieseppä, Jaana Suvisaari

S230. DEFICIT SYNDROME IN SCHIZOPHRENIA IS NOT RELATED TO DURATION OF ILLNESS, AGE OF ONSET, OR GENDER, IN A SPANISH SAMPLE OF PATIENTS.
Álvaro López-Díaz*, José Luis Fernández-González, Pablo Lorenzo-Herrero

S231. A LINGUISTIC COMPARISON BETWEEN AUDITORY VERBAL HALLUCINATIONS IN PATIENTS WITH A PSYCHOTIC DISORDER AND IN NONPSYCHOTIC INDIVIDUALS: NOT JUST WHAT THE VOICES SAY, BUT HOW THEY SAY IT
Janna de Boer*, Sophie Herina, Edwin van Dellen, Frank Wijnen, Iris Sommer

S232. SYMPTOM CONTENT STUDY OF PERCEPTUAL ABNORMALITIES IN THOSE AT CLINICAL HIGH RISK FOR PSYCHOSIS
Yun Lu*, Catherine Marshall, Kristin Cadenhead, Tyrone Cannon, Barbara Cornblatt, Diana Perkins, Larry Seidman, Ming Tsuang, Elaine Walker, Scott Woods, Carrie Bearden, Daniel Mathalon, Thomas McGlashan, Jean Addington

S233. INSIGHT EVOLUTION: IS THERE A DIFFERENCE BETWEEN SELF AND HETERO ASSESSMENT?
Delphine Capdevielle*, Joanna Norton, Aurélie Schandrin, guillaume FOND, Pierre-Michel LLORCA

S234. TARDIVE DYSKINESIA AND TARDIVE DYSTONIA WITH SECOND-GENERATION ANTIPSYCHOTICS IN SCHIZOPHRENIA AND BIPOLAR DISORDER PATIENTS UNEXPOSED TO FIRST-GENERATION ANTIPSYCHOTICS
So Yung Yang, Seunghyong Ryu, Jae Hyun Yoo, Ahram Lee, Ji Hyun Baek, Ji Sun Kim, Mi Ji Choi, Kyooseob Ha, Kyung Sue Hong*

S235. PAM-2, A POSITIVE ALLOSTERIC MODULATOR OF THE α7 NACHRS, REVERSES SCHIZOPHRENIA-LIKE COGNITIVE DEFICITS IN RATS.
Agnieszka Nikiforuk*, Agnieszka Potasiewicz, Tomasz Kos, Małgorzata Hołuj, Piotr Popik, Hugo R Arias

S236. GABAERGIC DYSFUNCTION FOLLOWING PRENATAL INFECTION IN MICE: MODULATORY ACTIVITY OF CHRONIC LURASIDONE ADMINISTRATION.
Juliet Richetto, Alessia Luoni, Linda Longo, Teresa Calzoni, Urs Meyer, Marco Andrea Riva*

S237. A POLYGENIC SCORE REFLECTING PREFRONTAL DOPAMINE D2 RECEPTOR CO-EXPRESSION AND ADMINISTRATION OF BROMOCRIPTINE INTERACT NON-LINEARLY ON PREFRONTAL ACTIVITY DURING WORKING MEMORY
Pierluigi Selvaggi*, Giulio Pergola, Barbara Gelao, Maria Antonietta Nettis, Pasquale Di Carlo, Valentina Felici, Leonardo Fazio, Giuseppe Blasi, Alessandro Bertolino
S238. HOW WELL DO PATIENTS WITH A FIRST EPISODE OF SCHIZOPHRENIA RESPOND TO ANTIPSYCHOTICS: A META-ANALYSIS
Yikang Zhu*, Chunbo Li, Maximilian Huhn, Philipp Rothe, Susanne Bächer, Johannes Schneider, Matteo Rabaioli, Stefan Leucht

S239. TRAJECTORIES OF TREATMENT RESPONSE IN HALLUCINATION
Igne Sinkeviciute*, Kenneth Hugdahl, Rolf Gjestad, Eirik Kjelby, Rune A. Kroken, Else-Marie Løberg, Hugo A. Jørgensen, Erik Johnsen

S240. PRIOR D2 ANTAGONIST ANTIPSYCHOTIC DRUG TREATMENT PREVENTS RESPONSE TO NOVEL TARGET COMPOUNDS IN MAM MODEL OF SCHIZOPHRENIA: POTENTIAL CIRCUMVENTION USING ARIPIPRAZOLE
Susan Sonnenschein*, Kathryn Gill, Sarah Miller, Anthony Grace

S241. MAINTENANCE ANTIPSYCHOTIC DOSE CAN BE DECREASED IN LATE-LIFE SCHIZOPHRENIA: A PROSPECTIVE DOPAMINED2/3 RECEPTOR OCCUPANCY STUDY WITH [11C]-RACLOPRIDE
Shinichiro Nakajima*, David Mamo, Fernando Caravaggio, Takefumi Suzuki, Hiroyuki Uchida, Philip Gerretsen, Wanna Mar, Taref Rajji, Benoit Mulsant, Bruce Pollock, Ariel Graff-Guerrero

S242. THE PHOSPHODIESTERASE 10A SELECTIVE INHIBITOR TAK-063 IMPROVES COGNITIVE FUNCTIONS ASSOCIATED WITH SCHIZOPHRENIA IN RODENT MODELS
Kazunori Suzuki*, Eri Shiraishi, Akina Harada, Noriko Suzuki, Haruhide Kimura

S243. LONG-TERM ANTIPSYCHOTIC USE AND BRAIN VOLUME CHANGES IN SCHIZOPHRENIA: THE NORTHERN FINLAND BIRTH COHORT 1966 STUDY
Sanna Huhtaniska*, Tuomas Heikka, Erika Jääskeläinen, Jani Moilanen, Tanja Nordström, Jussi Tohka, Jose V. Manjon, Pierrick Coupe, Lassi Björnholm, Juha Veijola, Matti Isohanni, Vesa Kiviniemi, Graham Murray, Jouko Miettunen

S244. THE DOPAMINE D2 RECEPTOR PARTIAL AGONIST 2-BROMOTERGURIDE AMELIORATES PCP-INDUCED DEFICITS IN PREPULSE INHIBITION AND NOVEL OBJECT RECOGNITION IN RATS
Emilia Tarland*, Heinz Pertz, Heidrun Fink, Jan Brosda

S245. PRESCRIBING PATTERNS OF ANTIDEPRESSANTS AND OTHER DRUGS IN KOREAN BIPOLAR AFFECTIVE DISORDER PATIENTS
Dayae Baek*, Woon Yoon, Yeon Ho Joo, JungSun Lee, Chang Yoon Kim

S246. PATTERNS OF USE OF ARIPIPRAZOLE LONG-ACTING INJECTABLE IN STANDARD CLINICAL PRACTICE
Sergio Sánchez Alonso*, Laura Mata, Elsa Arrúa, Constanza Vera, Miren Iza, Raquel Álvarez, Santiago Ovejero

S247. USE OF ARIPIPRAZOLE LONG-ACTING INJECTABLE IN TWO INPATIENT UNITS
Santiago Overjero*, Raquel Alvarez, Miren Iza, Nore Palomar, Marta Migoya, Fanny Cegla, Laura Mata, Sergio Sanchez
S248. THE MODULATION OF CYCLIC NUCLEOTIDE DEPENDENT PATHWAYS IN THE RAT STRIATUM BY CPL-500-036-02 - A PHOSPHODIESTERASE 10A INHIBITOR.
Sylwia Janowska*, Piotr Pankiewicz, Maciej Świątkiewicz, Marlena Welniak-Kaminska, Malgorzata Borkowska, Jakub Majer, Rafal Moszczyński-Petkowski, Krzysztof Dubiel, Maciej Wieczorek, Mikołaj Matłoka

S249. RELATIVE EFFICACY AND SAFETY OF INDIVIDUAL SECOND-GENERATION ANTIPSYCHOTICS IN TREATING FIRST EPISODE PSYCHOSIS: A SYSTEMATIC REVIEW AND META-ANALYSIS
Jianping Zhang*, Juan Gallego, Tianxu Xia, Delbert Robinson, Anil Malhotra, John Kane, Christoph Correll

S250. ELECTROCONVULSIVE THERAPY AUGMENTATION IN CLOZAPINE-RESISTANT SCHIZOPHRENIA: A FRENCH SAMPLE.
Maud Rotharmel*, Pierre Quesada, Vincent Compere, Olivier Guillin

S251. ERRONEOUS INTERVIEWING AND RATING PATTERNS DETECTED DURING SCREENING PREDICT SUBSEQUENT QUALITY ISSUES
David Daniel*, Alan Kott

S252. RELATIONSHIP BETWEEN PSYCHIATRIC PRESCRIPTION PATTERN AND ADHERENCE IN PATIENTS WITH SCHIZOPHRENIA
Soo hyun Joe*, Yeonho Joo, Changyoon Kim, Joonho Ahn, Joong Sun Lee

S253. 1 YEAR MIRROR STUDY USING PALIPERIDONE PALMITATE FOR RELAPSE PREVENTION OF SCHIZOPHRENIA IN 4 UNIVERSITY HOSPITALS IN CANADA.
Philippe Vincent*, Marie-France Demers, Josée Duchesneau, Violaine Masson

S254. AUGMENTING NMDA RECEPTOR SIGNALING IN SCHIZOPHRENIA ENHANCES NEURAL RESPONSIVITY AND WORKING MEMORY WITHOUT AFFECTING EXPERIENCE-DEPENDENT PLASTICITY.
Jen Forsyth*, Peter Bachman, Daniel Mathalon, Brian Roach, Elissa Ye, Robert Asarnow

S255. THE RELATION OF THOUGHT DISORDERS IN SCHIZOPHRENIA WITH REMISSION OF SYMPTOMS AND PSYCHOSOCIAL IMPROVEMENT
Berna Yalinçetin, Koksal Alptekin*, Levent Var, Halis Ulaş, İ. Tolga Binbay, Berna Binnur Akdede

S256. EFFECT OF BEXIPRAZOLE ON LONG-TERM FUNCTIONING IN ADULTS WITH SCHIZOPHRENIA: RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MAINTENANCE STUDY
Wolfgang Fleischhacker*, Mary Hobart, John Ouyang, Andy Forbes, Catherine Weiss, Emmanuelle Weiller

S257. PSYCHOSIS IN INTRA-FAMILIAL HOMICIDE
Dominique Bourget*, Pierre Gagné, Alain Labelle
S258. RESEARCHER KNOW THY AUDIENCE: GETTING TRANSLATION RIGHT
Eoin Killackey*

S259. PREVALENCE AND CORRELATES OF SELF-STIGMA AMONG A SAMPLE OF NIGERIAN PATIENTS WITH SCHIZOPHRENIA
Babatunde Fadipe*, Timothy Adebawole, Adeboyega Ogunwale, Andrew Olagunju, Yetunde Fadipe

S260. SOCIAL SKILLS EVALUATION OF PATIENTS WITH SCHIZOPHRENIA: COMPARISON BETWEEN TREATMENT RESISTANT, NON TREATMENT RESISTANT AND NORMAL CONTROLS
Silvia Scemes, Mariangela Gentil Savoia, Zilda Del Prette, Paulo Mestriner, Aline Roberta da Silva, Helio Elkis*

S261. RELATIONSHIP OF INSIGHT WITH COGNITIVE FUNCTION, PSYCHOPATHOLOGY AND PSYCHOSOCIAL FACTORS IN PATIENTS WITH SCHIZOPHRENIA
Seung Hyun Kim*, Jung-Seo Yi, Jung Jin Kim

S262. PREDICTORS AND OUTCOMES FOR PATIENTS WHO REDUCE OR DISCONTINUE THEIR ANTI-PSYCHOTIC TREATMENT AFTER FIRST EPISODE PSYCHOSIS.
Nikolai Albert*, Carsten Hjorthoj, Heidi Jensen, Kelly Allott, Marianne Melau, Merete Nordentoft

S263. COGNITIVE ADAPTATION TRAINING HELPS YOU LIVE AT HOME: INTERIM RESULTS OF THE FINNISH CAT-STUDY
Eila Sailas*, Tuukka Mehtälä, Satu Viertio

S264. DOES BASELINE APATHY PREDICT SOCIAL AND VOCATIONAL OUTCOME AT TWO YEARS FOLLOW UP IN A VOCATIONAL REHABILITATION STUDY?
Helen Bull*, Torill Ueland, June lystad, Stig Evensen, Erik Falkum

S265. COGNITIVE ADAPTATION AS A NURSING INTERVENTION FOR LONG-TERM HOSPITALIZED PATIENTS
Annemarie Stiekema*, Jeroen Redmeijer, Marian Dethmers, Kees Rietberg, Jaap van Weeghel, André Aleman, Dawn Velligan, Richard Bruggeman, Lisette van der Meer

S266. THE EFFICACY OF 12 WEEKS PHYSICAL HEALTH PROMOTION PROGRAM IN PATIENTS WITH MAJOR PSYCHIATRIC DISORDER
Kyuyoung Lee*, Minjung Kang

S267. ASSOCIATION BETWEEN FAMILY HISTORY OF PSYCHIATRIC DISORDERS AND LONG-TERM OUTCOME IN SCHIZOPHRENIA – THE NORTHERN FINLAND BIRTH COHORT 1966 STUDY
Juha Kakela*, Riikka Marttila, Juha Veijola, Matti Isohanni, Heli Koivumaa-Honkanen, Erika Jääskeläinen, Jouko Miettunen

S268. NEGATIVE SYMPTOMS MEDIATE THE RELATIONSHIP BETWEEN SOCIAL COGNITION AND FUNCTIONING IN SCHIZOPHRENIA: A PILOT STUDY
Miguel Bajouco*, Nuno Madeira, Salomé Caldeira, Carolina Roque, Ana Telma Pereira, Maria João Martins, David Mota, Vitor Santos, Sofia Morais, Joana Ribeiro, Ana Sofia Cabral, António Macedo
S269. INVESTIGATION OF THE CORRELATES OF HAPPINESS, LIFE SATISFACTION AND SUCCESS IN SCHIZOPHRENIA
Sarah Saperia*, Ishraq Siddiqui, Krysta McDonald, Gagan Fervaha, Ofer Agid, Gary Remington, George Foussias

S270. SELF-CLARITY AND DIFFERENT CLUSTERS OF INSIGHT AND SELF-STIGMA IN SERIOUS MENTAL ILLNESS
Ilanit Hasson-Ohayon*, Michal Mashiah-Eizenberg, David Roe, Paul Lysaker

S271. HEALTH RELATED QUALITY OF LIFE IN ANTIPSYCHOTIC-TREATED CHILDREN AND ADOLESCENTS WITH PSYCHOSIS
Dea Gowers Klauber*, Ditte Rudå, Karsten Gjessing Jensen, Marie Stentebjerg-Olesen, Birgitte Fagerlund, Jens R. Jepsen, Anders Fink-Jensen, Christoph U Correll, Anne Katrine Pagsberg

S272. A 24-MONTH FOLLOW-UP EVALUATION OF QUALITY OF LIFE (QOL) AS AN OUTCOME MEASURE FOR COMMUNITY TREATMENT ORDERS (CTOS) IN CENTRAL ALBERTA, CANADA
Cornelius Ehlers*

S273. THE SOCIAL FUNCTIONALITY OF SCHIZOPHRENIC PATIENTS AND THE BURDEN EXPERIENCED BY THEIR CAREGIVERS: A SAMPLE OF TURKEY
Yunus Kayar*, Fatma Öz

S274. CAREGIVER BURDEN IN SCHIZOPHRENIA: POOLED ANALYSIS OF THE INVOLVEMENT EVALUATION QUESTIONNAIRE DATA FOR PALPERIDONE PALMITATE 3-MONTH FORMULATION
Srihari Gopal*, Haiyan Xu, Kelly McQuarrie, Adam Savitz, Isaac Nuamah, Kimberly Woodruff, Maju Mathews

S275. HEALTH-RELATED QUALITY OF LIFE AND BURDEN CAREVIGER’S OF PEOPLE WITH SEVERE MENTAL HEALTH DISORDERS.
Gemma Prat*, Jordi Giménez-Salinas, Crespo Maria de la Cruz, Gonzalez Jennifer, Monreal Rebeca, Fernández-Capó Maria

S276. QUALITY OF LIFE AND RESILIENCE IN OUTPATIENTS WITH SCHIZOPHRENIA
Fabienne Wartelsteiner*, Beatrice Frajo-Apor, Georg Kemmler, Anna-Sophia Welte, Yuya Mizuno, Hiroyuki Uchida, Wolfgang Fleischhacker, Alex Hofer

S277. BELIEF AND DISTRESS IN PSYCHOTIC COMPARED TO NON-PSYCHOTIC HALLUCINATORS
Megan Kelley*, Philip Corlett

S278. TREATMENT DECISIONMAKING AMONG YOUTH WITH EARLY PSYCHOSIS IN THE US: PRELIMINARY FINDINGS
Neely Myers*

S279. YOUTH MENTAL HEALTH SERVICES IN ITALY: AN ACHIEVABLE DREAM?
S280. RELATIONSHIP BETWEEN DIRECTOR LEADERSHIP OF COMMUNITY MENTAL HEALTH CENTER AND ORGANIZATIONAL EFFECTIVENESS
Myungsun Cho, Jung-Seo Yi, Myung Hun Jung*

S281. DO ROUTINE OUTCOME MONITORING RESULTS TRANSLATE TO CLINICAL PRACTICE? A CROSS-SECTIONAL STUDY IN PATIENTS WITH A PSYCHOTIC DISORDER
Magda Tasma*, Marte Swart, Gert Wolters, Edith Liemburg, Richard Bruggeman, Henderikus Kneegtering, Stynke Castelein

S282. BIAS BLASTER, A GAME TO BEAT INTERPRETATION BIAS IN PATIENTS WITH PSYCHOSIS
Nynke Boonstra*, Annemieke Zwart, Aaltsje Malda, Mechteld Radermacher, Job van’t Veer, Lian van der Krieke

S283. PERSON CENTERED PSYCHOSIS CARE (PCPC) IN AN INPATIENT SETTING: THE IMPLEMENTATION PROCESS AND STAFF EXPERIENCES
Anneli Goulding*, Lilas Ali, Katarina Allerby, Margda Waern

S284. WHAT DRIVES THE HIGHER INCIDENCE OF PSYCHOSIS IN LONDON COMPARED TO PALERMO?
Alice Mulè, Lucia Sideli, Marta Di Forti, Laura Ferraro, Caterina La Cascia, Crocettarachele Sartorio, Fabio Seminerio*, Giada Tripoli, Daniele La Barbera, Robin Murray

S285. DECIDE STUDY: EFFECTIVENESS OF SHARED DECISION MAKING IN TREATMENT PLANNING AT DISCHARGE OF INPATIENT WITH SCHIZOPHRENIA: DESIGN, TOOLS, CLINICAL AND SUBJECTIVE EXPERIENCES.
José Pérez Revuelta*, Ignacio Lara Ruiz-Granados, Juan Manuel Pascual Paño, Jesús Mestre Morales, José María Villagrán Moreno

S286. DECIDE STUDY: EFFECTIVENESS OF SHARED DECISION MAKING IN TREATMENT PLANNING AT DISCHARGE OF INPATIENT WITH SCHIZOPHRENIA. PRELIMINARY DATA CONCLUSIONS AFTER 20 MONTHS OF THE STUDY
José Pérez Revuelta*, Francisco González Sáiz, José María Mongil San Juan, Carmen Rodríguez Gómez, José María Villagrán Moreno

S287. NEURAL CORRELATES OF FAUX PAS-DETECTION: THE ROLE OF SCHIZOTYPAL PERSONALITY TRAITS
Amelie Schreier, Alexander Rapp*

S288. WHITE MATTER CONNECTIVITY AND PREFRONTAL CORTICAL FOLDING ALTERATIONS IN SCHIZOPHRENIA
C. Christoph Schultz*, Kathrin Koch, Gerd Wagner, Heinrich Sauer

S289. IMPACT OF ASSERTIVE COMMUNITY TREATMENT IN THE OPTIMIZATION OF PHARMACOLOGICAL TREATMENT IN PATIENTS WITH SEVERE MENTAL ILLNESS.
María-José Alvarez*, Pere Roura-Poch, Núria Riera, Clara Blanch, Ana-Cristina Martin, Judit Pons, Josep-Manuel Santos, Francesc Arrufat
S290. INCREASED PERFUSION OF HIGHER ORDER MOTOR CONTROL AREAS IS RELEVANT FOR CATATONIA IN SCHIZOPHRENIA
Lea Schäppi*, Katharina Stegmayer, Nadja Razavi, Andrea Federspiel, Jeanne Moor, Roland Wiest, Werner Strik, Sebastian Walther

S291. USING ARTIFICIAL INTELLIGENCE (AI) TO MONITOR MEDICATION ADHERENCE ON MOBILE DEVICES
Adam Hanina*, Laura Shafner

S292. THE RELATIONSHIP BETWEEN THEORY OF MIND AND THOUGHT- LANGUAGE DISORDER IN SCHIZOPHRENIA
Damlacan Güneyer, Onur Küçük çoban, Halis Ulaş, Tolga Binbay, Koksal Alptekin, Berna Akdede*

S293. BRAIN GREY MATTER ABNORMALITIES RELATED TO LACK OF INSIGHT IN PSYCHOSIS: A VOXEL-BASED MORPHOMETRY INVESTIGATION.
Diana Tordesillas-Gutiérrez, Rosa Ayesa-Arriola, Javier-David Lopez-Morinigo, Anthony David, Benedicto Crespo-Facorro*

S294. CHILDHOOD RESIDENTIAL MOBILITY AND PSYCHOSIS WITHIN A UK SAMPLE
Kathryn Hubbard, Charlotte Gayer-Anderson, Stephanie Beards, Tjasa Velikonja, Valeria Mondelli, Paola Dazzan, Robin Murray, Carmine Pariante, Craig Morgan*

S295. VALIDITY AND BIAS IN ASSESSMENTS OF ABUSE AMONG CASES WITH PSYCHOSIS.
Kathryn Hubbard, Charlotte Gayer-Anderson, Stephanie Beards, Valeria Mondelli, Carmine Pariante, Paola Dazzan, Robin Murray, Ulrich Reininghaus, Craig Morgan*
M1. CHILDHOOD ADVERSITIES IN FIRST EPISODE PSYCHOSIS
Maija Lindgren*, Teemu Mäntylä, Minna Torniainen, Tuula Kieseppä, Outi Mantere, Jaana Suvisaari

M2. CLOZAPINE AS A TREATMENT FOR TARDIVE DYSKINESIA: A META ANALYSIS
Thierry Mentzel*, Rene Snoek, van der, Margreet Oorschot, Wolfgang Viechtbauer, Oswald Bloemen, Ritsaert Lieverse, Peter Van Harten

M3. IMPACT OF ADVERSE CHILDHOOD EXPERIENCES ON PSYCHOTIC-LIKE SYMPTOMS AND STRESS REACTIVITY IN DAILY LIFE IN NONCLINICAL YOUNG ADULTS
Tamara Sheinbaum*, Paula Cristóbal-Narváez, Sergi Ballespí, Mercè Mitjavila, Inez Myin-Germeys, Thomas R. Kwapil, Neus Barrantes-Vidal

M4. SEXUAL DYSFUNCTION IN PATIENTS WITH SCHIZOPHRENIA: IS ANTIPSYCHOTIC MEDICATION TO BLAME?
Mette Nielsen*, Birte Glenthoj, Bjorn Ebdrup, Signe During, Henrik Nørbak-Emig

M5. THE EFFECT OF CHILDHOOD ABUSE ON OUTCOME IN INDIVIDUALS AT ULTRA HIGH RISK FOR PSYCHOSIS
Tamar Kraan*, Eva Velthorst, Lieuwe De Haan, Mark Van der Gaag

M6. IS IT WORTH TO GIVE CLOZAPINE A SECOND CHANCE? A SERIES OF 12 SUBJECTS RECHALLENGED WITH CLOZAPINE FOLLOWING A NEUTROPENIA
Esthel Malenfant*, Mireille Nadeau, Guillaume Chalifour, Marc-André Roy, Jocelyne Moisan, Marie-France Demers

M7. RISK FACTORS FOR TREMOR IN A POPULATION OF PATIENTS WITH SEVERE MENTAL ILLNESS: AN 18-YEAR PROSPECTIVE STUDY IN A GEOGRAPHICALLY REPRESENTATIVE SAMPLE
Charlotte Mentzel*, P. Roberto Bakker, Jim Van Os, Marjan Drukker, Michiel van den Oever, Glen Matroos, Hans Hoek, Marina Tijssen, Peter Van Harten

M8. THE EFFECT OF CHILDHOOD TRAUMA AND FIVE-FACTOR MODEL PERSONALITY TRAITS ON EXPOSURE TO ADULT LIFE EVENTS IN PATIENTS WITH PSYCHOTIC DISORDERS
Karin Pos*, Lindy-lou Boyette, Carin Meijer, Maarten Koeter, Lydia Krabbendam, Lieuwe De Haan

M9. CABERGOLINE USE TO COUNTERACT ANTIPSYCHOTIC SYMPTOMATIC RELATED HYPERPROLACTINEMIA: A RETROSPECTIVE LONGITUDINAL CASE-SERIES.
Marie-France Demers*, Vanessa Simard, Nathalie Dion, Esthel Malenfant, Marc-André Roy, Sophie Lauzier

M10. DIFFERENTIAL EFFECTS OF CHILDHOOD TRAUMA AND CANNABIS USE DISORDERS IN PATIENTS SUFFERING FROM NON-AFFECTIVE PSYCHOSIS
Grégoire Baudin*, Ophelia Godin, Mohamed Lajnfe, Pierre-Michel Llorca, Franck Schürhoff
M11. CHILDHOOD MALTREATMENT, ANTENATAL ATTACHMENT AND SYMPTOM SEVERITY IN WOMEN AT RISK OF POSTPARTUM PSYCHOSIS
Alessandra Biaggi*, Katie Hazelgrove, Susan Conroy, Susan Pawlby, Montserrat Fustè-Boadella, Carmine M. Pariante, Paola Dazzan

M12. ADJUNCTIVE ARIPIPRAZOLE FOR RISPERIDONE/PALIPERIDONE INDUCED HYPERPROLACTINEMIA. EFFECT OF FUNCTIONAL POLYMORPHISMS IN DOPAMINE-RELATED GENES.
Ainara Arnaiz, Nieves Basterreche, Aurora Arrúe, Olga Olivas, Estibaliz Gordo, Leire Erkoreka, Ihintza Angoitia, Mercedes Zumárraga*

M13. SECOND-GENERATION ANTIPSYCHOTIC COMBINATION IS A MAJOR RISK FACTOR FOR AKATHISIA AND LONG-TERM BENZODIAZEPINES DON’T HELP. RESULTS FROM THE FACE-SZ COHORT
Fabrice Berna, Guillaume Fond*, David Misrahi, Laurent Boyer, Pierre-Michel Llorca

M14. BIRTH BY CESAREAN SECTION AND SCHIZOPHRENIA. RESULTS FROM THE MULTI-CENTER FACE-SZ DATA-SET.
Guillaume Fond*, Ewa Bulzacka, Laurent Boyer, Pierre-Michel Llorca, Marion Leboyer

M15. PERIPHERAL SUB-INFLAMMATION IS ASSOCIATED WITH ANTIDEPRESSANT CONSUMPTION IN SCHIZOPHRENIA. RESULTS FROM THE MULTI-CENTER FACE-SZ DATA SET.
Guillaume Fond*, Ophelie Godin, Franck Schurhoff, Pierre-Michel Llorca, Marion Leboyer

M16. EARLY COGNITIVE INFLAMMAGING IN SCHIZOPHRENIA
Guillaume Fond*, Ewa Bulzacka, Laurent Boyer, Pierre-Michel Llorca, Franck Schurhoff, Marion Leboyer

M17. CAN LESSONS LEARNT FROM CARDIAC STRESS TESTING BE APPLIED TO THE EARLY IDENTIFICATION OF PSYCHOSIS?
Deepak D’Souza*, Swapnil Gupta, Mohini Ranganathan

M18. PREDICTING TRANSITION TO PSYCHOSIS ON THE BASIS OF ELECTROPHYSIOLOGICAL SELF-SUPPRESSION ABNORMALITIES IN ULTRA-HIGH RISK INDIVIDUALS
Thomas Whitford*, Lavoie Suzie, Barnaby Nelson, Judith Ford, Daniel Mathalon, Brian Roach, Patrick McGorry

M19. CYTOKINE DYSREGULATION IN CEREBROSPINAL FLUID OF PATIENTS WITH SCHIZOPHRENIA
Juan Gallego*, Juan Del Ojo-Jimenez, Paula Moreno-Merino, Sehba Husain-Krautter, Christopher Morell, Anil Malhotra

M20. ANTIOXIDATIVE FUNCTION OF ALBUMIN MAY STRATIFYING TWO DIFFERENT GROUPS IN FIRST-EPISODE, DRUG-NAÏVE SCHIZOPHRENIC PATIENTS.
Varvara Kalinina, Marat Uzbekov*, Natalia Smolina, Alexandr Shmukler, Eduard Misionzhnil, Sergei Shikhov, Gennadi Dobretsov
M21. THE STATE OF ANTIOXIDANT ENZYME ACTIVITIES IN PATIENTS WITH CHRONIC SCHIZOPHRENIA UNDER ANTIPSYCHOTIC TREATMENT.
Marat Uzbekov*, Svetlana Ivanova, Ludmila Smirnova, Nikolai Bokhan, Arkadi Semke

M22. DIFFERENTIAL PERIPHERAL BIOMARKERS OF NEGATIVE DIMENSION IN SCHIZOPHRENIA
Leticia García-Alvarez, M Paz García-Portilla, Leticia Gonzalez-Blanco*, Lorena De La Fuente-Tomas, Celso Iglesias, Pilar Saiz-Martín, Julio Bobes

M23. AUTOANTIBODY PROFILING IN PATIENTS WITH SCHIZOPHRENIA
David Just*, Anna Häggmark, Eva Lindholm Carlström, Erik Jönsson, Janet Cunningham, Peter Nilsson

M24. ASSOCIATION OF SERUM SFILT-1 WITH PROGRESSIVE REDUCTION IN CORTICAL THICKNESS: A PRELIMINARY LONGITUDINAL STUDY OF FAMILIAL HIGH RISK FOR PSYCHOSIS SUBJECTS.
Paulo Lizano*, Jeffrey Yao, Neeraj Tandon, Matcheri Keshavan

M25. COMBINED EFFECT OF GENETIC VARIANTS IN GLUN2B CODING GENE (GRIN2B) ON PREFRONTAL FUNCTION DURING WORKING MEMORY PERFORMANCE
Dalila Albergo*, Giulio Pergola, Pasquale Di Carlo, Ileana Andriola, Barbara Gelao, Silvia Torretta, Leonardo Fazio, Antonio Rampino, Giuseppe Blasi, Alessandro Bertolino

M26. ODOR DEFICITS IN CHRONIC SCHIZOPHRENIA –RELATIONSHIP TO COGNITION, SYMPTOMS, AND EPIGENETIC MARKERS
Robert C. Smith*, Henry Sershen, Mohammed Sharifi, Mary Youssef, Abel Lajtha, Hua Jin, Alessandro Guidotti, John M. Davis

M27. ASSOCIATION BETWEEN ERYTHROCYTE MEMBRANE FATTY ACIDS AND PSYCHOPATHOLOGY IN INDIVIDUALS AT ULTRA-HIGH RISK FOR PSYCHOSIS
Min Jhon*, Sung-Wan Kim, Jae-Min Kim, Stefan Smesny, Simon Rice, Michael Berk, Miriam R Schäfer, Claudia M Klier, G. Paul Amminger

M28. PREDICTION OF FUNCTIONAL OUTCOME IN THE EARLY ONSET PSYCHOSIS AND PSYCHOSIS PRODROME USING NEUROANATOMICAL AND RESTING STATE PATTERN CLASSIFICATION
Lana Kambeitz-Ilankovic*, Carlos Cabral, Eva Meisenzahl, Joseph Kambeitz, Peter Falkai, Nikolaos Koutsouleris

M29. PRO- AND ANTI-INFLAMMATORY CYTOKINES IN YOUNG PEOPLE IN ULTRA-HIGH RISK OF DEVELOPING SCHIZOPHRENIA AND BIPOLAR DISORDER
Maiara Zeni Graiff Gama*, Lucas Rizzo, Pawan Kumar Maurya, Cinthia Higuchi, Ary Gadelha, Pedro Pan, Graccielle Rodrigues de Cunha, Rodrigo Bressan, Elisa Brietzke
M30. EFFECTS OF OMEGA-3 PUFA ON MARKERS OF IMMUNE FUNCTION IN INDIVIDUALS AT ULTRA-HIGH RISK OF PSYCHOSIS
Stefan Smesny*, Berko Millet, Miriam Schaefer, Uta-Christina Hipler, Heinrich Sauer, G Paul Amminger

M31. RETINAL ANOMALIES IN SCHIZOPHRENIA PATIENTS AND REGULAR CANNABIS USERS: A POTENTIAL WAY TO A BIOLOGICAL MARKER?
Thomas Schwitzer, Raymund Schwan, Anne Giersch, Vincent Laprevote*

M32. MARKERS OF THE GLUTATHIONE ANTIOXIDATIVE DEFENSE SYSTEM ARE ASSOCIATED WITH STRUCTURAL BRAIN CHANGES IN UNTREATED FIRST-EPISTODE SCHIZOPHRENIA
Kerstin Langbein*, Jana Hesse, Alexander Gussew, Uta-Christina Hipler, Berko Millet, Heinrich Sauer, Stefan Smesny

M33. NIACIN SKIN SENSITIVITY DECREASED IN CLOSE TO PSYCHOSIS ULTRA-HIGH RISK GROUPS AND ASSOCIATED WITH PREPSYCHOTIC SYMPTOMATOLOGY – AN OPTICAL REFLECTION SPECTROSCOPY STUDY
Kerstin Langbein*, Ulrike Schmidt, Stephan Schack, Natalie J. Biesel, Maria Rudzok, G. Paul Amminger, Heinrich Sauer, Stefan Smesny

M34. THE DUTCH BIPOLAR AND SCHIZOPHRENIA OFFSPRING STUDY; PSYCHOPATHOLOGY OUTCOME DURING EARLY ADOLESCENCE.
Manon Hillegers*, Matthijs Vink, Neeltje Van Haren, René Kahn

M35. AGE DIFFERENCES IN THE DIAGNOSTIC STABILITY OF PATIENTS WITH PSYCHOSIS NOS: A META-ANALYSIS
Daniel Ilzarbe*, Ditte Lammers Vernal, Alberto Ramos-Caneda, Christoph U Correll

M36. ADVERSE CHILDHOOD EVENTS AND ADULT PSYCHOSIS

M37. THE LINK BETWEEN BULLYING VICTIMIZATION AND PSYCHOTIC-LIKE EXPERIENCES: AN EXPLORATORY VIEW IN THE YOUNG ADOLESCENT POPULATION.
Roberta Marotta*, Simone Pisano, Annarita Montesanto, Margherita Siciliano, Filomena Salerno, Antonella Gritti, Matthew R. Broome, Gennaro Catone

M38. EMOTION RECOGNITION AND SOCIAL SKILLS IN CHILD AND ADOLESCENT OFFSPRING OF PARENTS WITH SCHIZOPHRENIA
Leslie Horton*, Miranda Bridgwater, Gretchen Haas

M39. COGNITIVE DEVELOPMENT AND THE EMERGENCE OF PSYCHOTIC EXPERIENCES IN CHILDREN AT HIGH RISK OF SCHIZOPHRENIA: A LONGITUDINAL STUDY OF 22Q11.2 DELETION SYNDROME
Samuel Chawner*, Michael Owen, Marianne van den Bree
M40. NEUROTOXIC AUTOANTIBODIES AND FAMILIAR HISTORY OF AUTOIMMUNE DISEASE IN ACUTE CHILD AND ADOLESCENT PSYCHOPATHOLOGY
Maria Gariup*, Azucena Gonzalez, Carles Serra-Pagés, Roger Borrás, Ricard Cervera, Astrid Morer

M41. SIGNIFICANT DIFFERENCES IN SUBTEST RALVT BETWEEN A PEP’S GROUP AND CONTROLS.
Maria Isabel Calvo-Rubiales*, Manuel Canal-Rivero, Andrea Morina, Miguel Ruiz Veguilla

M42. ADOLESCENT TRAJECTORIES OF MOTOR FUNCTION AND RISK FOR PSYCHOSIS
Hannah Dickson*, Ruth Roberts, Melody To, Max Loh, Sheilagh Hodgins, Kristin Laurens

M43. NEGATIVE SYMPTOMS AT FIRST EPISODE AND THEIR IMPACT ON TREATMENT OUTCOMES IN EARLY-ONSET PSYCHOSIS
Johnny Downs*, Harry Dean, Suzannah Lechler, Nicola Sears, Rashmi Patel, Hitesh Shetty, Matthew Hotopf, Tamsin Ford, Celso Arango, James MacCabe, Richard Hayes, Laura Pina-Camacho

M44. FROM NEUROLOGICAL SOFT SIGNS TO FUNCTIONAL OUTCOME IN YOUNG INDIVIDUALS IN TREATMENT WITH SECONDARY SERVICES FOR NON-PSYCHOTIC DISORDERS.
Amedeo Minichino*, Marta Francesconi, Kristin Cadenhead, Ricardo Carrion, Maurizio Parisi, Santo Rullo, Francesco Saverio Bersani, Massimo Biondi, Arturo Bevilaqua, Roberto Delle Chiaie

M45. THEORY OF MIND AS A MEDIATOR VARIABLE BETWEEN NEUROCOGNITION AND FUNCTIONING IN YOUNG INDIVIDUALS IN TREATMENT WITH SECONDARY SERVICES FOR NON-PSYCHOTIC DISORDERS.
Marta Francesconi*, Amedeo Minichino, Kristin Cadenhead, Ricardo Carrion, Maurizio Parisi, Santo Rullo, Arturo Bevilaqua, Francesco Saverio Bersani, Massimo Biondi, Roberto Delle Chiaie

M46. NUCLEUS REUNIENS REGULATION OF VENTRAL TEGMENTAL AREA DOPAMINE NEURON ACTIVITY: RELEVANCE TO PSYCHOSIS
Eric Zimmerman*, Nicole Jakobowski, Anthony Grace

M47. BEHAVIORAL EFFECTS OF D-AMPHETAMINE APPLIED TO THE ASSOCIATE STRIATUM OF THE RAT AS A CIRCUITY PARADIGM OF PSYCHOSIS
Severine Bandinelli, Daniela Alberati, Bart Ellenbroek, Eric Prinssen*

M48. A NEW INSIGHTS AT THE INTERACTION BETWEEN MGLU4 AND 5-HT1A RECEPTORS IN ANIMAL MODELS OF SCHIZOPHRENIA DISORDERS.
Monika Wozniak*, Karolina Noworyta-Sokolowska, Krystyna Golembowska, Krzysztof Tokarski, Magdalena Kusek, Piotr Branski, Grzegorz Burnat, Andrzej Pilc, Joanna Wieronska

M49. α5 NACHR MODULATION OF CORTICO-MESOLIMBIC CIRCUITRY AND FUNCTION
William Howe*, Patrick Tierney, Julie Brooks, Edward Guilmette, Damon Young, Rouba Kozak

M50. THE RELIABILITY OF THE REMISSION AND EXACERBATION CRITERIA (REC) OF SCHIZOPHRENIA AND SCHIZOAFFECTIVE DISORDERS USING THE STANDARD FOR CLINICIANS’ INTERVIEW IN PSYCHIATRY (SCIP)
Ahmed Aboraya*, Ahmed Elshazly
M51. INVESTIGATION OF “CRITICAL PERIOD” IN THE TREATMENT FOR FIRST-EPISODE SCHIZOPHRENIA: ANALYSIS OF THE ASSOCIATION BETWEEN DURATION OF UNTREATED PSYCHOSIS AND CLINICAL OUTCOME.
Naohisa Tsujino*, Takahiro Nemoto, Tomoyuki Funatogawa, Yoko Baba, Yo Wada, Yuko Yorozuya, Taiju Yamaguchi, Naoyuki Katagiri, Masafumi Mizuno

M52. PANSS-6 MEASURES THE SEVERITY OF SCHIZOPHRENIA USING ONLY SIX ITEMS
Soren Dinesen Ostergaard*, Ole Lemming, Ole Mors, Christoph Correll, Per Bech

M53. ELECTRONIC CIGARETTES AS A HARM-REDUCTION STRATEGY IN PEOPLE WITH SERIOUS MENTAL ILLNESS: A PILOT CLINICAL TRIAL

M54. AN ASSESSMENT OF INJECTION SITE REACTIONS AND INJECTION SITE PAIN OF ONCE-EVERY ONE MONTH AND THREE-MONTH LONG-ACTING INJECTABLE FORMULATIONS OF PALIPERIDONE PALMITATE (PP1M VS PP3M)
Erica Elefant, Jennifer Kern Sliwa, Adam Savitz, Isaac Nuamah, Maju Mathews*, Srihari Gopal, Dean Najarian, Larry Alphs

M55. VALIDATION OF THE KOREAN VERSION OF THE CLINICAL ASSESSMENT INTERVIEW FOR NEGATIVE SYMPTOMS (CAINS)

M56. OPEN BOARD

M57. JOINT MODELING OF DROPOUT AND OUTCOME IN THREE PIVOTAL CLINICAL TRIALS OF SCHIZOPHRENIA
Stephen Levine*, Yair Goldberg, Myrto Samara, John Davis, Stefan Leucht

M58. A POSSIBLE ROLE FOR PROLACTIN IN EMERGING PSYCHOSIS
Sarah Ittig, Erich Studerus*, Anita Riecher-Rössler

M59. ENHANCING COMPUTER-ASSISTED COGNITIVE REMEDIATION FOR SCHIZOPHRENIA: AN OPEN-LABEL STUDY WITH ANODAL TDCS ON LEFT LATERAL PREFRONTAL CORTEX
Giorgio Di Lorenzo*, Emiliano Santarnecchi, Dario Serrone, Cherubino Di Lorenzo, Fabiola Ferrentino, Valerio De Lorenzo, Andrea Daverio, Cinzia Nioli, Stefano Seri, Simone Rossi, Alberto Siracusano

M60. SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF A NOVEL PDE10A INHIBITOR, TAK-063, FOLLOWING MULTIPLE DOSING IN SUBJECTS WITH STABLE SCHIZOPHRENIA AND HEALTHY JAPANESE SUBJECTS
Paul Goldsmith*, John Affinito, Tom Macek, Max Tsai, Jinhui Xie, Lev Gertsik
M61. STABILITY IN A 52-WEEK SCHIZOPHRENIA EXTENSION STUDY OF TREATMENT WITH LONG-ACTING INJECTABLE ARIPIPRAZOLE LAUROXIL
Arielle Stanford, Robert Risinger*, Yangchun Du, Jacqueline Zummo, Hassan Jamal, Chih-Chin Liu, Amy Claxton

M62. SPECIFICITY AND PROGNOSTIC ACCURACY OF THE BASEL SCREENING INSTRUMENT FOR PSYCHOSIS (BSIP) AND THE SO FAR OFTEN NEGLECTED PROBLEM OF FALSE NEGATIVES
Martina Papmeyer*, Jacqueline Aston, Judith Everts-Graber, Ulrike Heitz, Erich Studerus, Stefan Borgwardt, Rolf-Dieter Stieglitz, Anita Riecher-Rössler

M63. A PHASE 3 STUDY TO DETERMINE THE ANTIPSYCHOTIC EFFICACY AND SAFETY OF ALKS 3831 IN ADULT SUBJECTS WITH ACUTE EXACERBATION OF SCHIZOPHRENIA
Bernard Silverman*, Sanjeev Pathak, Lauren DiPetrillo, Adam Simmons, Ying Jiang, Jacqueline Zummo, Hassan Jamal, David McDonnell

M64. A PHASE 2, EFFICACY, SAFETY, AND TOLERABILITY STUDY OF ALKS 3831 IN SCHIZOPHRENIA WITH ALCOHOL USE DISORDER
Sanjeev Pathak, David McDonnell*, Lauren DiPetrillo, Adam Simmons, Ying Jiang, Jacqueline Zummo, Hassan Jamal, Bernard Silverman

M65. SAFETY, TOLERABILITY, & PK OF MULTIPLE RISING DOSES OF BI 425809 TABLETS GIVEN ORALLY ONCE DAILY FOR 12 DAYS TO YOUNG HEALTHY MALE & FEMALE VOLUNTEERS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, WITHIN-DOSE GROUPS, PHASE I STUDY
Holger Schmitt, Michael Desch, Sophia Goetz, Armin Schultz, Karl-Heinz Liesenfeld, Sven Wind, Glen Wunderlich, Sun-Young A. Yum*

M66. METABOLIC SYNDROME IN PATIENTS WITH SCHIZOPHRENIA RECEIVING LONG-TERM TREATMENT WITH LURASIDONE, QUETIAPINE XR, OR RISPERIDONE
John W. Newcomer, Michael Tocco*, Andrei Pikalov, Hanzhe Zheng, Josephine Cucchiaro, Antony Loebel

M67. POSITIVE PHASE 3 CLINICAL TRIAL OF ITI-007 FOR THE TREATMENT OF SCHIZOPHRENIA: SECONDARY ENDPOINTS AND SUBGROUP ANALYSES FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
Michal Weingart, Kimberly Vanover*, Robert Davis, Cedric O’Gorman, Jelena Saillard, Sharon Mates

M68. USING AN MHEALTH APPROACH TO DELIVER A PSYCHOSOCIAL INTERVENTION IN EARLY PSYCHOSIS: PRELIMINARY RESULTS FROM THE ACTISSIST TRIAL
Sandra Bucci*

M69. WHICH ARE THE MOST IMPORTANT FIRST-GENERATION ANTIPSYCHOTIC DRUGS? SURVEY OF INTERNATIONAL SCHIZOPHRENIA EXPERTS
Stefan Leucht, Maximilian Huhn*, Philipp Rothe, Johannes Schneider, Yikang Zhu
M70. REDUCE - A RANDOMIZED CLINICAL TRIAL TO EVALUATE GRADUAL NEUROLEPTIC DISCONTINUATION IN CHRONIC STABLE SCHIZOPHRENIC PATIENTS
Maximilian Huhn*, Claudia Leucht, Markus Dold, Philipp Rothe, Stefan Heres, Stefan Leucht

M71. MORE PRONOUNCED COGNITIVE DEFICITS IN ADOLESCENT SUBJECTS AT CLINICAL HIGH RISK OF PSYCHOSIS
HuiRu Cui, HuiJun Li, William S. Stone, TianHong Zhang, YingYing Tang, ChunBo Li, Min Zhao Zhao, Larry J. Seidman, Jijun Wang, Larry Seidman*

M72. EFFECTS OF COGNITIVE TRAINING USING BRAIN TRAINING GAMES ON BRAIN STRUCTURE IN PATIENTS WITH SCHIZOPHRENIA
Kunio Iizuka*, Kazunori Matsumoto, Rui Nouchi, Yasuyuki Taki, Takayuki Nozawa, Hiroshi Hashizume, Ryoichi Yokoyama, Yukako Sasaki, Ikki Ueda, Chika Obara, Tatsuo Kikuchi, Hiroo Matsuoka, Ryuta Kawashima

M73. USE OF PRIOR KNOWLEDGE IN PERCEPTUAL INference DIssociates COMPUTATIONAL MECHANISMS OF ANOMALOUS PERCEPTIONS AND DELUSIONS
Daniel Davies*, Christoph Teufel, Paul Fletcher

M74. DOES CHANGE IN COGNITION AFFECT PSYCHOSOCIAL FUNCTIONING AFTER COGNITIVE REMEDIATION FOR SCHIZOPHRENIA?
Jean-Pierre Lindenmayer*, Samantha Fregenti, Veronica Ozog, Isidora Ljuri, Abraham Goldring, Guoxin Kang, Anzalee Khan

M75. EMOTIONAL INTELLIGENCE DEFICITS IN SCHIZOPHRENIA: THE IMPACT OF NON-SOCIAL COGNITION
Silvia Pardeller*, Beatrice Frajo-Apor, Georg Kemmler, Anna-Sophia Welte, Alex Hofer

M76. WORKING MEMORY DEFICITS IN YOUNG ADULTS BORN SMALL FOR GESTATIONAL AGE
Annamaria Porcelli*, Annabella Di Giorgio, Leonardo Fazio, Barbara Gelao, Linda Antonella Antonucci, Daniela Marvulli, Giancarlo Maddalena, Aurora Bonvino, Raffaella Romano, Marina Mancini, Gianluca Ursini, Fabio Sambataro, Giuseppe Blasi, Alessandro Bertolino

M77. JUMPING TO CONCLUSIONS PREDICTS 4 YEAR-CLINICAL OUTCOME IN FIRST EPISODE PSYCHOSIS
Victoria Rodriguez*, Olesya Ajnakina, Aurora Falcone, Simona Stilo, Anthony David, Marta Di Forti, Robin Murray

M78. RELATIONSHIP BETWEEN COGNITIVE INSIGHT AND DIFFERENT DIMENSIONS OF SOCIAL COGNITION IN RECENT ONSET PSYCHOSIS
Esther Pousa*, Susana Ochoa, Raquel Lopez Carrilero, Maria Luisa Barrigon, Ana Barajas, Esther Lorente Rovira, Fermin Gonzalez Higueros, Eva Grasa, Jordi Cid, Spanish Metacognition Study Group Study Group
M79. FORMAL THOUGHT DISORDER IN ADOLESCENTS WITH AUTISM SPECTRUM DISORDER: RELATIONS WITH EXECUTIVE FUNCTIONING
Tim Ziermans*, Sophie van Rijn, Esther de Bruin, Hanna Swaab

M80. SCHIZOPHRENIA AND SHORT LIFETIME EXPECTANCY - THE IMPORTANCE OF IDENTIFYING RISK FACTORS EARLY IN THE ILLNESS.
Lars Helldin*, Fredrik Hjärthag, Anna-Karin Olsson

M81. DEFECTIVE TRANSLATION OF EMOTIONAL SALIENCE INTO MOTIVATED BEHAVIOUR: A ONE YEAR FOLLOW-UP STUDY IN FIRST-EPISODE SCHIZOPHRENIA
Simon S. Y. Lui*, William W H Chui, Amy C Y Liu, Hai-song Shi, Dong-jie Xie, Zhi Li, Eric F. C. Cheung, Raymond C. K. Chan

M82. PERSPECTIVE MEMORY PERFORMANCE AND ITS CLINICAL CORRELATES DURING THE FIRST YEAR OF TREATMENT IN FIRST-EPISODE SCHIZOPHRENIA: A FOLLOW-UP STUDY
Fu-Chun Zhou*, Yu-Tao Xiang, Chuan-Yue Wang

M83. CORRELATIONS OF NEUROCOGNITIVE FUNCTIONING WITH NEGATIVE SYMPTOMS AND DAILY FUNCTIONING IN A FIRST EPISODE PSYCHOSIS SAMPLE
Emily Revell*, Richard Drake, Michael Harte, Joanna Neill

M84. SCHIZOTYPY AND NEUROCOGNITIVE PERFORMANCE IN PSYCHOSIS: AN ANALYSIS FROM THE FIRST PRONIA SAMPLE
Maria F. Urquijo*, Dominic Dwyer, Johanna Weiske, Sebastian Von Saldern, Joseph Kambeitz, Lana Kambeitz-Ilankovic, Carlos Cabral, Nikolaos Koutsouleris

M85. FUNCTIONAL STATUS AND FINANCIAL CAPACITY IN INDIVIDUALS WITH FIRST PSYCHOSIS
Alexandra Oliveira*, Valmira Toledo, Graça Oliveira, Danielle Bio, Martinus Van De Bilt, Wagner Gattaz, Paulo Sallet

M86. THE COURSE OF NEUROCOGNITIVE CHANGES IN ACUTE PSYCHOSIS: RELATION TO SYMPTOMATIC CHANGE
Liss Anda*, Kolbjørn Brønnick, Erik Johnsen, Rune Kroken, Else-Marie Løberg

M87. THE ROLE OF DISORGANIZATION SYMPTOMS IN THE RELATIONSHIP BETWEEN EXECUTIVE FUNCTIONS AND WHITE MATTER IN SCHIZOPHRENIA
Ainara Gómez-Gastiasoro, Leire Zubiaurre-Elorza, Javier Peña, Naroa Ibarretxe-Bilbao, Oiane Rilo, David Schretlen, Natalia Ojeda*

M88. IT’S ALL IN THE WORDS: LEXICAL PROCESSING IS IMPAIRED IN SCHIZOPHRENIA AND BIPOLAR MANIA
Susan Rossell*, Tamsyn Van Rheenen

M89. THE PERCEPTION OF INTENTIONALITY IN EARLY PSYCHOSIS
Anne-Kathrin Fett*, Clara Isabel Gonzales-Berdugo, Esther Hanssen, Imke Lemmers-Jansen, Sukhi Shergill, Lydia Krabbendam
M90. AUTOBIOGRAPHICAL MEMORY IMPAIRMENT IN CHRONIC SCHIZOPHRENIA
Marc Montgomery Lässer*, Christina J. Herold, Lena A. Schmid, Li Kong, Ulrich Seidl, Johannes Schröder

M91. TAKING IT AT 'FACE VALUE': THE USE OF FACE PROCESSING STRATEGIES IN SCHIZOPHRENIA AND BIPOLAR DISORDER
Tamsyn Van Rheenen*, Nicole Joshua, David Castle, Susan Rossell

M92. VERBAL MEMORY IN FIRST EPISODE PSYCHOSIS PATIENTS: IS THE HIPPOCAMPUS RESPONSIBLE FOR THE DEFICIT?
Rosa Ayesa-Arriola*, Diana Tordesillas-Gutiérrez, Esther Setién Suero, Benedicto Crespo-Facorro

M93. SCHIZOPHRENIA & MUSIC SYNTACTIC PROCESSING- AN EEG STUDY
Christian Mikutta*, Stefan Koelsch, Werner Strik, Andreas Altorfer, Daniel Mathalon

M94. PRELIMINARY EVIDENCE FOR THE INFLUENCE OF WORKING MEMORY LOAD ON THE LEARNED PREDICTIVENESS EFFECT IN SCHIZOPHRENIA PATIENTS
Daniel Núñez*, Vogel Edgar, Pinto Jorge, Calvo Jorge, Yuponqui José

M95. WHAT DOES 2D:4D TELL US ABOUT SOCIAL COGNITION?
Ozge Akgul, Onur Kucukcoban*, İ. Tolga Binbay, Koksal Alptekin, Berna Binnur Akdede

M96. THE EFFECT OF THE MUSCARINIC M1 RECEPTOR ANTAGONIST BIPERIDEN ON COGNITION IN PATIENTS WITH A PSYCHOTIC DISORDER AND HEALTHY CONTROLS
Claudia Vingerhoets*, Geor Bakker, Oswald Bloemen, Matthan Caan, Jan Booij, Therese van Amelsvoort

M97. COOPERATION AND THE EFFECT OF SOCIAL FEEDBACK IN A PUBLIC GOODS PARADIGM IN SCHIZOPHRENIA
Esther Hanssen*, Thomas White, Anne-Kathrin Fett, Caroline Caddy, Sukhi Shergill

M98. ASSESSING CHANGE IN NEUROCOGNITION: RELIABLE CHANGE INDICES FOR NEUROCOGNITIVE ASSESSMENT IN SCHIZOPHRENIA
Anzalee Khan*, Jean-Pierre Lindenmayer, Isidora Ljuri, Veronica Ozog, Samantha Fregenti, Abraham Goldring

M99. THE EXPERIENCE OF SELF-AGENCY IN CHILDREN WITH AND WITHOUT FAMILIAL RISK FOR SCHIZOPHRENIA OR BIPOLAR DISORDER.
Merel Prikken*, Matthijs Vink, Anouk Van Der Weiden, Martijn Koevoets, René Kahn, Manon Hillegers, Neeltje Van Haren

M100. INTRA-INDIVIDUAL VARIABILITY ACROSS COGNITIVE FUNCTIONS IN FIRST-EPIODE SCHIZOPHRENIA-SPECTRUM DISORDER
TT Lui, Wing Chung Chang*, FC Lau, LM Hui, KW Chan, HM Lee, EYH Chen
M101. HYPERVULNERABILITY OF THE ADOLESCENT PERIOD TOWARDS THE PREFRONTAL NEURONAL CONSEQUENCES OF OBESITY ARE MEDIATED BY REELIN, AN EXTRACELLULAR MATRIX PROTEIN LINKED TO EARLY ONSET PSYCHIATRIC DISEASES
Marie Labouesse*, Olivier Lassalle, Juliet Richetto, Ulrike Weber-Stadlbauer, Tina Notter, Lluis Pujadas, Eduardo Soriano, Wolfgang Langhans, Pascale Chavis, Urs Meyer

M102. LOWER FREQUENCY OF METABOLIC SYNDROME PREDICTED BY SCHIZOTYPAL TRAITS IN DISCORDANT SIBLINGS OF PATIENTS WITH SCHIZOPHRENIA
Cem Atbasoglu*, Guvem Gumus Akay, Meram Can Saka, Sinan Guloksuz, Alp Ucok, Koksal Alptekin, Sevim Gullu, Jim Van Os

M103. INTERVENTION STUDY: THE EFFECT OF AN LIFESTYLE INTERVENTION IN INPATIENTS WITH SEVERE MENTAL ILLNESS (SMI)
Jeroen Deenik*, Diederik Tenback, Ingrid Hendriksen, Erwin Tak, Peter Van Harten

M104. COMORBID OBSESSIVE COMPULSIVE DISORDER AND SOCIAL FUNCTION IN PATIENTS WITH CHRONIC SCHIZOPHRENIA
Tae Yong Kim*, Hae Gyung Chung, Jin Hee Choi, Hyung Seok So, Suk Hoon Kang, Tai Kiu Choi

M105. THE COURSE OF DIABETES IN SCHIZOPHRENIA AND BIPOLAR DISORDERS: AN EPIDEMIOLOGICAL STUDY
Arad Kodesh*, Stephen Levine, Liora Valinsky, Fabienne Hershkowitz Sikron

M106. NEUROANATOMICAL IMPLICATIONS OF CONCOMITANT MOOD DISORDERS IN SUBJECTS AT CLINICAL HIGH RISK FOR PSYCHOSIS
Yoo Bin Kwak*, TAE YOUNG LEE, Kang Ik Cho, MINAH KIM, SUNG NYUN KIM, JUN SOO KWON

M107. A NETWORK ANALYSIS ON TRAUMA, DISSOCIATION AND SCHIZOPHRENIC SYMPTOMS IN SCHIZOPHRENIA SPECTRUM DISORDERS
Selwyn Renard*, Marieke (Gerdina) Pijnenborg, Paul Lysaker, Rafea Huntjens, Andre Aleman

M108. PHARMACOLOGIC MANAGEMENT IN CASES OF DUAL DIAGNOSIS- SCHIZOPHRENIA AND ALCOHOL USE DISORDER
Daniel Vasile*, Octavian Vasiloiu, Diana Gabriela Vasiloiu, Florin Vasile

M109. THE ADVERSE EFFECT OF NICOTINE DEPENDENCE AND CANNABIS USE ON OUTCOME OF FIRST EPISODE PSYCHOSIS IS MEDIATED BY POOR MEDICATION ADHERENCE
Marco Colizzi*, Elena Carra, Sara Fraietta, John Lally, Diego Quattrone, Olesya Ajnakina, Paola Dazzan, Antonella Trotta, Anna Kolliakou, Fiona Gaughran, Mizanur Khondoker, Anthony David, Robin Murray, James MacCabe, Marta Di Forti

M110. 36 MONTH RESULTS OF A SMOKING AND HEALTHY LIFESTYLES INTERVENTION AMONG PEOPLE WITH A PSYCHOTIC DISORDER
Amanda Baker*, Robyn Richmond, Frances Kay-Lambkin, Sacha Filia, David Castle, Robin Callister, Jill Williams, Vanessa Clark, Terry Lewin, Kerrin Palazzi
M111. IMPACT OF CANNABIS USE ON CLINICAL OUTCOMES AND TREATMENT FAILURE IN FIRST EPISODE PSYCHOSIS
Rashmi Patel*, Robin Wilson, Richard Jackson, Michael Ball, Hitesh Shetty, Matthew Broadbent, Robert Stewart, Philip McGuire, Sagnik Bhattacharyya

M112. BETTER SOCIAL BUT WORSE ACADEMIC PREMORBID ADJUSTMENT IN CANNABIS-USERS PSYCHOTIC PATIENTS ACROSS EUROPE
Laura Ferraro, Capuccio Veronica, Caterina La Cascia, Lucia Sideli, Alice Mulè, Fabio Seminerio*, Crocettarachele Sartorio, Giada Tripoli, Robin Murray, Daniele La Barbera, Marta Di Forti

M113. COMPARISON OF CHR RISK SYMPTOMS IN THE PRONIA POPULATION - FIRST RESULTS FROM THE PRONIA STUDY

M114. ADDRESSING THE RISKS OF BEING ‘AT RISK’: THE EFFECTS OF LABELING VERSUS SYMPTOM SEVERITY ON PUBLIC ATTITUDES TOWARDS INDIVIDUALS AT RISK FOR PSYCHOSIS
Dan Koren*, Shulamit Gilboa-Radin, Yulia Libas

M115. AT RISK FOR PSYCHOSIS OR BIPOLAR DISORDER? EVALUATION OF BIPOLAR AT-RISK (BAR) CRITERIA IN A UK SAMPLE
Irina Falkenberg*, Ceri Jones, Lida Xenaki, Philip McGuire, Lucia Valmaggia, Paolo Fusar-poli

M116. EFFECTIVITY OF A DIGITAL PANSS-TRAINING
Nicky Klaasen*, Leonie van Asperen, Claire Kos, Pieter-Jan Mulder, Henderikus Knegtering, André Aleman, Kristy Wolanski, Christian Yavorski, Richard Bruggeman

M117. VENOUS COMPARED TO CAPILLARY BLOOD SAMPLING WITH A POINT-OF-CARE DEVICE IN CLOzapine TREATMENT: PATIENTS’ PREFERENCES
Jan Bogers*, Dan Cohen

M118. INSIGHT AND SUICIDALITY IN PSYCHOSIS: A CROSS-SECTIONAL STUDY
Carmina Massons*, Javier-David Lopez-Morinigo, Jesús Cobo, Esther Pousa, Anthony David, Rina Dutta

M119. ASSOCIATIONS BETWEEN PARANOIA AND LEVELS OF DEPRESSION AND ANXIETY IN THE GENERAL POPULATION: TWO META-ANALYSES
Yeuk Lai Law*, Suzanne So

M120. THE SCHIZOTYPY FACTORS ARE A SUITABLE MODEL FOR THE SYMPTOMS OF SCHIZOPHRENIA
Elizabeth Thomas*, Kiymet Bozaoglu, Erica Neill, Tamsyn Van Rheenen, Stephanie Louise, Eric Tan, Susan Rossell, Caroline Gurvich
M121. CLINICAL INSIGHT IN NON-AFFECTIVE PSYCHOSIS AND PSYCHIATRIC HOSPITAL READMISSION: A SYSTEMATIC REVIEW  
Ewa Klamerus*, Marianna Antoniadou, Enrico Foglia, Kevin Morgan, Sagnik Bhattacharyya

M122. REPORTED CHILDHOOD ABUSE AND STRESS REACTIVITY IN PSYCHOSIS: A REPLICATION ATTEMPT.  
Jonas Weijers*, Wolfgang Viechtbauer, Fabian Termorshuizen, Jean-Paul Selten

M123. IS SIMPLE SCHIZOPHRENIA THAT SIMPLE? AN OBSERVATIONAL STUDY  
Adriana Fortea*, Daniel Ilzarbe, Laura Espinosa, Laura Nuño, Maria Emilia Chavez, Eduard Parellada

M124. COMPARISON OF FACTOR STRUCTURE OF THE POSITIVE AND NEGATIVE SYNDROME SCALE (PANSS) IN PATIENTS WITH REFRACTORY VERSUS AND NON-REFRACTORY SCHIZOPHRENIA IN A LARGE BRAZILIAN SAMPLE  
Rosana Freitas, Cinthia Higushi, Bernardo dos Santos, Adriana Vizzotto, Belquiz Avrichir, Silvia Scemes, Antônio de Sá Júnior, Mario Rodrigues Louzã Neto, Rodrigo Bressan, Ary Gadelha, Helio Elkis*

M125. A SYSTEMATIC REVIEW EXPLORING NEGATIVE SYMPTOMS AND DEPRESSION IN SCHIZOPHRENIA – AN UPDATE OF THE LITERATURE  
Carl Krynicki*, John Deakin, Thomas Barnes, Rachel Upthegrove

M126. DEVELOPMENT AND PSYCHOMETRIC VALIDATION OF THE QUESTIONNAIRE OF STRESSFUL LIFE EVENTS (QSLE). SPANISH VERSION.  
Anna Butjosa*, Juana Gómez-Benito, Inez Myin-Germeys, Elena Huerta-Ramos, Núria Del Cacho, Montserrat Dolz, Andrea Estela, GENIPE group, Susana Ochoa

M127. PSYCHOMETRIC SCHIZOTYPY PREDICTS PRODROMAL AND SCHIZOPHRENIA-SPECTRUM SYMPTOMS, PSYCHOLOGICAL MEASURES, AND FUNCTIONAL ADAPTATION: A 4-YEAR LONGITUDINAL STUDY  
Anna Racioppi*, Tamara Sheinbaum, Sergi Ballespí, Mercè Mitjavila, Georgina M. Gross, Thomas R. Kwapił, Neus Barrantes-Vidal

M128. AUTISM TRAITS AND POSITIVE PSYCHOTIC EXPERIENCES IN ADOLESCENTS FROM THE GENERAL POPULATION: ASSOCIATIONS WITH THEORY OF MIND  
Ashleigh Lin*, Ahmad Abu-Akel, Renate Reniers, Katharine Chisholm, Elsa Walsh, Zoe Spruce, Rachel Royston, Stephen Wood

M129. THEORY OF MIND AND ATTEMPTS OF SUICIDE AFTER FIRST EPISODE OF PSYCHOSIS  
Manuel Canal-Rivero*, Maria Isabel Calvo-Rubiales, Jordi E. Obiols Llandrich, Miguel Ruiz Veguilla

M130. INSIGHT AND THEORY OF MIND  
Manuel Canal-Rivero*, Maria Isabel Calvo-Rubiales, Jordi E. Obiols Llandrich, Miguel Ruiz-Veguilla

M131. PARENTAL PSYCHOSIS AND EARLY DEVELOPMENTAL VULNERABILITY IN OFFSPRING  
Kimberlie Dean, Maina Kariuki, Alessandra Raudino, Melissa Green, Stacy Tzoumakis, Titia Sprague, Rhoshel Lenroot, Kristin Laurens, Vaughan Carr*
M132. ANTI-PYSCHOTIC MEDICATION AND REMISSION OF PSYCHOTIC SYMPTOMS 10 YEARS AFTER A FIRST-EPISODE PSYCHOSIS
Merete Nordentoft*, Regitze Wills, Ditte Resendal Gotfredsen, Carsten Hjorthøj, Ole Mors, Stephen Austin, Nikolai Albert, Gry Secher, Anne Thorup

M133. ASSOCIATION OF WHITE BLOOD CELL COUNT AND C-REACTIVE PROTEIN LEVEL WITH SYMPTOMS OF PSYCHOTIC DISORDERS: FINDINGS FROM A LARGE COHORT
Edith Liemburg*, Ilja Nolte, Hans Klein, Henderikus Knegtering

M134. SYMPTOMATIC, FUNCTIONAL AND PERSONAL REMISSION IN SCHIZOPHRENIA AND RELATED PSYCHOTIC DISORDERS: PERSISTENT PATTERNS IN A LARGE NATURALISTIC COHORT STUDY
Stynke Castelein*, Edith Liemburg, Richard Bruggeman, Ellen Visser

M135. ASSOCIATION BETWEEN SCHIZOPHRENIA AND DEMENTIA: DOES SCHIZOPHRENIA IN OFFSPRING INCREASE THE RISK OF DEVELOPING DEMENTIA? A DANISH POPULATION-BASED STUDY.
Christopher Rohde*, Philip Finn Rising Nielsen, Esben Agerbo

M136. GENERAL FERTILITY RATE IN NON-AFFECTIVE PSYCHOSIS: ROUTINE DATA-LINKAGE USING MATERNITY AND PSYCHIATRIC DATA
Angus MacBeth*, Sarah Barry, Paula McSkimming, John Park, Sohinee Bhattacharya, Roch Cantwell, David St Clair, Andrew Gumley

M137. PROSPECTIVE AND CROSS-SECTIONAL ASSOCIATIONS BETWEEN THEORY OF MIND, SOCIAL FUNCTIONING, AND PSYCHOTIC EXPERIENCES IN ADOLESCENTS IN THE GENERAL POPULATION.
Laura Steenhuis*, Marieke (Gerdina) Pijnenborg, Maaike Nauta, Andre Aleman, Annegien Bartels-Velthuis

M138. COMPULSORY ADMISSION DURING FIRST EPISODE OF PSYCHOSIS: DOES ETHNICITY STILL MATTER?
Sheri Oduola*, Tom Craig, Dinesh Bhugra, Francois Bourque, Jason Tsang, Charlotte Gayer-Anderson, Craig Morgan

M139. PREVALENCE OF DEFICIT SYNDROME IN SCHIZOPHRENIA: AN UPDATED META-ANALYSIS
Álvaro López-Díaz*, José Luis Fernández-González, Pablo Lorenzo-Herrero

M140. ASSOCIATION BETWEEN POLYGENIC RISK SCORES AND TREATMENT RESISTANCE IN SCHIZOPHRENIA: RESULTS FROM THE CRESTAR COLLABORATION
Theresa Wimberley*, Sandra Meier, Christiane Gasse, Esben Agerbo, James MacCabe, Henriette Horsdal

M141. PARENTAL SOMATIC ILLNESS’ EFFECT ON PRODROMAL SYMPTOMS OF CHILDREN – NORTHERN FINLAND BIRTH COHORT 1986 STUDY
Lotta Kinnunen*, Tanja Nordström, Mika Niemelä, Sami Räsänen, Juha Veijola, Jouko Miettunen
M142. MONITORING OF RISK OF VIOLENCE AND PATIENTS’ CLINICAL CHARACTERISTICS: A PROSPECTIVE COHORT STUDY
Giovanni de Girolamo*, Viola Bulgari, Valentina Candini, Laura Iozzino, Beatrice Segalini

M143. NEIGHBOURHOOD CHARACTERISTICS AND THE INCIDENCE OF FIRST EPISODE PSYCHOSIS (FEP) AND DURATION OF UNTREATED PSYCHOSIS (DUP)
Brian O'Donoghue*, John Lyne, Laoise Renwick, Abbie Lane, Kevin Madigan, Anthony Staines, Mary Clarke

M144. SERUM C-REACTIVE PROTEIN IN ADOLESCENCE AND SUBSEQUENT SCHIZOPHRENIA IN ADULTHOOD: A POPULATION-BASED PROSPECTIVE BIRTH COHORT STUDY
Stephen Metcalf, Peter Jones, Tanja Nordstrom, Markku Timonen, Pirjo Maki, Jouko Miettunen, Erika Jääskeläinen, Marjo-Riitta Järvelin, Graham Murray, Jan Stochl, Juha Veijola, Golam Khandaker*

M145. HIGH PREVALENCE RATE OF AGITATION IN THE CHINESE POPULATION WITH NEWLY HOSPITALIZED PATIENTS SUFFERING FROM SCHIZOPHRENIA: RESULTS FROM AN OBSERVATIONAL SURVEY IN CHINA
Hongyan Zhang*, Suzhen Zhang, Wifeng MI, Qi Liu, Lingzhi Li

M146. EFFECT OF WIDER SOCIAL ENVIRONMENT ON RELAPSES IN SCHIZOPHRENIA: A SIX-YEAR FOLLOW-UP STUDY
Burcu Ünal, Tolga Binbay*, Mehtap Az, Halis Ulaş, Köksal Alptekin, Berna Akdede

M147. SUB-CLINICAL PSYCHOTIC EXPERIENCES INCREASE RATE OF CONTACT WITH MENTAL HEALTH SERVICES
Vishal Bhavsar*, Matthew Hotopf, Stephani Hatch, Philip McGuire, Victoria Harris, Jane Boydell

M148. PSYCHOTIC-LIKE EXPERIENCES AND VIOLENCE AMONG YOUNG CHINESE MEN
Simone Ullrich*

M149. PREVALENCE OF NON-RESPONSE AND NON-REMISSION IN SCHIZOPHRENIA
Myrto Samara*, Adriani Nikolakopoulou, Georgia Salanti, Stefan Leucht

M150. SHIFT IN POSITIVE AND NEGATIVE PSYCHOTIC SYMPTOMS AND VIOLENCE
Jeremy Coid*

M151. METABOLIC SCREENING AND STATUS AMONG NEWLY DIAGNOSED PATIENTS WITH SCHIZOPHRENIA: A POPULATION-BASED CROSS-SECTIONAL STUDY
Henriette Horsdal, Michael Benros, Ole Köhler*, Jesper Krogh, Christiane Gasse

M152. LONGITUDINAL EPIGENETIC ANALYSIS OF CLOzapine USE IN TREATMENT-RESISTANT SCHIZOPHRENIA: DATA FROM THE CRESTAR CONSORTIUM
Amy Gillespie*, Eilis Hannon, Emma Dempster, Grant McQueen, Alessia Avila, John Lally, David Collier, Alice Egerton, Jonathan Mill, James MacCabe

M153. STIMULUS REPETITION EFFECTS ON NEUROPHYSIOLOGICAL CORRELATES OF MENTAL WORKLOAD IN PSYCHOTIC PATIENTS
Gregoire Favre*, Sibylle Horat, Pascal Missonnier, François Herrmann, Damien Debatisse, Marco Merlo
M154. SEPARATION OF RECENT-ONSET PSYCHOSIS PATIENTS FROM HEALTHY CONTROLS BASED ON RESTING-STATE FUNCTIONAL CONNECTIVITY PATTERN CLASSIFICATION
Shalaila Haas*, Carlos Cabral, Maria Urquijo, Sebastian Von Saldern, Joseph Kambeitz, Nikolaos Koutsouleris, Lana Kambeitz-Illankovic

M155. LOWER HIPPOCAMPAL MUSCARINIC M1 RECEPTOR EXPRESSION IS RELATED TO VISUAL SPATIAL LEARNING AND MEMORY DEFICITS IN FIRST EPISODE PSYCHOSIS PATIENTS.
Geor (IM) Bakker*, Wilhelmina Vingerhoets, Daphne Boucherie, Matthan Caan, Oswald Bloemen, Jan Booij, Therese van Amelsvoort

M156. CORTICAL HIERARCHY UNDERLIES PREFERENTIAL CONNECTIVITY DISTURBANCES IN SCHIZOPHRENIA
Genevieve Yang, John Murray, Grega Repovs, Michael Cole, Xiao-Jing Wang, David Glahn, Godfrey Pearlson, John Krystal, Alan Anticevic*

M157. ABNORMAL BRAIN ACTIVITY IN THE LEFT PREFRONTAL CORTEX IS RELATED TO DEFICIT IN USING SEMANTIC ENCODING STRATEGIES IN SCHIZOPHRENIA
Synthia Guimond*, Colin Hawco, Martin Lepage

M158. ALTERED CORTICO-LIMBIC CONNECTIVITY DURING THE FACIAL PERCEPTION IN INDIVIDUALS WITH SOCIAL ANHEDONIA
Yi Wang*, Zhi Li, Wen-hua Liu, Xin-hua Wei, Xin-qing Jiang, Raymond C.K. Chan

M159. FUNCTIONAL CONNECTIVITY AND STRIATAL DOPAMINE SYNTHESIS IN SCHIZOPHRENIA TREATED WITH ANTIPSYCHOTIC DRUGS: MULTIMODAL IMAGING STUDY USING [18F]DOPA PET AND RESTING MRI
Euitae Kim*, Young Woo Yoon, Wi Hoon Jung, Mattia Veronese, Oliver Howes, Federico Turkheimer, Jun Soo Kwon

M160. ADJUNCTIVE SELECTIVE ESTROGEN RECEPTOR MODULATOR INCREASES NEURAL ACTIVITY IN THE HIPPOCAMPUS AND INFERIOR FRONTAL GYRUS DURING EMOTIONAL FACE RECOGNITION IN SCHIZOPHRENIA
Ellen Ji*, Cynthia Shannon Weickert, Rhoshel Lenroot, Jochen Kindler, Ashley Skilleter, Ans Vercammen, Christopher White, Raquel Gur, Thomas Weickert

M161. BRAIN ACTIVATION FINDINGS FROM A FAMILY STUDY OF EMOTIONAL AND NON-EMOTIONAL FACE RECOGNITION IN SCHIZOPHRENIA
Michael Spilka*, Vina Goghari

M162. BRAINS OF FIRST-EPILOGUE PSYCHOSIS PATIENTS DO NOT SYNCHRONIZE WITH OTHERS DURING MOVIE VIEWING CONDITIONS
Teemu Mantyla*, Eva Rikandi, Tuula Kieseppä, Riitta Hari, Lauri Nummenmaa, Jaana Suvisaari, Tuukka Raij
M163. ASSOCIATION OF GENETIC VARIANTS WITH THE BRAIN ACTIVITY DURING EMOTIONAL PROCESSING: A MULTIVARIATE STUDY
Daniela Marvulli*, Tiziana Quarto, Pasquale Di Carlo, Raffaella Romano, Paolo Taurisano, Leonardo Fazio, Antonio Rampino, Alessandro Bertolino, Giulio Pergola, Giuseppe Blasi

M164. HYPERACTIVATION OF SALIENCE NETWORK DURING EYE GAZE PERCEPTION IN SCHIZOPHRENIA
Ivy Tso*, Beier Yao, Stephan Taylor

M165. NEUROIMAGING OF APPRAISALS OF PSYCHOTIC EXPERIENCES: AN EXPERIMENTAL INVESTIGATION OF SYMPTOMATIC AND NON-NEED-FOR-CARE INDIVIDUALS
Raphael Underwood*, Emmanuelle Peters, Veena Kumari

M166. THALAMIC MEDIO-DORSAL CONNECTIVITY DURING ATTENTIONAL CONTROL MEASURED WITH INDEPENDENT COMPONENT ANALYSIS IS ASSOCIATED WITH FAMILIAR RISK FOR SCHIZOPHRENIA AND WITH A POLYGENIC RISK SCORE
Linda A. Antonucci*, Paolo Taurisano, Leonardo Fazio, Raffaella Romano, Giulio Pergola, Roberta Passiatore, Pasquale Di Carlo, Barbara Gelao, Alessandro Bertolino, Giuseppe Blasi

M167. ASSOCIATION OF THE BDNF VAL66MET POLYMORPHISM WITH NEGATIVE SYMPTOMS SEVERITY, BUT NOT COGNITIVE FUNCTION, IN FIRST-EPISEDE SCHIZOPHRENIA SPECTRUM DISORDERS
Gisela Mezquida*, Rafael Penades, Bibiana Cabrera Llorca, George Savulich, Antonio Lobo, Ana Gonzalez-Pinto, Maria Jose Penzol, Iluminada Corripio, Emilio Fernandez-Egea, Patricia Gassó, Manuel J. Cuesta, Miguel Bernardo, PEps Group

M168. DIFFERENTIAL CONSISTENCY OF SUBCORTICO-CORTICAL INTRINSIC CONNECTIVITY PATTERNS IN SCHIZOPHRENIA
Henning Peters*

M169. DEFICITS IN CONTEXT-DEPENDENT ADAPTIVE CODING OF REWARD IN SCHIZOPHRENIA
Matthias Kirschner*, Oliver Hager, Martin Bischof, Matthias Hartmann, Agne Kluge, Erich Seifritz, Philippe Tobler, Stefan Kaiser

M170. VENTRAL STRIATAL ACTIVATION DURING REWARD PROCESSING IN PSYCHOSIS: A NEUROFUNCTIONAL META-ANALYSIS
André Schmidt*, Joaquim Radua, Stefan Borgwardt, Andreas Heinz, Florian Schlagenhauf, Philip McGuire, Paolo Fusar-poli

M171. NEURAL CORRELATES OF TRUST IN HEALTH, PSYCHOSIS AND IN PATIENTS AT ULTRA-HIGH RISK FOR PSYCHOSIS.
Imke Lemmers-Jansen*, Anne-Kathrin Fett, Esther Hanssen, Dick Veltman, Lydia Krabbendam

M172. SUICIDE ATTEMPT IN SCHIZOPHRENIA AND FIRST-EPISEDE PSYCHOSIS: CLINICAL AND BIOLOGICAL ASSOCIATIONS.
Ahmed Mhalla*, Rim Mensi, Amel Messaoud, Badii Amamou, Wahiba Douki, Lotfi Gaha
M173. CHILDHOOD TRAUMA MODERATES THE EFFECTS OF COMMON VARIANTS OF THE FK506 BINDING PROTEIN 5 (FKBP5) GENE ON RIGHT HIPPOCAMPAL VOLUME IN SCHIZOPHRENIA
Nina Teroganova*, Yann Quidé, Joshua Atkins, Murray Cairns, Natalie Matosin, Vaughan Carr, Melissa Green

M174. CONNECTOMICS IN SCHIZOPHRENIA: FROM EARLY PIONEERS TO RECENT BRAIN NETWORK FINDINGS
Guusje Collin*, Elise Turk, Martijn Van Den Heuvel

M175. CHILDHOOD TRAUMA IN YOUNG ADULTS AT ULTRA HIGH RISK FOR PSYCHOSIS IS ASSOCIATED TO LOWER FRACTIONAL ANISOTROPY IN THE LEFT UNCINATE FASCICULUS AND PARAHIPPOCAMPAL CINGULUM.
Attilio Rapisarda*, Chennao Wang, Jimmy Lee, Juan Zhou

M176. KETAMINE INDUCED NMDA-RECEPTOR BLOCKADE AND HIPPOCAMPAL GLUTAMATE IN HEALTHY VOLUNTEERS
Nina Kraguljac*, Michael Froelich, Steve Tran, David White, Nona Nichols, Meredith Reid, Adrienne Lahti

M177. A TSPO BLOCKING STUDY TO DETERMINE THE SPECIFIC BINDING OF [11C]-PBR28 IN PATIENTS WITH SCHIZOPHRENIA
Tiago Reis Marques*, Peter Bloomfield, David Owen, Mattia Veronese, Federico Turkheimer, Oliver Howes

M178. WHITE MATTER INTEGRITY IN TREATMENT-REFRACTORY SCHIZOPHRENIA: A DIFFUSION TENSOR IMAGING STUDY

M179. INCREASED GLUTAMATE IN PREFRONTAL CORTEX OF PATIENTS WITH PSYCHOTIC DISORDERS AND AUDITORY VERBAL HALLUCINATIONS
Branislava Curcic-Blake*, Leonie Bais, Marieke Pijnenborg, Edith Liemburg, Andre Aleman

M180. THE EFFECT OF CIGARETTE SMOKING ON BRAIN STRUCTURE IN PATIENTS WITH SCHIZOPHRENIA AND HEALTHY SUBJECTS: A SYSTEMATIC REVIEW AND META-ANALYSIS
Elisabetta Miglietta*, Annalisa Giordano, Joaquim Radua, Kempton Matthew, Dazzan Paola

M181. THE EFFECT OF MANUAL EDITING IN FREESURFER
Kasper Jessen*, Kristine Krakauer, Rene Mandl, Egill Rostrup

M182. GREY MATTER VOLUME PATTERNS IN THALAMIC NUCLEI PREDICT GENETIC RISK FOR SCHIZOPHRENIA AND SYMPTOMS SEVERITY
Giulio Pergola*, Silvestro Trizio, Pasquale Di Carlo, Paolo Taurisano, Marina Mancini, Maria Antonietta Nettis, Grazia Caforio, Annabella Di Giorgio, Alessandro Bertolino, Giuseppe Blasi
M183. WHITE MATTER MICROSTRUCTURE AND PHOSPHOLIPASE A2 ACTIVITY IN DRUG-NAIVE PATIENTS WITH FIRST-EPISODE PSYCHOSIS: A STATE-DEPENDENT STUDY
Mauricio Serpa*, Jimit Doshi, Tiffany Chaim, Martinus Van De Bilt, Paulo Sallet, Helena Passarelli Giroud Joaquim, Leda Leme Talib, Wagner Gattaz, Geraldo Busatto, Davatzikos Christos, Marcus Zanetti

M184. A COMPREHENSIVE AND SYSTEMATIC REVIEW OF THE STRUCTURAL NEUROIMAGING UNDERPINNINGS OF THOUGHT DISORDER IN SCHIZOPHRENIA
Philip Sumner*, Imogen Bell, Susan Rossell

M185. BRAIN SUBTYPING ENHANCES NEUROIMAGING PREDICTIONS OF SCHIZOPHRENIA GROUP MEMBERSHIP
Dominic B. Dwyer*, Carlos Cabral, Lana Kambeitz-Ilankovic, Joseph Kambeitz, Peter Falkai, Nikolaos Koutsoureris

M186. IDENTIFICATION OF TWO CLUSTERS WITHIN SCHIZOPHRENIA DIAGNOSIS WITH DIFFERENT STRUCTURAL, FUNCTIONAL AND CLINICAL CHARACTERISTICS.
Alba Lubeiro Juárez*, Cristina Rueda, Juan Antonio Hernandez, Javier Sanz, Fernando Sarramea, Vicente Molina Rodriguez

M187. ABNORMALITIES OF LANGUAGE PATHWAYS IN PATIENTS WITH SCHIZOPHRENIA WITH AND WITHOUT AUDITORY HALLUCINATIONS: A DTI-BASED TRACTOGRAPHY STUDY
Leroux Elise*, Delcroix Nicolas, Sonia Dolfus

M188. SCHIZOPHRENIA AND PSYCHOTIC BIPOLAR I DISORDER: CORTICAL GYRIFICATION AND BRAINAGE SCORES DIFFERENCES
Igor Nenadic*, Raka Maitra, Kerstin Langbein, Maren Dietzek, Heinrich Sauer, Christian Gaser

M189. HETEROGENEITY OF BRAIN STRUCTURAL ENDOPHENOTYPES OF SCHIZOPHRENIA
Igor Nenadic*, Heinrich Sauer, Christian Gaser

M190. THE INFLUENCE OF AHI1 VARIANTS ON THE DIAGNOSIS AND TREATMENT OUTCOME IN SCHIZOPHRENIA
Jung Jin Kim*, Seung Hyun Kim, Jung-Seo Yi, Chi-Un Pae

M191. WHITE MATTER RELATED GENES: ASSOCIATION STUDY IN BOTH SCHIZOPHRENIA AND AUTISM SPECTRUM DISORDERS
Mar Fatjo-Vilas*, Claudia Prats, Maria Jose Penzol, Kebir Ossama, Laura Pina, Gilles Martinez, Fayçal Mouffak, Carmen Moreno, Nemat Jaafari, Edith Pomerol-Clotet, Salvador Miret, Ana Gonzalez-Pinto, Víctor Peralta, Mara Parelleda, Marie-Odile Krebs, Lourdes Fañanas

M192. EXPRESSION OF GRM3 AND OF THE SPLICING ISOFORM GRM3∆4 IN HUMAN POST-MORTEM HIPPOCAMPAL TISSUE ACROSS THE LIFESPAN: RELEVANCE TO SCHIZOPHRENIA
Elisabetta F. Buonaguro*, Gianluca Ursini, Joo Heon Shin, Andrew E. Jaffe, Thomas M. Hyde, Joel E. Kleinmann, Andrea de Bartolomeis, Daniel R. Weinberger
M193. DIFFERENT MULTILEVEL PHENOTYPES FOR SCHIZOPHRENIA BASED ON DISRUPTED SIGNALING GENES
Dolores Malaspina*, Thorsten Kranz, Karen Rothman, Adam Berns, Jerry Shields, Raymond Goetz, Moses Chao

M194. GENOME-WIDE EXPRESSION AND DNA METHYLATION ANALYSIS IN A BRAZILIAN COHORT OF ANTIPSYCHOTIC-NAIVE FIRST EPISODE OF PSYCHOSIS PATIENTS
Marcos Leite Santoro*, Simone De Jong, Vanessa Ota, Patricia Moretti, Eduardo Gouvea, Cristiano Noto, Ary Gadelha, Quirino Cordeiro, Rodrigo Bressan, Gerome Breen, Belangero Sintia

M195. BRAIN ASYMMETRY AND SCHIZOPHRENIA IN THE POSTGENOMIC AGE – HOW A SYMPTOM-BASED APPROACH MIGHT HELP UNCOVERING THE GENETIC LINK
Marco Hirnstein*, Onur Güntürkün, Kenneth Hugdahl, Sebastian Ocklenburg

M196. LACK OF ASSOCIATION AND LINKAGE OF SCHIZOPHRENIA TO CHROMOSOME 22Q11 IN KOREAN POPULATION
Yu Sang Lee*, Kyung Sue Hong, Se-Chang Yoon, Eunsoog An

M197. DISTURBANCE OF METABOTROPIC GLUTAMATE RECEPTOR-MEDIATED LONG-TERM DEPRESSION (MGLU-LTD) OF EXCITATORY SYNAPTIC TRANSMISSION IN THE RAT HIPPOCAMPUS AFTER PRENATAL IMMUNE CHALLENGE
Mélanie Cavalier, Azza Ben Sedrine, Léa Thevenet, Nadine Crouzin, Janique Guiramand, Marie-Céleste de Jésus Ferreira, Catherine Cohen-Solal, Gérard Barbanel, Michael Vignes*

M198. ERBB SIGNALING INHIBITION AMELIORATE BEHAVIORAL DEFICIT INDUCED BY PHENCYCLIDINE (PCP) IN MICE
Alon Shamir*

M199. GLUTAMATE DEHYDROGENASE-DEFICIENT MICE: A NOVEL MOUSE MODEL OF SCHIZOPHRENIA-LIKE PHENOTYPES
Sharon S. Lander*, Reut Donner, Nicole Lewandowski, Susana Mingote, Pierre Maechler, Stephen Rayport, Scott S. Small, Inna Gaisler-Salomon

M200. DEFICITS IN NEURONAL AND GABAERGIC MARKERS IN THE FRONTAL CORTEX FOLLOWING SUB-CHRONIC PHENCYCLIDINE TREATMENT IN THE RAT – CORRELATES WITH SCHIZOPHRENIA
Daniela Cadinu*, Samuel Marsh, Stephen Williams, Giovanni Podda, Charles Large, Joanna Neill, Michael Harte

M201. CONSTITUTIVE LOSS OF ERBB4 SIGNALING DOES NOT AFFECT ATTENTION AND INHIBITORY CONTROL IN MICE
Elena Marchisella*, Ruud Wijnands, August B. Smit, Sabine Spijker, Maarten Loos
M202. MULTIMODAL BRAIN ANALYSIS IN PSYCHOSIS RISK – THE OULU BRAIN AND MIND STUDY

M203. THE EFFECT OF DEVIANCE PREDICTABILITY ON MISMATCH NEGATIVITY IN SCHIZOPHRENIA PATIENTS
Bernhard Müller*, Magdalena Horacek, Christian Kärgel, Norbert Scherbaum

M204. DEVELOPMENTAL MOLECULAR PROFILES OF HUMAN CHOROID PLEXUS EPITHELIAL CELLS DETERMINED BY WHOLE TRANSCRIPTOME RNA SEQUENCING
Katina Athanas*, Emily Kohlbrenner, Stephen Jackson, Kamini Varma, Sarah Mauney, Sabina Baretta, Kai Sonntag, Tsung-Ung Wilson Woo

M205. AUGMENTATION OF HUMAN NEOCORTICAL GAMMA OSCILLATIONS WITH A NOVEL KV3 POSITIVE MODULATOR IN VITRO.
Claire Gillougley, Tamara Modebadze, Damian Holliman, Otto Major, Claire Nicholson, Guiseppe Alvaro, Charles Large, Fiona LeBeau, Mark Cunningham*

M206. FRAGMENTATION OF THE PRESYNAPTIC PROTEIN SNAP-25 IS REDUCED IN THE ORBITOFRONTAL CORTEX OF SUBJECTS WITH SCHIZOPHRENIA: A POSSIBLE MECHANISM ENHANCING SNARE FUNCTION
Alfredo Ramos-Miguel*, Alasdair Barr, Andrew Dwork, Gozard Rosoklija, John Mann, William Honer

M207. GLUTAMATE DECARBOXYLASE, SOMATOSTATIN AND PARVALBUMIN EXPRESSION IN THE THALAMIC RETICULAR NUCLEUS IN PATIENTS WITH SCHIZOPHRENIA AND MOOD DISORDERS.
Martin Burgess*, Debora Rothmond, Maree Webster, Cyndi Shannon Weickert

M208. OBSTETRIC COMPLICATIONS AND NEUROCOGNITION IN EARLY-ONSET SCHIZOPHRENIA
Bjorn Rund*, Charlotte Teigset, Christine Mohn

M209. N-ACETYL-L-CYSTEINE PREVENTS THE EMERGENCE OF SCHIZOPHRENIA-LIKE BEHAVIORS IN AN ENVIRONMENTAL TWO-HIT MOUSE MODEL
Ana Herrmann*, Sandra Giovanoli, Urs Meyer, Elaine Elisabetsky

M210. RISK FACTORS MODERATING THE RELATIONSHIP BETWEEN CHILDHOOD TRAUMA AND PREMORBID ADJUSTMENT IN FIRST-EPISODE SCHIZOPHRENIA (FES) PATIENTS.
Sanja Kilian*, Jonathan Burns, Soraya Seedat, Laila Asmal, Bonginkosi Chiliza, Robin Emsley

M211. AUTISM – SCHIZOPHRENIA CONTINUUM HYPOTHESIS IN THE LIGHT OF SOCIAL COGNITION
Gilles Martinez*, Célia Mam-Lam-Fook, Charlotte Alexandre, Narjes Bendjemaa, Raphaël Gaillard, Marie-Odile Krebs, Isabelle Amado
M212. ACUTE OR CHRONIC TREATMENT WITH THE ANTIOXIDANT N-ACETYL-CYSTEINE (NAC) RESTORES BEHAVIOR DEFICITS IN MALE RATS OF AN ANIMAL MODEL OF SCHIZOPHRENIA BASED ON NEURODEVELOPMENT
Cristiane Salum*, Inda Lages Nascimento, Angela Rodrigues, Erickson Alves da Silva Souza

M213. FUNCTIONAL ANALYSIS OF SCHIZOPHRENIA-ASSOCIATED GENES DURING ZEBRAFISH DEVELOPMENT
Summer Thyme*, Eric Li, Carrie Sha, Owen Randlett, Steven Zimmerman, Lindsey Pieper, Elizabeth Hubbard, Alix Lacoste, Steven McCarroll, Alexander Schier

M214. COMBINATION OF MAINTENANCE ELECTROCONVULSIVE THERAPY (ECT) AND CLOZAPINE IN PATIENT WITH REFRACTORY SCHIZOPHRENIA: A CASE REPORT
Chul Eung Kim*, Seri Maeng, Jun Hwan Shin

M215. GROUP COGNITIVE–BEHAVIORAL THERAPY FOR KOREAN PATIENTS WITH EARLY PSYCHOSIS
Sung-Wan Kim*, Ga-Young Lee, Hye-Young Yu, Jin-Hee Hong, Jae-Kyeong Kim, Eun-I Jung, Ji-Hyun Park, Cheol Park, Ji-Eun Jang, Jin-Sang Yoon

M216. PEER SUPPORT GROUPS IN THE COMMUNITY AS AN EVOLUTION FROM A PSYCHOEDUCATION PROGRAM: THE EXPERIENCE FROM RIO DE JANEIRO
Leonardo Palmeira*, Olga Leão, Elias Carim Neto, Alexandre Keusen

M217. BASELINE TONE MATCHING ABILITY FACILITATES PERSONALIZATION OF COGNITIVE REMEDIATION APPROACH
Alice Medalia*, Alice Saperstein, Daniel Javitt, Seonjoo Lee

M218. ENVIRONMENTAL ENRICHMENT PREVENTS THE CONTEXTUAL FEAR CONDITIONING DEFICIT IN AN ANIMAL MODEL OF SCHIZOPHRENIA: POSSIBLE ROLE OF BDNF
Camila Santos, Agustin Anastasia, Fernanda Peres, Mariana Diana, Douglas Gouvêa, Vanessa Abilio*

M219. COGNITIVE BEHAVIOURAL THERAPY FOCUSING ON SOCIAL FUNCTIONING IN ADOLESCENTS WITH RECENT ONSET SCHIZOPHRENIA
Carin Meijer*, Eva Velthorst, Frederike Schirmbeck, Nathalie Franke, Elles Messchaert, Lieuwe De Haan

M220. A SMARTPHONE APPLICATION APPROACH TO SUPPORT TREATMENT OF (ATTENUATED) PSYCHOTIC SYMPTOMS IN ADOLESCENTS
Nina Traber-Walker*, Stephan Philipp, Miriam Gerstenberg, Maria Raquel Joris, Susanne Walitza, Maurizia Franscini

M221. TRANSCRANIAL MAGNETIC STIMULATION, TRANSCRANIAL DIRECT CURRENT STIMULATION AND ELECTROCONVULSIVE THERAPY FOR MEDICATION-RESISTENT PSYCHOSIS OF SCHIZOPHRENIA
Sanne Koops*, Wendy Nieuwdorp, Metten Somers, Iris Sommer
M222. STEM CELL DERIVED INTERNEURON TRANSPLANTS AS A TREATMENT FOR SCHIZOPHRENIA: PRECLINICAL VALIDATION IN A RODENT MODEL.
Jennifer Donegan*, Jennifer Tyson, Sarah Branch, Michael Beckstead, Stewart Anderson, Daniel Lodge

M223. CAPTURING THE INDIVIDUAL ENVIRONMENT OF PATIENTS. BASIS FOR TARGETED PSYCHOTHERAPY.
Inez Myin-Germeys*, Dina Collip, Margreet Oorschot, Johan Lataster, Nicole Geschwind, Marieke Wichers, Tineke Lataster

M224. CLIMB: A MOBILE APP INTERVENTION TO TREAT SOCIAL COGNITION IMPAIRMENTS AND IMPROVE SOCIAL FUNCTIONING IN CHRONIC PSYCHOSIS
Bruno Biagianti*, Danielle Schlosser, Josh Woolley, Mor Nahum, Sophia Vinogradov

M225. HARNESURING THE POWER OF LATENT PROFILE ANALYSIS TO CLASSIFY NONCLINICAL ADOLESCENTS USING PSYCHOMETRIC INDICATORS OF RISK
Diane Carol Gooding*, Eduardo Fonseca-Pedrero, Javier Ortuno-Sierra, Madeline Pflum, Mercedes Paino, José Muñiz

M226. LONGITUDINAL CHANGES IN AUDITORY VERBAL HALLUCINATIONS IN SCHIZOPHRENIA
Samuel Hwang*, Yong Sik Kim, Hee-Yeon Jung

M227. COGNITIVE BIASES MODERATE PARANOIA AND SUBJECTIVE DISTRESS IN RESPONSE TO SOCIAL STRESS
Wim Veling*, Roos Pot-Kolder, Jacqueline Counotte, Jim Van Os, Mark van der Gaag

M228. ASSOCIATIONS BETWEEN ACOUSTICALLY MEASURED TONGUE AND JAW MOVEMENTS AND NEGATIVE SYMPTOM SEVERITY IN PATIENTS WITH SCHIZOPHRENIA IN ITALY AND THE UNITED STATES
Francesco Bernardini*, Anya Lunden, Michael Covington, Beth Broussard, Brooke Halpern, Yazeed Alolayan, Anthony Crisafio, Luca Pauselli, Leslie Capulong, Roberto Quartesan, Michael Compton

M229. THE CHICKEN OR THE EGG? WHETHER RESILIENCE PRECEDE OR FOLLOW RECOVERY IN SCHIZOPHRENIA.
Anne-Kari Torgalsboen*, Susie Fu, Nikolai Czajkowski

M230. COMPARING THE LIVED-EXPERIENCES OF FIRST-EPISODE PSYCHOSIS SERVICE-USERS WITH DIFFERING EARLY NEGATIVE SYMPTOM TRAJECTORIES: A MIXED METHODS STUDY
Broney Gee*, Jo Hodgekins, David Fowler, Caitlin Notley, Anna Lavis

M231. THE CASCADE OF STRESS: A NETWORK APPROACH TO EXPLORE DIFFERENTIAL DYNAMICS IN POPULATIONS VARYING IN FAMILIAL RISK FOR PSYCHOSIS
Annelie Klippel*, Wolfgang Viechtbauer, Ulrich Reininghaus, Johanna Wigman, Claudia Van Borkulo, Inez Myin-Germeys, Marieke Wichers
M232. A PROVISIONAL QUALITATIVE ANALYSIS OF THE MEANING OF AND INFLUENCES ON RECOVERY ACCORDING TO PEOPLE DIAGNOSED WITH A FIRST EPISODE PSYCHOSIS 20 YEARS AGO AND THEIR FAMILY MEMBERS/PARTNERS  
Donal O’Keeffe*, Ann Sheridan, Aine Kelly, Roisin Doyle, Kevin Madigan, Elizabeth Lawlor, Mary Clarke

M233. A SYSTEMATIC REVIEW AND META-SYNTHESIS OF SERVICE USERS’ PERCEPTIONS OF THE MEANING OF AND INFLUENCES ON RECOVERY IN PSYCHOSIS  
Donal O’Keeffe*, Brian Keogh, Angela Kearney, Carla Senf, Mary Clarke, Agnes Higgins

M234. CLOZAPINE THERAPEUTIC DRUG MONITORING FROM CAPILLARY BLOOD USING THE DRIED BLOOD SPOTS TECHNIQUE.  
Dan Cohen*, Lisanne Geers, Daan Touw, Anton Loonen

M235. FIRST INTERVENTION PHARMACOLOGICAL TREATMENT OF INVOLUNTARILY COMMITTED PATIENTS WITH SCHIZOPHRENIA, SCHIZOTYPAL OR DELUSIONAL DISORDER OVER A 16 YEAR OBSERVATION PERIOD  
Monika Edlinger*, Anna-Sophia Welte, Georg Kemmler, Nursen Yalcin-Siedentopf, Wolfgang Fleischhacker, Alex Hofer

M236. ANTIPSYCHOTIC-RELATED FATAL POISONING (ENGLAND AND WALES, 1993-2013)  
Simon Handley, Maxine Patel*, Robert Flanagan

M237. CORRELATES OF CLOZAPINE USE AFTER A FIRST EPISODE OF SCHIZOPHRENIA COMPARED TO PATIENTS NOT PRESCRIBED CLOZAPINE: RESULTS FROM A LONG-TERM, PROSPECTIVE STUDY OF 105 FIRST-EPISODE PATIENTS  
Alp Ucok*, Uğur Çıkırkçılı, Sercan Karabulut, Özşur Tabak, Ada Salaj, Ceylan Ergül, Christoph Correll

M238. ASSOCIATION BETWEEN WEIGHT GAIN AND REMISSION STATUS IN FIRST-EPISODE PSYCHOSIS  
Nicholas Oh, Yuen Mei See, Gary Remington, Jimmy Lee*

M239. ADJUNCTIVE LURASIDONE SUPPRESSES FOOD INTAKE AND WEIGHT GAIN ASSOCIATED WITH OLANZAPINE ADMINISTRATION IN RATS  
Gavin Reynolds*, Caroline Dalton, William Watremez, Joshua Jackson, Michael Harte

M240. MULTIDRUG RESISTANCE 1 C3435T AND CYP3A4*1B POLYMORPHISMS MAY DETERMINE ANTIPSYCHOTIC RESPONSE BASED ON THE FIVE SYMPTOMATIC DOMAINS OF SCHIZOPHRENIA AND RELATED DISORDERS  
Rosa Catalán*, Alexandre González-Rodríguez, Rafael Penadés, María Jesús Arranz, Blanca Gutiérrez, Fina Pérez-Blanco, Victoria Ruiz, Mercè Torra, Miquel Bernard

M241. THE IMPACT OF MENOPAUSE IN TREATMENT OUTCOMES IN WOMEN WITH SCHIZOPHRENIA  
Diego Novick*, William Montgomery, Maria Victoria Moneta, Ahmed El-Shafei, Yan Cheng, Josep Maria Haro
M242. MORTALITY AND CUMULATIVE EXPOSURE TO ANTIPSYCHOTICS, ANTIDEPRESSANTS AND BENZODIAZEPINES
Jari Tiihonen*, Ellenor Mittendorfer-Rutz, Minna Torniainen, Kristina Alexanderson, Antti Tanskanen

M243. THE INFLUENCE OF ANTIPSYCHOTIC TREATMENT ON PERIPHERAL CYTOKINES
Rune A Kroken*, Øystein Bruserud, Farivar Fathian, W. Wolfgang Fleischhacker, Else-Marie Løberg, Solveig Klæbo Reitan, Maria Rettenbacher, Vidar Steen, Silje Skrede, Erik Johnsen

M244. RATE AND PREDICTORS OF NON-RESPONSE TO FIRST-LINE TREATMENT IN FIRST-EPISODE SCHIZOPHRENIA
Bonginkosi Chiliza*, Laila Asmal, Sanja Kilian, Lebogang Phahladira, Robin Emsley

M245. MODAFINIL COMBINED WITH COGNITIVE TRAINING IMPROVES NEURAL EFFICIENCY DURING WORKING MEMORY RELATIVE TO PLACEBO COMBINED WITH COGNITIVE TRAINING IN HEALTHY VOLUNTEERS: A RANDOMISED-CONTROLLED TRIAL WITH FMRI.
James Gilleen*, Panagiota Michalopoulou, Sukhi Shergill, James Gilleen

M246. GWAS ANALYSIS OF TREATMENT SCHIZOPHRENIA: INTERACTION EFFECT OF CHILDHOOD TRAUMA

M247. CLOZAPINE IS PRESCRIBED ONCE DAILY IN A MAJORITY OF PATIENTS IN NORTH AMERICA: FINDINGS FROM TWO PSYCHIATRIC INSTITUTES IN UNITED STATES AND CANADA
Hiroyoshi Takeuchi*, Valerie Powell, Stephen Geisler, Michelle DeSanti, Gagan Fervaha, Ofer Agid, John Kane, Gary Remington

M248. ANTIPSYCHOTIC DOSE REDUCTION IN SCHIZOPHRENIA: A SYSTEMATIC REVIEW
Hideaki Tani*, Hiroyuki Uchida, Takefumi Suzuki, Nobuhiro Nagai, Masaru Mimura, Hiroyoshi Takeuchi

M249. LONG-ACTING INJECTABLE ANTIPSYCHOTICS IN FIRST EPISODE PSYCHOSIS-PERSPECTIVES OF FAMILIES
Nishardi Wijeratne*, Ranjith Chandrasena

M250. EARLY SCHIZOPHRENIA PATIENTS TREATED WITH ONCE-MONTHLY PALIPERIDONE PALMITATE OVER A 12-MONTH PERIOD - A RETROSPECTIVE OBSERVATIONAL STUDY
Ludger Hargarter*, Paul Bergmans, Pierre Cherubin, Andreas Schreiner

M251. ASSOCIATION OF BIRTH WEIGHT AND THE DEVELOPMENT OF ANTIPSYCHOTIC INDUCED ADIPOSIETY IN INDIVIDUALS WITH SCHIZOPHRENIA
Emilio Fernandez-Egea*, Hisham Ziauddeen, Clemente Garcia-Rizo, Yulia Worbe, Miquel Bernardo, Brian Kirkpatrick, Sue Ozanne, Peter Jones
M252. ANTIPSYCHOTIC RESPONSE RATES AND CORRELATIONS WITH THE FIVE SYMPTOMATIC DOMAINS IN SCHIZOPHRENIA AND DELUSIONAL DISORDER: A CASE-CONTROL STUDY
Alexandre González-Rodríguez*, Rafael Penadés, Victoria Ruiz, Mercè Torra, Miquel Bernardo, Rosa Catalán

M253. CLINICAL PREDICTORS OF TREATMENT RESISTANCE IN FIRST EPISODE SCHIZOPHRENIA; A 5 YEAR FOLLOW UP STUDY
John Lally*, Olesya Ajnakina, Arsime Demjaha, Anna Kolliakou, Antonella Trotta, Valeria Mondelli, Tiago Reis Marques, Carmine Pariente, Dazzan Paola, Sukhi Shergill, Oliver Howes, Anthony David, James H MacCabe, Fiona Gaughran, Robin Murray

M254. PHARMACOLOGICAL CHARACTERIZATION OF THE NOVEL GLYCINE TRANSPORTER-1 INHIBITOR BI 425809 ON TARGET ENGAGEMENT IN-VIVO AND IN ANIMAL MODELS RELATED TO COGNITIVE SYMPTOMS OF SCHIZOPHRENIA
Holger Rosenbrock*, Riccardo Giovannini, Bernhard Schmid, Gert Kramer, Roberto Arban, Cornelia Dorner-Ciossek

M255. EXAMINING THE ASSOCIATION BETWEEN SOCIAL COGNITION AND FUNCTIONING IN INDIVIDUALS AT ULTRA-HIGH RISK FOR PSYCHOSIS
Jack Cotter*, Cali Bartholomeusz, Alicia Papas, Kelly Allott, Barnaby Nelson, Alison Yung, Andrew Thompson

M256. ONSET AGE AS A PREDICTOR FOR CLINICAL OUTCOME IN SCHIZOPHRENIA – A SYSTEMATIC REVIEW AND META-ANALYSIS
Johanna Immonen*, Jouko Miettunen, Erika Jääskeläinen

M257. LEVELS OF STRESS, TOLERANCE TO STRESS, AND THE RELATIONSHIP BETWEEN STRESS AND DISTRESS ASSOCIATED WITH ATTENUATED POSITIVE SYMPTOMS IN PEOPLE AT ULTRA-HIGH RISK FOR PSYCHOSIS.
Hannah Ball*, Kinza Janjua, Renate Reniers, Stephen Wood

M258. BEYOND A SINGULAR APPROACH: EXPLORING THE MULTIPLE FACETS OF MOTIVATION IN SCHIZOPHRENIA
Susana Da Silva*, Sarah Saperia, Gagan Fervaha, Ishraq Siddiqui, Ofer Agid, Arun Ravindran, Konstantine Zakzanis, Gary Remington, George Foussias

M259. CLINICAL AND SOCIAL TRAJECTORIES OF FIRST EPISODE PSYCHOSIS PATIENTS OVER FIVE YEARS: THE ROLE OF GENDER DIFFERENCES
Carla Comacchio*, Antonio Lasalvia, Dorian Cristofalo, Chiara Bonetto, Sarah Tosato, Gioia Zanatta, Elisabetta Miglietta, Silvia Zoppei, Sara Petterlini, Katia De Santi, Stylianos Nicolaou, Rossana Riolo, Mirella Ruggeri

M260. INSIGHT AND ADHERENCE IN PRIMARY AND SECONDARY PERSISTENT NEGATIVE SYMPTOMS: A LONGITUDINAL INVESTIGATION OF FIRST-EPIODE SCHIZOPHRENIA.
Michael Bodnar*, Ashok Malla, Ridha Joober, Martin Lepage
M261. ARE SELF-REPORT MEASURES OF SOCIAL FUNCTIONING ASSOCIATED WITH REAL-LIFE SOCIAL FUNCTIONING? AN ESM STUDY IN PATIENTS WITH SCHIZOPHRENIA AND HEALTHY CONTROL INDIVIDUALS
Maude Schneider*, Ulrich Reininghaus, Martine Van Nierop, Mayke Janssens, Inez Myin-Germeys, on behalf of GROUP

M262. A 6-YEAR FOLLOW-UP OF PATIENTS WITH SEVERE SCHIZOPHRENIA UNDERGOING INTENSIVE AND COMPREHENSIVE TREATMENT: CLINICAL AND FUNCTIONAL OUTCOMES
Juan J. Fernandez-Miranda*, Silvia Diaz-Fernandez

M263. ACTIVE RECOVERY TRIAD. A NEW INITIATIVE TO PROVIDE HOPE AND PERSPECTIVE FOR PATIENTS WITH SEVERE MENTAL ILLNESS IN NEED OF LONG-TERM CLINICAL CARE
Lisette Van der Meer*, Tom van Mierlo, Bram Berkvens, Bert Stavenuiter, Yolande Voskes, Jaap van Weeghel

M264. INTERPERSONAL CONSEQUENCES OF SUBCLINICALLY REDUCED EXPRESSIVENESS - AN EMG STUDY OF FACIAL EXPRESSIONS
Marcel Riehle*, Tania M. Lincoln

M265. LANGUAGE DISTURBANCE AND FUNCTIONAL OUTCOME FOLLOWING FIRST EPISODE PSYCHOSIS
Eric Roche*, Ricardo Segurado, Brian O’Donoghue, Felicity Fanning, Laoise Renwick, Caragh Behan, Kevin Madigan, John Lyne, Mary Clarke

M266. LONG TERM TRAJECTORIES OF POSITIVE AND NEGATIVE SYMPTOMS IN FIRST EPISODE PSYCHOSIS: A 10 YEAR FOLLOW-UP STUDY IN THE OPUS COHORT.
Stephen Austin*, Esben Budtz-Jørgensen, Ole Mors, Rikke Gry Secher, Carsten Hjorthøj, Mette Bertelsen, Pia Jeppesen, Lone Petersen, Anne Thorup, Merete Nordentoft

M267. VALIDATION OF A GERMAN VERSION OF THE RESILIENCE SCALE FOR ADULTS (RSA)
Nathalie Kaiser*, Mauro Seves, Stephan Ruhrmann

M268. PSYCHOPATHOLOGY AND FUNCTIONING IN PATIENTS WITH A RECENT ONSET PSYCHOSIS (ROP) - FIRST RESULTS FROM THE PRONIA STUDY

M269. ATTITUDE TOWARD MEDICATION, SUBJECTIVE WELL-BEING, AND PSYCHOPATHOLOGY IN THE EARLY TREATMENT OF SCHIZOPHRENIA PATIENTS.
Christian Widschwendter*, Susanne Baumgartner, Georg Kemmler, Maria Rettenbacher, Nursen Yalcın-Siedentopf, Wolfgang Fleischhacker, Alex Hofer
M270. CHARACTERIZING OUTCOME PREFERENCES IN PATIENTS WITH PSYCHOTIC DISORDERS: A DISCRETE CHOICE CONJOINT EXPERIMENT
Robert Zipursky*, Charles Cunningham, Bailey Stewart, Heather Rimas, Emily Cole, Stephanie McDermdid Vaz

M271. “I'M OUT OF SYNCH AND ON MY OWN. I AM A SCHIZOPHRENIC.” A MINI ETHNOGRAPHY OF PATIENTS DIAGNOSED WITH SCHIZOPHRENIA IN POLAND.
Karolina Bryl*

M272. INSTRUMENTS TO MEASURE PUBLIC STIGMA AND SELF STIGMA – A REVIEW
Bouwina Sportel*, Marieke (Gerdina) Pijnenborg, Stynke Castelein

M273. IMPAIRED CARDIORESPIRATORY FITNESS (CRF) IN SCHIZOPHRENIA
Richard Hodgson*, Hiram Wildgust

M274. DEVELOPMENT OF THE SUBJECTIVE RECOVERY SCALE FOR THE PATIENTS WITH SCHIZOPHRENIA (SRS)
Mustafa Yıldız*, Rahsan Erim, Haldun Soygür, Ümit Tural

M275. ASSESSING THE RELEVANCE OF THE QUALITY OF LIFE SCALE IN SCHIZOPHRENIA: PATIENT AND CAREGIVER PERSPECTIVES
Dieter Naber*, Maud Beillat, Dana B. DiBenedetti, T. Michelle Brown

M276. ON THE RELATIONSHIP BETWEEN DELUSIONS AND QUALITY OF LIFE IN SCHIZOPHRENIA
Eric Tan*, Susan Rossell

M277. FIRST EPISODE PSYCHOSES FIDELITY SCALE
Donald Addington*, Ross Norman, Gary Bond, Tamara Sales, Ryan Melton, Emily McKenzie, JianLi Wang

M278. DISCONTENTED RESIDENTS OF SHELTERED HOMES: BETTER FUNCTIONING AND WORSE QUALITY OF LIFE
Satu Viertio*, Eila Sailas

M279. DEVELOPMENT OF THE DANISH OPUS-FIDELITY-SCALE FOR SPECIALIZED EARLY INTERVENTION TEAMS
Marianne Melau*, Merete Nordentoft

M280. ANALYZING THE IMPACT OF EARLY DETECTION ON DURATION OF UNTREATED PSYCHOSIS: QUANTILE REGRESSION
Sinan Guloksz, Fangyong Li, Cenk Tek, Scott Woods, Thomas McGlashan, Svein Friis, Vinod Srihari*

M281. OUTCOME EVALUATION OF A CANADIAN FIRST EPISODE PSYCHOSES PROGRAM.
Sharman Robertson*, Paul Roy, Gretchen Conrad, Angela Stevens
M282. IMPACT OF THE “UNLOCKING AND TREATMENT” INTERVENTION ON FAMILY BURDEN: A FOLLOW-UP STUDY FOR THE FAMILIES WHERE LOCKING OF PATIENTS WITH SMI WERE PRACTICED
Lili Guan*, Jin Liu, Xiamin Wu, Dafang Chen, Xun Wang, Ning Ma, Yan Wang, Byron Good, Xin Yu, Mary-Jo Good, Hong Ma

M283. EXTENT OF MONITORING AND INTERVENTION FOR PHYSICAL HEALTH ISSUES IN THE SINGAPORE EARLY PSYCHOSIS INTERVENTION PROGRAMME (EPIP)
Charmaine Tang*, Swapna Verma

M284. DEVIATION FROM THE 12-HOUR STANDARD SAMPLING TIME DURING THERAPEUTIC DRUG MONITORING OF CLOzapine – DOES IT MATTER?
Michelle Jakobsen*, Julie Larsen, Camilla Svensson, Sys Johansen, Kristian Linnet, Jimmy Nielsen, Anders Fink-Jensen

M285. CARDIAC AND CARDIOMETABOLIC ADVERSE EFFECTS IN CHILDREN AND ADOLESCENTS DURING TREATMENT WITH ARipipraZOlE OR QUetiapine ER – 12-WEEK RESULTS FROM THE TEA STUDY
Karsten Gjessing Jensen*, Christoph Correll, Stefan Gärtner, Ditte Rudã, Dea Gowers Klauber, Marie Stentebjerg-Olesen, Birgitte Fagerlund, Jens Richardt Jepsen, Anders Fink-Jensen, Anne Katrine Pagsberg

M286. DIFFERENCES IN EMOTION RECOGNITION AND ATTRIBUTIONAL STYLE BETWEEN PATIENTS WITH SCHIZOPHRENIA AND HEALTHY CONTROLS
Ingrid Tortadès*, Susana Ochoa, Emma Casas-Anguera, Mar Garcia-Franco, Maria José Escandell, José Ramón Martin, Sònia Vilamala, Gemma Prat, Pablo Gonzalez, Joaquin Fernandez

M287. NEUROLOGICAL SOFT SIGNS AS PREDICTORS OF CLINICAL OUTCOME FOR A MULTI-ELEMENT PSYCHOSOCIAL INTERVENTION ON FEP PATIENTS AND THEIR FAMILIES IN THE CLUSTER-RANDOMIZED CONTROLLED GET UP PIANO TRIAL
Sarah Tosato, Chiara Bonetto, Antonio Lasalvia, Angelo Fioritti, Giovanni de Girolamo, Paolo Santonastaso, Simona Tomassi, Silvio Scarone, Maurizio Miceli, Anna Meneghelli, Katia De Santi, Fausto Mazzi, Emanuela Pileggi, DoriAnna Cristofalo, Mirella Ruggeri*, The GET UP Group

M288. INTRA-ABDOMINAL FAT GAIN IN PATIENTS INITIATING TREATMENT WITH CLOzapine.
Marina Garriga, Lourdes Serrano, Andrea Mallorquí, Anxela Torras, Cristina Oliveira, Miguel Bernardo Arroyo, Clemente Garcia-Rizo*

M289. GLUCOSE DISTURBANCES AT THE ONSET OF SERIOUS MENTAL ILLNESSES
Clemente Garcia-Rizo*, Brian Kirkpatrick, Cristina Oliveira, Emilio Fernandez-Egea, Miguel Bernardo

M290. RESTING STATE NETWORKS ALTERATION IN SCHIZOPHRENIA
Gianluca Mingoia*, Igor Nenadic
M291. EFFICACY AND SIDE EFFECTS OF ANTIPSYCHOTIC POLYPHARMACY IN A REAL CLINICAL SETTING
Jose Maria Pelayo-Teran*, Yolanda Zapico-Merayo, Jovita Martínez-Díez, Nicolás Martín-Navarro

M292. NEUROPHYSIOLOGICAL MARKERS OF PARANOID SCHIZOPHRENIA.
Andrei Arkhipov*

M293. THE STAR STATUS OF CLOzapine IN THE TREATMENT OF POSITIVE SYMPTOMS IN SCHIZOPHRENIA IS LESS VIGOROUS: AN UMBRELLA REVIEW
Ellen Letsoin, Peter F.J. Schulte, Jim Van Os, P. Roberto Bakker*

M294. REWARD LEARNING IN ADULTS WITH 22Q11DS.
Esther van Duin*, Zuzana Kasanova, merrit beck, Dennis Hernaus, Inez Myin-Germeys, Therese van Amelsvoort

M295. CROSS-COUNTRY VARIATIONS IN THE EFFECTS OF CHILDHOOD ABUSE ON PSYCHOSIS: INITIAL RESULTS FOR THE EU-GEI STUDY
Charlotte Gayer-Anderson, Kathryn Hubbard, Stephanie Beards, Bart Rutten, Jim van Os, Marta Di Forti, Robin Murray, Craig Morgan*

M296. INTERPLAY BETWEEN LIFE EVENTS AND FAMILIAL RISK IN THE ONSET OF PSYCHOSIS
Stephanie Beards, Charlotte Gayer-Anderson, Kathryn Hubbard, Valeria Mondelli, Paola Dazzan, Carmine Pariante, Robin Murray, Craig Morgan*
USING A STRATIFIED APPROACH IN PSYCHIATRY – IMPLICATIONS FOR TREATMENT AND THE SEARCH FOR UNDERLYING MECHANISMS OF MENTAL ILLNESS
Martine Van Nierop*, Ruud van Winkel, Inez Myin-Germeys, Jim Van Os, Ron de Graaf, Margreet ten Have

T2. RELATIONSHIP BETWEEN CLOZAPINE INDUCED EEG ABNORMALITIES AND THE SERUM CONCENTRATION OF CLOZAPINE IN JAPANESE PATIENTS WITH SCHIZOPHRENIA
Yuka Kikuchi*, Wataru Sato, Yumiko Akamine, Takashi Kanbayashi, Tetsuo Shimizu

T3. EXTRAPYRAMIDAL SYMPTOMS DURING RISPERIDONE MAINTENANCE TREATMENT IN SCHIZOPHRENIA: A PROSPECTIVE, MULTICENTER STUDY
Qi-Jing Bo*, Xian-Bin Li, An-Ning Li, Zhi-Min Wang, Xin Ma, Chuan-Yue Wang

T4. THRESHOLD OF DOPAMINE D2/3 RECEPTOR OCCUPANCY FOR HYPERPROLACTINEMIA IN OLDER PATIENTS WITH SCHIZOPHRENIA

T5. CHILDHOOD NEGLECT DIFFERENTIALLY AFFECTS PSYCHOTIC PATIENTS IN COMPARISON TO HEALTHY SIBLINGS AND CONTROLS
Nadja Maric*, Marina Mihaljevic, Sanja Andric, Tijana Mirjanic

T6. IMMIGRATION AND COMMUNITY MENTAL HEALTH SERVICES: AN EXAMPLE OF AN EFFECTIVE OUTREACH DRUG TREATMENT PROGRAM.
Fran Calvo-García*, Cristina Giralt-Vázquez

T7. RISK OF SUICIDE AMONG HOMELESS WOMEN: GENDER DIFFERENCES IN THE STREETS OF GIRONA (CATALONIA).
Fran Calvo-García*, Cristina Giralt-Vázquez

T8. EFFECT OF BREXIPRAZOLE ON WEIGHT AND METABOLIC PARAMETERS: AN ANALYSIS OF SHORT- AND LONG-TERM TRIALS IN SCHIZOPHRENIA
Hans Eriksson*, Catherine Weiss, Mary Hobart, John Ouyang, Emmanuelle Weiller

T9. THE INTERACTION BETWEEN BULLYING AND FKBP5 HAPLOTYPE ON PSYCHOTIC-LIKE EXPERIENCES AND REACTIVITY TO STRESS: DOES IT MATTER IN REAL LIFE?
Paula Cristóbal-Narváez*, Tamara Sheinbaum, Araceli Rosa, Sergi Ballespí, Mercè Mitjavila, Marta de Castro-Català, Elionora Peña, Thomas R. Kwapil, Neus Barrantes-Vidal
T10. MISMATCH NEGATIVITY AND P3A AMPLITUDE IN YOUNG ADOLESCENTS WITH FIRST EPISODE PSYCHOSIS: A COMPARISON WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER
Jacob Rydkjaer, Jens Richardt Jepsen, Anne Katrine Pagsberg, Birgitte Fagerlund, Birte Glenthoj, Bob Oranje*

T11. THE FECAL MICROBIOTA OF PATIENTS WITH FIRST EPISODE PSYCHOSIS AND HEALTHY CONTROLS
Jaana Suvisaari*, Emanuel Schwarz, Tuula Kieseppä, Matej Oresic, Sarven Sabunciyan, Outi Mantere, Maria Saarela, Robert Yolken, Johanna Maukonen

T12. ASSOCIATIONS OF NEONATAL MARKERS OF INFLAMMATION AND RISK OF AUTISM SPECTRUM DISORDERS
Christina Dalman*, Brian K Lee, Renee Gardner, Håkan Karlsson

T13. EPISODIC MEMORY IMPAIRMENTS ARE ASSOCIATED WITH FUNCTIONAL ALTERATIONS WITHIN THE MEMORY NETWORK IN SCHIZOPHRENIA
Viola Oertel*, Michael Stäblein, Denisa Ghinea, Helena Storchak, Dominik Kraft, Christian Knöchel, Andreas Reif

T14. CORPUS CALLOSUM INTEGRITY DISRUPTION IN TREATMENT RESISTANT SCHIZOPHRENIA
Idaiane Assunção*, Luciana Monteiro de Moura, André Zugman, João Ricardo Sato, Deyvis Rocha, Bruno Bertolucci Ortiz, Cristiano Noto, Rodrigo Bressan, Andrea Andrea Parolin Jackowski, Ary Gadelha

T15. POST-MORTEM EVIDENCE FOR INCREASED MICROGLIA ACTIVITY IN SCHIZOPHRENIA
Iris Sommer*, Charissa Van Kesteren, Rene Kahn

T16. A SYSTEMATIC REVIEW ON THE NEURAL CORRELATES OF APATHY WITHIN MULTIPLE PATIENT POPULATIONS, INCLUDING SCHIZOPHRENIA
Claire Kos*, Marie-Jose Van Tol, Jan Bernard Marsman, Henderikus Knegtering, Andre Aleman

T17. COGNITION AND PSYCHOPATHOLOGY IN FIRST EPISODE OF PSYCHOSIS: ARE THEY RELATED TO INFLAMMATION?
Bibiana Cabrera Llorca*, Miquel Bioque, Rafael Penades, Ana Gonzalez-Pinto, Mara Parellada, Julio Bobes, Antonio Lobo, Borja García-Bueno, Juan Carlos Leza, Miquel Bernardo

T18. RESPONSE TO CLOZAPINE TREATMENT AND NEUROTROPHIC FACTORS LEVEL AMONG SCHIZOPHRENIA PATIENTS
Amir Krivoy*, Eldar Hochman, Hollander Sarah, Weizman Abraham, Michal Taler

T19. IMPAIRMENTS IN PRE-ATTENTIVE AUDITORY PROCESSING AND THE CORTICAL THICKNESS OF ITS STRUCTURAL CORRELATES IN SCHIZOPHRENIA
Jiyoon Seol*, Minah Kim, Kang Ik Cho, June Sic Kim, Tae Young Lee, Jun Soo Kwon
T20. GLUTAMATE-RELATED AMINOACIDS BEFORE AND AFTER 10 WEEKS OF ANTIPSYCHOTIC TREATMENT IN DRUG NAïVE FIRST-EPIsODE PSYCHOSIS
Beyazit Garip*, Hakan Kayıır

T21. ABERRANT TYROSINE TRANSPORT ACROSS PLASMA MEMBRANE - AN ENDOPHENOTYPE MARKER IN SCHIZOPHRENIA
Lena Flyckt*, Nikolaos Venizelos

T22. STRUCTURAL BRAIN CORRELATES OF STRESS REACTIVITY IN THE AT-RISK MENTAL STATE
Maria Calem*, Ulrich Reininghaus, Lucia Valmaggia, Barnaby Nelson, Eva Velthorst, Inez Myin-Germeys, Craig Morgan, Philip McGuire, Matthew Kempton, . EU-GEI At Risk Study

T23. LOW SERUM NOGO-A, UCH-L1 AND α-SYNUCLEIN LEVELS IN PATIENTS WITH SCHIZOPHRENIA COMPARED TO HEALTHY CONTROLS
Ömer Faruk Demirel*, İlhan Çetin, Tarrık Sağlam, Nazım Yıldız, Alaattn Duan

T24. MISMATCH NEGATIVITY: ALTERATIONS IN NONCLINICAL ADULTS FROM THE GENERAL POPULATION WHO REPORT SUBCLINICAL PSYCHOTIC SYMPTOMS

T25. CLINICAL AND COGNITIVE PERFORMANCE AND THE RS53576 SNP OF OXITOCINE RECEPTOR GENE (OXTR) IN RECENT ONSET PSYCHOSIS AND AT RISK MENTAL STATE (ARMS) SUBJECTS
Vanessa Sanchez-Gistau*, Sara Arranz, Montserrat Sole, Angel Cabezás, MJose Algora, Javier Labad, Elisabet Vilèlla

T26. DYSREGULATED 14-3-3 FAMILY IN SCHIZOPHRENIA
Ying Qing*, Liya Sun, Chao Yang, Jie Jiang, Xuhan Yang, Xiaowen Hu, Donghong Cui, Yifeng Xu, Lin He, Dongmei Han, Chunling Wan

T27. AEROBIC EXERCISE INCREASES BDNF AND PREDICTS ENHANCED COGNITIVE AND GLOBAL FUNCTIONING IN FIRST EPISODE SCHIZOPHRENIA: A UCLA PILOT RCT
Sarah McEwen*, Joseph Ventura, Kenneth Subotnik, Keith Nuechterlein

T28. CORRELATION BETWEEN BDNF SERUM LEVELS AND BASAL CLINICAL CHARACTERISTICS IN FIRST EPISODE PSYCHOSIS
Alba Toll*, Anna Mané, Daniel Berge, Víctor Pérez-Solà

T29. PLATELET SEROTONIN CONCENTRATIONS AND DEPRESSIVE SYMPTOMS OF SCHIZOPHRENIA
Vjekoslav Peitl*, Ante Silić, Draženka Ostojić, Ana Kovak Mufić, Danijel Crnković, Dalibor Karlović
T30. IS P300 AN ENDOPHENOTYPE FOR SCHIZOPHRENIA OR A STATE MARKER OF NEUROCOGNITIVE DEFICIT?: EVIDENCE FROM INTER-TRIAL VARIABILITY ANALYSIS
Minah Kim*, Hanwoom Hong, Ji-Hun Kim, Tak Hyung Lee, Tae Young Lee, Sung Nyun Kim, Youngjo Lee, Jun Soo Kwon

T31. EXAMINING THE RELATIONSHIP BETWEEN GLUTAMATE AND AUDITORY MISMATCH NEGATIVITY (MMN) IN ANTI-PSYCHOTIC-NAÏVE/FREE PATIENTS WITH SCHIZOPHRENIA: PRELIMINARY FINDINGS FROM AN (1)H-MRS-EEG STUDY
Sri Mahavir Agarwal*, Anushree Bose, Hema Nawani, Venkataram Shivakumar, Anekal Amaresha, Boban Joseph, Janardhanan Narayanawamy, Ganesan Venkatasubramanian

T32. INTERPERSONAL SENSITIVITY, BULLYING AND PARANOID IDEATION AMONG HELP-SEEKING ADOLESCENTS AND YOUNG ADULTS.
Alice Masillo*, Lucia Valmaggia, Riccardo Saba, Martina Brandizzi, Nella Lo Cascio, Juliana Fortes Lindau, Ludovica Telesforo, Paola Venturini, Valentino Righetti, Marco D’Alema, Paolo Girardi, Paolo Fiori Nastro

T33. MANAGEMENT OF PSYCHIATRIC SYMPTOMS IN PEDIATRIC ANTI-NMDA RECEPTOR ENCEPHALITIS: CASE REPORT AND SYSTEMATIC REVIEW
Sunny Tang*, Orna Alpert

T34. PREDICTING THE NEXT THREE YEARS: TESTING MULTIVARIATE PSYCHOSIS-RISK OUTCOME ALGORITHMS IN AN UNSELECTED ADOLESCENT PSYCHIATRIC SAMPLE
Sebastian Therman*, Maija Lindgren, Jaana Suvisaari, Tyrone Cannon

T35. SCHIZOTYPY IN THE EARLY- TO MID-TEENS PREDICTS PASSIVE SUICIDAL IDEATION TWO YEARS LATER
Richard Linscott*

T36. THE DISCRIMINATIVE VALUE OF THE STRAUSS AND CARPENTER PROGNOSTIC SCALE FOR PREDICTION OF CLINICAL DIAGNOSIS IN EARLY ONSET PSYCHOSIS
Raquel Vicente, Pilar Baos, Celso Arango*, Beatriz Paya, Angel del Rey-Mejias, Josefina Castro-Fornieles, Ana Gonzalez-Pinto, Montse Graell, Dolores Moreno, Marta Rapado-Castro

T37. BASELINE CHARACTERISTICS OF CHILDREN AND ADOLESCENTS WITH PSYCHOSIS RISK SYNDROME: A COMPARISON STUDY VERSUS HEALTHY CONTROLS
Inmaculada Baeva Pertegaz*, Elena De la Serna, Gisela Sugranyes, Olga Puig-Navarro, Clara Espelt, Marta Pardo, Daniel Muñoz, Jordina Tor, Ana Sintes,Montserrat Dolz

T38. TRANSITION TO PSYCHOSIS IN CHILDREN AND ADOLESCENTS AT ULTRA HIGH RISK IN ITALIAN NEUROPSYCHIATRY SERVICES: A FOLLOW-UP STUDY
Giulia Spada*, Silvia Molteni, Michela Tantardini, Federica Ferro, Matteo Chiappedi, Paolo Fusar-Poli, Umberto Balottin
T39. PSYCHOSOCIAL CHARACTERISTICS OF VOICE HEARING IN NORWEGIAN ADOLESCENTS: A POPULATION-BASED STUDY
Else-Marie Løberg*, Rolf Gjestad, Maj-Britt Posserud, Kristiina Kompus, Astri Johansen Lundervold

T40. PREVALENCE, CLINICAL DIFFERENCES AND IMPACT OF ANXIETY DISORDERS ON CONVERSION TO PSYCHOSIS IN YOUTH AT HIGH RISK OF DEVELOPING PSYCHOSIS
Espadas Marta, Jordina Tor, Marta Carulla, Inmaculada Baeza, Montserrat Dolz*, Elena De la Serna

T41. ADOLESCENT TRAJECTORIES OF COGNITION AND RISK FOR PSYCHOSIS
Hannah Dickson*, Alexis Cullen, Rebecca Jones, Abraham Reichenberg, Ruth Roberts, Sheilagh Hodgins, Robin Morris, Kristin Laurens

T42. THE PRESENCE OF COMORBID MOOD DISORDER IN PSYCHOSIS RISK SYNDROME IN A CHILD AND ADOLESCENT SAMPLE HAS NO INFLUENCE IN TRANSITION RATES TO PSYCHOSIS
Marta Rodríguez, Xavier Álvarez, Álvaro Armendáriz, Jordina Tor, Marta Carulla, Marta Pardo, Daniel Muñoz, Elena De la Serna, Inma Baeza, Montse Dolz*

T43. NEURODEVELOPMENTAL DISORDERS AND THEIR IMPACT ON INITIAL TREATMENT FAILURE IN EARLY ONSET PSYCHOSIS: A HISTORICAL COHORT STUDY USING ELECTRONIC PATIENT RECORDS
Johnny Downs*, Suzannah Lechler, Harry Dean, Nicola Sears, Rashmi Patel, Hitesh Shetty, Matthew Hotopf, Tamsin Ford, Celso Arango, James MacCabe, Richard Hayes, Laura Pina-Camacho

T44. PREDICTION OF FUNCTIONAL OUTCOME IN YOUNG PATIENTS WITH A RECENT-ONSET PSYCHIATRIC DISORDER: BEYOND THE TRADITIONAL DIAGNOSTIC CLASSIFICATION SYSTEM.
Amedeo Minichino*, Francesconi Marta, Ricardo Carrion, Kristin Cadenhead, Francesco Saverio Bersani, Maurizio Parisi, Santo Rullo, Massimo Biondi, Arturo Bevilqua, Roberto Delle Chiaie

T45. PSYCHOSIS PREDICTION IN SECONDARY MENTAL HEALTH SERVICES. A BROAD, COMPREHENSIVE APPROACH TO THE “AT RISK MENTAL STATE” SYNDROME.
Marta Francesconi*, Amedeo Minichino, Kristin Cadenhead, Ricardo Carrion, Arturo Bevilqua, Santo Rullo, Maurizio Parisi, Francesco Saverio Bersani, Massimo Biondi, Roberto Delle Chiaie

T46. THE BDNF VAL66MET GENOTYPE REGULATES PREPULSE INHIBITION OF ACOUSTIC STARTLE, AN ENDOPHENOTYPE OF SCHIZOPHRENIA: SENSITIVITY TO GLUCOCORTICOID STRESS HORMONE
Michael Notaras, Rachel Hill, Joseph Gogos, Maarten van den Buuse*

T47. ARC/ARG3.1 GENETIC DISRUPTION IN MICE CAUSES DOPAMINE SYSTEM ALTERATIONS AND NEUROBEHAVIORAL PHENOTYPES RELATED TO SCHIZOPHRENIA
Francesco Papaleo*, Francesca Managò, Kuan Wang

T48. PHASE II, DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED STUDY OF ADJUNCTIVE TAURINE IN FIRST-EPISODE PSYCHOSIS
Colin O’Donnell, Kelly Allott, Hok Pan Yuen, Patrick D. McGorry*
T49. THE EFFECT OF VIRTUAL REALITY EXPOSURE THERAPY ON SOCIAL PARTICIPATION IN PEOPLE WITH A PSYCHOTIC DISORDER: A MULTI-SITE RANDOMIZED CONTROLLED TRIAL
Roos Pot-Kolder*, Wim Veling, Mark Van der Gaag

T50. CORRELATION BETWEEN FUNCTIONALITY AND SYMPTOM CONTROL IN ACUTE SCHIZOPHRENIA PATIENTS
Tian mei Si*, Hua Fei Lu, Li Li Zhang, Yu Feng, Jian Min Zhuo, Shangli Cai

T51. ASSOCIATIONS OF NEGATIVE SYMPTOMS AND PSYCHOSOCIAL FUNCTIONING IN PATIENTS AT RISK FOR PSYCHOSIS
Katharina Beck*, Christina Andreou, Erich Studerus, Ulrike Heitz, Stephanie Menghini-Müller, Laura Egloff, Anita Riecher-Rössler

T52. EVALUATING THE VERBAL EPISODIC MEMORY DEFICITS IN EMERGING PSYCHOSIS USING STRUCTURAL EQUATION MODELING
Laura Egloff*, Erich Studerus, Ulrike Heitz, Stephanie Menghini-Müller, Sarah Ittig, Stefan Borgwardt, Anita Riecher-Rössler

T53. GENDER DIFFERENCES IN THE SYMPTOMATOLOGY OF PATIENTS AT-RISK FOR PSYCHOSIS - RESULTS FROM THE EU-GEI STUDY
Stephanie Menghini-Müller*, Erich Studerus, Ulrike Heitz, Laura Egloff, Sarah Ittig, EU-GEI Work Package 5, Anita Riecher-Rössler

T54. BEAT VICTIMIZATION! A PSYCHOMOTOR RESILIENCE TRAINING WITH ELEMENTS OF KICKBOXING FOR INDIVIDUALS WITH A PSYCHOTIC DISORDER: RESULTS OF A FEASIBILITY STUDY.
Elisabeth van der Stouwe*, Bertine de Vries, André Aleman, Jooske van Busschbach, Marieke Pijnenborg

T55. SUBJECTIVE EXPERIENCES IN PSYCHOSIS EARLY DETECTION – FACTOR STRUCTURE OF THE FRANKFURT COMPLAINT QUESTIONNAIRE
Martina Uttinger*, Erich Studerus, Sarah Ittig, Ulrike Heitz, Frauke Schultze-Lutter, Anita Riecher-Rössler

T56. PLASMA AND SERUM BRAIN DERIVED NEUROTROPHIC FACTOR LEVELS AND THEIR ASSOCIATION WITH NEUROCOGNITION IN AT-RISK MENTAL STATE, FIRST EPISODE AND CHRONIC SCHIZOPHRENIA PATIENTS
Ulrike Heitz*, Martina Papmeyer, Erich Studerus, Tobias Vogel, Konstanze Römer, Sarah Ittig, Stefan Borgwardt, Marc Graf, Anne Eckert, Anita Riecher-Rössler

T57. LONG-TERM TOLERABILITY OF ARIPIPRAZOLE ONCE-MONTHLY IN PATIENTS WITH SCHIZOPHRENIA FOLLOWING TREATMENT OF AN ACUTE EXACERBATION
John Kane, Timothy Peters-Strickland, Na Jin, Pamela Perry, Michelle Gara, Peter Hertel, Phyllis Salzman*, Anna Eramo, Raymond Sanchez, Robert D. McQuade
T58. RESULTS OF AN FDA DEVICE CLEARANCE TRIAL FOR PLASTICITY-BASED ADAPTIVE COGNITIVE REMEDIATION (PACR)
Henry Mahncke*, Sarah-Jane Kim, Catherine Stasio, Trina Walker, Peter Buckley, Stanley Caroff, Erica Duncan, Philip D. Harvey, L. Fredrik Jarskog, Steven Lamberti, Keith Neuchterlein, Martin Strassnig, Dawn Velligan, Joseph Ventura, Sarah Yasmin, Richard Keefe

T59. LONG-TERM SAFETY AND DURABILITY OF EFFECT OF ARIPIPRAZOLE LAUROXIL IN A ONE YEAR SCHIZOPHRENIA EXTENSION STUDY
Robert Risinger*, Arielle Stanford, Yangchun Du, Jacqueline Zummo, Hassan Jamal, Chih-Chin Liu, Amy Claxton

T60. THE IMPORTANCE OF VULNERABILITY FACTORS IN AT-RISK MENTAL STATE OF PSYCHOSIS INDIVIDUALS
Martina Papmeyer*, Irène Würsch, Erich Studerus, Rolf-Dieter Stieglitz, Anita Riecher-Rössler

T61. THE INFLUENCE OF A MUSCARINIC M1 RECEPTOR ANTAGONIST ON BRAIN CHOLINE LEVELS IN PATIENTS WITH A PSYCHOTIC DISORDER AND HEALTHY CONTROLS.
Claudia Vingerhoets*, Geor Bakker, Oswald Bloemen, Jan Booij, Matthan Caan, Therese van Amelsvoort

T62. ALKS 3831 DEMONSTRATED EQUIVALENT ANTIPSYCHOTIC EFFICACY WHILE ADDRESSING WEIGHT GAIN: RESULTS FROM A PHASE 2, RANDOMIZED, OLANZAPINE-CONTROLLED STUDY
Bernard Silverman*, Christoph Correll, Peter Weiden, Ying Jiang, Sanjeev Pathak, Lauren DiPetrillo, William Martin, Anjana Bose, Srdjan Stankovic, Elliot Ehrich

T63. A PHASE 3 STUDY TO EVALUATE WEIGHT GAIN OF ALKS 3831 COMPARED TO OLANZAPINE IN ADULTS WITH SCHIZOPHRENIA
David McDonnell*, Sanjeev Pathak, Lauren DiPetrillo, Adam Simmons, Ying Jiang, Jacqueline Zummo, Hassan Jamal, Bernard Silverman

T64. SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SINGLE RISING DOSES OF BI 425809 GIVEN ORALLY TO HEALTHY MALE VOLUNTEERS: A PARTIALLY RANDOMISED (WITHIN DOSE GROUPS), SINGLE-BLIND, PLACEBO-CONTROLLED, PHASE I STUDY
Viktoria Moschetti, Michael Desch, Sophia Goetz, Karl-Heinz Liesenfeld, Sven Wind, Glen Wunderlich, Sun-Young A. Yum*

T65. SAFETY OF LURASIDONE IN OLDER ADULTS WITH SCHIZOPHRENIA: A POOLED ANALYSIS OF SHORT-TERM PLACEBO-CONTROLLED STUDIES
Steven G. Potkin, Michael Tocco*, Andrei Pikalov, Jay Hsu, Josephine Cucchiaro, Antony Loebel

T66. POSITIVE PHASE 3 CLINICAL TRIAL OF ITI-007 FOR THE TREATMENT OF SCHIZOPHRENIA: SAFETY RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
Cedric O’Gorman, Kimberly Vanover*, Robert Davis, Jelena Saillard, Michal Weingart, Sharon Mates
T67. YOGA REDUCES THE BRAIN’S AMPLITUDE OF LOW-FREQUENCY FLUCTUATIONS IN PATIENTS WITH EARLY PSYCHOSIS
Jingxia Jessie Lin*, Xiujuan Geng, Edwin HM Lee, Sherry KW Chan, Wing Chung Chang, Christy LM Hui, Michael Tse, Cecilia LW Chan, PL Khong, William G Honer, Eric YH Chen

T68. CAN RESTING-STATE PATTERNS PREDICT ABERRANT SALIENCE IN EARLY PSYCHOSIS SPECTRUM?
Johanna Weiske*, Carlos Cabral, Sebastian Von Saldern, Maria Urquijo, Joseph Kambeitz, Nikolaos Koutsouleris, Lana Kambeitz-Ilankovic

T69. THE ASSOCIATION BETWEEN COGNITION AND SUB-DOMAINS OF NEGATIVE SYMPTOMS IN SCHIZOPHRENIA
Zixu Yang*, Madeline Lim, Bhing-Leet Tan, Jimmy Lee

T70. BELIEF FLEXIBILITY AND DELUSIONS IN PSYCHOSIS: A SYSTEMATIC REVIEW
Chen Zhu*, Xiaqi Sun, Suzanne So

T71. LONGITUDINAL CHANGE IN NEUROCOGNITION AND ITS RELATION TO SYMPTOMATIC AND FUNCTIONAL CHANGES OVER 2 YEARS IN INDIVIDUALS AT CLINICAL HIGH-RISK FOR PSYCHOSIS
Ye Seul Shin*, So-Yeon Kim, Tae Young Lee, Ji-Won Hur, Na Young Shin, Sung Nyun Kim, Min-Sup Shin, Jun Soo Kwon

T72. PROSPECTIVE MEMORY REMAINS IMPAIRED TWO YEARS AFTER ONSET OF SCHIZOPHRENIA
Eric Cheung*, Simon S Y Lui, Ya Wang, Amy C Y Liu, Raymond C K Chan

T73. TRAJECTORIES OF SOCIAL COGNITION IN SCHIZOPHRENIA AND SCHIZOPHRENIA SPECTRUM DISORDERS
Oleg Papsuev*, Maria Minyaycheva, Larisa Movina, Isaac Gurovich

T74. THEORY OF MIND IMPAIRMENT AS A VULNERABILITY MARKER FOR SCHIZOPHRENIA AND ITS RELATION WITH SCHIZOTYPAL TRAITS: A FAMILY BASED STUDY.
Maria Giralt, Helena Palma-Gudiel*, Salvador Miret, Jordi Soler, Claudia Prats, Lourdes Fañanás, Mar Fatjó-Vilas

T75. UNCOVERING THE COMPUTATIONAL PROCESSES UNDERLYING MOTIVATIONAL DEFICITS IN EARLY SCHIZOPHRENIA
Gagan Fervaha*, Ofer Agid, George Foussias, Hiroyoshi Takeuchi, Ariel Graff-Guerrero, Konstantine Zakzanis, Gary Remington

T76. ENCENICLINE INCREASES THE MATRICS CONSENSUS COGNITIVE BATTERY NEUROCOGNITIVE COMPOSITE SCORE IN PATIENTS WITH SCHIZOPHRENIA
Andrew Ho, Keith Neuchterlein, Richard Keefe, Nancy Dgetluck, Vicki Davis, Ji Yu, Dana Hilt*
T77. THE GOALS FOR BETTER WORK OUTCOME IN JAPANESE PATIENTS WITH SCHIZOPHRENIA: CUT-OFF PERFORMANCES ON MEASURES OF FUNCTIONAL OUTCOMES
Chika Sumiyoshi*, Philip D. Harvey, Manabu Takaki, Yuko Okahisa, Taku Sato, Ichiro Sora, Keith H. Nuechterlein, Kenneth L. Subotnik, Tomiki Sumiyoshi

T78. IMPACT OF THE FEATURAL/CONFIGURAL PROCESSING OF FACES TO THE FEELING OF FAMILIARITY IN SCHIZOPHRENIA
Delphine Pins*, Alexandra Colin, Sébastien Szaffarczyk, Guillaume Vaiva, Pierre Thomas

T79. MODELLING DIFFICULTIES IN ABSTRACT THINKING IN PSYCHOSIS; THE IMPORTANCE OF SOCIO-DEVELOPMENTAL BACKGROUND
Akiah Berg*, Ingrid Melle, Verena Zuber, Carmen Simonsen, Mari Nerhus, Torill Ueland, Ole A. Andreassen, Kjetil Sundet, Anja Vaskinn

T80. IS CUMULATIVE LIFE TIME DEPRESSION POSITIVELY LINKED TO BETTER COGNITION IN SCHIZOPHRENIA?
Felicitas Meier*, Jennifer Engelen, Bröhl Henrike, Heinen Jessica, Dietsche Bruno, Dannlowski Udo, Kircher Tilo, Krug Axel

T81. DEVELOPMENT OF A PLATFORM AGNOSTIC SOFTWARE ENGINE TO FACILITATE WIDESPREAD ADOPTION OF COGNITIVE REMEDIATION THERAPY IN SCHIZOPHRENIA
Brent Nelson, Elias Boroda, Suzanne Geier Jasberg*, Jazmin Camchong, Kelvin Lim

T82. THE EFFECT AND MECHANISMS OF IMPLEMENTATION INTENTION IN IMPROVING PROSPECTIVE MEMORY PERFORMANCE IN SCHIZOPHRENIA SPECTRUM DISORDERS

T83. PUPIL DILATION RESPONSE TO IMAGINED EMOTIONAL FUTURE EVENTS: RELATIONS TO HIGH AND LOW LEVELS OF APATHY IN A NON-CLINICAL SAMPLE
Marie-Jose Van Tol*, Jan Bernard Marsman, Nora Parigi, Sander Martens, Andre Aleman

T84. ONE YEAR DURABILITY OF THE COMPUTER-ASSISTED COGNITIVE REMEDIATION THERAPY: NEUROCOGNITION, SELF-ESTEEM, QUALITY OF LIFE AND USE OF PSYCHIATRIC EMERGENCY SERVICES
Gemma Garrido*, Maite Barrios, Rafael Penadés, Ana Costas-Carrera, Josep Mª Vendrell, Roser Guillamat, Vicenç Valles

T85. NEUROCOGNITION IN HELP-SEEKING INDIVIDUALS AT RISK OF PSYCHOSIS AND BIPOLAR DISORDER: OUTCOME AFTER 24 MONTHS
Sibylle Metzler*, Diane Dvorsky, Christine Wyss, Susanne Walitza, Karsten Heekeren, Wulf Rössler, Anastasia Theodoridou

T86. SMOKING IN PREGNANCY, ADOLESCENT MENTAL HEALTH AND COGNITIVE PERFORMANCE IN YOUNG ADULT OFFSPRING IN A FINNISH COHORT SAMPLE
Hugh Ramsay*, Jennifer Barnett, Graham Murray, Pirjo Mäki, Tuula Hurtig, Tanja Nordström, Jouko Miettunen, Vesa Kiviniemi, Zdenka Pausova, Tomas Paus, Juha Véijola
T87. COGNITIVE PROFILES IN FIRST EPISODE SCHIZOPHRENA SPECTRUM DISORDERS
Mabel Rodriguez*, Zuzana Kratochvilova, Iveta Fajnerova, Veronika Vorackova, Aneta Dorazilova, Katerina Sedlakova, Jitka Prajsova, Martin Pastrnak, Juraj Jonas, Filip Spaniel

T88. THE VALUE OF NOVELTY IN SCHIZOPHRENA
Cristina Martinelli*, Francesco Rigoli, Sukhi Shergill

T89. PERCEPTUAL METACOGNITIVE ACCURACY AND GREY MATTER VOLUME IN FIRST-EPISODE PSYCHOSIS
Geoff Davies*, Charlotte Rae, Sarah Garfinkel, Anil Seth, Medford Nick, Hugo Critchley, Kathy Greenwood

T90. VISUAL VERSUS AUDITORY COGNITIVE TRAINING FOR PEOPLE WITH SCHIZOPHRENA
Linda Scoriels*, Larissa Genaro, André Poloet, Stella Keffer, Paulo Santos, Luana Gonçalves, Walter Sena, Melissa Fisher, Sophia Vinogradov, Rogério Panizzutti

T91. REDUCED SUSCEPTIBILITY TO THE SOUND-INDUCED FLASH FUSION ILLUSION IN SCHIZOPHRENA
Lucy Vanes*, Rebekah Wigton, thomas white, daniel joyce, Sukhi Shergill

T92. THE EFFECT OF CHILDHOOD TRAUMA ON COGNITIVE FUNCTION IN A SAMPLE OF CHINESE PATIENTS WITH SCHIZOPHRENA
Chuan-Yue Wang

T93. COUNTERFACTUAL REASONING DEFICITS ARE RELATED WITH ACUTE NEGATIVE SYMPTOMS IN SCHIZOPHRENA
Auria Albacete*, Fernando Conrreras, José Manuel Menchón

T94. INITIAL PSYCHOMETRIC EVALUATION OF SOCIAL COGNITIVE MEASURES IN SINGAPORE
Sara-Ann Lee*, Keane Lim, Amy Pinkham, Max Lam, Junghee Lee, Jimmy Lee

T95. PERCEPTUAL INFERENCES IN SCHIZOPHRENA: A PRELIMINARY STUDY IN HEALTHY PARTICIPANTS
Pantelis Leptourgos*, Charles - Edouard Notredame, Renaud Jardri, Sophie Denève

T96. TOWARDS A CORE DYSFUNCTIONAL TIMING NETWORK IN SCHIZOPHRENA: A META-ANALYSIS
Irene Alústiza*, Joaquim Radua, Antón Albajes-Eizagirre, Manuel Domínguez, Felipe Ortuño

T97. DOES SCHIZOPHRENA IMPAIR THE ABILITY TO SUSTAIN ATTENTION? INVESTIGATION OF THE PROACTIVE AND REACTIVE MODES OF CONTROL BY EXPLORING THE UNDERPINNING OSCILLATORY ACTIVITY.
Marc Hoonakker*, Nadege Doignon-Camus, Anne Bonnefond

T98. ORTHOGRAPHIC PROCESSING AND LEXICAL ACCESS IN PATIENTS WITH SCHIZOPHRENA: ANALYSIS OF THE N170 COMPONENT
Maxime Curzietti*, Anne Bonnefond, Pierre Vidailhet, Nadege Doignon-Camus
T99. EFFECTS OF TRANSCRANIAL DIRECT CURRENT STIMULATION (TDCS) ON COGNITION, BRAIN CONNECTIVITY AND SYMPTOMS IN SCHIZOPHRENIA

T100. AGE-SPECIFIC ABNORMALITIES IN WORKING MEMORY IN EARLY ONSET PSYCHOSIS
Maria Isabel Calvo-Rubiales*, Manuel Canal-Rivero, Andrea Morina, Miguel Ruiz Veguilla

T101. THE RELATION OF SCHIZOTYPY AND COGNITION WITH THEORY OF MIND IN FIRST-DEGREE RELATIVES OF PATIENTS WITH DIAGNOSIS OF SCHIZOPHRENIA
Onur Kucukcoban*, Damla Gündeyer, Aylin Yurdakul, Özge Akgül, Meliha Diriöz, İ. Tolga Binbay, Koksal Alptekin, Berna Binur Akdede

T102. SOCIAL COGNITION IMPAIRMENT PROFILES IN TREATMENT-RESISTANT SCHIZOPHRENIA
Anzalee Khan*, Jean-Pierre Lindenmayer, Isidora Ljuri, Abraham Goldring, Samantha Fregenti, Veronica Ozog, Luka Lucic

T103. METABOLIC SYNDROME, ABDOMINAL OBESITY AND HYPERURICEMIA IN SCHIZOPHRENIA: RESULTS FROM THE FACE-SZ COHORT
Ophelia Godin, Pierre-Michel Llorca, Nicolas Gired, Marion Leboyer, Guillaume Fong*

T104. SOMATIC DISEASES INCREASE THE RISK OF EARLY RE-HOSPITALIZATION AMONG 6,987 INCIDENT PATIENTS WITH SCHIZOPHRENIA
Ole Köhler*, Holger Jelling Sørensen, Michael Eriksen Benros, Christiane Gasse

T105. BODY WEIGHT AND CLINICAL OUTCOMES IN FIRST EPISODE PSYCHOSIS PATIENTS: A 1-YEAR FOLLOW-UP STUDY
Priyanthi Borgen Gjerde*, Carmen Simonsen, Tatiana Polushina, Ingrid Dieset, Ole Andreas Andressen, Vidar Martin Steen, Ingrid Melle

T106. PROLACTIN CONCENTRATIONS IN ANTIPSYCHOTIC-NAÏVE PATIENTS WITH SCHIZOPHRENIA AND RELATED DISORDERS: A META-ANALYSIS
Leticia Gonzalez-Blanco*, Anne Marie Greenhalgh, Clemente Garcia-Rizo, Emilio Fernandez-Egea, Brian Miller, Brian Kirkpatrick

T107. LIPID PROFILE IN SCHIZOPHRENIA: TUNISIAN STUDY ABOUT 78 PATIENTS WITH SCHIZOPHRENIA AND 68 CONTROLS
Ahmed Mhalla*, Rim Mensi, Amel Messaoud, Walid Bel Hadj Salah, Wahiba Douki, Lotfi Gaha

T108. BLOOD METABOLITE SIGNATURE OF THE DEVELOPMENT OF METABOLIC SYNDROME IN FIRST-EPIODE PSYCHOSIS
Tommi Suviäälä*, Jaana Suvisaari, Outi Mantere, Tuula Kieseppä, Tuulia Hyötyläinen, Matej Oresic

T109. SCHIZOPHRENIA AND METABOLIC SYNDROME: FOLLOW-UP STUDY
Gokhan Yoca*, Mumin Kazim Yazici, A. Elif Anil Yaglioglu, Nurhayat Eni, Sevilay Karahan, Inci Turkoglu, Emine Akal Yildiz
T110. CLINICAL FEATURES OF SCHIZOPHRENIA PATIENTS WITH VIOLENT BEHAVIOURS: THE NEED TO CONSIDER DISTINCT SUBTYPES  
Mathilde Horn*, Laura Gangloff, Axelle Gharib, Pierre Thomas, Delphine Pins

T111. RELIABILITY AND VALIDITY OF LOW SCORES ON THE POSITIVE AND NEGATIVE SYNDROME SCALE (PANSS) AND THE INFLUENCE OF PRIOR INFORMATION  
Steven De Jong*, Selwyn Renard, Wilko Bodde, Pieter-Jan Mulder, Paul Lysaker

T112. DEMOGRAPHIC, CLINICAL, FUNCTIONAL AND COGNITIVE PROFILES OF INDIVIDUALS PRESENTING WITH AT-RISK MENTAL STATE (ARMS) FOR PSYCHOSIS TO ARMS SCREENING PROGRAM IN HONG KONG  
HC Lee, Wing Chung Chang*, SI Chan, SY Chiu, LM Hui, KW Chan, HM Lee, EYH Chen

T113. EARLY PSYCHOSIS PATIENTS’ AND RELATIVES’ ATTACHMENT STYLE: ASSOCIATION WITH CLINICAL AND FUNCTIONAL PRESENTATION  
Lídia Hinojosa-Marqués*, Tamara Sheinbaum, Paula Cristóbal-Narváez, Manel Monsonet, Thomas R. Kwapil, Tecelli Domínguez-Martínez, Neus Barrantes-Vidal

T114. AFFECTIVE SYMPTOMS IN FIRST EPISODE PSYCHOSIS: A DIMENSIONAL APPROACH  
Diego Quattrone*, Olesya Ajnakina, Marco Colizzi, Elena Carra, Sara Fraietta, Fiona Gaughran, Marta Di Forti, Robin Murray

T115. A MULTIDIMENSIONAL EXAMINATION OF DELUSIONALITY AND INSIGHT IN BODY DYSMORPHIC DISORDER VERSUS PSYCHOTIC DISORDERS  
Wei Lin Toh*, David Castle, Rachael Mountjoy, Ben Buchanan, Susan Rossell

T116. AUDITORY VERBAL HALLUCINATIONS IN BIPOLAR DISORDER (BD) AND MAJOR DEPRESSIVE DISORDER (MDD): A SYSTEMATIC REVIEW  
Wei Lin Toh*, Neil Thomas, Susan Rossell

T117. DOMAINS OF PSYCHOSIS IN SCHIZOPHRENIA SPECTRUM DISORDERS  
Kristan Armstrong*, Stephan Heckers

T118. LOW VITAMIN D ASSOCIATED WITH NEGATIVE AND DEPRESSIVE SYMPTOMS IN PSYCHOTIC DISORDERS, BUT NOT WITH PRO-INFLAMMATORY IMMUNE MARKERS  
Mari Nerhus*, Akiah Berg, Ingrid Melle

T119. EFFECT OF STRESSFUL LIFE EVENTS ON SCHIZOTYPAL SYMPTOMS IN SIBLINGS OF PATIENTS WITH FIRST-EpISODE PSYCHOSIS AND HEALTHY CONTROLS.  
Anna Butjosa*, Ulrich Reininghaus, Juana Gómez-Beníto, Susana Ochoa, GROUP investigators

T120. POSITIVE AND NEGATIVE SCHIZOTYPY PREDICTION OF PRODROMAL SYMPTOMS AND SCHIZOPHRENIA-SPECTRUM PERSONALITY DISORDER TRAITS: A 3-YEAR PROSPECTIVE STUDY  
Anna Racioppi*, Tamara Sheinbaum, Sergi Ballespí, Mercè Mitjavila, Georgina M. Gross, Thomas R. Kwapil, Neus Barrantes-Vidal
T121. AGE AT FIRST-CONTACT AND 9-MONTH OUTCOME IN PATIENTS WITH FIRST-EPI SODE SCHIZOPHRENIA SPECTRUM DISORDERS
Giovanni de Girolamo for the GET-UP Group*

T122. TEMPERAMENT IN INDIVIDUALS WITH PSYCHOTIC DISORDERS BEFORE AND AFTER THE ONSET OF ILLNESS
Jouko Miettunen*, Nina Rautio, Matti Penttilä, Eka Roivainen, Juha Veijola, Matti Isohanni, Erika Jääskeläinen

T123. NEIGHBOURHOOD CHARACTERISTICS AND THE RATE OF IDENTIFICATION OF YOUNG PEOPLE AT ULTRA-HIGH RISK FOR PSYCHOSIS AND RISK OF TRANSITION
Brian O’Donoghue*, Alison Yung, Stephen Wood, Abbie Lane, Andrew Thompson, Ashleigh Lin, Patrick D McGorry, Barnaby Nelson

T124. A POPULATION-BASED LONGITUDINAL STUDY OF MATERNAL PRENATAL DEPRESSION AND RISKS OF PSYCHOSIS AND DEPRESSION IN ADULT OFFSPRING: ROLE OF CHILDHOOD SERUM INTERLEUKIN 6
Golam Khandaker*, Sarah Rabhi, Jan Stochl, Rebecca Pearson, Jonathan Evans, Stan Zammit, Glyn Lewis, Peter Jones

T125. CHILDHOOD TRAUMAS IN YOUNG ADULTS WITH CLINICAL AND FAMILIAL RISK FOR PSYCHOSIS - THE NORTHERN FINLAND 1986 BIRTH COHORT
Pirjo Mäki*, Tuija Mähönen, Tanja Nordström, Juha Veijola

T126. TOBACCO SMOKING AND RISK OF FIRST EPISODE PSYCHOSIS: A CASE-CONTROL STUDY IN SAO PAULO, BRAZIL
Paulo Menezes*, Geraldo Busatto, Philip McGuire, Robin Murray, Marcia Scazufca

T127. THE INFLUENCE OF POLYGENIC RISK SCORES ON THE ASSOCIATION BETWEEN INFECTIONS AND SCHIZOPHRENIA
Michael Benros*, Betina Trabjerg, Sandra Melanie Meier, Manuel Mattheisen, Preben Mortensen, Ole Mors, Anders Børglum, David Hougaard, Bent Nørgaard-Pedersen, Merete Nordentoft, Esben Agerbo

T128. INADEQUATE CANCER DIAGNOSTICS AMONG PERSONS WITH SEVERE MENTAL ILLNESS: A POPULATION-BASED COHORT STUDY
Anita Tønder Nielsen*, Trine Munk-Olsen, Mogens Vestergaard, Janne Tidselbak Larsen, Nis Palm Suppli, Susanne Oksbjerg Dalton, Peter Vedsted, Merete Nordentoft, Thomas Munk Laursen

T129. PATHWAY FROM PERINATAL CIRCUMSTANCES TO MORTALITY AT MIDLIFE IN PSYCHOSES: A 45-YEAR FOLLOW-UP STUDY OF THE NORTHERN FINLAND BIRTH COHORT 1966
Nina Rautio*, Erika Jääskeläinen, Tanja Nordström, Jouko Miettunen, Matti Isohanni, Jussi Seppälä

T130. JOINT EFFECTS OF PRENATAL EXPOSURE TO INFECTION AND PERIPUBERTAL ADVERSITY IN SCHIZOPHRENIA
Jean-Christophe Debost*, Janne Tidselbak Larsen, Liselotte Petersen, Trine Munk-Olsen, Preben Bo Mortensen
T131. CANNABIS USE AND ADHERENCE TO ANTIPSYCHOTICS: A SYSTEMATIC REVIEW AND META-ANALYSIS.
Enrico Foglia*, Tabea Schoeler, Ewa Klamerus, Kevin Morgan, Sagnik Bhattacharyya

T132. IS HYPER-THEORY-OF-MIND SPECIFICALLY AND INDEPENDENTLY ASSOCIATED TO PSYCHOTIC EXPERIENCES IN PREADOLESCENCE?
Lars Clemmensen*, Jim van Os, Marjan Drukker, Anja Munkholm, Martin K. Rimvall, Mette Væver, Charlotte Ulrikka Rask, Agna Bartels-Velthuis, Anne Mette Skovgaard, Pia Jeppesen

T133. USING HOME-RECRUITMENT TO INCREASE PARTICIPATION AND REPRESENTATIVENESS OF RESEARCH AMONG INDIVIDUALS WITH PSYCHOSIS
Marianne Haapea*, Matti Isohanni, Erika Jääskeläinen, Juha Veijola, Jouko Miettunen

T134. EXPLORING RISK FACTORS IN EARLY AND LATE ONSET SCHIZOPHRENIA
Ajit Selvendra*, Laura Chen, Anne Stewart, David Castle

T135. ESTIMATION OF INCIDENCE RATE OF FIRST EPISODE PSYCHOSIS IN A BRAZILIAN LARGE CATCHMENT AREA
Rosana Shuhama*, Camila Loureiro, Taciana Ragazzi, Craig Morgan, Jim van Os, Antonio Santos, Paulo Louzada-Junior, Cristina Del-Ben

T136. RESILIENCE IN SCHIZOPHRENIA: A COMPARATIVE STUDY BETWEEN A REMOTE ISLAND AND AN URBAN AREA IN JAPAN
Kazunari Yoshida*, Takefumi Suzuki, Yasushi Imasaka, Ken-ichiro Kubo, Yuya Mizuno, Juri Saruta, Keiichi Tsukinoki, Masaru Mimura, Hiroyuki Uchida

T137. SOCIO DEMOGRAPHIC AND CLINICAL CHARACTERISTICS IN FIRST EPISODE PSYCHOSIS
Ahmet Ayer*, Esra Aydinli, Koksal Alptekin

T138. SCHIZOPHRENIA-SPECTRUM DISORDERS AND VIOLENT REOFFENDING: A NATIONAL COHORT STUDY OF CONVICTED PRISONERS
Seena Fazel*, Zheng Chang, Henrik Larsson, Paul Lichtenstein

T139. PREDICTING CLINICAL OUTCOMES IN PSYCHOTIC DISORDERS USING ELECTRONIC CASE REGISTERS AND NATURAL LANGUAGE PROCESSING
Rashmi Patel*, Robert Stewart, Philip McGuire

T140. A COMPARATIVE STUDY ON THE PREVALENCE RATE AND TREATMENT OF AGITATION AMONG CHINESE NEWLY HOSPITALIZED SCHIZOPHRENICS BETWEEN PSYCHIATRIC HOSPITALS AND GENERAL HOSPITALS
Hongyan Zhang*, Suzhen Zhang, Wifeng MI, Qi Liu, Lingzhi Li

T141. THE GOTHENBURG RESEARCH AND INVESTIGATION ON PSYCHOSIS - GRIP: OUTCOMES FROM A STANDARDIZED CLINICAL PROTOCOL FOR PSYCHOTIC PATIENTS
Anneli Goulding*, Kristina Annerbrink, David Berg, Mikael Landén
T142. EXPLORING THE EFFECT OF COMT AND BDNF POLYMORPHISMS ON ASSOCIATION BETWEEN PSYCHOTIC EXPERIENCES AND DEPRESSION-SUICIDAL IDEATION IN A SIX-YEAR FOLLOW-UP OF GENERAL POPULATION BASED SAMPLE
Tolga Binbay*, Umut Kılı, Hayriye Elbi, Bülent Kayahan, Hüseyin Onay, Ferda Özkenay, Jim van Os, Koksal Alptekin

T143. EVIDENCE FOR NEIGHBOURHOOD EFFECTS ON SUB-CLINICAL PSYCHOTIC EXPERIENCES: PRELIMINARY RESULTS FROM THE SOUTH EAST LONDON COMMUNITY HEALTH STUDY
Vishal Bhavsar*, Philip McGuire, Matthew Hotopf, Victoria Harris, Stephani Hatch, Jane Boydell

T144. DETERMINANTS OF OUTCOME IN FIRST-EPISTODE PSYCHOSIS: RE-ADMISSIONS TO PSYCHIATRIC INPATIENT CARE
Simone Ullrich*

T145. DOES A SYNDENIC OR ETHNICITY EXPLAIN DISPARITIES IN PSYCHOSIS IN THE UK?
Jeremy Coid*

T146. ACADEMIC PERFORMANCE IN CHILDREN OF MOTHERS WITH SCHIZOPHRENIA AND OTHER SEVERE MENTAL ILLNESS, AND RISK FOR THE DEVELOPMENT OF PSYCHOSIS: A POPULATION-BASED STUDY
Ashleigh Lin*, Patricia DiPrinzio, Deidra Young, Peter Jacoby, Andrew Whitehouse, Flavie Waters, Assen Jablensky, Vera Morgan

T147. HIGHER COMPLEXITY OF EEG SIGNAL AS A STATE MARKER IN FIRST EPISODE PSYCHOSIS COMPARED TO INDIVIDUALS WITH AT RISK MENTAL STATE FOR PSYCHOSIS AND HEALTHY CONTROLS.
Vincent Laprevote*, Avinash Ramyead, Julien Krieg, Erich Studerus, Christina Andreou, Raymund Schwan, Anita Riecher-Rössler

T148. MISMATCH NEGATIVITY (MMN) IN PSYCHOSIS FOLLOWING TRAUMATIC BRAIN INJURY (PFTBI)
Rachel Batty*, Philip Makarios, Susan Rossell

T149. C9ORF72 REPEAT EXPANSIONS THAT CAUSE FRONTOTEMPORAL DEMENTIA ARE DETECTABLE AMONG PATIENTS WITH PSYCHOSIS.
Annie Watson, Mochtar Pribadi, Kodavali Chowdari, Sue Clifton, Joel Wood, Bruce L. Miller, Giovanni Coppola, Vishwajit Nimgaonkar*

T150. NEUROTROPHIN SIGNALING IN FIRST EPISODE PSYCHOSIS: RELATION TO RESPONSE TO ANTIPSYCHOTICS AFTER 1 YEAR OF FOLLOW-UP
Monica Martinez-Cengotitabengoa*, Karina MacDowell, Susana Alberich, Mara Parellada, Pilar Saiz, Roberto Rodriguez, Esther Berrocoso, Miguel Bernardo, Ana Gonzalez-Pinto, Juan Carlos Leza
T151. MINOR NEUROLOGICAL SIGNS AND CLINICAL COURSE IN FIRST-EPISODE PSYCHOSIS: A TEN-YEAR FOLLOW-UP STUDY
Naika Ferruccio*, Julia Lappin, Margaret Heslin, Kevin Morgan, Adanna Onyejiaka, Tim Croudace, Peter B. Jones, Robin Murray, Paul Fearon, Gillian Doody, Craig Morgan, Paola Dazzan

T152. PSYCHOSIS-RISK IS ASSOCIATED WITH INCREASED CEREBRAL BLOOD FLOW IN THE STRIATUM: RESULTS OF AN ARTERIAL SPIN LABELING MR-STUDY
Jochen Kindler*, Frauke Schultze-Lutter, Martinus Hauf, Chantal Michel, Thomas Dierks, Benno G. Schimmelmann, Daniela Hubl

T153. VISUAL HABITUATION IS IMPAIRED IN UNAFFECTED SIBLINGS OF SUBJECTS AFFECTED BY SCHIZOPHRENIA: A PATTERN-REVERSAL VEP STUDY
Giorgio Di Lorenzo*, Fabio Ciabattini, Emanuela Bianciardi, Fabiola Ferrentino, Cherubino Di Lorenzo, Gianluca Coppola, Michele Ribolsi, Cinzia Niolu, Francesco Pierelli, Alberto Siracusano, Stefano Seri

T154. THE EFFECTS OF TAK-063 ON COGNITION IN A MULTIPLE DOSE, PHASE 1 STUDY IN HEALTHY JAPANESE SUBJECTS AND SUBJECTS WITH SCHIZOPHRENIA ARE CONSISTENT WITH ITS SOMNOLENT EFFECTS
Tom Macek*, Maggie McCue, Jinhui Xie, Keith Wesnes

T155. TAK-063 INCREASES GAMMA SYNCHRONY IN SUBJECTS WITH SCHIZOPHRENIA
Tom Macek*, Maggie McCue, Jinhui Xie, Jack Johnstone, Peter Boeijinga

T156. THE PDE-10A INHIBITOR TAK-063 REVERSES KETAMINE-INDUCED CHANGES IN FMRI BOLD SIGNAL
Deborah Yurgelun-Todd, Perry Renshaw, Paul Goldsmith, Jinhui Xie, Tolga Uz, Tom Macek*

T157. ALTERED RIGHT ANTERIOR INSULA ACTIVITY DURING ANTICIPATION OF FOOD AND SOCIAL REWARDS IN SCHIZOPHRENIA: AN FMRI STUDY
Chao Yan*, Zheng-hui Yi, Qin-yu Lv, Xu Li, Raymond C K Chan

T158. PET IMAGING EVIDENCE OF ALTERED DOPAMINERGIC MODULATION OF REWARD RESPONSES IN VENTRAL STRIATUM IN FAMILIAL RISK TO PSYCHOSIS
Zuzana Kasanova*, Jenny Ceccarini, Therese van Amelsvoort, Michael Frank, Jan Booij, Alexander Heinzel, Ye Rong, Oliver Winz, Felix Mottaghy, Inez Myin-Germeys

T159. NEURAL CORRELATES OF THE NEGATIVE PRIOR EXPECTANCY BIAS IN SCHIZOPHRENIA: AN FMRI MULTIVARIATE ANALYSIS.
Ilvana Dzafic, Andrew Martin*, Hana Burianová, Bryan Mowry

T160. ABERRANT SHIFT OF NEURAL ACTIVITY DURING HAND GESTURE PERFORMANCE IN SCHIZOPHRENIA: LESS MOTOR BUT MORE LIMBIC ACTIVITY
Katharina Stegmayer*, Stephan Bohlhalter, Tim Vanbellingen, Andrea Federspiel, Roland Wiest, René Müri, Werner Strik, Sebastian Walther
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>T161.</td>
<td>THE EFFECT OF ARIPIPRAZOL VERSUS RISPERIDONE ON PLANNING-RELATED BRAIN</td>
<td>Edith Liemburg*, Frank Van Es, Henderikus Kneegtering, Andre Aleman</td>
</tr>
<tr>
<td></td>
<td>ACTIVATION</td>
<td></td>
</tr>
<tr>
<td>T162.</td>
<td>ARE EMOTION PROCESSING DEFICITS IN SCHIZOPHRENIA AND MAJOR DEPRESSION</td>
<td>Jennifer Engelen*, Felicitas Meier, Bröhl Henrike, Heinen Jessica, Dietsche</td>
</tr>
<tr>
<td></td>
<td>MOOD-RELATED SYMPTOMS?</td>
<td>Bruno, Krug Axel, Kircher Tilo, Dannlowski Udo</td>
</tr>
<tr>
<td>T163.</td>
<td>NEUROBIOLOGY OF INSIGHT IN SCHIZOPHRENIA: FINDINGS FROM A SYSTEMATIC</td>
<td>Rose Mary Xavier*, Allison Vorderstrasse</td>
</tr>
<tr>
<td></td>
<td>REVIEW</td>
<td></td>
</tr>
<tr>
<td>T164.</td>
<td>STRESS AND EMOTION PROCESSING IN SIBLINGS OF SCHIZOPHRENIA PATIENTS:</td>
<td>Judith M.C. van Leeuwen*, Matthijs Vink, Sebastiaan F.W. Neggers, Marian</td>
</tr>
<tr>
<td></td>
<td>PRELIMINARY RESULTS</td>
<td>Joëls, René S. Kahn, Christiaan H. Vinkers</td>
</tr>
<tr>
<td>T165.</td>
<td>EMOTION REGULATION AND INSIGHT IN SCHIZOPHRENIA: AN FMRI TASK STUDY</td>
<td>Daouia Larabi*, Lisette van der Meer, Branislava Cur ić-Blake, André Aleman</td>
</tr>
<tr>
<td>T166.</td>
<td>THE EFFECT OF MENTALIZATION-BASED TREATMENT IN PATIENTS WITH FIRST EPISODE</td>
<td>Gabriele Sachs*, Helga Felsberger, Julia Furtner, Andreas Erfurth</td>
</tr>
<tr>
<td></td>
<td>SCHIZOPHRENIA – A FMRI STUDY</td>
<td></td>
</tr>
<tr>
<td>T167.</td>
<td>FRONTO-SUBCORTICAL FUNCTIONAL CONNECTIVITY IN PATIENTS WITH SCHIZOPHRENIA AND BIPOLAR DISORDER DURING A VERBAL FLUENCY TASK.</td>
<td>Leroux Elise*, Vandevelde Anais, Delcroix Nicolas, Sonia Dollfus</td>
</tr>
<tr>
<td>T168.</td>
<td>BRAIN PDE10A OCCUPANCY MEASURED BY PET AFTER ORAL ADMINISTRATION OF</td>
<td>Akihiro Takano, Per Stenkrona, Vladimir Stepanov, Nahid Amini, Stefan</td>
</tr>
<tr>
<td></td>
<td>TAK-063, A NEWLY DEVELOPED PDE10A INHIBITOR, IN HUMAN VOLUNTEERS</td>
<td>Martinsson, Max Tsai, Paul Goldsmith*, Jingtao Wu, Jinhui Xie, Tolga Uz,</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tom Macek, Christer Halldin</td>
</tr>
<tr>
<td>T169.</td>
<td>CHOOSING WITH OTHERS IN MIND: NEURAL MECHANISMS OF SOCIAL MINDFULNESS IN HEALTH AND PSYCHOSIS.</td>
<td>Imke Lemmers-Jansen*, Anne-Kathrin Fett, Dick Veltman, Lydia Krabbendam</td>
</tr>
<tr>
<td>T170.</td>
<td>NEURAL CORRELATES OF REWARD PROCESSING IN HEALTHY SIBLINGS OF PATIENTS</td>
<td>Esther Hanssen*, Jorien Van Der Velde, Paula Gromann, Sukhi Shergill, Lieuwe</td>
</tr>
<tr>
<td></td>
<td>WITH SCHIZOPHRENIA</td>
<td>De Haan, Richard Bruggeman, Lydia Krabbendam, Andre Aleman, Nienke van</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Atteveldt</td>
</tr>
<tr>
<td>T171.</td>
<td>PREVALENCE OF METABOLIC SYNDROME IN PATIENTS WITH SCHIZOPHRENIA IN KOREA: A MULTICENTER NATIONWIDE CROSS-SECTIONAL STUDY</td>
<td>JungSun Lee, Yeon Ho Joo*, Korean Society for Schizophrenia Research Group</td>
</tr>
</tbody>
</table>
T172. METABOLIC RISK FACTORS IN FIRST EPISODES OF PSYCHOSIS: FINDINGS FROM THE PEPS STUDY

T173. STUDYING CORTICAL THINNING IN SCHIZOPHRENIA WITH ULTRA HIGH-FIELD MRI
Bart Ferguson*, Natalia Petridou, Hilleke E. Hulshoff Pol, Wiepke Cahn, René S. Kahn, Rene C. W. Mandl

T174. NEUROANATOMICAL MARKERS OF AUTISTIC TRAITS IN FIRST EPISODE PSYCHOSIS
Renate Reniers, Katharine Chisholm, Ashleigh Lin, Rachel Upthegrove, Stephen Wood*

T175. HPA AXIS FUNCTION AND GREY MATTER VOLUME REDUCTIONS: IMAGING THE DIAThESIS–STRESS MODEL IN INDIVIDUALS AT ULTRA HIGH-RISK OF PSYCHOSIS
Isabel Váll*, Nicolas Crossley, Fern Day, James Stone, Stefania Tognin, Valeria Mondelli, Lucia Valmaggia, Carmine Pariante, Philip McGuire

T176. INDIVIDUAL PREDICTION OF LONG-TERM OUTCOME IN ADOLESCENTS AT ULTRA-HIGH RISK FOR PSYCHOSIS FROM BASELINE MRI BRAIN SCANS
Hugo Schnack*, Sanne de Wit, Tim Ziemans, Mireille Nieuwenhuis, Patricia Schothorst, Herman van Engeland, René Kahn, Sarah Durston

T177. INTRINSIC CONNECTIVITY OF FRONTO-TEMPORAL NETWORKS IN ADOLESCENTS AT ULTRAHIGH RISK FOR PSYCHOSIS: COMPARISON WITH FIRST EPISODE PSYCHOSIS PATIENTS AND CONTROLS
Gisela Sugranyes*, Cristina Sole-Padullés, Elena De la Serna, Vanessa Sanchez-gistau, Olga Puig-Navarro, Clara Espelt, Mireia Rosa, Josefina Castro-Fornieles, Inmaculada Baeza

T178. HIPPOCAMPAL GLUTAMATE AND HIPPOCAMPAL FUNCTIONAL CONNECTIVITY IN SCHIZOPHRENIA
Adrienne Lahti*, Nina Kraguljac, David White

T179. COGNITIVE CORRELATES OF FUNCTIONAL CONNECTIVITY IN SCHIZOPHRENIA: A RESTING-STATE FMRI STUDY
Dominik Kraft*, Viola Oertel-Knöchel, Michael Stäblein, Claudia Schmied

T180. RELATIONSHIP BETWEEN ABNORMAL GYRIFICATION AND CLINICAL VARIABLES IN FIRST-EPISODE SCHIZOPHRENIA
Daiki Sasabayashi*, Yoichiro Takayanagi, Shimako Nishiyama, Tsutomu Takahashi, Atsushi Furuichi, Mikio Kido, Yumiko Nishikawa, Mihoko Nakamura, Kyo Noguchi, Michio Suzuki

T181. INFORMATION PROCESSING SPEED MEDIATES THE RELATIONSHIP BETWEEN WHITE MATTER AND GENERAL INTELLIGENCE IN SCHIZOPHRENIA
Clara Alloza*
T182. WHITE MATTER CORRELATES OF IMPAIRED GESTURE PERFORMANCE AND RECOGNITION IN SCHIZOPHRENIA
Petra Viher*, Katharina Stegmayer, Stéphanie Giezendanner, Andrea Federspiel, Stephan Bohlhalter, Tim Vanbellingen, René Mürri, Roland Wiest, Werner Strik, Sebastian Walther

T183. PREVENTING PSYCHOSIS: IMPROVING BRAIN NETWORKS IN ULTRA HIGH RISK PATIENTS BY MEANS OF PSYCHOLOGICAL INTERVENTIONS.
Tina Kristensen*

T184. SCHIZOTYPY AND PSYCHOSIS PRONENESS EFFECTS IN A WORKING MEMORY FMRI PARADIGM
Igor Nenadic*, Kerstin Langbein, Maren Dietzek, Gerd Wagner, Ralf Schlösser, Heinrich Sauer

T185. BRAIN STRUCTURAL CORRELATES OF SCHIZOTYPY IN HEALTHY SUBJECTS: CORTICAL THICKNESS AND FOLDING
Igor Nenadic*, Alexander Rapp, Kerstin Langbein, Maren Dietzek, Amelie Schreier, Heinrich Sauer, C. Christoph Schultz

T186. STRUCTURAL PLASTICITY OF WHOLE BRAIN NETWORKS FOLLOWING AEROBIC ENDURANCE TRAINING IN MULTI-EPIISODE SCHIZOPHRENIA PATIENTS AND HEALTHY CONTROLS
Joseph Kambeitz*, Daniel Keeser, Katriona Keller-Varady, Peter Falkai, Berend Malchow

T187. SUBCORTICAL SHAPE DIFFERENCES IN REGIONS SUPPORTING WORKING MEMORY IN HIGH AND LOW FUNCTIONING SCHIZOPHRENIA
Eva Alden*, Derin Cobia, James Reilly, Matthew Smith

T188. EXTRACELLULAR AND BRAIN TISSUE RELATED ABNORMALITIES IN SUBJECTS AT CLINICAL HIGH RISK FOR PSYCHOSIS IN SHANGHAI
Yingying Tang, Ofer Pasternak, Marek Kubicki, Yogesh Rathi, TianHong Zhang*, Junjie Wang, Huijun Li, LiHua Xu, Zhenying Qian, Katharine O’Neal, Anni Zhu, Robert W. McCarley, Martha E. Shenton, Jijun Wang, Larry J. Seidman

T189. THE EFFECTS OF GENETIC AND ENVIRONMENTAL RISK FACTORS FOR SCHIZOPHRENIA ON CORTICAL THICKNESS
Emma Neilson*, Catherine Bois, Jude Gibson, Lynsey Hall, Heather Whalley, Andrew McIntosh, Stephen Lawrie

T190. DECREASED EEG SPECTRAL ENTROPY MODULATION ASSOCIATED WITH COGNITIVE IMPAIRMENT IN SCHIZOPHRENIA.
Alba Lubeiro Juárez*, Javier Gómez Pilar, Vicente Molina Rodríguez

T191. HIPPOCAMPAL-STRIATAL-MIDBRAIN CONNECTIVITY DURING REWARD PREDICTION IN HIGH-RISK SUBJECTS FOR PSYCHOSIS: CORRELATIONS WITH ABNORMAL BELIEF FORMATION AND DOPAMINE
André Schmidt*, Toby Winton-Brown, Anthony Grace, Paolo Fusar-poli, Philip McGuire
T192. CONTRIBUTION OF OXYTOCIN PATHWAY GENES TO AMYGDALA ACTIVITY IN SCHIZOPHRENIA, BIPOLAR DISORDER AND HEALTHY CONTROLS  
Marit Haram*, Lars Tjelta Westlye, Ole A. Andreassen, Ingrid Melle, Martin Tesli

T193. EFFECTS OF MUSCARINIC M1 RECEPTOR SEQUENCE VARIATION ON EXECUTIVE FUNCTION IN SCHIZOPHRENIA AND HEALTHY CONTROLS  
Sean Carruthers*, Susan Rossell, Caroline Gurvich

T194. A STUDY OF GENE-GENE INTERACTIONS BETWEEN GENES ON CHROMOSOME 22Q11 IN SCHIZOPHRENIA IN KOREA  
Yu Sang Lee*, Kyung Sue Hong, Eunsoog An

T195. GENDER-SPECIFIC ASSOCIATIONS OF THE BRAIN-DERIVED NEUROTROPHIC FACTOR VAL66MET POLYMORPHISM WITH NEUROCOGNITIVE FUNCTIONING AND CLINICAL FEATURES IN PATIENTS WITH SCHIZOPHRENIA  
Sung-Wan Kim*, Yo-Han Lee, Min Jhon, Ju-Yeon Lee, Hee-Ju Kang, Seon-Young Kim, Kyung-Yeol Bae, Jae-Min Kim, Il-Seon Shin, Jin-Sang Yoon

T196. ASSOCIATION BETWEEN ZNF804A AND THE RISK OF SCHIZOPHRENIA AND BIPOLAR DISORDERS ACROSS DIAGNOSTIC BOUNDARIES  
So Yung Yang*, Ji Hyun Baek, Youngah Cho, Ik Soo Huh, Eun-Young Cho, Taesung Park, Kyooseob Ha, Kyung Sue Hong

T197. EXOME SEQUENCING IN PATIENTS WITH SCHIZOPHRENIA  
Anna Koller, Frederick Neukirch, Lisa Winkler, Kerstin Ludwig, Julian Hecker, Jana Strohmaier, Holger Thiele, Marcella Rietschel, Markus M Nöthen, Franziska Degenhardt*

T198. VITAMIN D TREATMENT DURING PREGNANCY PREVENTS SCHIZOPHRENIA-RELATED PHENOTYPES IN A MATERNAL IMMUNE ACTIVATION ANIMAL MODEL  
Darryl Eyles*, Stephanie Vulliermot, Leon Luan, Urs Meyer

T199. IL-6 IS A CRITICAL FACTOR IN THE HIPPOCAMPUS-MEDIATED NEURAL CIRCUIT ALTERATION UNDERLYING PSYCHOSIS-ASSOCIATED PHENOTYPES  
Daisuke Fukudome*, Mari Kondo, Tomoaki Tezuka, Catherine Foss, Martin Pomper, Atsushi Kamiya, Akira Sawa

T200. PERINATAL ASPHYXIA AND CESAREAN SECTION CHANGES THE EXPRESSION OF NOVEL SCHIZOPHRENIA RISK GENES IN RAT  
Keiko Iwata*, Alessandra Paparelli, Tomoyasu Wakuda, Conrad Iyegbe, Robin Murray, Nori Takei

T201. OVEREXPRESSION OF G-PROTEIN COUPLED RECEPTOR 85 (GPR85) IN THE RAT HIPPOCAMPUS INDUCES DEFICITS IN SPATIAL SHORT-TERM MEMORY  
Eliza Koros*, Birgit Stierstorfer, Roberto Arban, Thorsten Lamla
T202. AGE-DEPENDENT ALTERATIONS IN GABAERIC SIGNALING, MEDIATORS OF INFLAMMATORY PATHWAYS AND REDOX HOMOEOSTASIS IN FRONTAL CORTEX OF THE MAM RAT MODEL
Thomas Lanz*, Nathaniel Hodgson, Gabriel Sholder, Simon Xi, William Howe, Rouba Kozak, Takao Hensch, Patricio O’Donnell

T203. TRANSGENERATIONAL TRANSMISSION AND MODIFICATION OF BEHAVIORAL DEFICITS INDUCED BY PRENATAL IMMUNE ACTIVATION
Ulrike Weber-Stadlbauer*, Juliet Richetto, Marie Labouesse, Urs Meyer

T204. ROLE OF AMPA RECEPTOR DEFICIENCY IN THE ONSET OF SCHIZOPHRENIA IN AN INDUCIBLE GENETIC MOUSE MODEL
Dragos Inta*, Miriam Vogt, Hasan Elkin, Peter Gass

T205. UBE3B EXPRESSION IN THE PREFRONTAL CORTEX DURING DEVELOPMENT AND IN SCHIZOPHRENIA
Emily Kohlbrenner*, Tsung-Ung Wilson Woo

T206. THE DOPAMINERGIC RESPONSE TO ACUTE STRESS IN HEALTH AND PSYCHOPATHOLOGY: A SYSTEMATIC REVIEW
Thomas Vaessen*, Dennis Hernaus, Inez Myin-Germeyns, Thérèse van Amelsvoort

T207. NO LINK BETWEEN DURATION OF PRODROMAL AND PSYCHOTIC SYMPTOMS AND BRAIN STRUCTURAL VOLUMES IN EMERGING PSYCHOSIS
Charlotte Rapp*, Carlos Canela, Erich Studerus, Anna Liisa Walter, Jacqueline Aston, Stefan Borgwardt, Anita Riecher-Rössler

T208. INCREASED EXPRESSION OF ALPHA-2,8-SIALYLTRANSFERASE 8 (ST8SIA2) IN SUPERIOR TEMPORAL GYRUS OF ELDERLY PATIENTS WITH SCHIZOPHRENIA
Toni Mueller*, Stefani Yates, Vahram Haroutunian, James Meador-Woodruff

T209. UNRAVELLING THE ROLE OF SCHIZOPHRENIA RISK GENES IN MICROGLIA: SPECIFIC FUNCTIONS IN THE ANTI-INFLAMMATORY PHENOTYPE?
Lot de Witte, Lynn van Olst, Manja Litjens, Elly Hol, Christaana Vinkers, René Kahn, Marjolein Sneeuwboer*

T210. EFFECT OF CLOzapine AND HALOPERIDOL IN THE MORPHOLOGY AND NEURODEVELOPMENT OF ZEBRAFISH EMBRYO.
Carles Garcia-Ribera*, Gretsen Velezmore, Javier Terriente, Javier Joya, Oriol Vall, Cristina Pujades

T211. PREFRONTAL GRAY MATTER VOLUME LOSS IS ASSOCIATED WITH DECREASED WORKING MEMORY PERFORMANCE IN ADOLESCENTS WITH A FIRST EPISODE OF PSYCHOSIS
Marta Rapado-Castro*, Mara V. Arenzana, Joost Janssen, David Fruguas, Josefina Castro-Fornieles, Ana Gonzalez-Pinto, Montse Graell, Soraya Otero, Manuel Desco, Christos Pantelis, Celso Arango
T212. WHY IS EXOTROPIA (ONE SPECIFIC TYPE OF STRABISMUS) A SIGNIFICANT RISK FACTOR FOR SCHIZOPHRENIA?
Christopher von Bartheld, Andrea Agarwal, Cheng-yuan Feng, Austin Christensen, Dan Wen, Kellie Cassinelli, L. Alan Johnson, Brian Kirkpatrick*

T213. VERY PRETERM BORN ADULTS EXPERIENCE ELEVATED LEVELS OF PSYCHOPATHOLOGY THAT ARE ASSOCIATED WITH THE VOLUMES OF CORTICOSTRIATAL WHITE MATTER TRACTS
Jasmin Kroll*, Sean Froudist-Walsh, Jane Tseng, Philip Brittain, Slava Karolis, Chiara Nosarti

T214. UNCOVERING COMPONENTS OF COGNITIVE BEHAVIOURAL CASE MANAGEMENT (CBCM) IN UHR INDIVIDUALS: WHAT IS IMPLEMENTED AND WHAT IS EFFECTIVE?
Jessica A Hartmann*, Patrick D McGorry, G Paul Amminger, Hok Pan Yuen, Connie Markulev, Lavoie Suzie, Miriam R Schäfer, Meredith McHugh, Barnaby Nelson

T215. INDIVIDUALIZED METACOGNITIVE THERAPY FOR DELUSIONS: EFFECTIVENESS IN A PRAGMATIC CONTROLLED TRIAL
Christina Andreou*, Martina Fieker, Charlotte Wittekind, Brooke Schneider, Steffen Moritz

T216. EXERCISE IMPROVES CLINICAL SYMPTOMS, QUALITY OF LIFE, GLOBAL FUNCTIONING AND DEPRESSION IN SCHIZOPHRENIA: A SYSTEMATIC REVIEW AND META-ANALYSIS
Meenakshi Dauwan*, Marieke Begemann, Sophie Heringa, Iris Sommer

T217. THETA BURST TRANSCRANIAL MAGNETIC STIMULATION FOR AUDITORY VERBAL HALLUCINATIONS
Margot Slot*, Sanne Koops, Edwin van Dellen, Maya Schutte, Wendy Nieuwdorp, Sebastiaan F. W. Neggers, Iris Sommer

T218. COGNITIVE REMEDICATION GROUP THERAPY REDUCES PERSISTENT NEGATIVE SYMPTOMS IN SCHIZOPHRENIA OUTPATIENTS: RCT RESULTS
Daniel Mueller*, Volker Roder

T219. COGNITIVE THERAPY AND MOTIVATIONAL INTERVIEWING: REDUCING CANNABIS CONSUMPTION IN INDIVIDUALS WITH PSYCHOSIS
Henrietta Steinhart*, Ulrich Reininghaus, Cecile Henquet, Tineke Lataster, Maurice Smits, Christine Barrowclough, Inez Myin-Germeys

T220. AN EVENT-RELATED POTENTIAL EEG-NEUROFEEDBACK TRAINING TO TREAT AUDITORY VERBAL HALLUCINATIONS IN SCHIZOPHRENIA PATIENTS
Kathryn Heri*, Laura Diaz Hernandez, Daniela Hubl, Thomas Dierks, Thomas Koenig

T221. IMPACT OF PSYCHOSOCIAL INTERVENTIONS ON CAREGIVER BURDEN OF SCHIZOPHRENIC OUTPATIENTS. A SYSTEMATIC REVIEW OF RANDOMIZED CONTROLLED TRIALS
Elaine Di Sarno*, Mario Rodrigues Louzã Neto
T222. COMPARING THE EFFICACY OF TWO TYPES OF COGNITIVE REMEDIATION IN SCHIZOPHRENIA: RESULTS FROM A TWO-SITE RETROSPECTIVE COHORT STUDY.
Bruno Biagianti*, Matteo Cella, Clare Reeder, Sophia Vinogradov, Til Wykes

T223. PRELIMINARY EVIDENCE FOR IMPAIRED OBJECT RECOGNITION AS A NEURAL CORRELATE OF VISUAL DEREALISATION PHENOMENA IN FIRST EPISODE SCHIZOPHRENIA PATIENTS
Daniel Nuñez*, Rieke Oelkers-Ax, André Rupp, Heribert Sattel, Franz Resch, Matthias Weisbrod, Thomas Fuchs

T224. DIFFERENCES BETWEEN PATIENTS WITH SCHIZOPHRENIA AND UNAFFECTED CONTROLS IN COMPUTATIONALLY DERIVED ACOUSTIC PHONETIC PARAMETERS AND MEASURES OF LEXICAL VARIATION AND IDEA DENSITY
Luca Pauselli*, Michael Compton, Anya Lunden, Sean Cleary, Yazeed Alolayan, Brooke Halpern, Beth Broussard, Anthony Crisafio, Leslie Capulong, Benson Ku, Pierfrancesco Balducci, Francesco Bernardini, Bill Hollingsworth, Michael Covington

T225. UNAWARENESS AND MISATTRIBUTION OF SYMPTOMS IN SCHIZOPHRENIA: RELATIONSHIP WITH SYMPTOM CLUSTERS AND SOCIO-DEMOGRAPHIC VARIABLES
Ada Ruiz*, Esther Pousa, Carles Garcia-Ribera, Carmina Massons, Susana Ochoa, Judith Usall, Jesús Cobo

T226. STRESS IN THOSE AT RISK FOR PSYCHOTIC DISORDER: A POSSIBLE ROLE FOR MOMENTARY STRESS IN THE EXACERBATION OF AFFECTIVE AND PSYCHOTIC SYMPTOMS.

T227. RELIABILITY AND VALIDITY OF THE KOREAN VERSION OF THE MOTIVATION AND PLEASURE SCALE-SELF REPORT (MAP-SR), A SELF-REPORT MEASURE OF NEGATIVE SYMPTOMS
Ji Sun Kim*, Seon-Kyeong Jang, Seon-Cheol Park, Joong-Kyu Park, Jung Suk Lee, Kee-Hong Choi, Jung-Seo Yi, Seung-Hwan Lee

T228. EXPERIENCES OF ANTIPSYCHOTIC TREATMENT IN CLINICAL RECOVERY FROM FIRST EPISODE PSYCHOSIS
Jone Bjornestad*, Larry Davidson, Inge Joa, Tor Ketil Larsen, Wenche ten Velden Hegelstad, Johannes Langeveld, Marius Veseth, Ingrid Melle, Jan Olav Johannessen, Kolbjørn Brønnick

T229. PARANOIA AND FACETS OF SELF-ESTEEM IN EARLY PSYCHOSIS: ASSOCIATIONS ACROSS PSYCHOMETRIC AND REAL-LIFE ASSESSMENT METHODS
Manel Monsonet*, Paula Cristóbal-Narváez, Tamara Sheinbaum, Tecelli Domínguez-Martínez, Thomas R. Kwapiel, Neus Barrantes-Vidal

T230. AN EMBEDDED, EMBODIED, ENACTIVE ACCOUNT TO PSYCHOSIS
Inez Myin-Germeyn*
T231. THE DIFFERENCES BETWEEN INDIVIDUALS WITH PERSISTENT AND NON-PERSISTENT PSYCHOTIC-LIKE EXPERIENCES: A FOLLOW-UP STUDY IN THE GENERAL POPULATION OF HONG KONG
Kit Wai Lee*, Kit Wa Chan, Wing Chung Chang, Edwin Ho Ming Lee, Christy Lai Ming Hui, Jingxia Lin, Eric Yu Hai Chen

T232. THE COURSE OF ACOUSTIC VERBAL CHARACTERISTICS OVER TIME
Jack J.A. Jenner, L.B. Luteijn*

T233. QUETIAPINE ER VERSUS ARIPIPRAZOLE IN CHILDREN AND ADOLESCENTS WITH PSYCHOSIS—THE RANDOMISED, BLINDED CLINICAL TOLERABILITY AND EFFICACY OF ANTIPSYCHOTICS (TEA) TRIAL.
Anne Katrine Pagsberg*, Pia Jeppesen, Dea Klauber, Karsten Gjessing Jensen, Ditte Rudå, Marie Stentebjerg-Olesen, Eva Ann-Sofie Saldeen, Niels Bilenberg, Anne Dorte Stenstrøm, Jesper Pedersen, Jens Richardt Jepsen, Birgitte Fagerlund, Christian Gluud, Maria Skoog, Per Winkel, Christoph U. Correll, Anders Fink-Jensen

T234. ADOLESCENT CANNABINOID EXPOSURE INCREASES THE SUSCEPTIBILITY FOR A SCHIZOPHRENIA-LIKE PHENOTYPE IN A NOVEL RODENT MODEL
David Aguilar*, Stephanie Perez, Andrea Giuffrida, Daniel Lodge

T235. POTENTIAL DRUG-DRUG INTERACTIONS IN MEXICAN PATIENTS WITH SCHIZOPHRENIA.
María Conchita Ocaña Zurita*, Alma Genis, Isela Juárez-Rojop, Carlos Alfonso Tovilla-Zárate, Thelma Beatriz González-Castro, María Lilia López Narváez, Humberto Nicolini

T236. THE EFFECTS OF POSITIVE ALLOSTERIC MODULATOR OF α7 NICOTINIC RECEPTORS ON COGNITIVE AND SENSORIMOTOR GATING DEFICITS IN A SCHIZOPHRENIA-LIKE MODEL IN RATS.
Agnieszka Potasiewicz*, Agnieszka Nikiforuk, Małgorzata Holuń, Piotr Popik

T237. DRD2 CO-EXPRESS NETWORK AND A RELATED POLYGENIC SCORE PREDICT BRAIN ACTIVITY, BEHAVIORAL PHENOTYPES AND TREATMENT RESPONSE LINKED TO SCHIZOPHRENIA.
Pasquale Di Carlo*, Giulio Pergola, Enrico D’ambrosio, Jose A. Apud, Antonio Rampino, Grazia Caforio, Venkata S. Mattay, Daniel R. Weinberger, Giuseppe Blasi, Alessandro Bertolino

T238. THE EFFECT OF ANTIPSYCHOTIC TYPE AND DOSE CHANGES ON DYSKINESIA AND PARKINSONISM IN PATIENTS WITH A SERIOUS MENTAL ILLNESS (SMI)
Charlotte Mentzel*, P. Roberto Bakker, Glen Matroos, Hans Hoek, Marjan Drukker, Marina Tijssen, Peter Van Harten

T239. TREATMENT WITH ANTIPSYCHOTICS IN LATE-LIFE SCHIZOPHREニア
Rob Kok*, Shenara Sheikkariem, Nicolien Kist, Julia Van Den Berg
T240. CLINICAL AND FUNCTIONAL RESPONSE TO PALIPERIDONE PALMITATE IN EARLY SCHIZOPHRENIA – A RETROSPECTIVE OBSERVATIONAL STUDY IN NEWLY DIAGNOSED PATIENTS TREATED OVER A 12-MONTH PERIOD
Ludger Hargarter*, Paul Bergmans, Pierre Cherubin, Andreas Schreiner

T241. EFFECTIVENESS OF ANTIPSYCHOTICS USED IN FIRST EPISODE PSYCHOSIS: A NATURALISTIC COHORT STUDY
Andrew Thompson*, Michael Harris, Gail Kavanagh, Steven Marwaha, Vijitha Wickramasinghe, Ketan Jethwa, Nirmalan Ayadurai, Richard Whale

T242. A SYSTEMATIC REVIEW AND META-ANALYSIS OF TREATMENTS FOR CLOZAPINE-INDUCED OBESITY AND METABOLIC SYNDROME: EVIDENCE FROM RANDOMISED-CONTROLLED TRIALS
Jorge Zimbron, Golam Khandaker, Chiara Toschi, Peter Jones, Emilio Fernandez-Egea*

T243. A NOVEL KV3 POSITIVE MODULATOR AUGMENTS RODENT PREFRONTAL FAST NETWORK OSCILLATIONS IN VITRO FOLLOWING SUB-CHRONIC PCP TREATMENT.
Tamara Modebadze, Claire Gillougley, Guiseppe Alvaro, Charles Large, Fiona LeBeau, Mark Cunningham*

T244. THE EFFECT OF CUMULATED ESTROGEN EXPOSURE AND OTHER FEMALE HORMONAL EVENTS ON CLINICAL TRAJECTORIES AND ANTIPSYCHOTIC RESPONSE IN POSTMENOPAUSAL SCHIZOPHRENIA WOMEN
Alexandre González-Rodríguez*, Rosa Catalán, Rafael Penadés, Victoria Ruiz, Mercè Torra, Miquel Bernardo

T245. CLINICAL RISK FACTORS ASSOCIATED WITH CLOZAPINE INDUCED NEUTROPENIA
John Lally*, Steffi Malik, Megan Pritchard, Johnny Downs, James MacCabe

T246. SCREENING FOR ANTIPSYCHOTIC DRUGS WHICH DO NOT INTERACT WITH MONOAMINE RECEPTORS
Eric Prinssen*, Jean-Luc Moreau, Thomas Mueggler, Lucinda Steward, Taledn Hanania, Dani Brunner, Vadim Alexandrov, Emer Leahy, Sabine Kolczewski

T247. INHIBITION OF PDE1 LEADS TO MEMORY IMPROVEMENT IN ANIMAL MODELS RELATED TO COGNITIVE SYMPTOMS OF SCHIZOPHRENIA VIA ENHANCEMENT OF DOPAMINE D1 RECEPTOR SIGNALING
Holger Rosenbrock*, Niklas Schülert, Riccardo Giovannini, Roland Pfau, Birgit Stierstorfer, Scott Hobson, Anton Pekcec

T248. INFORMING CLINICIANS, PATIENTS AND GUIDELINES. NETWORK META-ANALYSIS ON 24 ANTIPSYCHOTIC DRUGS AND A BROAD RANGE OF IMPORTANT OUTCOMES FOR SCHIZOPHRENIA - A PROTOCOL
Maximilian Huhn*, Myrto SamaraDepartment of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technische Universität München, Germany, Yikang Zhu, Johannes Schneider, Philipp Rothe, Matteo Rabaioli-Fischer, Susanne Bächer, Stefan Leucht
T249. EFFECTS OF N-ACETYLCYSTEINE IN SCHIZOPHRENIA-LIKE BEHAVIORS INDUCED BY A PROGRESSIVE REGIMEN OF AMPHETAMINE SENSITIZATION IN MICE
Ana Herrmann*, Roberta Andrejew, Radharani Benvenutti, Elaine Elisabethsky

T250. PATTERN OF ANTIPSYCHOTIC PRESCRIPTION AMONG PATIENTS WITH SCHIZOPHRENIA AT A NIGERIAN NEUROPSYCHIATRIC HOSPITAL
Babatunde Fadipe*, Timothy Adebowale, Yetunde Fadipe, Andrew Olugbunju

T251. TREATMENT-RESISTANT SCHIZOPHRENIA: SIMPLE PAIRWISE AND NETWORK META-ANALYSIS OF ALL ANTIPSYCHOTICS
Myrto Samara*, Adriani Nikolakopoulou, Georgia Salanti, Stefan Leucht

T252. TREATMENT STRATEGIES IN CASE OF NON-RESPONSE IN SCHIZOPHRENIA: META-ANALYTICAL ASSESSMENTS OF INCREASING THE ANTIPSYCHOTIC DOSE AND SWITCHING THE ANTIPSYCHOTIC DRUG VERSUS CONTINUATION OF THE SAME ANTIPSYCHOTIC DOSE AND DRUG.
Myrto Samara*, Stefan Leucht

T253. A MOLECULAR IMAGING STUDY OF POSTSYNAPTIC DENSITY TRANSCRIPTS IN ANTIPSYCHOTIC-NAIVE VS. ANTIPSYCHOTIC-EXPOSED ANIMALS. A MOLECULAR EXPLANATION FOR DISCREPANCY IN TREATMENT RESPONSES DEPENDING ON TREATMENT HISTORY
Felice Iasevoli, Federica Marmo, Elisabetta F. Buonaguro*, Gianmarco Latte, Rodolfo Rossi, Carmine Tomasetti, Andrea de Bartolomeis

T254. DIFFERENT RECEPTOR PROFILE AND DOSE OF ANTIPSYCHOTICS INDUCE DIFFERENTIAL CHANGES IN LEVEL AND TOPOGRAPHY OF POSTSYNAPTIC DENSITY TRANSCRIPTS ASSOCIATED TO PSYCHOSIS PATHOPHYSIOLOGY.
Andrea de Bartolomeis, Felice Iasevoli, Federica Marmo, Anna Eramo, Gianmarco Latte, Camilla Avagliano, Carmine Tomasetti, Elisabetta F. Buonaguro*

T255. PREVENTION OF DISABILITY IN TREATMENT RESISTANT SCHIZOPHRENIA (TRS) NEEDS INDIVIDUATION OF FACTORS CONTRIBUTING TO SOCIAL IMPAIRMENT. RESULTS FROM A PILOT STUDY USING A STRINGENT OPERATIVE PROCEDURE TO CATEGORIZE TRS PATIENTS.
Felice Iasevoli, Maria Vittoria Formato, Raffaele Balletta, Sara Giordano, Emiliano Prinzivalli, Gianmarco Latte, Rodolfo Rossi, Elisabetta F. Buonaguro*, Andrea de Bartolomeis

T256. SYMPTOMATIC REMISSION STATUS IN PATIENTS WITH SCHIZOPHRENIA TREATED WITH PALIPERIDONE PALMITATE (1-MONTH AND 3-MONTH FORMULATIONS)
Adam Savitz*, Haiyan Xu, Srihari Gopal, Isaac Nuamah, David Hough, Maju Mathews

T257. RESILIENCE IN INDIVIDUALS CLINICALLY AT HIGH RISK FOR PSYCHOSIS - FIRST RESULTS FROM THE PRONIA STUDY
T258. PEER PROBLEMS AND LOW SELF-ESTEEM MEDIATES THE SCHIZOTYPY – REACTIVE AGGRESSION RELATIONSHIP IN ADOLESCENTS
Keri Wong*, Adrian Raine

T259. SOCIAL AND ROLE FUNCTIONING IN A HIGH RISK CHILD AND ADOLESCENT SAMPLE
Montserrat Dolz*, Jordina Tor, Marta Pardo, Daniel Muñoz, Marta Carulla, Xavier Álvarez, Elena De la Serna, Gisela Sugranyes, Inmaculada Baexa

T260. COMPARING DOMAINS OF FUNCTIONING IN CLINICAL HIGH RISK SUBJECTS, RECENT ONSET PSYCHOSIS AND RECENT ONSET DEPRESSION PATIENTS – FIRST RESULTS FROM THE PRONIA STUDY

T261. THE BULLYING SCALE – FIRST RESULTS FROM THE PRONIA STUDY

T262. SELF-STIGMA AND ITS RELATIONSHIP WITH VICTIMIZATION, PSYCHOTIC SYMPTOMS AND SELF-ESTEEM AMONG PEOPLE WITH SCHIZOPHRENIA SPECTRUM DISORDERS.
Ellen Horsselenberg*, Jooske van Busschbach, Marieke Pijnenborg, Andre Aleman

T263. MENTALIZING ABILITY AS A MEDIATOR BETWEEN REPORTED CHILDHOOD ABUSE AND NON-AFFECTIVE PSYCHOTIC DISORDER.
Jonas Weijers*, Liesbeth Eurelings-Bontekoe, Jean-Paul Selten

T264. LANGUAGE DISTURBANCE AND FUNCTIONAL CAPACITY IN EARLY PSYCHOSIS
Eric Roche*, Ricardo Segurado, Aisling McLenaghan, Maurice Bonar, Mary Clarke

T265. PREDICTING PSYCHOSOCIAL FUNCTIONING IN SCHIZOPHRENIA: THE ROLE OF CLINICAL SYMPTOMS AND THE AWARENESS OF ILLNESS
Álvaro López-Díaz*, Fermín González-Higuera, Pedro Torres-Hernández

T266. RECOVERY IN SCHIZOPHRENIA: A NATURAL 5-YEAR FOLLOW-UP STUDY IN A PRIVATE PRACTICE
Mustafa Yıldız*

T267. ATTEMPTS OF SUICIDE IN FIRST EPISODE OF PSYCHOSIS AND PSYCHOSOCIAL FUNCTIONING
Manuel Canal-Rivero*, Jorge García Egea, Jordi E. Obiols Llandrich, Miguel Ruiz Veguilla

T268. CANNABIS USE AND ATTEMPTS OF SUICIDE IN FIRST EPISODE OF PSYCHOSIS
Manuel Canal-Rivero*, Gloria Benítez, Alba Yañez Castro, Jorge García Egea, Jordi E. Obiols Llandrich, Miguel Ruiz Veguilla
T269. VALIDATION AND IMPLEMENTATION OF THE INDIVIDUAL RECOVERY OUTCOMES COUNTER (I.ROC) IN AN SMI POPULATION IN THE NETHERLANDS – RESEARCH PLAN
Bouwina Sportel*, Hettie Aardema, Nynke Boonstra, Stynke Castelein, Marieke (Gerdina) Pijnenborg

T270. HEALTH RELATED QUALITY OF LIFE IN SCHIZOPHRENIA AND OTHER PSYCHOSES: AQOL-4D FINDINGS FROM THE SECOND AUSTRALIAN NATIONAL SURVEY OF PSYCHOSIS
Amanda Neil, Vaughan Carr*, Andrew Mackinnon, Anna Waterreus, Helen Stain, Mary-Claire Hanlon, Sam Korn, Vera Morgan

T271. RELIABILITY AND VALIDITY OF THE SPECIFIC LEVELS OF FUNCTION SCALE - JAPANESE VERSION; RELATION TO COGNITIVE INSIGHT
Tomiki Sumiyoshi*, Keiichiro Nishida, Hidehito Niimura, Atsuhito Toyomaki, Tsubasa Morimoto, Masayuki Tani, Ken Inada, Taiga Ninomiya, Hikaru Hori, Yosuke Koshikawa, Toshihiko Kinoshita, Ichiro Kusumi, Akira Iwanami, Takefumi Ueno, Takeshi Terao, Kazuyuki Nakagome

T272. WHAT DO SERVICE USERS WANT FROM A SMARTPHONE APP FOR PSYCHOSIS?
Sandra Bucci*

T273. QUALITY OF LIFE ASSESSMENT IN SCHIZOPHRENIA DIAGNOSED PATIENTS WITH PREDOMINANT NEGATIVE SYMPTOMS
Daniel Vasile*, Octavian Vasiliu, Diana Gabriela Vasiliu, Florin Vasile

T274. ASSESSING THE RELEVANCE OF THE SUBJECTIVE WELL-BEING UNDER NEUROLEPTICS–SHORT FORM IN SCHIZOPHRENIA: PATIENT AND CAREGIVER PERSPECTIVES
Dieter Naber*, Maud Beillat, Dana B. DiBenedetti, T. Michelle Brown

T275. MEASURING WELL-BEING IN CHRONIC SCHIZOPHRENIA: THE SIGNIFICANCE OF POSITIVE SYMPTOMS
Julia Brown*, Gisela Mezquida, Emilio Fernandez-Egea

T276. DOES FUNCTIONING AND LIFE SATISFACTION DIFFER FOR SCHIZOPHRENIA PATIENTS WITH CO-MORBID DEPRESSION?
Eric Tan*, Susan Rossell

T277. ASSOCIATION OF KNOWLEDGE AND CAUSAL EXPLANATION OF SCHIZOPHRENIA STUDENTS’ ATTITUDE TOWARDS SERVICE USERS: A COMPARISON BETWEEN NURSING AND MEDICAL UNDERGRADUATES
Lucia Sideli, Caterina La Cascia, Fabio Seminerio*, Valentina Barone, Crecettarachele Sartorio, Roberta D’agostino, Alice Mulè, Laura Ferraro, Giada Tripoli, Michel Inguglia, Antonio Francomano, Daniele La Barbera, Marta Di Forti, Robin Murray

T278. AN AUDIT OF CLOzapINE USE IN FIRST EPISODE PSYCHOSIS
Roisin Doyle, Donal O’Keeffe*, Caragh Behan, Sarah Masterson, Aine Kelly, Ann Sheridan, Dolores Keating, Caroline Hynes, Kevin Madigan, Elizabeth Lawlor, Mary Clarke
T279. DOES LONG ACTING ARIPIPRAZOLE IMPROVE OUTCOMES IN ROUTINE CLINICAL PRACTICE?
Richard Hodgson*, Chandan Aladakatti, Brittany Davenport

T280. FIVE-YEAR OUTCOMES OF FEP PATIENTS RECEIVING INTEGRATED VS. FUNCTIONAL MENTAL HEALTH CARE. A PILOT STUDY FROM THE PICOS
Elisabetta Miglietta*, Antonio Lasalvia, Dorian Cristofalo, Sarah Tosato, Chiara Bonetto, Gioia Zanatta, Silvia Zoppe, Sara Petterlini, Carla Comacchio, Giorgia Dimitri, Dario Lamonaca, Francesco Gardellin, Mirella Ruggeri

T281. FREE ASSOCIATIONS AS BOTH A VERBAL AND NONVERBAL PHENOMENON IN DANCE/MOVEMENT THERAPY - A CASE STUDY WITH PATIENTS DIAGNOSED WITH SCHIZOPHRENIA AND VARYING DEGREES OF RELATED FORMS OF PSYCHIATRIC DIAGNOSES.
Karolina Bryl*

T282. THE MORAY PSYCHOSIS SURVEY: PREVALENCE, DEMOGRAPHICS AND TREATMENT CHARACTERISTICS IN A RURAL COHORT OF PATIENTS DIAGNOSED WITH SCHIZOPHRENIA
Angus MacBeth*, Hannah Greaves

T283. META-ANALYSIS OF OXYTOCIN IN SCHIZOPHRENIA: EFFECTS ON SOCIAL COGNITION
Angus MacBeth*, Andrew Gumley

T284. PREDICTORS OF PRE-DIABETES IN OVERWEIGHT OR OBESE SCHIZOPHRENIA PATIENTS TREATED WITH CLOzapine OR OLANZAPINE: BASELINE RESULTS FROM AN ONGOING RANDOMISED CONTROLLED TRIAL
Julie Larsen*, Louise Vedtofte, Kamuran Koyuncu, Mathilde Jakobsen, Hans Jespersen, Michelle Jakobsen, Camilla Svensson, Christoph Correll, Tina Villsbøll, Anders Fink-Jensen

T285. CATATONIA IN FIRST EPISODE OF PSYCHOSIS: CORRELATIONS WITH HYPERPROLACTINEMIA AND DUP
Jorge Cuevas-Esteban*, Anna Butjosa, Núria Del Cacho, Regina Vila-Badia, Elena Rubio-Abadal, Maria Jose Rodriguez, Montserrat Dolz, GRUP PEP-PROLACTINA, Judith Usall

T286. PRELIMINARY RESULTS OF THE EFFECTIVENESS OF THE MCT GROUP IN PEOPLE WITH PSYCHOSIS IN REHABILITATION SERVICES
Mar García-Franco*, Gemma Prat, Sonia Vilamala-Anton, Maria Jose Escandell-Morcillo, Jose Ramón Martín-Martinez, Ingrid Tortades-Arumí, J. Gonzalez, R. Monreal, Susana Ochoa

T287. RISK OF PSYCHOSIS AND INTERNAL MIGRATION: RESULTS FROM THE BOLOGNA FIRST EPISODE PSYCHOSIS STUDY
Ilaria Tarricone, Jane Boydell, Armisa Kokona, Federico Triolo, Lisa Gamberini, Enrico Sutti, Michela Marchetta, Marco Menchetti, Marta Di Forti*, Robin Murray, Craig Morgan, Domencio Berardi
T288. ANTHROPOMETRIC VALUES IN NAÏVE FIRST EPISODE OF NON AFFECTIVE PSYCHOSIS: THE ROLE OF WEIGHT AT BIRTH
Clemente Garcia-Rizo*, Fernandez-Egea Emilio, Cristina Oliveira, Brian Kirkpatrick, Miguel Bernardo Arroyo

T289. METABOLIC SYNDROME OR GLUCOSE ABNORMALITIES IN FIRST EPISODE OF PSYCHOSIS?
Clemente Garcia-Rizo*, Emilio Fernandez-Egea, Cristina Oliveira, Ana Meseguer, Bibiana Cabrera, Gisela Mezquida, Miquel Bioque, Rafael Penades, Eduard Parellada, Miguel Bernardo Arroyo, Brian Kirkpatrick

T290. BONE MINERAL DENSITY AS A MARKER OF CUMULATIVE ESTROGEN EXPOSURE IN PSYCHOTIC DISORDER: A 3 YEAR FOLLOW-UP STUDY
Christine van der Leeu, Sanne Peeters, Patrick Domen, Marinus van Kroonenburgh, Jim Van Os, Machteld Marcelis*

T291. PREVENTING FIRST AND SUBSEQUENT RELAPSES IN FIRST EPISODE OF NON-AFFECTIVE PSYCHOSIS IN A THREE YEAR LONGITUDINAL FOLLOW-UP: THE ROLE OF ADHERENCE
Jose Maria Pelayo-Teran*, Gajardo Galán Virginia, García de la Foz Víctor, Martínez-García Obdulia, Ayesa-Arriola Rosa, Crespo-Facorro Benedicto, Tabares-Seisdedos Rafael

T291. THE OPEN TRANSLATIONAL SCIENCE IN SCHIZOPHRENIA PROJECT: JANSSEN CLINICAL TRIAL AND NIH DATA TOGETHER IN AN OPEN-SCIENCE COLLABORATION
Marsha Wilcox

T293. SPATIAL DISTRIBUTION OF PSYCHOTIC DISORDERS IN AN URBAN AREA OF FRANCE
Baptiste Pignon*, Franck SCHURHOFF, Grégoire Baudin, Aziz Ferchiou, Jean-Romain Richard, Ghassen Saba, Marion Leboyer, James Kirkbride, Andrei Szoke

T294. GENETIC POLYMORPHISM OF THE INFLAMMATORY C-REACTIVE PROTEIN (CRP) AND SCHIZOPHRENIA
Ayari Fayza*, Ben Chaaben Arij, Ben Ammar Hanen, Aissa Amina, Abaza Hajer, Douik Hayet, Ouni Nesrine, Arfaoui Abir, Zid Zaineb, Harzallah Latifa, Boughzou Sabrine, Selmi Mouhamed Anis, Leboyer Marion, Tamouza Ryad, El hechmi Zouhaier, Guemira Fethi
## INDEX OF PRESENTERS AND AUTHORS*

<table>
<thead>
<tr>
<th>Name</th>
<th>Pages</th>
<th>Name</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abi-Dargham, Anissa</td>
<td>3, 29, 38</td>
<td>Bais, Leonie</td>
<td>84</td>
</tr>
<tr>
<td>Abilio, Vanessa</td>
<td>118</td>
<td>Bajouco, Miguel</td>
<td>93</td>
</tr>
<tr>
<td>Aboraya, Ahmed</td>
<td>101</td>
<td>Bak, Maarten</td>
<td>79</td>
</tr>
<tr>
<td>Abram, Samantha</td>
<td>55</td>
<td>Baker, Amanda</td>
<td>107</td>
</tr>
<tr>
<td>Abu-Akel, Ahmad</td>
<td>78</td>
<td>Bakker, Geor (IM)</td>
<td>112</td>
</tr>
<tr>
<td>Addington, Donald</td>
<td>124</td>
<td>Bakker, P. Roberto</td>
<td>126</td>
</tr>
<tr>
<td>Addington, Jean</td>
<td>4</td>
<td>Balado, Claudia Prats</td>
<td>76</td>
</tr>
<tr>
<td>Agarwal, Sri Mahavir</td>
<td>14, 130</td>
<td>Ball, Hannah</td>
<td>122</td>
</tr>
<tr>
<td>Agid, Ofer</td>
<td>60</td>
<td>Bang, Minji</td>
<td>79</td>
</tr>
<tr>
<td>Aguilar, David</td>
<td>150</td>
<td>Barch, Deanna</td>
<td>4</td>
</tr>
<tr>
<td>Akdede, Berna</td>
<td>96</td>
<td>Barron, David</td>
<td>80</td>
</tr>
<tr>
<td>Albacete, Auria</td>
<td>136</td>
<td>Bartels-Velthuis, Annegien</td>
<td>32</td>
</tr>
<tr>
<td>Albergó, Dalila</td>
<td>99</td>
<td>Bartholomeusz, Cali</td>
<td>84</td>
</tr>
<tr>
<td>Albert, Nikolai</td>
<td>40, 93</td>
<td>Barzilay, Ran</td>
<td>14, 71</td>
</tr>
<tr>
<td>Alden, Eva</td>
<td>145</td>
<td>Basu, Sutapa</td>
<td>80</td>
</tr>
<tr>
<td>Allen, Paul</td>
<td>26</td>
<td>Batty, Rachel</td>
<td>77, 141</td>
</tr>
<tr>
<td>Alloza, Clara</td>
<td>144</td>
<td>Baudin, Grégoire</td>
<td>97</td>
</tr>
<tr>
<td>Alonso, Sergio Sánchez</td>
<td>91</td>
<td>Beck, Katharina</td>
<td>132</td>
</tr>
<tr>
<td>Alphs, Larry</td>
<td>5</td>
<td>Begemann, Marieke</td>
<td>76</td>
</tr>
<tr>
<td>Alptekin, Koksal</td>
<td>92</td>
<td>Benes, Francine</td>
<td>47</td>
</tr>
<tr>
<td>Alústiza, Irene</td>
<td>136</td>
<td>Benros, Michael</td>
<td>14, 139</td>
</tr>
<tr>
<td>Alvarez, María-José</td>
<td>95</td>
<td>Ben-Zeev, Dror</td>
<td>28</td>
</tr>
<tr>
<td>Amminger, G. Paul</td>
<td>61</td>
<td>Berg, Akiah</td>
<td>135</td>
</tr>
<tr>
<td>Anand, Ravi</td>
<td>37</td>
<td>Bernardini, Francesco</td>
<td>119</td>
</tr>
<tr>
<td>Anda, Liss</td>
<td>105</td>
<td>Bernardo, Miquel</td>
<td>72</td>
</tr>
<tr>
<td>Andreou, Christina</td>
<td>148</td>
<td>Berretta, Sabina</td>
<td>41</td>
</tr>
<tr>
<td>Andric, Sanja</td>
<td>14, 81</td>
<td>Bertolino, Alessandro</td>
<td>4</td>
</tr>
<tr>
<td>Anticevic, Alan</td>
<td>12, 112</td>
<td>Bervoets, Chris</td>
<td>79</td>
</tr>
<tr>
<td>Antoniades, Mathilde</td>
<td>56</td>
<td>Bhattacharyya, Sagnik</td>
<td>56</td>
</tr>
<tr>
<td>Antonucci, Linda A.</td>
<td>113</td>
<td>Bhavsar, Vishal</td>
<td>111, 141</td>
</tr>
<tr>
<td>Arango, Celso</td>
<td>3, 16, 38, 41, 55, 130</td>
<td>Biaggi, Alessandra</td>
<td>98</td>
</tr>
<tr>
<td>Arias, Barbara</td>
<td>75</td>
<td>Biaggianti, Bruno</td>
<td>119, 149</td>
</tr>
<tr>
<td>Arkhipov, Andrei</td>
<td>126</td>
<td>Bilenberg, Niels</td>
<td>83</td>
</tr>
<tr>
<td>Armando, Marco</td>
<td>71</td>
<td>Binbay, Tolga</td>
<td>111, 141</td>
</tr>
<tr>
<td>Armstrong, Kristan</td>
<td>138</td>
<td>Bioque, Miquel</td>
<td>144</td>
</tr>
<tr>
<td>Asmal, Laila</td>
<td>14, 86</td>
<td>Birchwood, Max</td>
<td>40</td>
</tr>
<tr>
<td>Assunção, Idaiane</td>
<td>128</td>
<td>Bittner, Robert</td>
<td>84</td>
</tr>
<tr>
<td>Atbasoglu, Cem</td>
<td>107</td>
<td>Bjornestad, Jone</td>
<td>149</td>
</tr>
<tr>
<td>Athanas, Katina</td>
<td>117</td>
<td>Bloemen, Oswald</td>
<td>86</td>
</tr>
<tr>
<td>Austin, Stephen</td>
<td>61, 123</td>
<td>Blokland, Gabriëlla</td>
<td>14, 52</td>
</tr>
<tr>
<td>Ayer, Ahmet</td>
<td>80, 140</td>
<td>Bloomfield, Michael</td>
<td>29</td>
</tr>
<tr>
<td>Ayesa-Arriola, Rosa</td>
<td>77, 106</td>
<td>Bo, Qi-Jing</td>
<td>127</td>
</tr>
<tr>
<td>Baek, Dayae</td>
<td>91</td>
<td>Bodnar, Michael</td>
<td>122</td>
</tr>
</tbody>
</table>

* The Index of Authors and Presenters includes only First Authors of Posters, Speakers of Plenary Sessions, Symposia, and Workshops.
Index

Bohken, Marc 14, 52
Bojesen, Kirsten Borup 70
Boonstra, Nynke 95
Bortolato, Marco 29
Bossong, Matthijs 26
Bourget, Dominique 92
Bourque, Josiane 53
Bowie, Christopher 48
Bralet, Marie-Cécile 89
Brandizzi, Martina 94
Brannan, Stephen 37
Brouwer, Rachel 86
Brown, Julia 154
Bruggeman, Richard 78
Bryl, Karolina 124, 155
Bucci, Sandra 79, 103, 154
Buchanan, Robert 4, 5, 38
Büki, Alexandra 88
Bull, Helen 93
Buonaguro, Elisabetta F. 87, 115, 152
Burdick, Katherine 42
Burgess, Martin 117
Busatto, Geraldo 3
Butjosa, Anna 109, 138
Cabral, Carlos 70
Cadinu, Daniela 116
Cahalan, Susannah 14, 23
Calem, Maria 129
Calvo, Ana 66
Calvo-García, Fran 127
Calvo-Rubiales, Maria Isabel 101, 137
Canal-Rivero, Manuel 69, 109, 153
Cannon, Mary 4, 39, 66
Cannon, Tyrone 3
Capdevielle, Delphine 90
Caron, Marc 52
Carpenter, William 31, 65
Carruthers, Sean 146
Carr, Vaughan 60, 109, 154
Castelein, Stynke 110
Castle, David 4
Catalán, Rosa 120
Cella, Matteo 48, 61
Chang, Wing Chung 74, 106, 138
Chang, Xiao 86
Chan, Kit Wa Sherry 60
Chan, Raymond 5, 83
Chaumette, Boris 69
Chawner, Samuel 100
Chen, Eric 3, 4, 40
Cheung, Eric 134
Chiliza, Bonginkosi 121
Chong, Siow Ann 4
Chung, Young Chul 73
Cieslik, Paulina 72
Ciufolini, Simone 14, 58
Clementz, Brett 42
Clemmensen, Lars 140
Coenen, Michaela 31
Cohen, Dan 120
Coid, Jeremy 111, 141
Colizzi, Marco 107
Collin, Guusje 114
Comacchio, Carla 122
Conn, Jeff 15, 25
Cornblatt, Barbara 5
Coromina, Marta 85
Correll, Christoph 4, 28, 38
Cortes-Briones, Jose 14, 70
Cosgrove, Donna 14, 51
Cotter, David 64
Cotter, Jack 122
Crespo-Facorro, Benedito 96
Cristóbal-Narváez, Paula 127
Cropley, Vanessa 50
Crossley, Nicolas 14, 85
Cuevas-Esteban, Jorge 155
Cullen, Alexis 69
Cunningham, Mark 117, 151
Curcic-Blake, Branislava 114
Curzietti, Maxime 136
Dalman, Christina 4, 128
Daniel, David 92
Da Silva, Susana 122
Dauwan, Meenakshi 14, 148
David, Anthony 4, 13, 66
Davidson, Michael 73
Davies, Daniel 104
Davies, Geoff 61, 136
Dazzan, Paola 3, 4, 5, 13, 17, 38, 56
Deakin, John F. 4, 5, 16, 58
de Boer, Janna 90
Debost, Jean-Christophe 139
Deenik, Jeroen 107
Degenhardt, Franziska 146
<table>
<thead>
<tr>
<th>Name</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>de Girolamo, Giovanni</td>
<td>111, 139</td>
</tr>
<tr>
<td>De Jong, Steven</td>
<td>74, 138</td>
</tr>
<tr>
<td>De la Serna, Elena</td>
<td>75</td>
</tr>
<tr>
<td>DeLisi, Lynn</td>
<td>3, 4</td>
</tr>
<tr>
<td>De Luca, Vincenzo</td>
<td>121</td>
</tr>
<tr>
<td>Demartinis, Nicholas</td>
<td>37</td>
</tr>
<tr>
<td>Demers, Marie-France</td>
<td>97</td>
</tr>
<tr>
<td>Demirel, Ömer Faruk</td>
<td>129</td>
</tr>
<tr>
<td>de Zwarte, Sonja</td>
<td>14, 50</td>
</tr>
<tr>
<td>Di Carlo, Pasquale</td>
<td>150</td>
</tr>
<tr>
<td>Dickerson, Faith</td>
<td>31, 78</td>
</tr>
<tr>
<td>Dickson, Hannah</td>
<td>101, 131</td>
</tr>
<tr>
<td>Di Forti, Marta</td>
<td>29, 155</td>
</tr>
<tr>
<td>Di Lorenzo, Giorgio</td>
<td>102, 142</td>
</tr>
<tr>
<td>Di Prinzi, Patricia</td>
<td>14, 82</td>
</tr>
<tr>
<td>Dollfus, Sonia</td>
<td>48, 79</td>
</tr>
<tr>
<td>Dollfus, Sophia</td>
<td>5</td>
</tr>
<tr>
<td>Dolz, Montserrat</td>
<td>71, 131, 153</td>
</tr>
<tr>
<td>Domen, Patrick</td>
<td>56</td>
</tr>
<tr>
<td>Donegan, Jennifer</td>
<td>14, 119</td>
</tr>
<tr>
<td>Döring, Christian</td>
<td>129</td>
</tr>
<tr>
<td>Downs, Johnny</td>
<td>101, 131</td>
</tr>
<tr>
<td>Doyle, Roisin</td>
<td>81</td>
</tr>
<tr>
<td>Drake, Richard</td>
<td>75</td>
</tr>
<tr>
<td>D'Souza, Deepak</td>
<td>29, 57, 98</td>
</tr>
<tr>
<td>Du, Xin</td>
<td>88</td>
</tr>
<tr>
<td>Dwork, Andrew</td>
<td>30</td>
</tr>
<tr>
<td>Dwyer, Dominic</td>
<td>61, 115</td>
</tr>
<tr>
<td>Edlinger, Monika</td>
<td>120</td>
</tr>
<tr>
<td>Edye, Michelle</td>
<td>88</td>
</tr>
<tr>
<td>Egloff, Laura</td>
<td>132</td>
</tr>
<tr>
<td>Ehlers, Cornelius</td>
<td>94</td>
</tr>
<tr>
<td>Elboukhari, Hasna</td>
<td>88</td>
</tr>
<tr>
<td>Elena, Huerta-Ramos</td>
<td>88</td>
</tr>
<tr>
<td>Elise, Leroux</td>
<td>115, 143</td>
</tr>
<tr>
<td>Elkis, Helio</td>
<td>76, 93, 109</td>
</tr>
<tr>
<td>Emsley, Robin</td>
<td>4, 5</td>
</tr>
<tr>
<td>Engelen, Jennifer</td>
<td>143</td>
</tr>
<tr>
<td>Englund, Amir</td>
<td>29</td>
</tr>
<tr>
<td>Eriksson, Hans</td>
<td>127</td>
</tr>
<tr>
<td>Evans-Lacko, Sara</td>
<td>65</td>
</tr>
<tr>
<td>Eyles, Darryl</td>
<td>64, 146</td>
</tr>
<tr>
<td>Fadipe, Babatunde</td>
<td>14, 93, 152</td>
</tr>
<tr>
<td>Falkai, Peter</td>
<td>5, 49, 66</td>
</tr>
<tr>
<td>Falkenberg, Irina</td>
<td>108</td>
</tr>
<tr>
<td>Falkenberg, Liv E.</td>
<td>86</td>
</tr>
<tr>
<td>Fatjo-Vilas, Mar</td>
<td>115</td>
</tr>
<tr>
<td>Favre, Gregoire</td>
<td>111</td>
</tr>
<tr>
<td>Fayza, Ayari</td>
<td>156</td>
</tr>
<tr>
<td>Fazel, Seena</td>
<td>68, 140</td>
</tr>
<tr>
<td>Ferguson, Bart</td>
<td>144</td>
</tr>
<tr>
<td>Fernandez-Egea, Emilio</td>
<td>121, 151</td>
</tr>
<tr>
<td>Fernandez-Miranda, Juan J.</td>
<td>123</td>
</tr>
<tr>
<td>Ferruccio, Naika</td>
<td>142</td>
</tr>
<tr>
<td>Fervaha, Gagan</td>
<td>134</td>
</tr>
<tr>
<td>Fett, Anne-Kathrin</td>
<td>14, 49, 77, 105</td>
</tr>
<tr>
<td>Finke, Carsten</td>
<td>39</td>
</tr>
<tr>
<td>Firth, Joseph</td>
<td>89</td>
</tr>
<tr>
<td>Fischer, Elena</td>
<td>86</td>
</tr>
<tr>
<td>Fisher, Helen</td>
<td>27, 39</td>
</tr>
<tr>
<td>Fleischhacker, Wolfgang</td>
<td>4, 5, 51, 59, 92</td>
</tr>
<tr>
<td>Flores, Cecillia</td>
<td>29</td>
</tr>
<tr>
<td>Flyckt, Lena</td>
<td>75, 129</td>
</tr>
<tr>
<td>Foecking, Melanie</td>
<td>64</td>
</tr>
<tr>
<td>Foglia, Enrico</td>
<td>140</td>
</tr>
<tr>
<td>Fond, Guillaume</td>
<td>69, 98</td>
</tr>
<tr>
<td>Fong, Guillaume</td>
<td>137</td>
</tr>
<tr>
<td>Forsyth, Jen</td>
<td>92</td>
</tr>
<tr>
<td>Fortea, Adriana</td>
<td>109</td>
</tr>
<tr>
<td>Foussias, George</td>
<td>41</td>
</tr>
<tr>
<td>Frajo-Apor, Beatrice</td>
<td>76</td>
</tr>
<tr>
<td>Francesconi, Marta</td>
<td>101, 131</td>
</tr>
<tr>
<td>Fukudome, Daisuke</td>
<td>146</td>
</tr>
<tr>
<td>Galderisi, Silvana</td>
<td>41, 49</td>
</tr>
<tr>
<td>Galileo, Juan</td>
<td>98</td>
</tr>
<tr>
<td>Galletly, Cherrie</td>
<td>31, 78</td>
</tr>
<tr>
<td>Gama, Maiara Zeni Graiff</td>
<td>99</td>
</tr>
<tr>
<td>Ganella, Eleni</td>
<td>85</td>
</tr>
<tr>
<td>Garcia-Franco, Mar</td>
<td>155</td>
</tr>
<tr>
<td>Garcia, Jordi Soler</td>
<td>88</td>
</tr>
<tr>
<td>Garcia-Ribera, Carles</td>
<td>147</td>
</tr>
<tr>
<td>Garcia-Rizo, Clemente</td>
<td>125, 156</td>
</tr>
<tr>
<td>Gardner, Renee</td>
<td>69</td>
</tr>
<tr>
<td>Garip, Beyazit</td>
<td>129</td>
</tr>
<tr>
<td>Gariup, Maria</td>
<td>71, 101</td>
</tr>
<tr>
<td>Garrido, Gemma</td>
<td>135</td>
</tr>
<tr>
<td>Gattaz, Wagner</td>
<td>4</td>
</tr>
<tr>
<td>Gee, Broney</td>
<td>119</td>
</tr>
<tr>
<td>Geerts, Hugo</td>
<td>73</td>
</tr>
<tr>
<td>Gerstenberg, Miriam</td>
<td>38</td>
</tr>
<tr>
<td>Gevonden, Martin</td>
<td>68</td>
</tr>
<tr>
<td>Gilbert, Elsa</td>
<td>51</td>
</tr>
<tr>
<td>Gilles, James</td>
<td>51, 121</td>
</tr>
<tr>
<td>Gillespie, Amy</td>
<td>111</td>
</tr>
<tr>
<td>Gjerde, Priyanthi Borgen</td>
<td>137</td>
</tr>
<tr>
<td>Goldsmith, Paul</td>
<td>102, 143</td>
</tr>
<tr>
<td>Name</td>
<td>Page Numbers</td>
</tr>
<tr>
<td>-----------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>Gonzalez-Blanco, Leticia</td>
<td>99, 137</td>
</tr>
<tr>
<td>González-Rodriguez, Alexandre</td>
<td>122, 151</td>
</tr>
<tr>
<td>Gooding, Diane Carol</td>
<td>119</td>
</tr>
<tr>
<td>Gopal, Srihari</td>
<td>94</td>
</tr>
<tr>
<td>Goulding, Anneli</td>
<td>95, 140</td>
</tr>
<tr>
<td>Grace, Anthony</td>
<td>10, 26</td>
</tr>
<tr>
<td>Grazioplene, Rachael</td>
<td>56</td>
</tr>
<tr>
<td>Green, Melissa</td>
<td>42</td>
</tr>
<tr>
<td>Green, Michael</td>
<td>3</td>
</tr>
<tr>
<td>Grent-’t-Jong, Tineke</td>
<td>85</td>
</tr>
<tr>
<td>Groc, Laurent</td>
<td>39</td>
</tr>
<tr>
<td>Gruber, Oliver</td>
<td>83</td>
</tr>
<tr>
<td>Guan, Lili</td>
<td>125</td>
</tr>
<tr>
<td>Guilera, Georgina</td>
<td>31</td>
</tr>
<tr>
<td>Guimond, Synthia</td>
<td>112</td>
</tr>
<tr>
<td>Gur, Raquel</td>
<td>15, 27, 36</td>
</tr>
<tr>
<td>Haapea, Marianne</td>
<td>140</td>
</tr>
<tr>
<td>Haas, Shalaila</td>
<td>112</td>
</tr>
<tr>
<td>Hahn, Chang-Gyu</td>
<td>64</td>
</tr>
<tr>
<td>Haidl, Theresa</td>
<td>108, 153</td>
</tr>
<tr>
<td>Hanina, Adam</td>
<td>96</td>
</tr>
<tr>
<td>Hanssen, Esther</td>
<td>106, 143</td>
</tr>
<tr>
<td>Haram, Marit</td>
<td>146</td>
</tr>
<tr>
<td>Hargarter, Ludger</td>
<td>121, 151</td>
</tr>
<tr>
<td>Hartmann, Jessica</td>
<td>14, 148</td>
</tr>
<tr>
<td>Harvey, Phil</td>
<td>5</td>
</tr>
<tr>
<td>Harvey, Philip</td>
<td>16, 51, 75</td>
</tr>
<tr>
<td>Hasan, Alkomiet</td>
<td>59</td>
</tr>
<tr>
<td>Hasson-Ohayon, Ilanit</td>
<td>94</td>
</tr>
<tr>
<td>Hazegrove, Katie</td>
<td>53</td>
</tr>
<tr>
<td>He, Yujie</td>
<td>88</td>
</tr>
<tr>
<td>Heckers, Stephan</td>
<td>3, 48</td>
</tr>
<tr>
<td>Heitz, Ulrike</td>
<td>132</td>
</tr>
<tr>
<td>Helldin, Lars</td>
<td>105</td>
</tr>
<tr>
<td>Hensch, Takao</td>
<td>15, 46</td>
</tr>
<tr>
<td>Heres, Stephen</td>
<td>59</td>
</tr>
<tr>
<td>Heri, Kathryn</td>
<td>148</td>
</tr>
<tr>
<td>Heringa, Sophie</td>
<td>59</td>
</tr>
<tr>
<td>Herrmann, Ana</td>
<td>117, 152</td>
</tr>
<tr>
<td>Hickling, Lauren</td>
<td>102</td>
</tr>
<tr>
<td>Higuchi, Cinthia</td>
<td>80</td>
</tr>
<tr>
<td>Hilker, Rikke</td>
<td>81</td>
</tr>
<tr>
<td>Hillegers, Manon</td>
<td>47, 100</td>
</tr>
<tr>
<td>Hilt, Dana</td>
<td>134</td>
</tr>
<tr>
<td>Hinojosa-Marqués, Lidia</td>
<td>138</td>
</tr>
<tr>
<td>Hirnstein, Marco</td>
<td>116</td>
</tr>
<tr>
<td>Hjorthøj, Carsten</td>
<td>31</td>
</tr>
<tr>
<td>Ho, Newfei</td>
<td>70</td>
</tr>
<tr>
<td>Hodgson, Richard</td>
<td>124, 155</td>
</tr>
<tr>
<td>Honer, William</td>
<td>66</td>
</tr>
<tr>
<td>Hong, Kyung Sue</td>
<td>4, 90</td>
</tr>
<tr>
<td>Hoonakker, Marc</td>
<td>136</td>
</tr>
<tr>
<td>Horn, Mathilde</td>
<td>138</td>
</tr>
<tr>
<td>Horselenberg, Ellen</td>
<td>78, 153</td>
</tr>
<tr>
<td>Horton, Leslie</td>
<td>14, 100</td>
</tr>
<tr>
<td>Howes, Oliver</td>
<td>5, 40, 64</td>
</tr>
<tr>
<td>Howe, William</td>
<td>101</td>
</tr>
<tr>
<td>Hoy, Kate</td>
<td>60</td>
</tr>
<tr>
<td>Huang, Eric</td>
<td>37</td>
</tr>
<tr>
<td>Huhn, Maximilian</td>
<td>68, 103, 104, 151</td>
</tr>
<tr>
<td>Huhtaniska, Sanna</td>
<td>91</td>
</tr>
<tr>
<td>Husain-Krautter, Sehba</td>
<td>70</td>
</tr>
<tr>
<td>Huttunen, Matti</td>
<td>4</td>
</tr>
<tr>
<td>Hwang, Samuel</td>
<td>119</td>
</tr>
<tr>
<td>Hwang, Tzung-Jeng</td>
<td>83</td>
</tr>
<tr>
<td>Iizuka, Kunio</td>
<td>104</td>
</tr>
<tr>
<td>Ilzarbe, Daniel</td>
<td>100</td>
</tr>
<tr>
<td>Immonen, Johanna</td>
<td>122</td>
</tr>
<tr>
<td>Inta, Dragos</td>
<td>53, 147</td>
</tr>
<tr>
<td>Ishizuka, Koko</td>
<td>15, 63</td>
</tr>
<tr>
<td>Isohanni, Matti</td>
<td>49</td>
</tr>
<tr>
<td>Iwata, Keiko</td>
<td>146</td>
</tr>
<tr>
<td>Iwata, Yusuke</td>
<td>127</td>
</tr>
<tr>
<td>Iyegbe, Conrad</td>
<td>69</td>
</tr>
<tr>
<td>Jakobsen, Ane</td>
<td>89</td>
</tr>
<tr>
<td>Jakobsen, Michelle</td>
<td>125</td>
</tr>
<tr>
<td>Jang, Seon-Kyeong</td>
<td>102</td>
</tr>
<tr>
<td>Janowska, Sylwia</td>
<td>92</td>
</tr>
<tr>
<td>Janssen, Joost</td>
<td>37</td>
</tr>
<tr>
<td>Jardri, Renaud</td>
<td>32</td>
</tr>
<tr>
<td>Jasberg, Suzanne Geier</td>
<td>135</td>
</tr>
<tr>
<td>Jauhar, Sameer</td>
<td>56</td>
</tr>
<tr>
<td>Jensen, Karsten Gjessing</td>
<td>125</td>
</tr>
<tr>
<td>Jeppesen, Pia</td>
<td>32, 58</td>
</tr>
<tr>
<td>Jessen, Kasper</td>
<td>114</td>
</tr>
<tr>
<td>Jhon, Min</td>
<td>99</td>
</tr>
<tr>
<td>Ji, Ellen</td>
<td>112</td>
</tr>
<tr>
<td>Jingxia, Lin</td>
<td>65</td>
</tr>
<tr>
<td>Joe, Soohyun</td>
<td>92</td>
</tr>
<tr>
<td>Johnstone, Eve</td>
<td>65</td>
</tr>
<tr>
<td>Jones, Andrea</td>
<td>14, 82</td>
</tr>
<tr>
<td>Jongsma, Hannah</td>
<td>14, 54</td>
</tr>
<tr>
<td>Joo, Sung Woo</td>
<td>89</td>
</tr>
<tr>
<td>Joo, Yeon Ho</td>
<td>143</td>
</tr>
<tr>
<td>Juárez, Alba Lubeiro</td>
<td>115, 145</td>
</tr>
<tr>
<td>Jung, Myung Hun</td>
<td>95</td>
</tr>
<tr>
<td>Name</td>
<td>Page Numbers</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>Just, David</td>
<td>99</td>
</tr>
<tr>
<td>Kahn, René</td>
<td>3, 64</td>
</tr>
<tr>
<td>Kaiser, Nathalie</td>
<td>123, 152</td>
</tr>
<tr>
<td>Kaiser, Stefan</td>
<td>41</td>
</tr>
<tr>
<td>Kakela, Juha</td>
<td>93</td>
</tr>
<tr>
<td>Kambeitz-Ilankovic, Lana</td>
<td>99</td>
</tr>
<tr>
<td>Kambeitz, Joseph</td>
<td>87, 145</td>
</tr>
<tr>
<td>Kane, John</td>
<td>28</td>
</tr>
<tr>
<td>Kapur, Shitij</td>
<td>3, 5, 13, 38</td>
</tr>
<tr>
<td>Karlsson, Håkan</td>
<td>57</td>
</tr>
<tr>
<td>Kasanova, Zuzana</td>
<td>142</td>
</tr>
<tr>
<td>Katsel, Pavel</td>
<td>30</td>
</tr>
<tr>
<td>Katthagen, Teresa</td>
<td>56</td>
</tr>
<tr>
<td>Kaya, Yunus</td>
<td>94</td>
</tr>
<tr>
<td>Keefe, Richard</td>
<td>75</td>
</tr>
<tr>
<td>Kegeles, Lawrence</td>
<td>47</td>
</tr>
<tr>
<td>Kelleher, Ian</td>
<td>32, 39</td>
</tr>
<tr>
<td>Kelley, Megan</td>
<td>94</td>
</tr>
<tr>
<td>Kennedy, James</td>
<td>4, 5, 16, 52</td>
</tr>
<tr>
<td>Kent, Jerillyn</td>
<td>42, 84</td>
</tr>
<tr>
<td>Khan, Anzalee</td>
<td>106, 137</td>
</tr>
<tr>
<td>Khandaker, Golam</td>
<td>111, 139</td>
</tr>
<tr>
<td>Kikuchi, Yuka</td>
<td>127</td>
</tr>
<tr>
<td>Kilian, Sanja</td>
<td>117</td>
</tr>
<tr>
<td>Killackey, Eoin</td>
<td>93</td>
</tr>
<tr>
<td>Kim, Chul Eung</td>
<td>118</td>
</tr>
<tr>
<td>Kim, Euitae</td>
<td>112</td>
</tr>
<tr>
<td>Kim, Ji Sun</td>
<td>149</td>
</tr>
<tr>
<td>Kim, Jung Jin</td>
<td>115</td>
</tr>
<tr>
<td>Kim, Minah</td>
<td>130</td>
</tr>
<tr>
<td>Kim, Pinna</td>
<td>88</td>
</tr>
<tr>
<td>Kim, Seung Hyun</td>
<td>93</td>
</tr>
<tr>
<td>Kim, Sung-Wan</td>
<td>118, 146</td>
</tr>
<tr>
<td>Kim, Tae Yong</td>
<td>107</td>
</tr>
<tr>
<td>Kim, Yong Sik</td>
<td>68</td>
</tr>
<tr>
<td>Kimura, Haruhide</td>
<td>58</td>
</tr>
<tr>
<td>Kindler, Jochen</td>
<td>71, 142</td>
</tr>
<tr>
<td>Kinnunen, Lotta</td>
<td>110</td>
</tr>
<tr>
<td>Kircher, Tilo</td>
<td>28, 48</td>
</tr>
<tr>
<td>Kirkbridge, James</td>
<td>54, 83</td>
</tr>
<tr>
<td>Kirkpatrick, Brian</td>
<td>148</td>
</tr>
<tr>
<td>Kirli, Umut</td>
<td>55</td>
</tr>
<tr>
<td>Kirschner, Matthias</td>
<td>113</td>
</tr>
<tr>
<td>Kjelby, Eirik</td>
<td>80</td>
</tr>
<tr>
<td>Klaasen, Nicky</td>
<td>108</td>
</tr>
<tr>
<td>Klamarus, Ewa</td>
<td>109</td>
</tr>
<tr>
<td>Klauber, Dea Gowers</td>
<td>94</td>
</tr>
<tr>
<td>Kline, Emily</td>
<td>14, 78</td>
</tr>
<tr>
<td>Klippel, Annelie</td>
<td>119</td>
</tr>
<tr>
<td>Kodesh, Arad</td>
<td>107</td>
</tr>
<tr>
<td>Koevoets, Godefridus</td>
<td>14, 85</td>
</tr>
<tr>
<td>Kohlbrenner, Emily</td>
<td>147</td>
</tr>
<tr>
<td>Köhler, Ole</td>
<td>54, 82, 111, 137</td>
</tr>
<tr>
<td>Kok, Rob</td>
<td>150</td>
</tr>
<tr>
<td>Koops, Sanne</td>
<td>118</td>
</tr>
<tr>
<td>Koponen, Hannu</td>
<td>49</td>
</tr>
<tr>
<td>Koren, Dan</td>
<td>108</td>
</tr>
<tr>
<td>Koros, Eliza</td>
<td>146</td>
</tr>
<tr>
<td>Korth, Carsten</td>
<td>58</td>
</tr>
<tr>
<td>Kos, Claire</td>
<td>128</td>
</tr>
<tr>
<td>Koutsouleris, Nikolaos</td>
<td>15, 35, 37, 49</td>
</tr>
<tr>
<td>Kraan, Tamar</td>
<td>97</td>
</tr>
<tr>
<td>Kraft, Dominik</td>
<td>144</td>
</tr>
<tr>
<td>Kraguljac, Nina</td>
<td>114</td>
</tr>
<tr>
<td>Krakowski, Menahem</td>
<td>57</td>
</tr>
<tr>
<td>Kraus, Michael</td>
<td>75</td>
</tr>
<tr>
<td>Kristensen, Tina</td>
<td>145</td>
</tr>
<tr>
<td>Krivoy, Amir</td>
<td>128</td>
</tr>
<tr>
<td>Kroken, Rune A.</td>
<td>121</td>
</tr>
<tr>
<td>Kroll, Jasmin</td>
<td>88, 148</td>
</tr>
<tr>
<td>Krynicki, Carl</td>
<td>109</td>
</tr>
<tr>
<td>Kucukcoban, Onur</td>
<td>14, 106, 137</td>
</tr>
<tr>
<td>Kwak, Yoo Bin</td>
<td>107</td>
</tr>
<tr>
<td>Labouesse, Marie</td>
<td>14, 107</td>
</tr>
<tr>
<td>Lahti, Adrienne</td>
<td>144</td>
</tr>
<tr>
<td>Lally, John</td>
<td>58, 122, 151</td>
</tr>
<tr>
<td>Laloyaux, Julien</td>
<td>76</td>
</tr>
<tr>
<td>Lam, Max</td>
<td>76</td>
</tr>
<tr>
<td>Lancaster, Sarah</td>
<td>86</td>
</tr>
<tr>
<td>Lander, Sharon S.</td>
<td>116</td>
</tr>
<tr>
<td>Langbein, Kerstin</td>
<td>100</td>
</tr>
<tr>
<td>Lanz, Thomas</td>
<td>147</td>
</tr>
<tr>
<td>Laprevote, Vincent</td>
<td>100, 141</td>
</tr>
<tr>
<td>Larabi, Daouia</td>
<td>143</td>
</tr>
<tr>
<td>Larsen, Julie</td>
<td>155</td>
</tr>
<tr>
<td>Lasalvia, Antonio</td>
<td>65, 79</td>
</tr>
<tr>
<td>Lässer, Marc Montgomery</td>
<td>77, 106</td>
</tr>
<tr>
<td>Laursen, Thomas</td>
<td>52</td>
</tr>
<tr>
<td>Law, Yeuk Lai</td>
<td>108</td>
</tr>
<tr>
<td>Lawrie, Stephen</td>
<td>38</td>
</tr>
<tr>
<td>Lee, Jimmy</td>
<td>120</td>
</tr>
<tr>
<td>Lee, Junghhee</td>
<td>31, 49</td>
</tr>
<tr>
<td>Lee, Kit Wai</td>
<td>81, 150</td>
</tr>
<tr>
<td>Lee, Kyuyoung</td>
<td>93</td>
</tr>
<tr>
<td>Lee, Rico Sze Chun</td>
<td>80</td>
</tr>
<tr>
<td>Lee, Sara-Ann</td>
<td>136</td>
</tr>
<tr>
<td>Name</td>
<td>Age</td>
</tr>
<tr>
<td>-----------------------</td>
<td>-----</td>
</tr>
<tr>
<td>Miyata, Jun</td>
<td>84</td>
</tr>
<tr>
<td>Mizrah, Romina</td>
<td>29</td>
</tr>
<tr>
<td>Modinos, Gemma</td>
<td>26</td>
</tr>
<tr>
<td>Moghaddam, Bita</td>
<td>29</td>
</tr>
<tr>
<td>Mollon, Josephine</td>
<td>53</td>
</tr>
<tr>
<td>Monsonet, Manel</td>
<td>149</td>
</tr>
<tr>
<td>Moore, James</td>
<td>28</td>
</tr>
<tr>
<td>Moreines, Jared</td>
<td>72</td>
</tr>
<tr>
<td>Morgan, Craig</td>
<td>54, 96, 126</td>
</tr>
<tr>
<td>Morkved, Nina</td>
<td>60</td>
</tr>
<tr>
<td>Mortensen, Preben</td>
<td>4</td>
</tr>
<tr>
<td>Mothet, Jean-Pierre</td>
<td>41</td>
</tr>
<tr>
<td>Mouchlianitis, Elias</td>
<td>57</td>
</tr>
<tr>
<td>Mucci, Armida</td>
<td>41</td>
</tr>
<tr>
<td>Mueller, Daniel</td>
<td>148</td>
</tr>
<tr>
<td>Mueller, Toni</td>
<td>147</td>
</tr>
<tr>
<td>Müller, Bernhard</td>
<td>117</td>
</tr>
<tr>
<td>Müller, Daniel</td>
<td>87</td>
</tr>
<tr>
<td>Murray, Robin</td>
<td>27, 65</td>
</tr>
<tr>
<td>Myers, Neely</td>
<td>94</td>
</tr>
<tr>
<td>Myin-Germeyns, Inez</td>
<td>119, 149</td>
</tr>
<tr>
<td>Naber, Dieter</td>
<td>74, 124, 154</td>
</tr>
<tr>
<td>Nahar, Abhinav</td>
<td>86</td>
</tr>
<tr>
<td>Nakajima, Shinichiro</td>
<td>14, 91</td>
</tr>
<tr>
<td>Neilson, Emma</td>
<td>14, 145</td>
</tr>
<tr>
<td>Nelson, Barnaby</td>
<td>28, 39, 57</td>
</tr>
<tr>
<td>Nenadic, Igor</td>
<td>5, 16, 50, 115, 145</td>
</tr>
<tr>
<td>Nerhus, Mari</td>
<td>138</td>
</tr>
<tr>
<td>Newbury, Joanne</td>
<td>14, 82</td>
</tr>
<tr>
<td>Nielsen, Anita Tønder</td>
<td>139</td>
</tr>
<tr>
<td>Nielsen, Mette</td>
<td>97</td>
</tr>
<tr>
<td>Nieman, Dorien</td>
<td>57</td>
</tr>
<tr>
<td>Nijman, Saskia</td>
<td>30</td>
</tr>
<tr>
<td>Nikiforuk, Agnieszka</td>
<td>90</td>
</tr>
<tr>
<td>Nilsson, Peter</td>
<td>70</td>
</tr>
<tr>
<td>Nilsson, Sandra Feodor</td>
<td>31</td>
</tr>
<tr>
<td>Nimgaonkar, Vishwajit</td>
<td>141</td>
</tr>
<tr>
<td>Noordsy, Douglas</td>
<td>4</td>
</tr>
<tr>
<td>Nordentoft, Merete</td>
<td>17, 40, 61, 110</td>
</tr>
<tr>
<td>Noto, Cristiano</td>
<td>57</td>
</tr>
<tr>
<td>Notter, Tina</td>
<td>87</td>
</tr>
<tr>
<td>Novick, Diego</td>
<td>120</td>
</tr>
<tr>
<td>Nuechterlein, Keith</td>
<td>40, 60</td>
</tr>
<tr>
<td>Nuñez, Daniel</td>
<td>106, 149</td>
</tr>
<tr>
<td>Nuss, Philippe</td>
<td>69</td>
</tr>
<tr>
<td>O'Donnell, Patricio</td>
<td>4, 47</td>
</tr>
<tr>
<td>O'Donoghue, Brian</td>
<td>111, 139</td>
</tr>
<tr>
<td>Oduola, Sheri</td>
<td>110</td>
</tr>
</tbody>
</table>
### Index

<table>
<thead>
<tr>
<th>Author</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pocklington, Andrew</td>
<td>47</td>
</tr>
<tr>
<td>Pol, Hilleke Hulshoff</td>
<td>5, 16, 59, 66</td>
</tr>
<tr>
<td>Porcelli, Annamaria</td>
<td>104</td>
</tr>
<tr>
<td>Pos, Karin</td>
<td>97</td>
</tr>
<tr>
<td>Potasiewicz, Agnieszka</td>
<td>14, 150</td>
</tr>
<tr>
<td>Pot-Kolder, Roos</td>
<td>132</td>
</tr>
<tr>
<td>Pousa, Esther</td>
<td>104</td>
</tr>
<tr>
<td>Pratt, Gemma</td>
<td>94</td>
</tr>
<tr>
<td>Pratt, Judith</td>
<td>58</td>
</tr>
<tr>
<td>Preisig, Martin</td>
<td>47</td>
</tr>
<tr>
<td>Prikken, Merel</td>
<td>106</td>
</tr>
<tr>
<td>Prinssen, Eric</td>
<td>101, 151</td>
</tr>
<tr>
<td>Puig-Navarro, Olga</td>
<td>71</td>
</tr>
<tr>
<td>Purcell, Shaun</td>
<td>42</td>
</tr>
<tr>
<td>Purves-Tyson, Tertia</td>
<td>29</td>
</tr>
<tr>
<td>Qing, Ying</td>
<td>129</td>
</tr>
<tr>
<td>Quattrone, Diego</td>
<td>138</td>
</tr>
<tr>
<td>Rabinowitz, Jonathan</td>
<td>73</td>
</tr>
<tr>
<td>Racioppi, Anna</td>
<td>109, 138</td>
</tr>
<tr>
<td>Ragland, J, Daniel</td>
<td>51</td>
</tr>
<tr>
<td>Raij, Tuukka</td>
<td>90</td>
</tr>
<tr>
<td>Ramos-Miguel, Alfredo</td>
<td>117</td>
</tr>
<tr>
<td>Ramsay, Hugh</td>
<td>14, 135</td>
</tr>
<tr>
<td>Ranning, Anne</td>
<td>54</td>
</tr>
<tr>
<td>Rapado-Castro, Marta</td>
<td>14, 88, 89, 147</td>
</tr>
<tr>
<td>Rapisarda, Attilio</td>
<td>114</td>
</tr>
<tr>
<td>Rapp, Alexander</td>
<td>95</td>
</tr>
<tr>
<td>Rapp, Charlotte</td>
<td>147</td>
</tr>
<tr>
<td>Rautio, Nina</td>
<td>139</td>
</tr>
<tr>
<td>Reeder, Clare</td>
<td>30</td>
</tr>
<tr>
<td>Reichenberg, Abraham</td>
<td>40</td>
</tr>
<tr>
<td>Reichenberg, Avi</td>
<td>49</td>
</tr>
<tr>
<td>Renard, Selwyn</td>
<td>78, 107</td>
</tr>
<tr>
<td>Rendal, Yolanda</td>
<td>79</td>
</tr>
<tr>
<td>Revell, Emily</td>
<td>105</td>
</tr>
<tr>
<td>Revuelta, José Pérez</td>
<td>95</td>
</tr>
<tr>
<td>Reynolds, Gavin</td>
<td>120</td>
</tr>
<tr>
<td>Rey, Romain</td>
<td>79</td>
</tr>
<tr>
<td>Richetto, Juliet</td>
<td>72</td>
</tr>
<tr>
<td>Riecher-Rössler, Anita</td>
<td>4, 73</td>
</tr>
<tr>
<td>Riehle, Marcel</td>
<td>123</td>
</tr>
<tr>
<td>Rikandi, Eva</td>
<td>85</td>
</tr>
<tr>
<td>Rimvall, Martin</td>
<td>32</td>
</tr>
<tr>
<td>Risinger, Robert</td>
<td>103, 133</td>
</tr>
<tr>
<td>Riva, Marco Andrea</td>
<td>90</td>
</tr>
<tr>
<td>Rivollier, Fabrice</td>
<td>87</td>
</tr>
<tr>
<td>Rizk, Dalia Nagui</td>
<td>89</td>
</tr>
<tr>
<td>Rizvi, Asra</td>
<td>80</td>
</tr>
<tr>
<td>Robertson, Sharman</td>
<td>124</td>
</tr>
<tr>
<td>Roche, Eric</td>
<td>55, 81, 123, 153</td>
</tr>
<tr>
<td>Rodriguez, Mabel</td>
<td>136</td>
</tr>
<tr>
<td>Rodriguez, Victoria</td>
<td>104</td>
</tr>
<tr>
<td>Rohde, Christopher</td>
<td>110</td>
</tr>
<tr>
<td>Roos, Johannes</td>
<td>86</td>
</tr>
<tr>
<td>Rosenbrock, Holger</td>
<td>122, 151</td>
</tr>
<tr>
<td>Rosen, Marlene</td>
<td>123, 153</td>
</tr>
<tr>
<td>Rösler, Lara</td>
<td>56</td>
</tr>
<tr>
<td>Rossell, Susan</td>
<td>77, 105</td>
</tr>
<tr>
<td>Rotharmel, Maud</td>
<td>92</td>
</tr>
<tr>
<td>Rudá, Ditte</td>
<td>68</td>
</tr>
<tr>
<td>Ruggeri, Mirella</td>
<td>125</td>
</tr>
<tr>
<td>Ruiz, Ada</td>
<td>79, 149</td>
</tr>
<tr>
<td>Rund, Bjorn</td>
<td>40, 117</td>
</tr>
<tr>
<td>Rüsch, Nicolas</td>
<td>65</td>
</tr>
<tr>
<td>Rutigliano, Grazi</td>
<td>61</td>
</tr>
<tr>
<td>Sachs, Gabriele</td>
<td>77, 143</td>
</tr>
<tr>
<td>Sailas, Eila</td>
<td>93</td>
</tr>
<tr>
<td>Salum, Cristiano</td>
<td>118</td>
</tr>
<tr>
<td>Salzman, Phyllis</td>
<td>132</td>
</tr>
<tr>
<td>Samara, Myrto</td>
<td>14, 111, 152</td>
</tr>
<tr>
<td>Sanada, Kenji</td>
<td>89</td>
</tr>
<tr>
<td>Sanchez-Gistau, Vanessa</td>
<td>129</td>
</tr>
<tr>
<td>Sand, Michael</td>
<td>73</td>
</tr>
<tr>
<td>Santoro, Marcos Leite</td>
<td>14, 116</td>
</tr>
<tr>
<td>Saperia, Sarah</td>
<td>94</td>
</tr>
<tr>
<td>Sarno, Elaine Di</td>
<td>148</td>
</tr>
<tr>
<td>Sasabayashi, Daiki</td>
<td>144</td>
</tr>
<tr>
<td>Savitz, Adam</td>
<td>73, 152</td>
</tr>
<tr>
<td>Sawa, Akira</td>
<td>5, 13, 37, 41</td>
</tr>
<tr>
<td>Sawada, Ken</td>
<td>86</td>
</tr>
<tr>
<td>Schäppi, Lea</td>
<td>96</td>
</tr>
<tr>
<td>Schijven, Dick</td>
<td>87</td>
</tr>
<tr>
<td>Schiltz, Kolja</td>
<td>30</td>
</tr>
<tr>
<td>Schmidt, André</td>
<td>14, 113, 145</td>
</tr>
<tr>
<td>Schnack, Hugo</td>
<td>37, 144</td>
</tr>
<tr>
<td>Schneider, Maude</td>
<td>123</td>
</tr>
<tr>
<td>Schultz, C. Christoph</td>
<td>95</td>
</tr>
<tr>
<td>Schulz, Charles</td>
<td>5</td>
</tr>
<tr>
<td>Schutte, Maya</td>
<td>80</td>
</tr>
<tr>
<td>Schwab, Sibylle</td>
<td>4</td>
</tr>
<tr>
<td>Scoriels, Linda</td>
<td>14, 136</td>
</tr>
<tr>
<td>Scott, Madeline</td>
<td>88</td>
</tr>
<tr>
<td>Seidman, Larry</td>
<td>40, 72, 104</td>
</tr>
<tr>
<td>Seitz, Johanna</td>
<td>14, 56</td>
</tr>
<tr>
<td>Selvaggi, Pierluigi</td>
<td>90</td>
</tr>
<tr>
<td>Selvendra, Ajit</td>
<td>140</td>
</tr>
<tr>
<td>Name</td>
<td>Page</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>------------</td>
</tr>
<tr>
<td>Seminerio, Fabio</td>
<td>78, 95, 108, 154</td>
</tr>
<tr>
<td>Sendt, Kyra-Verena</td>
<td>114</td>
</tr>
<tr>
<td>Seol, Jiyoung</td>
<td>128</td>
</tr>
<tr>
<td>Seppälä, Jussi</td>
<td>49</td>
</tr>
<tr>
<td>Serpa, Mauricio</td>
<td>115</td>
</tr>
<tr>
<td>Shamir, Alon</td>
<td>116</td>
</tr>
<tr>
<td>Shannon-Weickert, Cynthia</td>
<td>3</td>
</tr>
<tr>
<td>Shapiro, Daniel</td>
<td>14, 76</td>
</tr>
<tr>
<td>Sheinbaum, Tamara</td>
<td>97</td>
</tr>
<tr>
<td>Shin, Ye Seul</td>
<td>134</td>
</tr>
<tr>
<td>Shuhama, Rosana</td>
<td>140</td>
</tr>
<tr>
<td>Siddiqui, Ishraaq</td>
<td>50</td>
</tr>
<tr>
<td>Siedman, Larry</td>
<td>11</td>
</tr>
<tr>
<td>Sigvard, Anne</td>
<td>85</td>
</tr>
<tr>
<td>Silverman, Bernard</td>
<td>103, 133</td>
</tr>
<tr>
<td>Sinkeviciute, Igne</td>
<td>91</td>
</tr>
<tr>
<td>Si, Tian mei</td>
<td>132</td>
</tr>
<tr>
<td>Skene, Nathan</td>
<td>64</td>
</tr>
<tr>
<td>Slot, Margot</td>
<td>148</td>
</tr>
<tr>
<td>Smeland, Olav</td>
<td>52</td>
</tr>
<tr>
<td>Smesny, Stefan</td>
<td>70, 100</td>
</tr>
<tr>
<td>Smith, Geoffrey</td>
<td>100</td>
</tr>
<tr>
<td>Smith, Matthew</td>
<td>84</td>
</tr>
<tr>
<td>Smith, Robert C.</td>
<td>99, 137</td>
</tr>
<tr>
<td>Sneebøer, Marjolein</td>
<td>147</td>
</tr>
<tr>
<td>Somers, Julian</td>
<td>59</td>
</tr>
<tr>
<td>Sommer, Iris</td>
<td>4, 27, 48, 128</td>
</tr>
<tr>
<td>Sonnenschein, Susan</td>
<td>91</td>
</tr>
<tr>
<td>Sormunen, Elina</td>
<td>53</td>
</tr>
<tr>
<td>Spada, Giulia</td>
<td>130</td>
</tr>
<tr>
<td>Spedding, Michael</td>
<td>5</td>
</tr>
<tr>
<td>Spilka, Michael</td>
<td>112</td>
</tr>
<tr>
<td>Sportel, Bouwina</td>
<td>124, 154</td>
</tr>
<tr>
<td>Srvhari, Vinod</td>
<td>28, 124</td>
</tr>
<tr>
<td>Ståblein, Michael</td>
<td>84</td>
</tr>
<tr>
<td>Stain, Helen</td>
<td>72</td>
</tr>
<tr>
<td>Steenhuis, Laura</td>
<td>110</td>
</tr>
<tr>
<td>Stegmayer, Katharina</td>
<td>142</td>
</tr>
<tr>
<td>Steiner, Johann</td>
<td>30</td>
</tr>
<tr>
<td>Steinhart, Henrietta</td>
<td>148</td>
</tr>
<tr>
<td>Stekema, Annemarie</td>
<td>93</td>
</tr>
<tr>
<td>Stilo, Simona</td>
<td>54</td>
</tr>
<tr>
<td>Strik, Werner</td>
<td>48</td>
</tr>
<tr>
<td>Studerus, Erich</td>
<td>74, 102</td>
</tr>
<tr>
<td>Subramaniam, Karuna</td>
<td>84</td>
</tr>
<tr>
<td>Suetani, Shuichi</td>
<td>81</td>
</tr>
<tr>
<td>Sugranyes, Gisela</td>
<td>144</td>
</tr>
<tr>
<td>Suk, Kyoungho</td>
<td>41</td>
</tr>
<tr>
<td>Sullivan, Sarah</td>
<td>82</td>
</tr>
<tr>
<td>Sumiyoshi, Chika</td>
<td>135</td>
</tr>
<tr>
<td>Sumiyoshi, Tomiki</td>
<td>154</td>
</tr>
<tr>
<td>Sumner, Philip</td>
<td>115</td>
</tr>
<tr>
<td>Supanya, Suttha</td>
<td>81</td>
</tr>
<tr>
<td>Suvisaari, Jaana</td>
<td>128</td>
</tr>
<tr>
<td>Suvitaival, Tommi</td>
<td>137</td>
</tr>
<tr>
<td>Suzuki, Kazunori</td>
<td>91</td>
</tr>
<tr>
<td>Swaminathan, Vaidy</td>
<td>83</td>
</tr>
<tr>
<td>Takeuchi, Hiroyoshi</td>
<td>121</td>
</tr>
<tr>
<td>Tan, Eric</td>
<td>77, 124, 154</td>
</tr>
<tr>
<td>Tandon, Rajiv</td>
<td>5</td>
</tr>
<tr>
<td>Tang, Charmaine</td>
<td>125</td>
</tr>
<tr>
<td>Tang, Sunny</td>
<td>130</td>
</tr>
<tr>
<td>Tani, Hideaki</td>
<td>14, 121</td>
</tr>
<tr>
<td>Tarland, Emilia</td>
<td>91</td>
</tr>
<tr>
<td>Tasma, Magda</td>
<td>95</td>
</tr>
<tr>
<td>Tatar, Zeynep Baran</td>
<td>79</td>
</tr>
<tr>
<td>Termorshuizen, Fabian</td>
<td>51</td>
</tr>
<tr>
<td>Teroganova, Nina</td>
<td>114</td>
</tr>
<tr>
<td>Theran, Sebastian</td>
<td>130</td>
</tr>
<tr>
<td>Thomas, Elizabeth</td>
<td>108</td>
</tr>
<tr>
<td>Thompson, Andrew</td>
<td>39, 73, 151</td>
</tr>
<tr>
<td>Thorup, Anne</td>
<td>53, 71</td>
</tr>
<tr>
<td>Thyme, Summer</td>
<td>118</td>
</tr>
<tr>
<td>Tianmei, Si</td>
<td>4</td>
</tr>
<tr>
<td>Tiihonen, Jari</td>
<td>5, 121</td>
</tr>
<tr>
<td>Tocco, Michael</td>
<td>103, 133</td>
</tr>
<tr>
<td>Todorov, Louise</td>
<td>80</td>
</tr>
<tr>
<td>Toh, Wei Lin</td>
<td>138</td>
</tr>
<tr>
<td>Tol, Marie-Jose Van</td>
<td>135</td>
</tr>
<tr>
<td>Toll, Alba</td>
<td>129</td>
</tr>
<tr>
<td>Torgalsboen, Anne-Kari</td>
<td>119</td>
</tr>
<tr>
<td>Torrey, E. Fuller</td>
<td>65</td>
</tr>
<tr>
<td>Tortadès, Ingrid</td>
<td>125</td>
</tr>
<tr>
<td>Tortelli, Andrea</td>
<td>83</td>
</tr>
<tr>
<td>Traber-Walker, Nina</td>
<td>118</td>
</tr>
<tr>
<td>Tréhout, Maxime</td>
<td>86</td>
</tr>
<tr>
<td>Trotta, Antonella</td>
<td>68</td>
</tr>
<tr>
<td>Tseng, Hual-Hsuan</td>
<td>50</td>
</tr>
<tr>
<td>Tso, Ivy</td>
<td>113</td>
</tr>
<tr>
<td>Tsuji, Naohisa</td>
<td>102</td>
</tr>
<tr>
<td>Turner, Jessica</td>
<td>38</td>
</tr>
<tr>
<td>Ucok, Alp</td>
<td>120</td>
</tr>
<tr>
<td>Ueland, Torill</td>
<td>30</td>
</tr>
<tr>
<td>Uher, Rudolf</td>
<td>47</td>
</tr>
<tr>
<td>Uhlhaas, Peter</td>
<td>47</td>
</tr>
<tr>
<td>Ullrich, Simone</td>
<td>111, 141</td>
</tr>
<tr>
<td>Name</td>
<td>Page</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>------</td>
</tr>
<tr>
<td>Underwood, Raphael</td>
<td>113</td>
</tr>
<tr>
<td>Upthegrove, Rachel</td>
<td>39</td>
</tr>
<tr>
<td>Urquijo, Maria F.</td>
<td>105</td>
</tr>
<tr>
<td>Uttinger, Martina</td>
<td>132</td>
</tr>
<tr>
<td>Uzbekov, Marat</td>
<td>98, 99</td>
</tr>
<tr>
<td>Vaessen, Thomas</td>
<td>147</td>
</tr>
<tr>
<td>Valiente, Alba</td>
<td>83</td>
</tr>
<tr>
<td>Valli, Isabel</td>
<td>144</td>
</tr>
<tr>
<td>van Dellen, Edwin</td>
<td>86</td>
</tr>
<tr>
<td>van den Buuse, Maarten</td>
<td>27, 131</td>
</tr>
<tr>
<td>Van der Gaag, Mark</td>
<td>27</td>
</tr>
<tr>
<td>Van der Meer, Lisette</td>
<td>123</td>
</tr>
<tr>
<td>van der Steen, Yori</td>
<td>149</td>
</tr>
<tr>
<td>van der Stouwe, Elisabeth</td>
<td>132</td>
</tr>
<tr>
<td>van der Zalm, Yvonne</td>
<td>83</td>
</tr>
<tr>
<td>van Duin, Esther</td>
<td>126</td>
</tr>
<tr>
<td>Vanes, Lucy</td>
<td>70, 136</td>
</tr>
<tr>
<td>Van Haren, Neeltje</td>
<td>5, 28, 75</td>
</tr>
<tr>
<td>Van Harten, Peter</td>
<td>42</td>
</tr>
<tr>
<td>van Leeuwen, Judith M.C.</td>
<td>143</td>
</tr>
<tr>
<td>Van Nierop, Martine</td>
<td>14, 27, 127</td>
</tr>
<tr>
<td>Van Os, Jim</td>
<td>42</td>
</tr>
<tr>
<td>Vanover, Kimberly</td>
<td>59, 74, 103, 133</td>
</tr>
<tr>
<td>Van Rheenen, Tamsyn</td>
<td>55, 77, 106</td>
</tr>
<tr>
<td>Van Winkel, Ruud</td>
<td>27</td>
</tr>
<tr>
<td>Varese, Filippo</td>
<td>27</td>
</tr>
<tr>
<td>Vasile, Daniel</td>
<td>72, 107, 154</td>
</tr>
<tr>
<td>Veijola, Juha</td>
<td>117</td>
</tr>
<tr>
<td>Veling, Wim</td>
<td>55, 119</td>
</tr>
<tr>
<td>Velligan, Dawn</td>
<td>4, 61</td>
</tr>
<tr>
<td>Velthorst, Eva</td>
<td>49</td>
</tr>
<tr>
<td>Ventura, Joseph</td>
<td>48, 73</td>
</tr>
<tr>
<td>Vernal, Ditte Lammers</td>
<td>38</td>
</tr>
<tr>
<td>Vernon, Anthony</td>
<td>78</td>
</tr>
<tr>
<td>Vidal, Gricel Orellana</td>
<td>75</td>
</tr>
<tr>
<td>Viertio, Satu</td>
<td>124</td>
</tr>
<tr>
<td>Vignes, Michael</td>
<td>116</td>
</tr>
<tr>
<td>Viher, Petra</td>
<td>145</td>
</tr>
<tr>
<td>Vincent, Angela</td>
<td>39</td>
</tr>
<tr>
<td>Vincent, Philippe</td>
<td>92</td>
</tr>
<tr>
<td>Vingerhoets, Claudia</td>
<td>106, 133</td>
</tr>
<tr>
<td>Vinogradov, Sophia</td>
<td>3</td>
</tr>
<tr>
<td>Vogel, Jelle Sjoerd</td>
<td>89</td>
</tr>
<tr>
<td>Voineskos, Aristotle</td>
<td>5, 13, 16, 38, 53</td>
</tr>
<tr>
<td>Voisey, Joanne</td>
<td>83</td>
</tr>
<tr>
<td>Voss, Martin</td>
<td>28</td>
</tr>
<tr>
<td>Walther, Sebastian</td>
<td>42</td>
</tr>
<tr>
<td>Wang, Chuan-Yue</td>
<td>136</td>
</tr>
<tr>
<td>Wang, Ya</td>
<td>135</td>
</tr>
</tbody>
</table>